var images_info;if (!images_info) images_info =[]; images_info["69"]={"69000":{"type":"graphic_picture","displayName":"Prostate CA perineural invasion","title":"Prostate cancer with perineural invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate cancer with perineural invasion</div><div class=\"cntnt\"><img style=\"width:375px; height:273px;\" src=\"images/ONC/69000_Prostate_CA_perineural_inva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an hematoxylin- and eosin-stained section of a prostate core needle biopsy. One of the diagnostic features of prostate adenocarcinoma is perineural invasion (arrow).</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 69000 Version 2.0</div></div></div>"},"69001":{"type":"graphic_figure","displayName":"Wavelengths of light used for venous laser therapy","title":"Wavelengths of light used for venous laser therapy (skin surface)","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Wavelengths of light used for venous laser therapy (skin surface)</div><div class=\"cntnt\"><img style=\"width:494px; height:296px;\" src=\"images/PC/69001_Laser_light_veins_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Potassium titanyl phosphate (KTP) lasers emit light at a wavelength of 532 nm. Long pulse dye lasers (PDL) emit light of 595 nm. Diode lasers emit light at a wavelength of 800 or 900 nm. Alexandrite lasers emit light at a wavelength of 755 nm. Neodymium-doped:yttrium aluminum garnet (Nd:YAG) lasers emit light at a wavelength of 1064 nm. Intense pulsed light sources (IPLS) are not lasers. These devices emit light in a range of wavelengths from 500 to 1000 nm simultaneously, with each wavelength emitted at a different intensity.</div><div class=\"graphic_footnotes\">* Not a laser.</div><div id=\"graphicVersion\">Graphic 69001 Version 5.0</div></div></div>"},"69005":{"type":"graphic_figure","displayName":"Arrhythmias alcoholic CMP","title":"Freedom from sustained VT, VF or SCD in ACM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Freedom from sustained VT, VF or SCD in ACM</div><div class=\"cntnt\"><img style=\"width:362px; height:274px;\" src=\"images/CARD/69005_Arrhythmias_alcoholic_CMP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This report compared 119 patients with idiopathic dilated cardiomyopathy (IDCM) and 75 patients with alcoholic cardiomyopathy (ACM). Among those with ACM, 47 abstained from alcohol consumption and 28 continued to drink. Major arrhythmic events were evaluated including sustained ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD), and the event-free survival for each group of patients was determined. The red line indicates patients with ACM and alcohol abstinence, the green line indicates IDCM, and the blue line indicates patients with ACM without abstinence. Compared&nbsp;with patients with ACM and alcohol abstinence, the relative risk of events was 8.0 for patients with ACM without abstinence and 7.3 for patients with IDCM.</div><div class=\"graphic_reference\">Reproduced with permission from: Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003; 123:1320. Copyright © 2003 American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 69005 Version 4.0</div></div></div>"},"69006":{"type":"graphic_table","displayName":"Pregnancy outcome B19 infection","title":"Summary of studies on pregnancy outcome and parvovirus B19 infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of studies on pregnancy outcome and parvovirus B19 infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Study</td>\n\n      <td class=\"subtitle1\">Number of pregnancies</td>\n\n      <td class=\"subtitle1\">Total fetal losses</td>\n\n      <td class=\"subtitle1\">Loss &#60;20 weeks</td>\n\n      <td class=\"subtitle1\">Loss &#62;20 weeks</td>\n\n      <td class=\"subtitle1\">Hydrops</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anand, A, et al. N Engl J Med 1987</td>\n\n      <td>6</td>\n\n      <td>2</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Schwartz, TF, et al. Lancet 1988</td>\n\n      <td>34</td>\n\n      <td>7</td>\n\n      <td>- </td>\n\n      <td>7</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rodis, JF, et al. Am J Obstet Gynecol 1990*</td>\n\n      <td>39</td>\n\n      <td>2</td>\n\n      <td>2</td>\n\n      <td>0</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>British Working Party, BMJ 1990*</td>\n\n      <td>186</td>\n\n      <td>30</td>\n\n      <td>27</td>\n\n      <td>3</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Guidozzi, F, et al. J Reprod Med 1994*</td>\n\n      <td>63</td>\n\n      <td>1</td>\n\n      <td>1</td>\n\n      <td>0</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gratacos, E, et al. J Infect Dis 1995*</td>\n\n      <td>60</td>\n\n      <td>5</td>\n\n      <td>5</td>\n\n      <td>0</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enders, M, et al Prenat Diagn 2004</td>\n\n      <td>1018</td>\n\n      <td>64</td>\n\n      <td>64</td>\n\n      <td>0</td>\n\n      <td>40</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Loss rate &lt;20 weeks 10 percent, &gt;20 weeks 0.9 percent.</div><div id=\"graphicVersion\">Graphic 69006 Version 1.0</div></div></div>"},"69008":{"type":"graphic_waveform","displayName":"EMG myokymia envenomation","title":"Electromyography in a patient with myokymia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electromyography in a patient with myokymia</div><div class=\"cntnt\"><img style=\"width:404px; height:342px;\" src=\"images/NEURO/69008_EMG_myokymia_envenomation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doublets and triplets with clinical myokymia following rattle snake envenomation.</div><div id=\"graphicVersion\">Graphic 69008 Version 3.0</div></div></div>"},"69011":{"type":"graphic_figure","displayName":"Metyrapone in hypopituitarism","title":"Subnormal response to metyrapone in hypopituitarism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subnormal response to metyrapone in hypopituitarism</div><div class=\"cntnt\"><img style=\"width:282px; height:472px;\" src=\"images/ENDO/69011_Metyrapone_in_hypopituitari.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum concentrations of 11-DOC after the administration of metyrapone (750 mg every four hours for six doses) in normal subjects and patients with hypopituitarism. The serum 11-DOC concentrations are much lower in the patients with hypopituitarism, due to the inability to substantially increase the secretion of ACTH. To convert serum 11-DOC values to nmol/L, multiply by 28.9.</div><div class=\"graphic_footnotes\">11-DOC: 11-deoxycortisol; ACTH: corticotropin.</div><div class=\"graphic_reference\">Data from: Spark RF. Simplified assessment of pituitary-adrenal reserve. Measurement of serum 11-deoxycortisol and cortisol after metyrapone. Ann Intern Med 1971; 75:717.</div><div id=\"graphicVersion\">Graphic 69011 Version 5.0</div></div></div>"},"69012":{"type":"graphic_figure","displayName":"GEJ after therapy","title":"The \"Stretta\" procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The &quot;Stretta&quot; procedure</div><div class=\"cntnt\"><img style=\"width:367px; height:283px;\" src=\"images/GAST/69012_GEJ_after_therapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing multiple thermal lesions within the smooth muscle of gastroesophageal junction after therapy.</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 69012 Version 2.0</div></div></div>"},"69015":{"type":"graphic_table","displayName":"NCI CTCAE v5 nausea and vomiting","title":"NCI CTCAE v5.0 nausea and vomiting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 nausea and vomiting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Nausea</td> <td>Loss of appetite without alteration in eating habits</td> <td>Oral intake decreased without significant weight loss, dehydration, or malnutrition</td> <td>Inadequate oral caloric or fluid intake; tube feedings, TPN, or hospitalization indicated</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Vomiting</td> <td>Intervention not indicated</td> <td>Outpatient intravenous hydration; medical intervention indicated</td> <td>Tube feeding, TPN, or hospitalization indicated</td> <td>Life-threatening consequences</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Nausea is characterized by a queasy sensation and/or the urge to vomit. Vomiting is characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 69015 Version 11.0</div></div></div>"},"69016":{"type":"graphic_table","displayName":"Highly toxic plants","title":"Highly toxic plants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Highly toxic plants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\"><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"http://alltopics.utd.com/index.html#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span>&nbsp;</td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Genus and species</td> <td class=\"subtitle1\">Toxicity</td> <td class=\"subtitle1\">Emergency&nbsp;management*</td> </tr> <tr class=\"divider_bottom\"> <td>Pokeweed</td> <td><em>Phytolacca americana</em></td> <td>Severe gastroenteritis, hypovolemic shock</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Castor bean</td> <td><em>Ricinus communis</em></td> <td>Severe gastroenteritis, GI hemorrhage, hemolysis, shock</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Jequirity bean</td> <td><em>Abrus precatorius</em></td> <td>Severe gastroenteritis, GI hemorrhage, shock, seizures, demyelinating encephalopathy</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Autumn crocus</td> <td><em>Colchicum autumnale</em></td> <td>Delayed gastroenteritis, multisystem organ failure</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>May apple</td> <td><em>Podophyllum peltatum</em></td> <td>GI mucosal necrosis, coma, polyneuropathy</td> <td>None</td> </tr> <tr> <td>Lily of the valley</td> <td><em>Convallaria majalis</em></td> <td class=\"divider_bottom\" rowspan=\"4\">Brady- and tachy-arrhythmias, gastroenteritis, weakness, hyperkalemia</td> <td class=\"divider_bottom\" rowspan=\"4\">Digoxin-specific Fab<sup>&#182;</sup></td> </tr> <tr> <td>Foxglove</td> <td><em>Digitalis purpurea</em></td> </tr> <tr> <td>Oleander</td> <td><em>Nerium oleander</em></td> </tr> <tr class=\"divider_bottom\"> <td>Yellow oleander</td> <td><em>Thevetia peruviana</em></td> </tr> <tr> <td>Azalea</td> <td><em>Azalea</em> (multiple species)</td> <td class=\"divider_bottom\" rowspan=\"4\">Bradycardia, hypotension, gastroenteritis, blurred vision, dizziness, altered mental status</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Clinically significant bradycardia:<br /> Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)</p> If unresponsive:<br /> Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing</td> </tr> <tr> <td>Rhododendron</td> <td><em>Rhododendron</em> (multiple species)</td> </tr> <tr> <td>Death camus</td> <td><em>Zigadenus</em> species</td> </tr> <tr class=\"divider_bottom\"> <td>Mountain laurel</td> <td><em>Kalmia latifolia</em></td> </tr> <tr class=\"divider_bottom\"> <td>Monkshood</td> <td><em>Aconitum</em> (multiple species)</td> <td>Ventricular arrhythmias, gastroenteritis, paresthesias, numbness, weakness, diaphoresis, altered mental status</td> <td> <p>Ventricular arrhythmias:<br /> Amiodarone (5 mg/kg IV, may repeat up to a maximum total daily dose of 15 mg/kg <strong>OR</strong> 2.2 grams)</p> <p>Sodium bicarbonate (1-2 mEq/kg IV bolus, maximum single dose 50 mEq) in patients with widened QRS</p> <p>Magnesium sulfate (20-50 mg/kg IV, maximum single dose 2 grams) in patients with torsades de pointes</p> <p>ECMO may provide temporary support to patients with refractory arrhythmias or cardiogenic shock until the toxin is metabolized but is rarely needed. </p> </td> </tr> <tr class=\"divider_bottom\"> <td>False hellebore</td> <td><em>Veratrum album</em></td> <td>Bradycardia, hypotension, gastroenteritis, paresthesias, syncope, transient blindness, seizures</td> <td> <p>Clinically significant bradycardia:<br /> Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)</p> If unresponsive:<br /> Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing</td> </tr> <tr class=\"divider_bottom\"> <td>Yew</td> <td><em>Taxus baccata</em></td> <td>AV block, ventricular arrhythmias, gastroenteritis, seizures, coma</td> <td> <p>Clinically significant bradycardia:<br /> Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)</p> <p>If unresponsive to atropine:<br /> Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing</p> <p>If refractory to the above treatments: Calcium gluconate 10 percent (60-100 mg/kg , maximum single dose 3 grams; may repeat every 10 minutes)</p> <p>ECMO may provide temporary support to patients with refractory arrhythmias or cardiogenic shock until the toxin is metabolized but is rarely needed. </p> </td> </tr> <tr> <td>Poison hemlock</td> <td><em>Conium maculatum</em></td> <td class=\"divider_bottom\" rowspan=\"6\">Nicotinic toxicity: Salivation, lacrimation, vomiting, diarrhea, wheezing, diaphoresis, small pupils, muscle fasciculations, muscle weakness, paralysis, coma, seizures</td> <td class=\"divider_bottom\" rowspan=\"6\">Atropine for muscarinic effects (0.02 mg/kg IV, minimum initial dose 0.1 mg, maximum dose 1 mg), repeat dose every five to 15 minutes as needed to dry bronchial secretions without causing anticholinergic toxicity (eg, delirium or hyperthermia)</td> </tr> <tr> <td>Wild tobacco</td> <td><em>Nicotiana tabacum</em></td> </tr> <tr> <td>Indian tobacco</td> <td><em>Lobelia inflata</em></td> </tr> <tr> <td>Blue wild or blue false indigo</td> <td><em>Baptisia australis</em></td> </tr> <tr> <td>Golden chain</td> <td><em>Laburnum anagyroides</em></td> </tr> <tr class=\"divider_bottom\"> <td>Golden chain tree</td> <td><em>Cytisus laburnum</em></td> </tr> <tr> <td>Jimson weed</td> <td><em>Datura stramonium</em></td> <td class=\"divider_bottom\" rowspan=\"4\">Anticholinergic toxicity: Tachycardia, flushing, hot and dry skin, dilated pupils and blurry vision, disorientation, bizarre behavior, paranoia, delirium hallucinations, seizures, decreased bowel sounds, urinary retention</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Physostigmine (0.01-0.03 mg/kg slowly over 5 minutes, maximum single dose 2 mg)<sup>&#916;</sup></p> Benzodiazepines for agitation (eg, lorazepam 0.05-1 mg/kg, maximum single dose 2-4 mg)</td> </tr> <tr> <td>Angel trumpet</td> <td><em>Brugmansia</em> (multiple species)</td> </tr> <tr> <td>Deadly nightshade</td> <td><em>Atropa belladonna</em></td> </tr> <tr class=\"divider_bottom\"> <td>Henbane</td> <td><em>Hyoscyamus niger</em></td> </tr> <tr> <td>Water hemlock</td> <td><em>Cicuta</em> (multiple species)</td> <td class=\"divider_bottom\" rowspan=\"2\">Severe and recurrent seizures, vomiting, abdominal pain, diaphoresis, bronchorrhea, salivation, flushing, bradycardia, hypotension, delirium</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Benzodiazepines (eg, lorazepam 0.05-0.1 mg/kg, maximum single dose 4 mg), repeat up to 0.3 mg/kg</p> If unresponsive:<br /> Phenobarbital (15-20 mg/kg, may repeat 5-10 mg/kg every 15-20 minutes as needed up to a maximum total dose of 40 mg/kg)<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Water dropwort</td> <td><em>Oenanthe crocata</em></td> </tr> <tr> <td>Morning glory</td> <td><em>Ipomea violacea</em></td> <td class=\"divider_bottom\" rowspan=\"4\">LSD effects: Visual hallucinations, vomiting, nausea, abdominal pain, flashbacks</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Quiet, dim environment</p> <p><strong>AND</strong></p> Benzodiazepines for agitation (eg, lorazepam 0.05-1 mg/kg, maximum single dose 2-4 mg)</td> </tr> <tr> <td>Baby woodrose</td> <td><em>Argyreia nervosa</em></td> </tr> <tr> <td>Hawaiian woodrose</td> <td><em>Merremia tuberosa</em></td> </tr> <tr class=\"divider_bottom\"> <td>Peyote</td> <td><em>Lopophora williamsii</em></td> </tr> <tr> <td>Pits or seeds from cherry, apricot, peach, plum, pear, apple</td> <td><em>Prunus</em> (multiple species)</td> <td>Cyanide toxicity: Cherry red skin, tachycardia, tachypnea, ventricular arrhythmias, coma, seizures, vomiting, abdominal pain, severe lactic acidosis</td> <td> <p>IV hydroxocobalamin (70 mg/kg, maximum dose 5 grams)</p> <p><strong>AND</strong></p> IV sodium thiosulfate 25 percent (1.65 mL/kg [412.5 mg/kg])</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; AV: atrioventricular; LSD: lysergic acid diethylamide; Fab: antibody fragments; ECMO: extracorporeal membrane oxygenation.<br />* All patients with symptomatic ingestion of highly toxic plants warrant administration of oral activated charcoal, fluid repletion, and supportive care of airway, breathing, and circulation.<br />¶ Although digoxin-specific Fab fragments will bind plant cardiac glycosides, doses higher than typically given for digoxin poisoning may be necessary.<br />Δ Physostigmine may provide diagnostic confirmation of anticholinergic poisoning and is indicated for patients with hyperthermia, life-threatening tachyarrhythmias, or seizures. Physostigmine should <STRONG>not </STRONG>be given to patients with widened QRS on electrocardiogram or those who have coingested agents with sodium channel blocking effects (eg, quinidine, cyclic antidepressants).<br /><FONT class=lozenge>◊</FONT> When giving phenobarbital with benzodiazepines, anticipate apnea and perform emergent endotracheal intubation as needed. Water hemlock and water dropwort may cause seizures that are difficult to control and recur despite treatment with benzodiazepines and phenobarbital. Administration of phenytoin or fosphenytoin should be avoided. (See \"Management of status epilepticus in children\").</div><div id=\"graphicVersion\">Graphic 69016 Version 7.0</div></div></div>"},"69017":{"type":"graphic_form","displayName":"Organ scoring of chronic GVHD","title":"NIH consensus criteria for organ scoring of chronic GVHD","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">NIH consensus criteria for organ scoring of chronic GVHD</div><div class=\"cntnt\"><img style=\"width:792px; height:2267px;\" src=\"images/HEME/69017_OrganscoringchronicGVHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GVHD: graft-versus-host disease; KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group; LPS: Lansky Performance Status; BSA: body surface area; ADL: activities of daily living; LFTs: liver function tests; AP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.<br />* Skin scoring should use both percentage of BSA involved by disease signs and the cutaneous features scales. When a discrepancy exists between the percentage of total body surface (BSA) score and the skin feature score, OR if superficial sclerotic features are present (score 2), but there is impaired mobility or ulceration (score 3), the higher level should be used for the final skin scoring.<br />¶ Weight loss within three months.<br />Δ Lung scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1 should be used in the final lung scoring where there is discrepancy between symptoms and FEV1 scores.<br /><FONT class=lozenge>◊</FONT> To be completed by specialist or trained medical providers.</div><div class=\"graphic_reference\">Reproduced from: Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2015; 21:389. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69017 Version 5.0</div></div></div>"},"69018":{"type":"graphic_figure","displayName":"Hand and wrist PI","title":"Hand and wrist bones","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Hand and wrist bones</div><div class=\"cntnt\"><img style=\"width:496px; height:610px;\" src=\"images/PI/69018_Hand-and-wrist-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the bones of the hand and wrist.</div><div id=\"graphicVersion\">Graphic 69018 Version 2.0</div></div></div>"},"69019":{"type":"graphic_diagnosticimage","displayName":"Radiographic views for acetabular fractures","title":"Radiographic views for acetabular fractures","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Radiographic views for acetabular fractures</div><div class=\"cntnt\"><img style=\"width:516px; height:407px;\" src=\"images/EM/69019_Acetabularxrays.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image depicts the normal lines and relationships of the acetabulum on different radiographic views and schematic pictures.<br> (A) Anteroposterior (AP) radiograph of the pelvis. 1, Iliopectineal line; 2, ilioischial line; 3, teardrop; 4, acetabular roof; 5, anterior rim of the acetabulum; 6, posterior rim of the acetabulum. The iliopectineal line, the anterior rim, and teardrop are landmarks of the anterior column; the ilioischial line and posterior rim are landmarks of the posterior columns.<br> (B) Iliac oblique radiograph of the pelvis. 1, Posterior border of the innominate bone. 2, Anterior rim of the acetabulum, which is seen best on this view. The iliac wing is seen en face, and fracture lines extending into the iliac wing are often best seen on this view. The proper amount of rotation is indicated by the tip of the coccyx lying just above the center of the contralateral femoral head.<br> (C) Obturator oblique radiograph of the pelvis. 1, Iliopectineal line. 2, Posterior rim of the acetabulum. The obturator ring is seen en face, and posterior wall fractures are seen best on this view. The proper amount of rotation is indicated by the tip of the coccyx lying just above the center of the ipsilateral femoral head.</div><div class=\"graphic_reference\">Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69019 Version 15.0</div></div></div>"},"69020":{"type":"graphic_diagnosticimage","displayName":"Volar displaced fx","title":"Displaced volar fracture","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Displaced volar fracture</div><div class=\"cntnt\"><img style=\"width:454px; height:344px;\" src=\"images/EM/69020_Volardisplacedfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reverse bayonet. Panel A) Typical volar bayonet fracture. Often the distal end of the proximal fragment is buttonholed through the extensor tendons (arrows). (Copyright © 1994 American Academy of Orthopaedic Surgeons. Reprinted from Operative Management of Upper Extremity Fractures in Children p.27 with permission.) Panel B) Intact volar periosteum and disrupted dorsal periosteum (arrows). The extensor tendons are displaced to either side of the proximal fragment.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69020 Version 13.0</div></div></div>"},"69022":{"type":"graphic_table","displayName":"Dx Legionella","title":"Diagnostic tests for <EM>Legionella</EM> species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for <EM>Legionella</EM> species</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test characteristic</td> <td class=\"subtitle1\">Culture</td> <td class=\"subtitle1\">Urine antigen</td> </tr> <tr> <td>Strains detected </td> <td>All species and serogroups</td> <td>Detects only <em>L. pneumophila</em> serogroup 1; this accounts for 70 to 80 percent of cases</td> </tr> <tr> <td>Speed to results </td> <td>&#8805;3 days</td> <td>15 minutes with some assays</td> </tr> <tr> <td>Technical demands</td> <td>Difficult - high rates of false negatives </td> <td>Easy - rare false negatives except with strains other than <em>L. pneumophila</em> serogroup 1</td> </tr> <tr> <td>Overall sensitivity </td> <td>&#60;10 to 80 percent</td> <td>70 to 80 percent<sup>[1]</sup></td> </tr> <tr> <td>Overall specificity </td> <td>100 percent</td> <td>&#62;99 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><br /><OL>&#xD;&#xA;<LI>Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol 2003; 41:838.</LI></OL></div><div id=\"graphicVersion\">Graphic 69022 Version 4.0</div></div></div>"},"69023":{"type":"graphic_table","displayName":"Examples of oxytocin infusion protocols","title":"Examples of oxytocin infusion protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of oxytocin infusion protocols</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Starting dose, milliunits/minute</td> <td class=\"subtitle1\">Incremental increase, milliunits/minute</td> <td class=\"subtitle1\">Dosage interval, minutes</td> </tr> <tr> <td>Low-dose</td> <td>0.5 to 1</td> <td>1</td> <td>30 to 40</td> </tr> <tr> <td>Alternative low-dose</td> <td>1 to 2</td> <td>1 to 2</td> <td>15 to 30</td> </tr> <tr> <td rowspan=\"2\">High-dose</td> <td rowspan=\"2\">6</td> <td> <p>6</p> The incremental increase should be reduced to 3 milliunits/minute if hyperstimulation is present, and reduced to 1 milliunit/minute if recurrent hyperstimulation.</td> <td rowspan=\"2\">15 to 40</td> </tr> <tr> <td>Some clinicians limit to a maximum cumulative dose of 10 units and a maximum duration of&nbsp;six hours.</td> </tr> <tr> <td>Alternative high-dose</td> <td>4</td> <td>4</td> <td>15</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Oxytocin should be administered by trained personnel who are familiar with its effects. It should be administered using an infusion pump that provides precise flow rate to ensure accurate minute to minute control. Most clinicians will not administer more than 40 milliunits/minute as the maximum dose.</div><div class=\"graphic_reference\">Sample oxytocin infusion protocols courtesy of author with additional information from ACOG Committee on Practice Bulletins -- Obstetrics, ACOG Practice Bulletin No. 107: Induction of Labor. Obstet Gynecol 2009; 114:386 (reaffirmed 2015).</div><div id=\"graphicVersion\">Graphic 69023 Version 9.0</div></div></div>"},"69024":{"type":"graphic_figure","displayName":"Non-continent cutaneous diversion PI","title":"Non-continent cutaneous diversion","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Non-continent cutaneous diversion</div><div class=\"cntnt\"><img style=\"width:464px; height:653px;\" src=\"images/PI/69024_Non_cont_cutan_diver_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts one option for people who have a cystectomy (removal of the bladder) for bladder cancer. With this procedure, called a non-continent cutaneous diversion or ileoconduit, urine is diverted from the kidneys through a segment of bowel to the skin's surface, where an opening (called a stoma) is created. A bag is attached to the stoma to collect the urine.</div><div id=\"graphicVersion\">Graphic 69024 Version 4.0</div></div></div>"},"69027":{"type":"graphic_picture","displayName":"Large granular lymphocytes","title":"Small lymphocytes versus large granular lymphocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small lymphocytes versus large granular lymphocytes</div><div class=\"cntnt\"><img style=\"width:387px; height:582px;\" src=\"images/HEME/69027_Large_gran_lymphocytes_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distinction between small lymphocytes (A) and large granular lymphocytes (B) on blood smears. The large granular lymphocyte is about twice the size of the red cells and has abundant cytoplasm containing azurophilic granules. Micrographs were viewed with a Leica Leitz DMRB microscope using a 100x/1.30 oil immersion objective. Images were captured with a Sony Exwave HAD camera and manipulated using Tribyn Version 1.3 software.</div><div class=\"graphic_reference\">This research was originally published in Blood. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764. Copyright &#169; 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 69027 Version 3.0</div></div></div>"},"69028":{"type":"graphic_table","displayName":"Additional ITP treatment options","title":"Management options in immune thrombocytopenia (ITP) unresponsive to initial glucocorticoids, splenectomy, and/or rituximab","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management options in immune thrombocytopenia (ITP) unresponsive to initial glucocorticoids, splenectomy, and/or rituximab</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Management</td> <td class=\"subtitle1\">Clinical setting</td> <td class=\"subtitle1\">Outcome</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Observation</strong></td> <td>No bleeding symptoms; platelet count &#8805;20,000/microL</td> <td>The platelet count may remain stable; most patients will be asymptomatic; patients with bleeding symptoms or who are at high risk of bleeding may require treatment.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Thrombopoietin receptor agonists</strong></td> <td>Persistent, symptomatic thrombocytopenia; platelet count &#60;20,000/microL or potential risk for clinically important bleeding</td> <td>The most important indication for these agents is in patients for whom initial and second-line therapies have not resulted in a durable response with a safe platelet count. In most patients, administration of these agents will result in a safe platelet count for as long as the agent is continued.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Observation with supportive care</strong> (eg, short courses of glucocorticoids or IVIG as needed for bleeding symptoms or preparation for procedures; platelet and/or red cell transfusions)</td> <td>Lack of response to treatment with thrombopoietin receptor agonists</td> <td>This may be the option preferred by many patients. Some patients may have minimal or no bleeding in spite of persistent severe thrombocytopenia.</td> </tr> <tr> <td><strong>Immunosuppressive agents or combination therapy</strong>&nbsp;(eg, danazol, azathioprine, cyclosporine, mecophenolate)</td> <td>Persistent thrombocytopenia with bleeding symptoms, platelet count &#60;20,000/microL</td> <td>Goal is only a safe platelet count with control of bleeding.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin.</div><div id=\"graphicVersion\">Graphic 69028 Version 8.0</div></div></div>"},"69029":{"type":"graphic_picture","displayName":"Leukocyte infiltration COPD","title":"Leukocyte infiltration in COPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukocyte infiltration in COPD</div><div class=\"cntnt\"><img style=\"width:447px; height:169px;\" src=\"images/PULM/69029_Leukocyte_infiltration_COPD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph showing leukocyte infiltration in a small airway of a smoker with severe COPD (A); and that of smoker with a mild COPD (B). Immunostaining with monoclonal antibody anti-CD45.&nbsp;Leukocytes are stained in red. Original magnification: X400.</div><div class=\"graphic_reference\">Reproduced with permission from: Turato G, Zuin R Miniati M et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105. Copyright &#169; 2002 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 69029 Version 2.0</div></div></div>"},"69030":{"type":"graphic_picture","displayName":"Thumb spica cast 3","title":"Thumb spica cast: Step 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 3</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/69030_Thumb_spica_cast_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cut a hole in the stockinette for the thumb. Cut the distal part of the stockinette covering the fingers at about the level of the proximal interphalangeal joints.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 69030 Version 5.0</div></div></div>"},"69031":{"type":"graphic_picture","displayName":"Montgomery straps","title":"Montgomery straps","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Montgomery straps</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/SURG/69031_Montgomery_straps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Montgomery straps make it possible to care for a wound without removing adhesive strips with each dressing change.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor CR, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing: The Art And Science Of Nursing Care, Sixth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69031 Version 1.0</div></div></div>"},"69034":{"type":"graphic_picture","displayName":"Defibulation 5","title":"Defibulation (reversal of female genital infibulation)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibulation (reversal of female genital infibulation)</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/69034_Defibulation_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 5: Place (4.0) absorbable subcuticular sutures on each side.</div><div id=\"graphicVersion\">Graphic 69034 Version 2.0</div></div></div>"},"69038":{"type":"graphic_table","displayName":"Fluoride supplementation","title":"Recommended dietary fluoride supplement* schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dietary fluoride supplement* schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"3\">Fluoride concentration in community drinking water</td> </tr> <tr> <td class=\"subtitle2\">&#60;0.3 ppm<sup>&#182;</sup></td> <td class=\"subtitle2\">0.3 to 0.6 ppm</td> <td class=\"subtitle2\">&#62;0.6 ppm</td> </tr> <tr> <td>0 to 6 months</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td>6 months to 3 years</td> <td>0.25 mg/day</td> <td>None</td> <td>None</td> </tr> <tr> <td>3 to 6 years</td> <td>0.5 mg/day</td> <td>0.25 mg/day</td> <td>None</td> </tr> <tr> <td>6 to 16 years</td> <td>1 mg/day</td> <td>0.5 mg/day</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Sodium fluoride (2.2 mg sodium fluoride contains 1 mg fluoride ion).<br />¶ ppm: parts per million; 1 ppm = 1 mg/L.</div><div class=\"graphic_reference\">Reproduced from MMWR Recommendations and Reports 2001; 50:RR-14. Sources: Meskin LH. J Am Dent Assoc 1995; 126 (suppl):1S; American Academy of Pediatric Dentistry. Pediatr Dent 1995; 16 (special issue):1 American Academy of Pediatrics. Pediatrics 1995; 95:777.</div><div id=\"graphicVersion\">Graphic 69038 Version 4.0</div></div></div>"},"69039":{"type":"graphic_picture","displayName":"Spontaneous intestinal perforation","title":"Spontaneous intestinal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous intestinal perforation</div><div class=\"cntnt\"><img style=\"width:299px; height:534px;\" src=\"images/PEDS/69039_SIP.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Brandt, MD.</div><div id=\"graphicVersion\">Graphic 69039 Version 3.0</div></div></div>"},"69040":{"type":"graphic_waveform","displayName":"LVH tutorial","title":"Left ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Left ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:534px; height:230px;\" src=\"images/CARD/69040_LVH_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrocardiogram demonstrates a number of features of left ventricular hypertrophy (LVH). The QRS complex is slightly widened (about 0.11 sec), the frontal plane axis is leftward, tall R waves are present in multiple leads, and ST-T changes (formerly called a \"strain\" pattern) are present. The somewhat prominent P waves also raise consideration of left atrial abnormality. Slow R wave progression (V1-V3) is non-specific and may be seen with LVH, or with multiple other factors. Underlying anteroseptal MI is not excluded.</div><div id=\"graphicVersion\">Graphic 69040 Version 4.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"69041":{"type":"graphic_algorithm","displayName":"Acute abdominal pain in postmenarchal girls","title":"Acute abdominal pain in postmenarchal girls","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Acute abdominal pain in postmenarchal girls</div><div class=\"cntnt\"><img style=\"width:776px; height:1313px;\" src=\"images/EM/69041_Algoacuteabdpainfem.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bold text: Life-threatening conditions.<br />Italic text: Common conditions.</div><div id=\"graphicVersion\">Graphic 69041 Version 6.0</div></div></div>"},"69042":{"type":"graphic_figure","displayName":"Osmotic fragility","title":"The osmotic fragility test in hereditary spherocytosis","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">The osmotic fragility test in hereditary spherocytosis</div><div class=\"cntnt\"><img style=\"width:566px; height:354px;\" src=\"images/HEME/69042_Osmotic_fragility.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows results of an incubated osmotic fragility test performed on red cells from an adult patient with hereditary spherocytosis, showing markedly increased osmotic fragility. Note that the patient's red cells were &gt;60 percent hemolyzed at a saline concentration (0.7 g/dL) that did not cause any osmotic lysis in normal, incubated red cells.</div><div class=\"graphic_reference\">Provided by Dr. Rebecca Connor.</div><div id=\"graphicVersion\">Graphic 69042 Version 2.0</div></div></div>"},"69044":{"type":"graphic_algorithm","displayName":"Approach to patient with ILD","title":"Interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:485px; height:709px;\" src=\"images/PULM/69044_ApproachpatientILDedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PFT: pulmonary function tests; HRCT: high resolution computed tomography; ILD: interstitial lung disease; BAL: bronchoalveolar lavage; UIP: usual interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; PLCH: pulmonary Langerhans cell histiocytosis; TBB: transbronchial lung biopsy.<br />* Serology as indicated by clinical findings: rheumatoid factor, anti-cyclic citrulinated peptide, antinuclear antibody, antisynthetase antibodies, creatine kinase, aldolase, Sjögren's antibodies and scleroderma antibodies.<br />¶ Classic HRCT features of UIP: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Reticular opacities in basal and peripheral distribution.</LI>&#xD;&#xA;<LI>Traction bronchiectasis.</LI>&#xD;&#xA;<LI>Honeycombing (clustered airspaces 3 to 10 mm diameter) in subpleural location.</LI>&#xD;&#xA;<LI>Ground glass opacities may be present but are less extensive than reticular opacities.</LI></OL></div><div class=\"graphic_reference\">Adapted from: Raghu G. Am J Respir Crit Care Med 1995; 151:909.</div><div id=\"graphicVersion\">Graphic 69044 Version 4.0</div></div></div>"},"69045":{"type":"graphic_diagnosticimage","displayName":"LLL atelectasis II","title":"Chronic left lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic left lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:354px; height:360px;\" src=\"images/PULM/69045_LLL_atelectasis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic atelectasis of the left lower lobe due to previous pneumonia. A triangular opacity is faintly visible in the retrocardiac region (arrows). The left hilum is displaced caudad. The residual left lung is hyperlucent. A band of opacity, called the top of the knob sign, is present around the aortic arch (arrowhead); this finding is due to mediastinal shift to the left.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69045 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"69047":{"type":"graphic_table","displayName":"Temperature tissue denaturation","title":"Temperature and tissue denaturation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Temperature and tissue denaturation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Up to 40&ordm;C</td>\n\n      <td>No significant cell damage.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Above 40&ordm;C</td>\n\n      <td>Reversible cell damage, depending on the duration of exposure.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Above 49&ordm;C</td>\n\n      <td>Irreversible cell damage.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Above 70&ordm;C</td>\n\n      <td>Coagulation. Collagen is converted to glucose.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Above 100&ordm;C</td>\n\n      <td>Phase transition from liquid to vapor of the intra- and\nextra-cellular water. The tissue rapidly dries out. Glucose has an\nadhesive effect after dehydration.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Above 200&ordm;C</td>\n\n      <td>Carbonization.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69047 Version 1.0</div></div></div>"},"69048":{"type":"graphic_picture","displayName":"90 90 rest position","title":"90/90 rest position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">90/90 rest position</div><div class=\"cntnt\"><img style=\"width:348px; height:188px;\" src=\"images/ENDO/69048_90_90_rest_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 90/90 rest position for patients with low back pain is achieved by lying on a flat surface and flexing both hips and knees to 90 degrees.</div><div class=\"graphic_reference\">By permission from Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 69048 Version 3.0</div></div></div>"},"69049":{"type":"graphic_figure","displayName":"Diastasis recti","title":"Diastasis recti","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diastasis recti</div><div class=\"cntnt\"><img style=\"width:323px; height:335px;\" src=\"images/SURG/69049_Diastasis_recti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diastasis recti occurs when bowel protrudes through a separation between the two rectus abdominis muscles. It appears as a midline ridge. The bulge may appear only when client raises head or coughs. The condition is of little significance.</div><div class=\"graphic_reference\">Reproduced with permission from: Weber J, Kelley J. Health Assessment in Nursing, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69049 Version 2.0</div></div></div>"},"69052":{"type":"graphic_diagnosticimage","displayName":"CT of a ureteral stone","title":"CT of a ureteral stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of a ureteral stone</div><div class=\"cntnt\"><img style=\"width:366px; height:288px;\" src=\"images/RADIOL/69052_Ureteral_stone_CT_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ureterolithiasis with obstruction. Image of the abdomen from a CT with intravenous contrast shows a stone (arrow) in the proximal left ureter with slight delayed enhancement and mild hydronephrosis of the left kidney. The right kidney is normal with high density contrast excretion in the right ureter (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69052 Version 6.0</div></div></div>"},"69054":{"type":"graphic_algorithm","displayName":"Management of unscheduled bleeding in women using contraception","title":"Management of unscheduled bleeding in women using contraception","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Management of unscheduled bleeding in women using contraception</div><div class=\"cntnt\"><img style=\"width:549px; height:748px;\" src=\"images/OBGYN/69054_Management_unsched_bleed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COCs: combined oral contraceptives; IUD: intrauterine contraceptive device; POPs: progestin only pills; NSAIDs: nonsteroidal anti-inflammatory drugs; EE: ethinyl estradiol.<br>* Not commercially manufactured or not available in the United States.</div><div id=\"graphicVersion\">Graphic 69054 Version 4.0</div></div></div>"},"69055":{"type":"graphic_picture","displayName":"Child with less severe presentation of acute epiglottitis","title":"Child with less severe presentation of acute epiglottitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child with less severe presentation of acute epiglottitis</div><div class=\"cntnt\"><img style=\"width:220px; height:432px;\" src=\"images/EM/69055_Epiglottitis_subtle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although not widely appreciated, epiglottitis caused by <EM>Haemophilus influenzae</EM> type b varies widely along the spectrum of severity. This one-year-old infant appears mildly anxious but looks much less toxic than patients with the \"classic\" presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69055 Version 3.0</div></div></div>"},"69056":{"type":"graphic_figure","displayName":"Hemodynamics with contractions","title":"Hemodynamics with contractions","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Hemodynamics with contractions</div><div class=\"cntnt\"><img style=\"width:479px; height:672px;\" src=\"images/OBGYN/69056_Hemodynamics_with_contracti.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Bonica JJ, McDonald JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2<SUP>nd</SUP> ed, Williams &amp; Wilkins, Baltimore 1994. p.66.</div><div id=\"graphicVersion\">Graphic 69056 Version 4.0</div></div></div>"},"69059":{"type":"graphic_table","displayName":"Caloric needs for children with burns Shriners Burn Institute","title":"Caloric needs for children with burns Shriners Burn Institute","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caloric needs for children with burns Shriners Burn Institute</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Calories (Kcal/day)</td> </tr> <tr> <td>0 to 1</td> <td>2100 Kcal/m<sup>2</sup> plus 1000 Kcal/m<sup>2</sup> burn</td> </tr> <tr> <td>1 to 11</td> <td>1800 Kcal/m<sup>2</sup> plus 1300 Kcal/m<sup>2</sup> burn</td> </tr> <tr> <td>12 to 18</td> <td>1500 Kcal/m<sup>2</sup> plus 1500 Kcal/m<sup>2</sup> burn</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Saffle JR, Graves C, Cochran A. Nutritional support of the burned patient. In: Total Burn Care, 4th ed, Herndon DN (Ed), Saunders Elsevier, Philadelphia 2012. p.335.</div><div id=\"graphicVersion\">Graphic 69059 Version 5.0</div></div></div>"},"69060":{"type":"graphic_figure","displayName":"Meta-regression","title":"Meta-regression of the association between follow-up duration and risk ratio of death in trials of zidovudine monotherapy","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Meta-regression of the association between follow-up duration and risk ratio of death in trials of zidovudine monotherapy</div><div class=\"cntnt\"><img style=\"width:577px; height:430px;\" src=\"images/PC/69060_Meta_regression.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Decrease in the magnitude of the treatment effect with increasing mean duration of follow-up in studies of zidovudine monotherapy. Studies are represented by dots the size of which is proportional to the inverse of the variance of the observed logarithm of the risk ratio. The depicted regression line is weighted by the inverse of the variance.</div><div class=\"graphic_reference\">Reproduced from: Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials 1997; 18:431. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69060 Version 1.0</div></div></div>"},"69061":{"type":"graphic_picture","displayName":"Malrotation due to metacarpal fracture","title":"Malrotation due to metacarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malrotation due to metacarpal fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/SURG/69061_Malrotation_metacarpal_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abnormal orientation of the fingernails shown here demonstrates rotational deformity because of a metacarpal fracture. Normally, all fingers are directed toward the scaphoid and there should be no overlap or rotation.</div><div id=\"graphicVersion\">Graphic 69061 Version 4.0</div></div></div>"},"69062":{"type":"graphic_figure","displayName":"Mobilization of left colon from lateral peritoneal attachments","title":"Mobilization of left colon from lateral peritoneal attachments","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Mobilization of left colon from lateral peritoneal attachments</div><div class=\"cntnt\"><img style=\"width:463px; height:626px;\" src=\"images/SURG/69062_Mobilization-left-colon-lateral-edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69062 Version 2.0</div></div></div>"},"69063":{"type":"graphic_table","displayName":"Acromioclavicular injury grading","title":"Acromioclavicular injury classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acromioclavicular injury classification</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle2_left\">\tType I</td><td>Acromioclavicular (AC) ligament sprain; AC joint intact</td></tr>\n\n<tr>\n<td class=\"subtitle2_left\">\tType II</td><td>Acromioclavicular ligament torn, coracoclavicular (CC) ligament intact; AC joint subluxed</td></tr>\n\t<tr>\n\t<td class=\"subtitle2_left\">\tType III</td><td>AC and CC ligaments torn; complete dislocation of the joint</td></tr>\n\t\t<tr>\n\t\t<td class=\"subtitle2_left\">\tType IV</td><td>Complete dislocation with posterior displacement of distal clavicle into or through trapezius muscle</td></tr>\n\t\t\t<tr>\n\t\t\t<td class=\"subtitle2_left\">\tType V</td><td>Superior dislocation of the joint of one to three times the normal spacing, increasing the CC ligament distance two to three times normal; disruption of the deltotrapezial fascia</td></tr>\n\t\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2_left\">\tType VI</td><td>Complete dislocation with inferior displacement of distal clavicle into a subacromial or subcoracoid position\n</td>\n\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69063 Version 2.0</div></div></div>"},"69064":{"type":"graphic_figure","displayName":"Fibrous dysplasia sites","title":"Skeletal distribution of fibrous dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal distribution of fibrous dysplasia</div><div class=\"cntnt\"><img style=\"width:247px; height:605px;\" src=\"images/PEDS/69064_Fibrous_dysplasia_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69064 Version 2.0</div></div></div>"},"69067":{"type":"graphic_table","displayName":"Lumber mill antigens in HP","title":"Hypersensitivity pneumonitides associated with milling and construction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with milling and construction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Environmental source</td>\n\n      <td class=\"subtitle1\">Major causative antigen</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Wood dust pneumonitis (oak, cedar, and mahogany dust, pine and spruce pulp) </td>\n\n      <td>Alternaria sp</td>\n\n    </tr>\n\n    <tr>\n      <td>Bacillus subtilis</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Sequoiosis (moldy wood dust)</td>\n\n      <td>Graphium</td>\n\n    </tr>\n\n    <tr>\n      <td>Pullularia</td>\n    </tr>\n    <tr>\n      <td>Trichoderma sp.</td>\n    </tr>\n    <tr>\n      <td>Aureobasidium pullulans</td>\n    </tr>\n    <tr>\n\n      <td>Maple bark disease (moldy maple bark) </td>\n\n      <td>Cryptostroma corticale</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wood trimmer's disease (contaminated wood trimmings)</td>\n\n      <td>Rhizopus sp, Mucor sp</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wood pulp worker's disease (oak and maple trees)</td>\n\n      <td>Penicillium sp</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Suberosis (moldy cork dust) </td>\n\n      <td>T. viridis</td>\n\n    </tr>\n\n    <tr>\n      <td>Penicillium glabrum</td>\n    </tr>\n    <tr>\n      <td>Conidia</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Composter's lung</td>\n\n      <td>T. vulgaris</td>\n\n    </tr>\n\n    <tr>\n      <td>Aspergillus</td>\n    </tr>\n    <tr>\n\n      <td>Dry rot lung</td>\n\n      <td>Merulius lacrymans</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thatched-roof lung (huts in New Guinea)</td>\n\n      <td>Saccharomonospora viridis (dead grasses and leaves)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Esparto dust (\"Stipatosis\"; Stipa tesnacissima is a grass of the graminea family)</td>\n\n      <td>Aspergillus fumigatus</td>\n\n    </tr>\n    <tr>\n      <td>T. actinomycetes</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69067 Version 1.0</div></div></div>"},"69071":{"type":"graphic_table","displayName":"Criteria for prophylaxis","title":"Criteria for antibiotic prophylaxis against Lyme disease following a tick bite","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for antibiotic prophylaxis against Lyme disease following a tick bite</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Antibiotic prophylaxis should be used only in patients who meet ALL of the following criteria*:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Attached tick identified as an adult or nymphal Ixodes scapularis tick (deer tick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tick is estimated to have been attached for &#8805;36 hours (by degree of engorgement or time of exposure)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Prophylaxis is begun within 72 hours of tick removal</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Local rate of infection of ticks with B. burgdorferi is &#8805;20 percent (these rates of infection have been shown to occur in parts of New England, parts of the mid-Atlantic States, and parts of Minnesota and Wisconsin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Doxycycline is not contraindicated (ie, the patient is not &#60;8 years of age, pregnant, or lactating)</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* If the patient meets ALL of these criteria, the recommended dose of doxycycline is 200 mg for adults and 4 mg/kg up to a maximum dose of 200 mg in children &#8805;8 years, given as a single dose. This regimen has never been tested in children; this recommendation is extrapolated from experience in adults.</div><div class=\"graphic_reference\">Wormser, GP, Dattwyler, RJ, Shapiro, ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.</div><div id=\"graphicVersion\">Graphic 69071 Version 1.0</div></div></div>"},"69072":{"type":"graphic_picture","displayName":"R parkeri eschar and rash","title":"R parkeri eschar and rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">R parkeri eschar and rash</div><div class=\"cntnt\"><img style=\"width:269px; height:439px;\" src=\"images/ID/69072_R_parkeri_eschar_and_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Paddock, CD, Finley, RW, Wright, CS, et al. Rickettsia parkeri Rickettsiosis and Its Clinical Distinction from Rocky Mountain Spotted Fever. Clin Infect Dis 2008; 47:1188. Copyright &#169;2008 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 69072 Version 1.0</div></div></div>"},"69073":{"type":"graphic_diagnosticimage","displayName":"MRI optic neuritis","title":"Optic neuritis MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic neuritis MRI</div><div class=\"cntnt\"><img style=\"width:288px; height:403px;\" src=\"images/NEURO/69073_MRI_optic_neuritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of the brain demonstrates abnormal enhancement of the left optic nerve (arrow), consistent with optic neuritis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 69073 Version 3.0</div></div></div>"},"69074":{"type":"graphic_table","displayName":"Classification of tremors","title":"Classification of tremors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of tremors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Rest tremors </td> </tr> <tr> <td>Parkinson disease</td> </tr> <tr> <td>Other parkinsonian syndromes (less commonly)</td> </tr> <tr> <td>Midbrain (\"rubral\") tremor: rest &#60; postural &#60; kinetic</td> </tr> <tr> <td>Wilson disease (also acquired hepatocerebral degeneration)</td> </tr> <tr> <td>Essential tremor - only if severe: rest &#60; &#60; postural &#38; action</td> </tr> <tr> <td class=\"subtitle1_single\">Postural and action (\"terminal\") tremors </td> </tr> <tr> <td>Physiological tremor</td> </tr> <tr> <td class=\"sublist1_start\">Exaggerated physiological tremor (these factors can also aggravate other forms of tremor) </td> </tr> <tr> <td class=\"sublist1\">Stress, fatigue, anxiety, emotion </td> </tr> <tr> <td class=\"sublist1\">Endocrine: Hypoglycemia, thyrotoxicosis, pheochromocytoma, adrenocorticosteroids </td> </tr> <tr> <td class=\"sublist1\">Drugs and toxins: Beta agonists, dopamine agonists, amphetamines, lithium, tricyclic antidepressants, neuroleptics, theophylline, caffeine, valproic acid, alcohol withdrawal, mercury (\"Hatter's shakes\"), lead, arsenic, others </td> </tr> <tr> <td>Essential tremor (familiar or sporadic)</td> </tr> <tr> <td>Primary writing tremor</td> </tr> <tr> <td class=\"sublist1_start\">With other CNS disorders </td> </tr> <tr> <td class=\"sublist1\">Parkinson disease </td> </tr> <tr> <td class=\"sublist1\">Other akinetic-rigid syndromes </td> </tr> <tr> <td class=\"sublist1\">Idiopathic dystonia, including focal dystonias </td> </tr> <tr> <td class=\"sublist1_start\">With peripheral neuropathy </td> </tr> <tr> <td class=\"sublist1\">Charcot-Marie-Tooth (controversial as to whether to call this the Roussy-Levy syndrome) </td> </tr> <tr> <td class=\"sublist1\">Variety of other peripheral neuropathies (especially dysgammaglobulinemia) </td> </tr> <tr> <td>Cerebellar tremor</td> </tr> <tr> <td class=\"subtitle1_single\">Kinetic (intention) tremor </td> </tr> <tr> <td>Disease of cerebellar \"outflow\" (dentate nucleus and superior cerebellar peduncle): Multiple sclerosis, trauma, tumour, vascular, Wilson disease, acquired hepatocerebral degeneration, drugs, toxins (eg, mercury), others </td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous rhythmical movement disorders </td> </tr> <tr> <td>Psychogenic tremor</td> </tr> <tr> <td>Orthostatic tremor</td> </tr> <tr> <td>Rhythmical movements in dystonia (dystonic tremor)</td> </tr> <tr> <td>Rhythmical myoclonus (segmental myoclonus - eg, palatal or branchial myoclonus, spinal myoclonus, limb myorhythmia)</td> </tr> <tr> <td>Oscillatory myoclonus</td> </tr> <tr> <td>Asterixis</td> </tr> <tr> <td>Clonus</td> </tr> <tr> <td>Epilepsia partialis continua</td> </tr> <tr> <td>Hereditary chin quivering</td> </tr> <tr> <td>Spasmus nutans</td> </tr> <tr> <td>Head bobbing with 3rd ventricular cysts</td> </tr> <tr> <td>Nystagmus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Jankovic, J, Lang, AE. Classification of movement disorders. In: Germano, IM, (Ed), Surgical Treatment of Movement Disorders, The American Association of Neurological Surgeons (AANS), Lebanon, NH, 1998. p. 3.</div><div id=\"graphicVersion\">Graphic 69074 Version 2.0</div></div></div>"},"69076":{"type":"graphic_waveform","displayName":"Advanced case 14","title":"Advanced case 14","html":"<div class=\"graphic normal\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Advanced case 14</div><div class=\"cntnt\"><img style=\"width:463px; height:379px;\" src=\"images/CARD/69076_Advanced_case_14.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69076 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"69077":{"type":"graphic_diagnosticimage","displayName":"Vascular malformation 9de","title":"Right and left uterine angiograms","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Right and left uterine angiograms</div><div class=\"cntnt\"><img style=\"width:504px; height:275px;\" src=\"images/OBGYN/69077_Vascular_malformation_9de.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right (A) and left (B) uterine angiograms before uterine artery embolization shows increased vascularity and an arteriovenous malformation (arrow in A) in the uterus with dilated uterine arteries (arrow in B).</div><div id=\"graphicVersion\">Graphic 69077 Version 3.0</div></div></div>"},"69078":{"type":"graphic_figure","displayName":"Anatomy AV accessory pathways","title":"Accessory pathways with preexcitation syndromes","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Accessory pathways with preexcitation syndromes</div><div class=\"cntnt\"><img style=\"width:457px; height:360px;\" src=\"images/CARD/69078_Anatomy_AV_accessory_pathwa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A number of atrioventricular (AV) accessory pathways resulting in preexcitation syndromes have been identified. The muscular AV fiber (AVF), which is also called the Kent bundle, traverses the AV annulus and is responsible for most cases of Wolff-Parkinson-White syndrome. Proposed pathways responsible for the Lown-Ganong-Levine syndrome or enhanced AV nodal conduction include an intranodal bypass tract (INBT) and atrionodal tracts (ANT), also known as James fibers. Traditionally, the etiology for a Mahaim fiber tachycardia was thought to result from a nodoventricular (NVF) and fasciculoventricular (FVF) fiber. However, the true etiology is likely an atriofascicular fiber (AFF) that arises from the right atrium close to the annulus, inserting into the apical part of the right ventricle close to a fascicular branch of the right bundle branch.</div><div id=\"graphicVersion\">Graphic 69078 Version 1.0</div></div></div>"},"69079":{"type":"graphic_figure","displayName":"Cardiac cycle","title":"The cardiac cycle and cardiac conduction system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The cardiac cycle and cardiac conduction system</div><div class=\"cntnt\"><img style=\"width:343px; height:680px;\" src=\"images/EM/69079_Cardiaccycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrical impulse is initiated in the sinus node and then activates the right and left atria, generating the P wave. Impulse conduction through the atrioventricular (AV) node and bundle of His, which are small structures, does not generate any ECG activity; this period of &quot;electrical silence&quot; is the PR interval. The first part of the ventricle to be depolarized is the left side of the interventricular septum, producing a small septal Q wave, followed by depolarization of the remainder of the ventricular myocardium, generating the full QRS complex. The T wave represents ventricular repolarization.</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69079 Version 10.0</div></div></div>"},"69080":{"type":"graphic_figure","displayName":"Fracture classification two","title":"Fracture classification: Part two","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Fracture classification: Part two</div><div class=\"cntnt\"><img style=\"width:509px; height:677px;\" src=\"images/EM/69080_Fracture_patterns_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Johnson, TR, Steinbach, LS (Eds): Essentials of Musculoskeletal imaging. Rosemonst, IL, American Academy of Orthopaedic Surgeons, 2004, p. 40-41. Copyright ©2004 American Academy of Orthopaedic Surgeons.</div><div id=\"graphicVersion\">Graphic 69080 Version 2.0</div></div></div>"},"69081":{"type":"graphic_picture","displayName":"Spaso technique for shoulder reduction","title":"Spaso technique for shoulder reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spaso technique for shoulder reduction</div><div class=\"cntnt\"><img style=\"width:360px; height:485px;\" src=\"images/EM/69081_Spaso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm is flexed forward and gentle traction and external rotation forces are applied.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 69081 Version 6.0</div></div></div>"},"69084":{"type":"graphic_diagnosticimage","displayName":"Bleeding tumor a","title":"Angiogram of the left cervicovaginal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiogram of the left cervicovaginal artery</div><div class=\"cntnt\"><img style=\"width:331px; height:494px;\" src=\"images/OBGYN/69084_Bleeding_tumor_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram of the left cervicovaginal artery on a 55-year-old woman with chronic vaginal bleeding due to cervical cancer shows moderate tumor staining and neovascularity in the region of cervix.</div><div id=\"graphicVersion\">Graphic 69084 Version 2.0</div></div></div>"},"69085":{"type":"graphic_figure","displayName":"Lung injury positive pressure","title":"Lung injury with positive pressure and high volume ventilation","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Lung injury with positive pressure and high volume ventilation</div><div class=\"cntnt\"><img style=\"width:557px; height:264px;\" src=\"images/PULM/69085_Lung_injury_positive_pressu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effects of various modalities of positive pressure ventilation in rats. Extravascular lung water (Qwl), dry lung weight, and albumin space are indicative of the development of lung injury. These abnormalities were induced in rats ventilated with high pressure and high tidal volume (HiP-HiV), low pressure and high volume (LoP-HiV), but not in those ventilated with high pressure and low volume (HiP-LoV). The HiP-HiV and LoP-HiV were always different from controls (p &lt;0.0001). Thus, ventilator-induced lung injury in this rat model appears to be more a function of high tidal volume than of high airway pressure.</div><div class=\"graphic_reference\">Redrawn from Dreyfuss, D, Soler, P, Bassett, G, Saumon, G, Am Rev Respir Dis 1988; 137:1159.</div><div id=\"graphicVersion\">Graphic 69085 Version 1.0</div></div></div>"},"69086":{"type":"graphic_table","displayName":"Confirmed targets autoantibodies T1 DM","title":"Confirmed targets of autoantibodies in type 1 diabetes of man","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Confirmed targets of autoantibodies in type 1 diabetes of man</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Insulin</td> </tr> <tr> <td>Glutamic acid decarboxylase</td> </tr> <tr> <td>Insulinoma associated antigens 2 (alpha and beta)</td> </tr> <tr> <td>ZnT8 (zinc transporter)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69086 Version 1.0</div></div></div>"},"69088":{"type":"graphic_table","displayName":"Cluster for aeroallergen SCIT","title":"Aeroallergen subcutaneous immunotherapy (SCIT) - Example of a cluster protocol ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT) - Example of a cluster protocol </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Visit number</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Color vial</td> </tr> <tr> <td rowspan=\"3\">1</td> <td>0.1</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>0.40</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>0.1</td> <td>1:100</td> <td>Blue</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">2</td> <td>0.20</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>0.40</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>0.07</td> <td>1:10</td> <td>Yellow</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">3</td> <td>0.10</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.15</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.25</td> <td>1:10</td> <td>Yellow</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">4</td> <td>0.35</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.5</td> <td>1:10</td> <td>Yellow</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">5</td> <td>0.07</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>0.10</td> <td>1:1</td> <td>Red</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">6</td> <td>0.15</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>0.20</td> <td>1:1</td> <td>Red</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">7</td> <td>0.30</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>0.40</td> <td>1:1</td> <td>Red</td> </tr> <tr class=\"divider_top\"> <td>8</td> <td>0.50</td> <td>1:1</td> <td>Red</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Example of a cluster allergen immunotherapy protocol: Injections are given 30 minutes apart, provided the patient does not experience a systemic allergic reaction. Visits are&nbsp;ideally on nonconsecutive days of the week.</div><div id=\"graphicVersion\">Graphic 69088 Version 4.0</div></div></div>"},"69089":{"type":"graphic_table","displayName":"WAS disease severity scoring system","title":"Disease severity scoring system for disorders associated with WAS mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease severity scoring system for disorders associated with WAS mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"7\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">XLN</td> <td class=\"subtitle1\">iXLT</td> <td class=\"subtitle1\" colspan=\"2\">XLT</td> <td class=\"subtitle1\" colspan=\"3\">Classic WAS</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">&#60;1</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> <td class=\"subtitle2\">5</td> </tr> <tr> <td>Thrombocytopenia</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Small platelets</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Eczema</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">(+)</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/(+)/+/++</td> </tr> <tr> <td>Immunodeficiency</td> <td class=\"centered\">&ndash;/(+)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/(+)</td> <td class=\"centered\">(+)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/(+)/+/++</td> </tr> <tr> <td>Infections</td> <td class=\"centered\">&ndash;/(+)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">(+)</td> <td class=\"centered\">+</td> <td class=\"centered\">+/++</td> <td class=\"centered\">&ndash;/(+)/+/++</td> </tr> <tr> <td>Autoimmunity and/or malignancy</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Congenital neutropenia</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Myelodysplasia</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Scoring system:</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>–: Absent</LI>&#xD;&#xA;<LI>–/+: Intermittent (thrombocytopenia) or may/may not be present (myelodysplasia)</LI>&#xD;&#xA;<LI>(+): Mild (eczema, immunodeficiency, infections)</LI>&#xD;&#xA;<LI>+: Moderate (eczema, immunodeficiency, infections) or finding present (thrombocytopenia, small platelets, autoimmunity, malignancy, congenital neutropenia)</LI>&#xD;&#xA;<LI>++: Severe​</LI></UL>Myelodysplasia may be present in XLN.<br />Thrombocytopenia in iXLT is intermittent.<br />Eczema can be mild and transient, persistent but therapy responsive, or severe and difficult to control.<br />Infections can be infrequent and not resulting in sequelae, recurrent and requiring treatment with antibiotics and possibly intravenous immune globulin prophylaxis, or severe and life threatening.</div><div class=\"graphic_footnotes\">WAS: Wiskott-Aldrich syndrome; XLN: X-linked neutropenia; iXLT: intermittent X-linked thrombocytopenia; XLT: X-linked thrombocytopenia.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Stiehm ER, Ochs HD, Winkelstein JA, Rich E (Eds). Immunologic disorders in infants and children, 5th ed. Philadelphia: Saunders, 2004. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69089 Version 9.0</div></div></div>"},"69090":{"type":"graphic_picture","displayName":"Diagnostic Reed-Sternberg cell","title":"Diagnostic Reed-Sternberg cell in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Diagnostic Reed-Sternberg cell in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:503px; height:756px;\" src=\"images/HEME/69090_DiagReedSterncell3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diagnostic Reed-Sternberg cell is seen in the center, and many mononucleated and multinucleated Reed-Sternberg variants are seen throughout the field.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69090 Version 8.0</div></div></div>"},"69094":{"type":"graphic_figure","displayName":"Felon cross section","title":"Cross section of felon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross section of felon</div><div class=\"cntnt\"><img style=\"width:360px; height:251px;\" src=\"images/PC/69094_Felon_cross_section.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fingertip pulp contains compartments of eccrine sweat glands and fat globules separated by fibrous septae. An abscess within these compartments is a felon. The locations of the neurovascular bundles are shown; these areas should be avoided when incision and drainage are performed.</div><div class=\"graphic_reference\">Adapted from Clark DC. Common acute hand infections. Am Fam Physician 2003; 68:2167.</div><div id=\"graphicVersion\">Graphic 69094 Version 3.0</div></div></div>"},"69096":{"type":"graphic_table","displayName":"Antibiotic prophylaxis derm surgery","title":"Antibiotic prophylaxis in dermatologic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic prophylaxis in dermatologic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Situation</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Regimen: single dose 30 to 60 min before procedure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Prevention of surgical site infection</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Surgery involving lips, ear, or nose</td> <td>Cephalexin</td> <td>2 g</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>600 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Azithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clarithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Surgery involving groin or lower extremities</td> <td>Cephalexin</td> <td>2 g</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> <td>160 mg trimethoprim/800 mg sulfamethoxazole</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Levofloxacin</td> <td>500 mg</td> </tr> <tr> <td class=\"indent1\">Any site, increased risk of MRSA infection</td> <td>Clindamycin</td> <td>600 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Prevention of infective endocarditis or hematogenous total joint infection</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Surgery involving the oral mucosa</td> <td>Amoxicillin</td> <td>2 g</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>600 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Azithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clarithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Surgery involving non-oral sites</td> <td>Cephalexin</td> <td>2 g</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>600 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Azithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clarithromycin</td> <td>500 mg</td> </tr> <tr> <td class=\"indent1\">Any site, increased risk of MRSA infection</td> <td>Clindamycin</td> <td>600 mg</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=98348&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">MRSA: methicillin resistant <EM>Staphylococcus aureus</EM>.</div><div id=\"graphicVersion\">Graphic 69096 Version 2.0</div></div></div>"},"69097":{"type":"graphic_figure","displayName":"Anatomy of the volar aspect of the wrist","title":"Anatomy of the volar aspect of the wrist","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Anatomy of the volar aspect of the wrist</div><div class=\"cntnt\"><img style=\"width:530px; height:601px;\" src=\"images/EM/69097_Anatomy_wrist_volar.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69097 Version 3.0</div></div></div>"},"69098":{"type":"graphic_table","displayName":"Treatment of acute episodes of HAE","title":"Treatment of acute episodes of hereditary angioedema (HAE)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acute episodes of hereditary angioedema (HAE)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Laryngeal attack</td> <td class=\"subtitle1\" rowspan=\"2\">Abdominal attack</td> <td class=\"subtitle1\" colspan=\"2\">Cutaneous attack</td> </tr> <tr> <td class=\"subtitle2\">Extremities, trunk</td> <td class=\"subtitle2\">Face, neck</td> </tr> <tr> <td><strong>C1INH concentrate (plasma-derived or recombinant)</strong></td> <td>Yes</td> <td>Yes</td> <td>Usually not needed</td> <td>Yes</td> </tr> <tr> <td><strong>Ecallantide (United States only)</strong></td> <td>Yes</td> <td>Yes</td> <td>Usually not needed</td> <td>Yes</td> </tr> <tr> <td><strong>Icatibant</strong></td> <td>Yes</td> <td>Yes</td> <td>Usually not needed</td> <td>Yes</td> </tr> <tr> <td><strong>Plasma (solvent/detergent-treated or fresh frozen)</strong></td> <td>Yes</td> <td>Yes if severe</td> <td>Usually not needed</td> <td>Yes if near upper airway</td> </tr> <tr> <td><strong>Intubation*, transfer to ICU, rarely emergent tracheotomy</strong></td> <td>Yes (consider early intubation if above agents are not available)</td> <td>Not appropriate</td> <td>Not appropriate</td> <td>May be necessary if attack spreads to involve upper airway</td> </tr> <tr> <td><strong>Wait and see (spontaneous resolution)</strong></td> <td>Not sufficient</td> <td>Acceptable if others not available</td> <td>Acceptable</td> <td>Not sufficient (because angioedema can spread to involve airway)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All acute attacks should be treated as early as possible, at first sign of prodromal symptoms and before the attack becomes fully established.</div><div class=\"graphic_footnotes\">C1INH: C1 inhibitor; ICU: intensive care unit.<br />* Consider intubation early in setting of progressive laryngeal edema or if C1 inhibitor preparations, ecallantide, or icatibant are not available.</div><div class=\"graphic_reference\">Modified with permission from: Bowen T, Cicardi M, Farkas H, et al. 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Allergy, Asthma, and Clinical Immunology; 2010; 6:24. Copyright &copy; 2010 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 69098 Version 19.0</div></div></div>"},"69099":{"type":"graphic_picture","displayName":"IDUS catheter","title":"Intraductal ultrasound catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound catheter</div><div class=\"cntnt\"><img style=\"width:436px; height:288px;\" src=\"images/GAST/69099_IDUS_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraductal ultrasound catheter positioned over a guidewire seen at the tip of an duodenoscope.</div><div class=\"graphic_reference\">Courtesy of Micheal J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 69099 Version 2.0</div></div></div>"},"69100":{"type":"graphic_figure","displayName":"Clamping cardinal ligament","title":"Clamp placement across cardinal ligament during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Clamp placement across cardinal ligament during hysterectomy</div><div class=\"cntnt\"><img style=\"width:495px; height:515px;\" src=\"images/OBGYN/69100_Clamping_cardinal_ligament.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69100 Version 2.0</div></div></div>"},"69101":{"type":"graphic_figure","displayName":"Insertion inflatoball pessary","title":"Inflatoball vaginal pessary in position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflatoball vaginal pessary in position</div><div class=\"cntnt\"><img style=\"width:340px; height:324px;\" src=\"images/OBGYN/69101_Insertion_inflatoball_pessa.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 69101 Version 2.0</div></div></div>"},"69103":{"type":"graphic_diagnosticimage","displayName":"Hydroureter","title":"Hydroureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydroureter</div><div class=\"cntnt\"><img style=\"width:364px; height:315px;\" src=\"images/NEPH/69103_Hydroureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram showing dilated calyces and a dilated ureter.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 69103 Version 2.0</div></div></div>"},"69104":{"type":"graphic_table","displayName":"Chemo dose modify liver disease","title":"Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Bilirubin</td> <td class=\"subtitle1\">Aminotransferases</td> <td class=\"subtitle1\">Percent dose administered</td> <td class=\"subtitle1\">Ref</td> </tr> <tr class=\"divider_bottom\"> <td>Abemaciclib</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bortezomib</td> <td>&#62;1.5 x ULN</td> <td>&nbsp;</td> <td>Reduced starting dose&nbsp;to 0.7 mg/m<sup>2</sup></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cyclophosphamide</td> <td>3.1 to 5 mg/dL</td> <td>AST &#8805;180 IU/L</td> <td>75%</td> <td class=\"centered divider_bottom\" rowspan=\"2\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5 mg/dL</td> <td>&nbsp;</td> <td>0%</td> </tr> <tr class=\"divider_bottom\"> <td>Cabazitaxel</td> <td>&#62;ULN</td> <td>AST/ALT &#8805;1.5 x ULN</td> <td>0%</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Cytarabine</td> <td>&nbsp;</td> <td>Any</td> <td>50%; subsequent increase by monitoring toxicity</td> <td class=\"centered\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>Dactinomycin</td> <td>&nbsp;</td> <td>Any</td> <td>50%; subsequent increase by monitoring toxicity</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Daunorubicin</td> <td>1.2 to 3 mg/dL</td> <td>&nbsp;</td> <td>75%</td> <td class=\"centered divider_bottom\" rowspan=\"3\">[1]</td> </tr> <tr> <td>3 to 5 mg/dL</td> <td>&nbsp;</td> <td>50%</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5 mg/dL</td> <td>&nbsp;</td> <td>0%</td> </tr> <tr class=\"divider_bottom\"> <td>Docetaxel</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Doxorubicin</td> <td>1.2 to 3 mg/dL</td> <td>ALT or AST &#62;3 x ULN</td> <td>50%</td> <td class=\"centered divider_bottom\" rowspan=\"3\">[1]</td> </tr> <tr> <td>3 to 5 mg/dL</td> <td>&nbsp;</td> <td>25%</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5 mg/dL</td> <td>&nbsp;</td> <td>0%</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Epirubicin</td> <td>1.2 to 3 mg/dL</td> <td>2 to 4 x ULN</td> <td>75%</td> <td class=\"centered divider_bottom\" rowspan=\"2\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;3 mg/dL</td> <td>&#62;4 x ULN</td> <td>50%</td> </tr> <tr class=\"divider_bottom\"> <td>Eribulin</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>1.5 to 3 mg/dL</td> <td>AST &#62;3 x ULN</td> <td>50%</td> <td class=\"centered\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil</td> <td>&#62;5 mg/dL</td> <td>&nbsp;</td> <td>0%</td> <td class=\"centered\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>&#62;1.6 mg/dL</td> <td>&nbsp;</td> <td>80%<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Ifosfamide</td> <td>&#62;3 mg/dL</td> <td>&nbsp;</td> <td>75%</td> <td class=\"centered\">[1,2]</td> </tr> <tr class=\"divider_bottom\"> <td>Irinotecan</td> <td>1.5 to 3 mg/dL</td> <td>&nbsp;</td> <td>75%</td> <td class=\"centered\">[1]</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Ixabepilone monotherapy</td> <td>&#8804;1 x ULN</td> <td>AST and ALT &#8804;2.5 x ULN</td> <td>Initial dose (40 mg/m<sup>2</sup>)</td> <td class=\"centered divider_bottom\" rowspan=\"4\">&nbsp;</td> </tr> <tr> <td>&#8804;1 x ULN</td> <td>AST and ALT &#8804;10 x ULN</td> <td>Initial dose (32 mg/m<sup>2</sup>)</td> </tr> <tr> <td>&#62;1.5 x ULN to &#8804;3 x ULN</td> <td>AST and ALT &#8804;10 x ULN</td> <td>Initial dose (20 to 30 mg/m<sup>2</sup>)</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;3 x ULN</td> <td>&#62;10 x ULN</td> <td>Not recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Ixabepilone plus capecitabine</td> <td>&#8805;2.5 x ULN</td> <td>Above ULN</td> <td>Omit</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Ixazomib</td> <td>&#62;1.5 x ULN&nbsp;</td> <td>&nbsp;</td> <td>Reduce starting dose to 3 mg</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Palbociclib</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Panobinostat</td> <td> <p>&#8805;1 x ULN</p> </td> <td> <p>AST &#62;1 x ULN</p> </td> <td> <p>75%</p> </td> <td class=\"centered divider_bottom\" rowspan=\"4\">&nbsp;</td> </tr> <tr> <td>&#62;1 to 1.5 x ULN</td> <td>Any</td> <td>75%</td> </tr> <tr> <td>&#62;1.5 to 3 x ULN</td> <td>Any</td> <td>50%</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;3 x ULN</td> <td>&nbsp;</td> <td>Not recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Pomalidomide&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Procarbazine</td> <td>&#62;5 mg/dL</td> <td>ALT or AST &#62;3 x ULN</td> <td>0%</td> <td class=\"centered\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>Ribociclib</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>See text</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Vincristine, vinblastine</td> <td>&#62;3 mg/dL</td> <td>&nbsp;</td> <td>50%</td> <td class=\"centered\">[3]</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Vinorelbine</td> <td>2.1 to 3 mg/dL</td> <td>&nbsp;</td> <td>50%</td> <td class=\"centered divider_bottom\" rowspan=\"2\">[1]</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;3 mg/dL</td> <td>&nbsp;</td> <td>25%</td> </tr> <tr> <td rowspan=\"2\">Vorinostat</td> <td>&#62;1 to 3 x ULN</td> <td>&nbsp;</td> <td>Reduce initial dose<sup>&#916;</sup></td> <td class=\"centered\" rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>&#62;3 x ULN</td> <td>&nbsp;</td> <td>Not recommended</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ULN: upper limit of normal; AST: aspartate aminotransferase; IU: international units; ALT: alanine aminotransferase.<br />* Not an inclusive list.<br />¶ Controversial. Supported by some studies<SUP>[4]</SUP>, but not others<SUP>[5]</SUP>.<br />Δ US Food and Drug Administration (FDA) guidelines; Canadian guidelines recommend avoiding the drug for total bilirubin ≥1.5 x ULN.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50. </LI>&#xD;&#xA;<LI>Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337. </LI>&#xD;&#xA;<LI>Desai ZR, Van den Berg HW,&nbsp;Bridges JM,&nbsp;Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8:211.</LI>&#xD;&#xA;<LI>Venook A, Egorin MJ, Rosner GL, et al.&nbsp;Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780</LI>&#xD;&#xA;<LI>Teusink A, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44:750</LI></OL></div><div id=\"graphicVersion\">Graphic 69104 Version 24.0</div></div></div>"},"69105":{"type":"graphic_figure","displayName":"Shh Gli pathway medulloblastoma","title":"The Shh-Gli pathway and potential sites for blocking it with therapeutic agents","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">The Shh-Gli pathway and potential sites for blocking it with therapeutic agents</div><div class=\"cntnt\"><img style=\"width:461px; height:429px;\" src=\"images/ONC/69105_Shh_Gli_pathway_medulloblas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonic hedgehog (Shh) acts on the membrane receptor complex formed by Patched (Ptc) and Smoothened (Smo) to inhibit the repression of Smo by Ptc. Smo is then thought to send the signal intracellularly through several cytoplasmic transduction steps (not shown), leading to the nuclear action of the Gli proteins, which regulate target genes. Thick blue arrows pointing up or down indicate activating or inactivating mutations, respectively, that might induce the pathway. Inhibitors of the the pathway with potential therapeutic value (red lines) include: agents that block the action of Smo in the receptor complex, such as the plant alkaloid cyclopamine; agents that inhibit specific aspects of the transduction of the signal, including the nuclear import or activation of Gli proteins; and agents that specifically inhibit Gli function.</div><div class=\"graphic_reference\">Reproduced with permission from: Ruiz i Altaba A, Sanchez P Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002; 2:361. Copyright © 2002 Nature Publishing Group.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 69105 Version 3.0</div></div></div>"},"69106":{"type":"graphic_diagnosticimage","displayName":"SVC stents","title":"Superior vena cava stenting for SVC syndrome","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Superior vena cava stenting for SVC syndrome</div><div class=\"cntnt\"><img style=\"width:519px; height:369px;\" src=\"images/ONC/69106_SVC_stents.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The venogram shows tight stenosis of the superior vena cava (SVC) (arrow). Flow in the markedly dilated azygos vein is reversed (arrowhead) due to obstruction of the SVC.<br />(B) Venogram after stent placement: there is good flow in the SVC within the stent (between the arrows), and the azygos vein is no longer opacified due to normalization of flow towards the SVC.</div><div class=\"graphic_reference\">Courtesy of Dmitry Rabkin, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69106 Version 3.0</div></div></div>"},"69107":{"type":"graphic_figure","displayName":"Barium swallow PI","title":"Barium swallow showing achalasia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Barium swallow showing achalasia</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/PI/69107_Barium_swallow_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows an actual X-ray of someone with achalasia. You can see that the lower esophagus is enlarged compared&nbsp;with the upper part, and that the lower esophageal sphincter is very narrow. The damaged lower esophageal sphincter makes it hard for food and fluid to pass into the stomach.</div><div id=\"graphicVersion\">Graphic 69107 Version 5.0</div></div></div>"},"69109":{"type":"graphic_diagnosticimage","displayName":"Chronic rotator cuff tear","title":"Chronic rotator cuff tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic rotator cuff tear</div><div class=\"cntnt\"><img style=\"width:369px; height:313px;\" src=\"images/RHEUM/69109_Chronic_rotator_cuff_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior view of the right shoulder demonstrates superior migration of the humeral head with significant narrowing of the acromio-humeral distance.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 69109 Version 2.0</div></div></div>"},"69110":{"type":"graphic_table","displayName":"United States child abuse neglect resources B","title":"United States child abuse and neglect resources (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States child abuse and neglect resources (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\">Military Family Resource Center (MFRC)</td>\r\n                    <td rowspan=\"2\">The MFRC, funded by the Department of Defense, collects, reviews, processes, and disseminates information on the military family lifestyle and quality of life issues of military members and their families. Program areas include family advocacy (child and spouse abuse), family support, relocation services, child and youth programs, and activities which affect force readiness and quality of life.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>1745 Jefferson Davis Hwy<br />\r\n                    CS4, Suite 302, Room 309<br />\r\n                    Arlington, VA 22202-3424<br />\r\n                    (703) 602-4964<br />\r\n                    <a href=\"http://www.militaryhomefront.dod.mil/\" target=\"_blank\">www.militaryhomefront.dod.mil</a></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\">National Children's Advocacy Center (NCAC)</td>\r\n                    <td rowspan=\"2\">The NCAC provides prevention, intervention, and treatment services to physically and sexually abused children and their families within a child-focused team approach. The NCAC also provides education and training to support the development of Children's Advocacy Centers across the country.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>200 Westside Sq., Suite 700<br />\r\n                    Huntsville, AL 35801<br />\r\n                    (256) 533-0531<br />\r\n                    <a href=\"http://www.nationalcac.org/\" target=\"_blank\">www.nationalcac.org/</a></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\">National Data Archive on Child Abuse and Neglect (NDACAN)</td>\r\n                    <td rowspan=\"2\">The mission of NDACAN is to facilitate the secondary analysis of research data relevant to the study of child abuse and neglect. By making data available to a larger number of researchers, NDACAN seeks to provide a relatively inexpensive and scientifically productive means for researchers to explore important issues in the child maltreatment field.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Family Life Development Center<br />\r\n                    Beebe Hall - FLDC<br />\r\n                    Cornell University<br />\r\n                    Ithaca, NY 14853-4401<br />\r\n                    (607) 255-7799<br />\r\n                    <a href=\"http://www.ndacan.cornell.edu/\" target=\"_blank\">www.ndacan.cornell.edu</a></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\">National Indian Child Welfare Association (NICWA)</td>\r\n                    <td rowspan=\"2\">The NICWA is the only Native American organization focused specifically on issues of child abuse and neglect and Tribal capacity to prevent and respond effectively to these problems. NICWA sponsors a national conference; provides publications and information packets and technical assistance; and maintains a library for information on child welfare and child abuse and neglect that is culturally relevant and useful to the American Indian population.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>5100 SW Macadam Ave., Suite 300<br />\r\n                    Portland, OR 97201<br />\r\n                    (503) 222-4044<br />\r\n                    <a href=\"http://www.nicwa.org/\" target=\"_blank\">www.nicwa.org</a></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\">Prevent Child Abuse America</td>\r\n                    <td rowspan=\"2\">Prevent Child Abuse America promotes healthy parenting and community involvement as effective strategies for preventing all forms of child abuse. The organization's nationwide network of chapters and local affiliates work to implement direct service programs in hundreds of communities.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>200 S. Michigan Ave., 17th Floor<br />\r\n                    Chicago, IL 60604-2404<br />\r\n                    (800) CHILDREN<br />\r\n                    (312) 663-3520<br />\r\n                    <a href=\"http://www.preventchildabuse.org/\" target=\"_blank\">www.preventchildabuse.org</a></td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=50812&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Additional resources are available at the Child Welfare Information Gateway: <A spellcheck=true href=\"https://www.childwelfare.gov/\" target=_blank>https://www.childwelfare.gov/</A> (Accessed on July 20, 2017).</div><div id=\"graphicVersion\">Graphic 69110 Version 3.0</div></div></div>"},"69111":{"type":"graphic_table","displayName":"Diff dx child vasculitis","title":"Differential diagnosis for systemic vasculitis in children based upon pathologic process","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for systemic vasculitis in children based upon pathologic process</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lesions outside the vessel wall </td> </tr> <tr> <td>Neurofibromatosis</td> </tr> <tr> <td>Malignancy (tumors, lymph nodes)</td> </tr> <tr> <td class=\"subtitle1_single\">Lesions inside the vessel wall </td> </tr> <tr> <td>Vessel thrombosis</td> </tr> <tr> <td>Disseminated intravascular coagulopathy</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td>Antiphospholipid antibody syndrome</td> </tr> <tr> <td>Thrombosis secondary to malignancy</td> </tr> <tr> <td>Embolic disease (endocarditis, atrial myxoma)</td> </tr> <tr> <td>Thrombocytopenia of any cause</td> </tr> <tr> <td>Bleeding diatheses</td> </tr> <tr> <td class=\"subtitle1_single\">Vessel spasms </td> </tr> <tr> <td>Raynaud's phenomenon</td> </tr> <tr> <td>Drug-induced vasospasm (eg, ergot, cocaine, phenylpropanolamine)</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal vessels </td> </tr> <tr> <td>Coarctation of the aorta</td> </tr> <tr> <td>Fibromuscular dysplasia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69111 Version 2.0</div></div></div>"},"69112":{"type":"graphic_waveform","displayName":"Intermediate case 7","title":"Intermediate case 7","html":"<div class=\"graphic normal\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Intermediate case 7</div><div class=\"cntnt\"><img style=\"width:505px; height:127px;\" src=\"images/CARD/69112_Intermediate_case_7.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69112 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"69113":{"type":"graphic_form","displayName":"Teacher questionnaire B","title":"Speech and language evaluation teacher questionnaire (continued)","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Speech and language evaluation teacher questionnaire (continued)</div><div class=\"cntnt\"><img style=\"width:614px; height:794px;\" src=\"images/PEDS/69113_Teacher_questionnaire_B.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 69113 Version 3.0</div></div></div>"},"69116":{"type":"graphic_diagnosticimage","displayName":"Acute pancreatitis superimposed upon chronic pancreatitis","title":"Acute pancreatitis superimposed upon chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute pancreatitis superimposed upon chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:355px; height:247px;\" src=\"images/GAST/69116_Acute_on_chronic_pancreatit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan through the upper abdomen in a patient with chronic pancreatitis demonstrates a large complex inflammatory mass in the head of the pancreas (arrow) with calcifications (indicative of chronic disease) and low attenuation areas of necrosis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69116 Version 3.0</div></div></div>"},"69118":{"type":"graphic_figure","displayName":"Four glass test","title":"Four-glass test","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Four-glass test</div><div class=\"cntnt\"><img style=\"width:490px; height:309px;\" src=\"images/ID/69118_Four_glass_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagnosis of chronic prostatitis is made by analyzing specimens obtained following prostatic massage. The periurethral area is cleaned and the patient allowed to void. The initial 5 to 10 mL (VB1) and a midstream specimen (VB2) are obtained for quantitative culture. The patient should stop voiding before the bladder is empty and the prostate should then be massaged. Any prostatic secretions that are expressed (EPS) should be cultured, as well as the first 5 to 10 mL of subsequently voided urine (VB3).</div><div id=\"graphicVersion\">Graphic 69118 Version 1.0</div></div></div>"},"69121":{"type":"graphic_table","displayName":"Risk primary brain tumors","title":"Factors studied in relationship to risk of primary brain tumors of neuroepithelial tissue or meninges","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors studied in relationship to risk of primary brain tumors of neuroepithelial tissue or meninges</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>\n      Hereditary syndromes*: tuberous sclerosis, neurofibromatosis types 1 and 2,\nnevoid basal cell carcinoma syndrome, and adenomatous\npolyposis syndromes, Li-Fraumeni cancer family syndrome (inherited p53\nmutations).</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Family history of brain tumors </td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> Constitutive\npolymorphisms  in glutathione transferases, cytochrome p450 2D6 and\n1A1, N-acetyltransferase, ERCC1 and ERCC2, other\ncarcinogen metabolizing, DNA repair, and immune function genes.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> \n      Lymphocyte mutagen sensitivity to gamma radiation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> \n      Prior cancers</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Infectious agents or immunologic response:  viruses (common colds, influenza, varicellazoster virus, BK virus, JC\nvirus, others), Toxoplasma gondii </td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Allergies </td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Head trauma</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> \n      Epilepsy, seizures, or convulsions</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Drugs and medications</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Diet and vitamins: nitrosamine/nitrosamide/nitrate/nitrite consumption,\ncured foods, calcium, food frequency</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Tobacco smoke exposures</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> \n      Alcohol</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Hair dyes and hairsprays</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Traffic-related air pollution</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td> Occupations\nand industries:  synthetic rubber manufacturing, vinyl chloride,\npetroleum refining/production work, licensed\npesticide applicators, agricultural work, others (see text), parental\nworkplace exposures</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>\n      Ionizing radiation: therapeutic*; diagnostic and other sources</td>\n\n\n    </tr>\n\n    <tr>\n      <td>\n      Cellular telephones</td>\n    </tr>\n    <tr>\n      <td>\n      Other radiofrequency exposures</td>\n    </tr>\n    <tr>\n      <td> Lower frequency\nelectromagnetic field</td>\n    </tr>\n\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">ERCC2: Excision repair cross complementation group 2 gene, complementation group 2 (xerodema pigmentosum D).<br> * These are the only factors that have been proven to cause primary brain tumors of neuroepithelial tissue or meninges. Evidence for or against associations of other factors is presented in the text.</div><div class=\"graphic_reference\">Reproduced with permission from: Wrensch, M, Minn, Y, Chew, T, et al. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncology 2002; 4:278. Copyright &#169; 2002 Margaret Wrensch, MD.</div><div id=\"graphicVersion\">Graphic 69121 Version 1.0</div></div></div>"},"69122":{"type":"graphic_picture","displayName":"Juvenile xanthogranuloma solitary lesion","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69122_JXG_solitary_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical solitary lesion on the abdomen of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69122 Version 5.0</div></div></div>"},"69123":{"type":"graphic_picture","displayName":"Botulinum toxin injection sites for mouth frown","title":"Example of botulinum toxin injection sites for mouth frown","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Example of botulinum toxin injection sites for mouth frown</div><div class=\"cntnt\"><img style=\"width:501px; height:347px;\" src=\"images/DERM/69123_Injec_sites_mouth_frown_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two lateral injections represent injection into the posterior margin of the DAO muscle. The medial injections are placed at the insertion points of the mentalis muscles.</div><div id=\"graphicVersion\">Graphic 69123 Version 3.0</div></div></div>"},"69124":{"type":"graphic_picture","displayName":"Pathology of linear IgA bullous dermatosis","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/69124_Path_line_IgA_bull_derma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subepidermal blister with neutrophils within the blister cavity and an underlying neutrophil-predominant inflammatory cell infiltrate is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69124 Version 4.0</div></div></div>"},"69125":{"type":"graphic_picture","displayName":"Loopmarks acute","title":"Loopmarks acute","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loopmarks acute</div><div class=\"cntnt\"><img style=\"width:360px; height:378px;\" src=\"images/EM/69125_Loopmarks_acute.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Stephen Ludwig, MD.</div><div id=\"graphicVersion\">Graphic 69125 Version 1.0</div></div></div>"},"69127":{"type":"graphic_diagnosticimage","displayName":"Burst fracture","title":"Burst fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Burst fracture</div><div class=\"cntnt\"><img style=\"width:357px; height:488px;\" src=\"images/PEDS/69127_Brst_frctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Note the irregular shape of C7 on the lateral radiograph (arrow). CT (B) and MRI (C) show the fracture of the body of C7 more clearly (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Charles A Reitman, MD.</div><div id=\"graphicVersion\">Graphic 69127 Version 4.0</div></div></div>"},"69128":{"type":"graphic_diagnosticimage","displayName":"Ultrasound megaureter","title":"Ultrasound imaging of a megaureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound imaging of a megaureter</div><div class=\"cntnt\"><img style=\"width:354px; height:354px;\" src=\"images/PEDS/69128_Ultrasound_megaureter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69128 Version 2.0</div></div></div>"},"69129":{"type":"graphic_picture","displayName":"General hand function","title":"Physical examination for general function of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physical examination for general function of the hand</div><div class=\"cntnt\"><img style=\"width:347px; height:291px;\" src=\"images/RHEUM/69129_General_hand_function.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is simply asked to open and close the hand, noting the ability to actively flex and extend the joints of the thumb and fingers.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 69129 Version 5.0</div></div></div>"},"69130":{"type":"graphic_figure","displayName":"Voiding diary","title":"Voiding diary","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Voiding diary</div><div class=\"cntnt\"><img style=\"width:594px; height:760px;\" src=\"images/PC/69130_Outpatientbladderdiary.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>This diary will help us determine why you have trouble holding your urine or why you go to the bathroom very often</LI>&#xD;&#xA;<LI><STRONG>Keep this record for at least&nbsp;two days.</STRONG></LI>&#xD;&#xA;<LI>Please write down four things every time you pass or leak urine: </LI>&#xD;&#xA;<OL>&#xD;&#xA;<LI>The time (for example, \"10:30 AM\")</LI>&#xD;&#xA;<LI>The amount of urine that you pass</LI>&#xD;&#xA;<LI>Whether you leaked any urine (were \"wet\") or not (were \"dry\")</LI>&#xD;&#xA;<LI>Whether anything special may have caused you to go (for instance, \"just had coffee,\" \"coughed,\" \"was running to the bathroom,\" \"just took my water pill\")</LI></OL>&#xD;&#xA;<LI>Start the record in the morning the first time you go to the bathroom after you get up. <STRONG>Please&nbsp;write on the form the time you got up and the time you went to bed.</STRONG></LI>&#xD;&#xA;<LI>To measure the amount of urine you pass, we will give you a special receptacle (called a \"hat\"). Place the hat in the toilet to catch the urine every time you go. Look at how high the urine fills the hat, and write down the amount from the numbers on the inside of the hat. Remember to empty the hat after each time you go.</LI>&#xD;&#xA;<LI>If you leak urine and cannot measure the amount that came out, write down your best guess.</LI></UL></div><div id=\"graphicVersion\">Graphic 69130 Version 3.0</div></div></div>"},"69132":{"type":"graphic_picture","displayName":"Superior ophthalmic vein","title":"The superior ophthalmic vein is surgically exposed for transvenous embolization of a carotid cavernous fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The superior ophthalmic vein is surgically exposed for transvenous embolization of a carotid cavernous fistula</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEURO/69132_Superior_ophthalmic_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vikram D Durairaj, MD, F.A.C.S.</div><div id=\"graphicVersion\">Graphic 69132 Version 2.0</div></div></div>"},"69133":{"type":"graphic_picture","displayName":"Suppurative cholangitis Endosc","title":"Suppurative cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suppurative cholangitis</div><div class=\"cntnt\"><img style=\"width:261px; height:226px;\" src=\"images/GAST/69133_Suppurative_cholangitis_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy in a patient with suppurative cholangitis shows pus coming out of the ampulla of Vater (arrow).</div><div id=\"graphicVersion\">Graphic 69133 Version 1.0</div></div></div>"},"69134":{"type":"graphic_table","displayName":"Major complications of Shigella","title":"Major complications of Shigella infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major complications of Shigella infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Prevalence (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intestinal</td> </tr> <tr> <td class=\"indent1\">Proctitis or rectal prolapse</td> <td class=\"centered\">*</td> </tr> <tr> <td class=\"indent1\">Toxic megacolon</td> <td class=\"centered\">3<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Intestinal obstruction</td> <td class=\"centered\">2.5<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colonic perforation</td> <td class=\"centered\">1<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic</td> </tr> <tr> <td class=\"indent1\">Bacteremia</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Moderate to severe hypovolemia</td> <td class=\"centered\">10 to 12<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Hyponatremia</td> <td class=\"centered\">29<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Leukemoid reaction</td> <td class=\"centered\">3<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Neurologic symptoms</td> <td class=\"centered\">12 to 45</td> </tr> <tr> <td class=\"indent1\">Reactive arthritis or Reiter syndrome</td> <td class=\"centered\">1.4</td> </tr> <tr> <td class=\"indent1\">Hemolytic-uremic syndrome</td> <td class=\"centered\">&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unknown.<br />¶ Prevalence rate has been reported for a subpopulation of individuals with <EM>Shigella</EM> enteritis, and therefore the reported prevalence probably represents an overestimation of the true prevalence in all individuals with the disease.</div><div id=\"graphicVersion\">Graphic 69134 Version 5.0</div></div></div>"},"69135":{"type":"graphic_figure","displayName":"CRP risk future MI","title":"Increasing concentrations of C-reactive protein predict the risk of myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Increasing concentrations of C-reactive protein predict the risk of myocardial infarction</div><div class=\"cntnt\"><img style=\"width:462px; height:319px;\" src=\"images/CARD/69135_CRP_risk_future_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In apparently healthy men (left panel) and women (right panel), the adjusted relative risk of future myocardial infarction is associated with increasing quintiles of high-sensitivity C-reactive protein. Risk estimates are adjusted for age, smoking status, body mass index (kg/m<SUP>2</SUP>), diabetes, history of hyperlipidemia, history of hypertension, exercise level, and family history of coronary disease.</div><div class=\"graphic_reference\">Data from: Ridker PM, Circulation 2001; 103:1813.</div><div id=\"graphicVersion\">Graphic 69135 Version 5.0</div></div></div>"},"69136":{"type":"graphic_figure","displayName":"Complexity in patients' IgE responses","title":"Complexity in patients' IgE responses","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Complexity in patients' IgE responses</div><div class=\"cntnt\"><img style=\"width:598px; height:418px;\" src=\"images/ALLRG/69136_Complexity_of_IgE_response.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the basis of the allergogram in the figure, the precipitates are ordered according to their relative importance in terms of IgE binding score. Allergen D is Fel d 1. The blue bars represent the sum of a graduated score of the IgE binding of each of the 22 patients. The solid red line represents the percentage of patients having all of their IgE reactivities covered by the allergens to the left of the point.<br />NOTE:&#xD;&#xA;<ol>&#xD;&#xA;    <li>None of the patients have all of their IgE reactivity covered by the two most important allergens.</li>&#xD;&#xA;    <li>In order to cover all IgE reactivity in one-half of the patients, six allergens are needed.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; CRIE: crossed radioimmunoelectrophoresis.</div><div class=\"graphic_reference\">Courtesy of Jørgen Nedergaard Larsen, PhD and Henning Løwenstein, PhD, DSc.</div><div id=\"graphicVersion\">Graphic 69136 Version 6.0</div></div></div>"},"69137":{"type":"graphic_figure","displayName":"STAR system","title":"The STAR (stereotactic alignment radiosurgery) system at the MGH northeast proton therapy center (MGH-NPTC)","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">The STAR (stereotactic alignment radiosurgery) system at the MGH northeast proton therapy center (MGH-NPTC)</div><div class=\"cntnt\"><img style=\"width:531px; height:326px;\" src=\"images/ONC/69137_STAR_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An isocentric patient positioning device designed to rotate the patient around a fixed proton beam line. The unit has five degrees of freedom, three linear and two rotations. Using these axes of movement, the patient is positioned such that the target lesion is at the center of the beam isocenter.</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 69137 Version 1.0</div></div></div>"},"69138":{"type":"graphic_table","displayName":"Indications pacing modes III","title":"Indications for different pacing modes - III","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for different pacing modes - III</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Mode</td>\n\n\t\t\t<td class=\"subtitle1\">Generally agreed upon indications</td>\n\n\t\t\t<td class=\"subtitle1\">Controversial indications</td>\n\n\t\t\t<td class=\"subtitle1\">Contraindicated</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>DDI</td>\n\n\t\t\t<td>Need for dual-chamber pacing in the presence of significant PSVT in the CC patient</td>\n\n\t\t\t<td>Sinus node dysfunction in the absence of AV block in the presence of of significant PSVT in the CC patient</td>\n\n\t\t\t<td>Chronotropic incompetence in the patient with a demonstrated need or improvement with rate responsiveness</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>DDIR*</td>\n\n\t\t\t<td>AV block and sinus node dysfunction in the CI patient in the presence of significant PSVT</td>\n\n\t\t\t<td>Sinus node dysfunction without AV block in the CI patient in the presence of significant PSVT</td>\n\n\t\t\t<td>&nbsp;</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>DDD</td>\n\n\t\t\t<td><p>AV block and sinus node dysfunction in the CC patient</p>\n\t\t\t<p>\n\t\t\tNeed for AV synchrony to maximize cardiac output in CC active patients</p>\n\t\t\t<p>\n\t\t\tPrevious pacemaker syndrome</p></td>\n\n\t\t\t<td>For any rhythm disturbance when atrial sensing and capture is possible for the potential purpose of minimizing future atrial fibrillation and improved morbidity and survival</td>\n\n\t\t\t<td><p>Presence of chronic atrial fibrillation, atrial flutter, giant inexcitable atrium or other frequent paroxysmal supraventricular tachyarrhythmias</p>\n\t\t\t<p>\n\t\t\tWhen adequate atrial sensing cannot be attained</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>DDDR</td>\n\n\t\t\t<td>AV block and sinus node dysfunction in the CI patient</td>\n\n\t\t\t<td>As for DDD</td>\n\n\t\t\t<td>As for DDD</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=5358&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Indications_pacing_modes_1.htm</title></head></div><div class=\"graphic_footnotes\">CC: chronotropically competent (ie, the ability to achieve an appropriate heart rate for a given physiologic activity); PSVT: paroxysmal supraventricular tachycardia; AV: atrioventricular; CI: chronotropically incompetent (ie, the inability to achieve an appropriate heart rate for a given physiologic activity).<br />* DDIR is being supplanted by DDD or DDDR pacemakers with the capability of mode-switching (ie, the pacemaker automatically reprograms to a mode incapable of tracking the atrial rhythm in the presence of an atrial rhythm that the pacemaker classifies as a pathological rhythm). When the pacemaker recognizes the atrial rhythm as being physiological, the pacemaker reprograms to the previously programmed mode.</div><div id=\"graphicVersion\">Graphic 69138 Version 2.0</div></div></div>"},"69139":{"type":"graphic_picture","displayName":"Myelofibrosis marrow collagen","title":"Bone marrow biopsy in primary myelofibrosis stained for collagen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow biopsy in primary myelofibrosis stained for collagen</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/HEME/69139_Myelofibrosis_marrow_collag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy from a patient with&nbsp;primary myelofibrosis stained for collagen (trichrome stain). The marrow cavity (arrows) is traversed by blue-staining collagen bands.</div><div class=\"graphic_reference\">Courtesy of Stephen A Landaw, MD.</div><div id=\"graphicVersion\">Graphic 69139 Version 2.0</div></div></div>"},"69140":{"type":"graphic_picture","displayName":"Phototoxic eruption on face","title":"Phototoxic eruption","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Phototoxic eruption</div><div class=\"cntnt\"><img style=\"width:516px; height:296px;\" src=\"images/DERM/69140_Phototoxic_erup_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, sunburn-like erythema is present on the face and ears.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69140 Version 7.0</div></div></div>"},"69141":{"type":"graphic_table","displayName":"Common casts","title":"Common cast types and fractures that they treat","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common cast types and fractures that they treat</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Cast type\n   </td>\n   <td  class=\"subtitle1\">\n   Fracture(s)\n   </td>\n   <td  class=\"subtitle1\">\n   Key features\n   </td>\n   </tr>\n   <tr>\n   <td><strong>Short arm cast</strong></td>\n   <td>\t<p>MC 2 to 5 base fx</p>\n\t<p>Nondisplaced triquetrum fx</p>\n</td>\n   <td>\t<p>Wrist 30 degrees</p>\n\t<p>Top of cast 2 cm below antecubital fossa</p>\n\t<p>One to two layers of padding</p>\n\t<p>Two layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Short arm cast</strong></td>\n   <td>Nondisplaced distal radius fx (Colles')</td>\n   <td>\t<p>Wrist neutral</p>\n\t<p>Top of cast 2 cm below antecubital fossa</p>\n\t<p>One to two layers of padding</p>\n\t<p>Two layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Long arm cast</strong></td>\n   <td>Reduced Colles' fx</td>\n   <td>\t<p>Wrist slight flexion and ulnar deviation, elbow 90 degrees</p>\n\t<p>Top of cast 3 cm below axilla</p>\n\t<p>One to two layers of padding</p>\n\t<p>Three layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Short arm cast with thumb spica</strong></td>\n   <td>\t<p>1st MC base extraarticular fx</p>\n\t<p>Suspected scaphoid fx</p>\n\t<p>Nondisplaced distal third scaphoid fx</p>\n</td>\n   <td>\t<p>Wrist 30 degrees</p>\n\t<p>Top of cast 2 cm below antecubital fossa</p>\n\t<p>One to two layers of padding</p>\n\t<p>Two layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Long arm cast with thumb spica</strong></td>\n   <td>Middle or proximal third nondisplaced scaphoid fx</td>\n   <td>\t<p>Wrist 30 degrees</p>\n\t<p>Top of cast 3 cm below axilla</p>\n\t<p>One to two layers of padding</p>\n\t<p>Three layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Short leg walking cast</strong></td>\n   <td>\t<p>Isolated fibular shaft fx</p>\n\t<p>Isolated maleolar fx or distal fibular shaft fx</p>\n\t<p>Calcaneus fx of anterior/medial/lateral process</p>\n\t<p>Talar dome (type 1 or 2)/head/avulsion fx</p>\n\t<p>Nondisplaced MT shaft fx</p>\n\t<p>Proximal 5th MT styloid avulsion fx</p>\n</td>\n   <td>\t<p>Ankle 90 degrees</p>\n\t<p>Top of cast 4 cm below popliteal fossa</p>\n\t<p>Three to four layers of padding</p>\n\t<p>Four layers of casting tape</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Short leg non-weight bearing cast</strong></td>\n   <td>\t<p>Calcaneus fx of the sustentaculum tali</p>\n\t<p>Talar neck/body fx</p>\n\t<p>Reduced MT shaft fx</p>\n\t<p>Proximal 5th MT metaphyseal-diaphyseal junction or diaphyseal fx</p>\n</td>\n   <td>\t<p>Ankle 90 degrees</p>\n\t<p>Top of cast 4 cm below popliteal fossa</p>\n\t<p>Three to four layers of padding</p>\n\t<p>Three layers of casting tape</p>\n</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">Fx: fracture; MC: metacarpal; MT: metatarsal.</div><div id=\"graphicVersion\">Graphic 69141 Version 1.0</div></div></div>"},"69142":{"type":"graphic_figure","displayName":"Diabetes endpoints and control","title":"Efficacy of intensive glycemic control in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of intensive glycemic control in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:430px; height:301px;\" src=\"images/ENDO/69142_Diabetes_endpoints_and_cont.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plots of any diabetes-related endpoint in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to either intensive therapy with a sulfonylurea or insulin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L). Intensive therapy was associated with a 12 percent reduction in the development of any diabetes-related endpoint (P = 0.03); it was estimated that 19.6 patients would have to be treated to prevent any single endpoint in one patient at 10 years.</div><div class=\"graphic_reference\">Data from UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352:837.</div><div id=\"graphicVersion\">Graphic 69142 Version 1.0</div></div></div>"},"69145":{"type":"graphic_table","displayName":"False neg endometrial sampling","title":"False negative endometrial biopsy in women with endometrial cancer undergoing hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">False negative endometrial biopsy in women with endometrial cancer undergoing hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Percent of endometrial cavity affected by disease</td>\n<td class=\"subtitle1\">Number of patients</td>\n<td class=\"subtitle1\">Cancer missed on sampling</td>\n</tr>\n<tr>\n<td>Less than 5</td>\n<td>3</td>\n<td>3</td>\n</tr>\n<tr>\n<td>5 to 25</td>\n<td>12</td>\n<td>4</td>\n</tr>\n<tr>\n<td>26 to 50</td>\n<td>20</td>\n<td>4</td>\n</tr>\n<tr>\n<td>over 50</td>\n<td>30</td>\n<td>0</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Guido RS, Kanbour A, Ruhn M, Christopherson WA. J Reprod Med 1995; 40:553.</div><div id=\"graphicVersion\">Graphic 69145 Version 2.0</div></div></div>"},"69146":{"type":"graphic_waveform","displayName":"ECG Mahaim tachy and AVNRT","title":"12-lead electrocardiogram (ECG) showing atrioventricular nodal reentrant tachycardia (AVNRT) and Mahaim fiber tachycardia","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing atrioventricular nodal reentrant tachycardia (AVNRT) and Mahaim fiber tachycardia</div><div class=\"cntnt\"><img style=\"width:461px; height:344px;\" src=\"images/CARD/69146_Mahaim_tachy_and_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with both atrioventricular nodal reentrant tachycardia (AVNRT) and Mahaim fiber tachycardia. The initial portion of the ECG shows a narrow QRS complex AVNRT at a rate of 180 beats/min. A brief burst of ventricular pacing terminates the AVNRT but initiates a Mahaim fiber tachycardia at a rate of 150 beats/min. The QRS is wide and there is a left bundle branch block morphology.</div><div id=\"graphicVersion\">Graphic 69146 Version 3.0</div></div></div>"},"69148":{"type":"graphic_diagnosticimage","displayName":"Pleural hematoma I CT","title":"Large pleural hematoma after trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large pleural hematoma after trauma</div><div class=\"cntnt\"><img style=\"width:400px; height:269px;\" src=\"images/PULM/69148_Pleural_hematoma_I_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan performed without intravenous injection of contrast material shows heterogeneous opacification of the right hemithorax with mostly higher attenuation material. A right-sided chest tube is in place. Cardiomediastinal shift to the left is seen. The interventricular cardiac septum is seen as a higher attenuation structure when compared to the interventricular blood. This suggests a severe dilutional anemia due to severe hemorrhage with a hemoglobin level of less than 7 g/dL.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69148 Version 4.0</div></div></div>"},"69149":{"type":"graphic_table","displayName":"ACOG thromboprophylaxis recommendations","title":"ACOG recommended thromboprophylaxis for pregnancies complicated by inherited thrombophilias*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACOG recommended thromboprophylaxis for pregnancies complicated by inherited thrombophilias*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical scenario</td> <td class=\"subtitle1\">Antepartum management</td> <td class=\"subtitle1\">Postpartum management</td> </tr> <tr class=\"divider_bottom\"> <td>Lower-risk thrombophilia<sup>&#182;</sup> without previous VTE</td> <td>Surveillance without anticoagulation therapy</td> <td>Postpartum anticoagulation therapy for patients with additional risks factors<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Low-risk thrombophila with a family history (first-degree relative) of VTE</td> <td>Surveillance without anticoagulation therapy</td> <td>Postpartum anticoagulation therapy or intermediate-dose<sup>&#9674;</sup> LMWH/UFH</td> </tr> <tr class=\"divider_bottom\"> <td>Low-risk thrombophilia<sup>&#182;</sup> with a single previous episode of VTE - not receiving long-term anticoagulation therapy</td> <td>Prophylactic or intermediate-dose LMWH/UFH or surveillance without anticoagulation therapy</td> <td>Postpartum anticoagulation therapy or intermediate-dose LMWH/UFH</td> </tr> <tr class=\"divider_bottom\"> <td>High-risk thrombophilia<sup>&#167;</sup> without previous VTE</td> <td>Surveillance without anticoagulation therapy, or prophylactic LMWH or UFH</td> <td>Postpartum anticoagulation therapy</td> </tr> <tr class=\"divider_bottom\"> <td>High-risk thrombophilia<sup>&#167;</sup> with a single previous episode of VTE or an affected first-degree relative - not receiving long-term anticoagulation therapy</td> <td>Prophylactic, intermediate-dose, or adjusted-dose LMWH/UFH regimen</td> <td>Postpartum anticoagulation therapy, or intermediate or adjusted-dose LMWH/UFH for six weeks (therapy level should be at least as high as antepartum treatment)</td> </tr> <tr class=\"divider_bottom\"> <td>No thrombophilia with previous single episode of VTE associated with transient risk factor that is no longer present - excludes pregnancy- or estrogen-related risk factor</td> <td>Surveillance without anticoagulation therapy</td> <td>Postpartum anticoagulation therapy<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>No thrombophilia with previous single episode of VTE associated with transient risk factor that was pregnancy- or estrogen-related</td> <td>Prophylactic-dose LMWH or UFH<sup>&#165;</sup></td> <td>Postpartum anticoagulation therapy</td> </tr> <tr class=\"divider_bottom\"> <td>No thrombophilia with previous single episode of VTE without an associated risk factor (idiopathic) - not receiving long-term anticoagulation therapy</td> <td>Prophylactic-dose LMWH or UFH<sup>&#165;</sup></td> <td>Postpartum anticoagulation therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Thrombophilia or no thrombophilia with two or more episodes of VTE - not receiving long-term anticoagulation therapy</td> <td> <p>Prophylactic or therapeutic-dose LMWH</p> <p>OR</p> Prophylactic or therapeutic-dose UFH</td> <td> <p>Postpartum anticoagulation therapy</p> <p>OR</p> Therapeutic-dose LMWH/UFH for six weeks</td> </tr> <tr> <td>Thrombophilia or no thrombophilia with two or more episodes of VTE - Receiving long-term anticoagulation therapy</td> <td>Therapeutic-dose LMWH or UFH</td> <td>Resumption of long-term anticoagulation therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; UFH: unfractionated heparin; VTE: venous thromboembolism.<br />* Postpartum treatment levels should be greater or equal to antepartum treatment. Treatment of acute VTE and management of antiphospholipid syndrome are addressed elsewhere.<br />¶ Low-risk thrombophilia: factor V Leiden heterozygous; prothrombin <EM>G20210A</EM> heterozygous; protein C or protein S deficiency.<br />Δ First-degree relative with a history of a thrombotic episode before age 50 years, or other major thrombotic risk factors (eg, obesity, prolonged immobility).<br /><FONT class=lozenge>◊</FONT> Intermediate dosing is variably defined in the literature. The American College of Chest Physicians has defined it as a pregnancy LMWH regimen of enoxaparin 40 mg or dalteparin 5000 units given every 12 hours. In UpToDate, intermediate dosing refers to prophylactic LMWH dosing that is increased as the pregnancy progresses and the patient's weight increases, up to a maximum dose of enoxaparin 1 mg/kg once daily.<br />§ High-risk thrombophilia: antithrombin deficiency; double heterozygous for prothrombin <EM>G20210A</EM> mutation and factor V Leiden; factor V Leiden homozygous or prothrombin <EM>G20210A</EM> mutation homozygous.<br />¥ Surveillance without anticoagulation therapy is supported as an alternative approach by some experts.</div><div class=\"graphic_reference\">Reprinted with permission from Inherited thrombophilias in pregnancy. Practice Bulletin No. 138. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013:122:706-17. Copyright &copy; 2013 ACOG.</div><div id=\"graphicVersion\">Graphic 69149 Version 20.0</div></div></div>"},"69150":{"type":"graphic_picture","displayName":"Cholesterol emboli retiform purpura","title":"Retiform purpura due to cholesterol emboli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retiform purpura due to cholesterol emboli</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69150_Chol_emboli_retiform_purp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura (purpura in a pattern reminiscent of livedo reticularis) are present on the buttocks.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69150 Version 4.0</div></div></div>"},"69151":{"type":"graphic_picture","displayName":"Wuchereria bancrofti smear","title":"<em>Wuchereria bancrofti</em> smear","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\"><em>Wuchereria bancrofti</em> smear</div><div class=\"cntnt\"><img style=\"width:548px; height:276px;\" src=\"images/ID/69151_Wuchereria_bancro_smear_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Microfilariae of <em>W. bancrofti</em> in thick blood smears stained with Giemsa. The organism has a sheath and no nuclei in its tail; body nuclei are distinct (arrow).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Lymphatic filariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 69151 Version 5.0</div></div></div>"},"69153":{"type":"graphic_figure","displayName":"Eyelid anatomy","title":"Oblique section through the upper and lower eyelids","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Oblique section through the upper and lower eyelids</div><div class=\"cntnt\"><img style=\"width:526px; height:555px;\" src=\"images/NEURO/69153_Eyelid_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Smith's Ophthalmic Plastic and Reconstructive Surgery, 2nd ed, Mosby, St. Louis 1998. Copyright © 1998 Frank A Nesi, MD and Richard D Lisman, MD.</div><div id=\"graphicVersion\">Graphic 69153 Version 2.0</div></div></div>"},"69154":{"type":"graphic_table","displayName":"2002 AJCC staging of STS","title":"AJCC staging system for soft tissue sarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AJCC staging system for soft tissue sarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n <td class=\"subtitle1_single\" colspan=\"5\">Primary tumor (T)</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1_start\">T1</td>\r\n <td class=\"sublist_other_start\" colspan=\"4\">&nbsp;</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1\">T1a</td>\r\n <td class=\"sublist_other\" colspan=\"4\">Superficial tumor*</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1\">T1b</td>\r\n <td class=\"sublist_other\" colspan=\"4\">Deep tumor*</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1_start\">T2</td>\r\n <td class=\"sublist_other_start\" colspan=\"4\">Tumor greater than 5 cm in greatest dimension</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1\">T2a</td>\r\n <td class=\"sublist_other\" colspan=\"4\">Superficial tumor</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"sublist1\">T2b</td>\r\n <td class=\"sublist_other\" colspan=\"4\">Deep tumor</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"subtitle1_single\" colspan=\"5\">Regional lymph node (N)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>N0</td>\r\n <td colspan=\"4\">No histologically verified metastasis to regional lymph nodes</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>N1</td>\r\n <td colspan=\"4\">Histologically verified regional lymph node metastasis</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"subtitle1_single\" colspan=\"5\">Distant metastasis (M)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>M0</td>\r\n <td colspan=\"4\">No distant metastasis</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>M1</td>\r\n <td colspan=\"4\">Distant metastasis</td>\r\n </tr>\r\n\r\n <tr>\r\n <td class=\"subtitle1_single\" colspan=\"5\">Histologic grade of malignancy (G)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>G1</td>\r\n <td colspan=\"4\">Low, well differentiated</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>G2</td>\r\n <td colspan=\"4\">Intermediate, moderately well differentiated</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>G3</td>\r\n <td colspan=\"4\">High, poorly differentiated</td>\r\n </tr>\r\n\r\n <tr>\r\n <td>G4</td>\r\n <td colspan=\"4\">Poorly differentiated or undifferentiated (4-tier systems only)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td class=\"subtitle1_single\" colspan=\"5\">Stage grouping</td>\r\n </tr>\r\n \r\n <tr>\r\n <td rowspan=\"2\">Stage I</td>\r\n <td>T1a, b</td>\r\n <td>N0</td>\r\n <td>M0</td>\r\n <td>G1-2 (G1 with a 3-tier system)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>T2a, b</td>\r\n <td>N0</td>\r\n <td>M0</td>\r\n <td>G1-2 (G1 with a 3-tier system)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td rowspan=\"2\">Stage II</td>\r\n <td>T1a, 1b</td>\r\n <td>N0</td>\r\n <td>M0</td>\r\n <td>G3-4 (G2-3 with a 3-tier system)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>T2a</td>\r\n <td>N0</td>\r\n <td>M0</td>\r\n <td>G3-4 (G2-3 with a 3-tier system)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>Stage III</td>\r\n <td>T2b</td>\r\n <td>N0</td>\r\n <td>M0</td>\r\n <td>G3-4 (G2-3 with a 3-tier system)</td>\r\n </tr>\r\n \r\n <tr>\r\n <td rowspan=\"2\">Stage IV</td>\r\n <td>Any T</td>\r\n <td>N1</td>\r\n <td>M0</td>\r\n <td>Any G</td>\r\n </tr>\r\n \r\n <tr>\r\n <td>Any T</td>\r\n <td>N0</td>\r\n <td>M1</td>\r\n <td>Any G</td>\r\n </tr>\r\n\r\n </table></div><div class=\"graphic_footnotes\">* Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia. Retroperitoneal, mediastinal, and pelvic sarcomas are classified as deep tumors.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.</div><div id=\"graphicVersion\">Graphic 69154 Version 1.0</div></div></div>"},"69156":{"type":"graphic_figure","displayName":"Pravastatin and inflammation","title":"Predictive value of inflammation post-MI attenuated by pravastatin","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Predictive value of inflammation post-MI attenuated by pravastatin</div><div class=\"cntnt\"><img style=\"width:476px; height:282px;\" src=\"images/CARD/69156_Pravastatin_and_inflammatio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the CARE trial, patients experiencing a recurrent coronary event within two years of a myocardial infarction (MI) had higher serum concentrations of C-reactive protein and amyloid A compared to those without an event. Pravastatin attenuated this effect; the risk of a coronary event in patients with evidence of inflammation taking pravastatin (third column) was lower than in those with inflammation taking placebo (fourth column) and was identical to those without evidence of inflammation (first two columns).</div><div class=\"graphic_reference\">Data from Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators, Circulation 1998; 98:839.</div><div id=\"graphicVersion\">Graphic 69156 Version 2.0</div></div></div>"},"69157":{"type":"graphic_table","displayName":"Ketamine intoxication - Rapid overview","title":"Ketamine intoxication: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ketamine intoxication: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td>Impaired consciousness is the most common presentation, although ketamine intoxication may cause a range of central neurologic symptoms, from mild agitation to hallucinations; mild tachycardia and hypertension often occur</td> </tr> <tr> <td>Massive overdose can cause coma or apnea</td> </tr> <tr> <td>Laryngospasm and heavy salivation may infrequently occur during intravenous use, even with standard doses; laryngospasm is rare but occurs most often in infants</td> </tr> <tr> <td>Vertical or rotatory nystagmus may occur</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic testing</td> </tr> <tr> <td>Diagnosis of ketamine intoxication is based on history and clinical evidence; no readily available definitive laboratory test exists</td> </tr> <tr> <td>Obtain fingerstick glucose, acetaminophen and salicylate concentrations, electrocardiogram, and pregnancy test in women of childbearing age</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td>Secure airway, breathing, and circulation</td> </tr> <tr> <td class=\"sublist1_start\">Laryngospasm and respiratory depression</td> </tr> <tr> <td class=\"sublist1\">Generally resolve with noninvasive support (eg, bag-mask ventilation; oxygen); endotracheal intubation is rarely required</td> </tr> <tr> <td class=\"sublist1_start\">Salivation that compromises respirations or interferes with procedures</td> </tr> <tr> <td class=\"sublist1\">Treat with <strong>atropine</strong> (0.01 to 0.02 mg/kg, minimum dose 0.1 mg, may be repeated every five minutes) or <strong>glycopyrrolate</strong> (5 mcg/kg, may be repeated once after five minutes)</td> </tr> <tr> <td class=\"sublist1_start\">Psychomotor agitation</td> </tr> <tr> <td class=\"sublist1\">Treat with <strong>benzodiazepines</strong> (eg, intravenous doses of <strong>diazepam</strong> 0.1 mg/kg or in adults 5 to 10 mg, or <strong>lorazepam</strong> 0.05 mg/kg or in adults 1 to 2 mg) until the desired level of sedation is achieved</td> </tr> <tr> <td class=\"sublist1\">Butyrophenones (eg, haloperidol, droperidol) and other antipsychotic agents <strong>should not be used</strong> to treat agitation</td> </tr> <tr> <td class=\"subtitle1_single\">Disposition</td> </tr> <tr> <td>Patients with uncomplicated ketamine toxicity may be observed and discharged when symptoms have resolved</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69157 Version 11.0</div></div></div>"},"69158":{"type":"graphic_picture","displayName":"Cytology brush for ERCP","title":"Cytology brush used during ERCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cytology brush used during ERCP</div><div class=\"cntnt\"><img style=\"width:429px; height:324px;\" src=\"images/GAST/69158_Cytology_brush_for_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cytology brush immediately after obtaining biliary samples. The head of the brush was cut and sent to pathology after being placed in fixative.</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD, and Susana Escalante-Glorsky, MD.</div><div id=\"graphicVersion\">Graphic 69158 Version 2.0</div></div></div>"},"69159":{"type":"graphic_picture","displayName":"Burkitt lymphoma endosc","title":"Burkitt lymphoma on endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Burkitt lymphoma on endoscopy</div><div class=\"cntnt\"><img style=\"width:370px; height:272px;\" src=\"images/HEME/69159_Burkitts_lymphoma_endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lobulated, ulcerated protuberances seen on retroflexed view during endoscopy in a patient with abdominal pain. Biopsy revealed them to be Burkitt lymphoma.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 69159 Version 2.0</div></div></div>"},"69162":{"type":"graphic_diagnosticimage","displayName":"Amniotic bands","title":"Amniotic bands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniotic bands</div><div class=\"cntnt\"><img style=\"width:432px; height:358px;\" src=\"images/OBGYN/69162_Amniotic_bands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of the extremities shows amniotic bands (arrows) stretching between the extremities.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 69162 Version 2.0</div></div></div>"},"69163":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of preplacental hematoma","title":"Preplacental hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preplacental hematoma</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/OBGYN/69163_Ultrasd_preplacen_hem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior placenta (arrows) with preplacental hematoma (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Wendy L Kinzler, MD.</div><div id=\"graphicVersion\">Graphic 69163 Version 3.0</div></div></div>"},"69164":{"type":"graphic_figure","displayName":"Transducer version","title":"Method of using an ultrasound transducer to guide the vertex into the pelvis","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Method of using an ultrasound transducer to guide the vertex into the pelvis</div><div class=\"cntnt\"><img style=\"width:543px; height:332px;\" src=\"images/OBGYN/69164_Transducer_version.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69164 Version 2.0</div></div></div>"},"69166":{"type":"graphic_picture","displayName":"Squamous cell carcinoma eyelid","title":"Squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:383px; height:267px;\" src=\"images/PC/69166_Squamous_cell_carcinoma_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 69166 Version 1.0</div></div></div>"},"69167":{"type":"graphic_table","displayName":"Causes of neuromuscular disease","title":"Causes of neuromuscular disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neuromuscular disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Spinal cord</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Demyelinating disease (multiple sclerosis)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Disc compression</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Epidural abscess</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hemorrhage</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Infarction</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Syringomyelia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tetanus</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Transverse myelitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Trauma</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tumor</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Motor nerves</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Amyotrophic lateral sclerosis (ALS)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cervical spondylosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Critical illness neuromyopathy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Poliomyelitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Diphtheria</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Guillain-Barre syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lymphoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Metabolic (porphyria, diabetes)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Mononeuritis multiplex</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Phrenic nerve injury</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Sarcoidosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Toxins (heavy metals)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Vasculitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Neuromuscular junction</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Botulism</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hypermagnesemia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lambert Eaton syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Myasthenia gravis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Medications (neuromuscular blocking agents, aminoglycosides, anticholinesterase inhibitors)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Organophosphate poisoning</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Scorpion sting</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Shellfish poisoning</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Snake venom</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Muscles</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Acid maltase deficiency</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Metabolic abnormalities (hypokalemia, hypophosphatemia)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Malnutrition</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Mitochondrial myopathy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Muscular dystrophy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Myotonic dystrophy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Polymyositis/dermatomyositis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Rhabdomyolysis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Thyroid disease</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 69167 Version 3.0</div></div></div>"},"69168":{"type":"graphic_picture","displayName":"Malignant mesothelioma EM","title":"Mesothelioma cell","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesothelioma cell</div><div class=\"cntnt\"><img style=\"width:360px; height:245px;\" src=\"images/PULM/69168_Malignant_mesothelioma_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a human mesothelioma cell showing abundant microvilli arising from the cell surface (Mag 10,500x).</div><div class=\"graphic_reference\">Courtesy of Giuseppe G Pietra, MD.</div><div id=\"graphicVersion\">Graphic 69168 Version 1.0</div></div></div>"},"69169":{"type":"graphic_diagnosticimage","displayName":"True anterior posterior radiograph of the thumb (Roberts view)","title":"True anterior posterior radiograph of the thumb (Roberts view)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">True anterior posterior radiograph of the thumb (Roberts view)</div><div class=\"cntnt\"><img style=\"width:369px; height:568px;\" src=\"images/EM/69169_AP_xray_thumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Roberts view or \"True\"&nbsp;AP radiograph of the thumb allows better visualization of the trapezium without significant overlap of other bones. A close-up of the trapezium (inset) shows a fracture.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 69169 Version 7.0</div></div></div>"},"69170":{"type":"graphic_table","displayName":"Contemporary estimates of duration of labor by parity","title":"Contemporary estimates of median and 95th percentile in hours by parity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contemporary estimates of median and 95th percentile in hours by parity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"> <p>Parity 0</p> Median number of hours<br /> (95<sup>th</sup> percentile)</td> <td class=\"subtitle1\"> <p>Parity 1</p> Median number of hours<br /> (95<sup>th</sup> percentile)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Change in cervix</td> </tr> <tr> <td class=\"indent1\">From 4 cm to 5 cm</td> <td class=\"centered\">1.3 (6.4)</td> <td class=\"centered\">1.4 (7.3)</td> </tr> <tr> <td class=\"indent1\">From 5 cm to 6 cm</td> <td class=\"centered\">0.8 (3.2)</td> <td class=\"centered\">0.8 (3.4)</td> </tr> <tr> <td class=\"indent1\">From 6 cm to 7 cm</td> <td class=\"centered\">0.6 (2.2)</td> <td class=\"centered\">0.5 (1.9)</td> </tr> <tr> <td class=\"indent1\">From 7 cm to 8 cm</td> <td class=\"centered\">0.5 (1.6)</td> <td class=\"centered\">0.4 (1.3)</td> </tr> <tr> <td class=\"indent1\">From 8 cm to 9 cm</td> <td class=\"centered\">0.5 (1.4)</td> <td class=\"centered\">0.3 (1.0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">From 9 cm to 10 cm</td> <td class=\"centered\">0.5 (1.8)</td> <td class=\"centered\">0.3 (0.9)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Duration of second stage</td> </tr> <tr> <td class=\"indent1\">Second stage with epidural analgesia</td> <td class=\"centered\">1.1 (3.6)</td> <td class=\"centered\">0.4 (2.0)</td> </tr> <tr> <td class=\"indent1\">Second stage without epidural analgesia</td> <td class=\"centered\">0.6 (2.8)</td> <td class=\"centered\">0.2 (1.3)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note the 95<SUP>th</SUP> percentile for duration of time to dilate from 4 to 6 cm is almost 10 hours in nulliparous women.</div><div class=\"graphic_reference\">Data from: Zhang J, Landy HJ, Branch DW, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281.</div><div id=\"graphicVersion\">Graphic 69170 Version 14.0</div></div></div>"},"69172":{"type":"graphic_algorithm","displayName":"Postnatal evaluation of bilateral fetal hydronephrosis","title":"Postnatal evaluation of bilateral fetal hydronephrosis*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postnatal evaluation of bilateral fetal hydronephrosis*</div><div class=\"cntnt\"><img style=\"width:428px; height:604px;\" src=\"images/PEDS/69172_PN_eval_bil_prenatal_hydro.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RPD: renal pelvic dilameter; VCUG: voiding cystourethrogram; VUR: vesicoureteral reflux; US: ultrasound; PUV: posterior uretheral valves.<br />* This algorithm is intended for use in conjunction with additional UpToDate content on postnatal evaluation of fetal hydronephrosis. Please refer to the topic on postnatal management of fetal hydronephrosis for more information.</div><div id=\"graphicVersion\">Graphic 69172 Version 12.0</div></div></div>"},"69174":{"type":"graphic_table","displayName":"Rx serious VISA child","title":"Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious vancomycin-intermediately susceptible <EM>Staphylococcus aureus </EM>infections* in children older than 30 days","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious vancomycin-intermediately susceptible <EM>Staphylococcus aureus </EM>infections* in children older than 30 days</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antimicrobial regimen</td> <td class=\"subtitle1\">Doses</td> </tr> <tr> <td rowspan=\"4\">Regimens of choice<sup>&#182;</sup></td> <td> <p>Linezolid<sup>&#916;</sup> &#177;</p> <p>Gentamicin (or &#177; rifampin)<sup>&#9674;</sup></p> </td> <td> <p>Linezolid: </p> <ul> <li>&#60;12 years: 30 mg/kg per day in 3 doses </li> <li>&#8805;12 years: 600 mg twice per day </li> </ul> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr> <td> <p>Daptomycin<sup>&#916;&#167;</sup> &#177;</p> <p>Gentamicin (or &#177; rifampin)&#9674;</p> </td> <td> <p>Daptomycin: </p> <ul> <li>1 through 6 years: 12 mg/kg per day in 1 dose </li> <li>7 through 11 years: 9 mg/kg per day in 1 dose </li> <li>12 through 17 years: 7 mg/kg per day in 1 dose </li> </ul> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr> <td> <p>Quinupristin-dalfopristin<sup>&#916;</sup> &#177;</p> <p>Gentamicin (or &#177; rifampin)<sup>&#9674;</sup></p> </td> <td> <p>Quinupristin-dalfopristin: 22.5 mg/kg per day in 3 doses</p> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr> <td> <p>Ceftaroline<sup>&#916; </sup>&#177; </p> <p>Gentamicin (or &#177; rifampin)<sup>&#9674;</sup></p> </td> <td> <p>Ceftaroline: 15 mg/kg per dose&nbsp;(administered over 2 hours) every eight hours; maximum dose 600 mg</p> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Alternative regimens</td> <td> <p>Vancomycin +</p> <p>Linezolid<sup>&#916;</sup> &#177;</p> <p>Gentamicin</p> </td> <td> <p>Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g<sup>&#165;</sup></p> <p>Linezolid: </p> <ul> <li>&#60;12 years: 30 mg/kg per day in 3 doses </li> <li>&#8805;12 years: 600 mg twice per day </li> </ul> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> </td> </tr> <tr> <td> <p>Vancomycin +</p> <p>TMP-SMX<sup>&#916;</sup> &#177;</p> <p>Gentamicin (or &#177; rifampin)<sup>&#9674;</sup></p> </td> <td> <p>Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g<sup>&#165;</sup></p> <p>TMP-SMX: 8-12 mg/kg TMP/40 to 60 mg/kg SMX per day in 4 doses</p> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr> <td>Cilndamycin<sup>&#135;</sup> (if strain susceptible and D-test negative)</td> <td>40 mg/kg per day in 3 to 4 doses; maximum daily dose 1.2 to 2.7 g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim-sulfamethoxazole.<br />*&nbsp;Minimum inhibitory concentration (MIC)&nbsp;4 through 8&nbsp;mcg/mL.<br />¶&nbsp;Optimal therapy is not known; dependent on in vitro susceptibility results.<br />Δ Consultation with an expert in infectious diseases is suggested before use.<br /><FONT class=lozenge>◊</FONT> Gentamicin or rifampin may be added for life-threatening infections, such as endocarditis or central nervous system, although there are no data from controlled trials to indicate that combination therapy is beneficial. Consultation with an expert in infectious diseases may be warranted to determine which agent to use and duration of use.<br />§ Daptomycin is active in vitro against multidrug-resistant gram-positive organisms, including <EM>S. aureus</EM> but is not well studied in children. It should not be used alone for the treatment of pulmonary infections. There is no experience with daptomycin in the treatment of central nervous system infections. Daptomycin is approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections in patients ≥1 year of age, the treatment of S. <EM>aureus </EM>bacteremia in children age 1 through 17 years, and the treatment of S. <EM>aureus </EM>bacteremia (including right-sided endocarditis) in patients ≥18 years of age. Dosing for&nbsp;other indications is not well established.&nbsp;&nbsp;<br />¥ Goal is to achieve trough levels &gt;15 to 20 mcg/mL based on adult studies.<br />‡&nbsp;Once bacteremia is cleared.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.715.&nbsp;</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881. </LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Ceftaroline for treatment of hematogenously acquired Staphylococcal aureus osteomyelitis in children. Available at: <A spellcheck=true href=\"https://clinicaltrials.gov/ct2/show/NCT02335905\" target=_blank>clinicaltrials.gov/ct2/show/NCT02335905 </A>(Accessed on June 30, 2015).</LI>&#xD;&#xA;<LI>Cubicin (daptomycin for injection). United States Prescribing Information. Revised September, 2017. US Food&nbsp;and Drug Administration. Available online: <A spellcheck=true href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm \" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm </A>(Accessed on September 07, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 69174 Version 8.0</div></div></div>"},"69175":{"type":"graphic_figure","displayName":"Cervical vertebrae anatomy","title":"Anatomy of the neck","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the neck</div><div class=\"cntnt\"><img style=\"width:542px; height:543px;\" src=\"images/PC/69175_Cervical_vertebrae_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69175 Version 2.0</div></div></div>"},"69179":{"type":"graphic_table","displayName":"Hunt and Hess grading system","title":"Hunt and Hess grading system for patients with subarachnoid hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hunt and Hess grading system for patients with subarachnoid hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Grade</td>\n<td class=\"subtitle1\">Neurologic status</td>\n</tr>\n<tr>\n<td>1</td>\n<td>Asymptomatic or mild headache and slight nuchal rigidity</td>\n</tr>\n<tr>\n<td>2</td>\n<td>Severe headache, stiff neck, no neurologic deficit except cranial nerve palsy</td>\n</tr>\n<tr>\n<td>3</td>\n<td>Drowsy or confused, mild focal neurologic deficit</td>\n</tr>\n<tr>\n<td>4</td>\n<td>Stuporous, moderate or severe hemiparesis</td>\n</tr>\n<tr>\n<td>5</td>\n<td>Coma, decerebrate posturing</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">10.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40817&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Hunt_and_Hess_grading_syste.htm</title></head></div><div class=\"graphic_lgnd\">Based upon initial neurologic examination.</div><div class=\"graphic_reference\">Adapted from: Hunt W, Hess R. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968; 28:14.</div><div id=\"graphicVersion\">Graphic 69179 Version 4.0</div></div></div>"},"69180":{"type":"graphic_diagnosticimage","displayName":"Echo restrictive cardiomyopathy","title":"Echocardiography of restrictive cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiography of restrictive cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:391px; height:231px;\" src=\"images/CARD/69180_Echo_restrictive_cardiomyop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The echocardiographic features typical of an idiopathic restrictive cardiomyopathy include a nondilated, nonhypertrophied ventricle with dilated atria. Panel A shows the left parasternal long axis view and panel B is a r apical four chamber view.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle; AO: aorta.</div><div class=\"graphic_reference\">Courtesy of Naser Ammash, MD.</div><div id=\"graphicVersion\">Graphic 69180 Version 2.0</div></div></div>"},"69181":{"type":"graphic_diagnosticimage","displayName":"CT bronchogenic cyst","title":"Computed tomography image of a bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography image of a bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:425px; height:311px;\" src=\"images/PEDS/69181_CT_bronchogenic_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cyst appears in the left upper lobe as a rounded mass (arrow) with soft tissue and fluid-filled cystic components. The lobe appears hyperinflated due to airways obstruction caused by the mass.</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 69181 Version 3.0</div></div></div>"},"69182":{"type":"graphic_algorithm","displayName":"Dysuria prepubertal female","title":"Diagnostic approach to the prepubertal female with dysuria","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the prepubertal female with dysuria</div><div class=\"cntnt\"><img style=\"width:756px; height:1013px;\" src=\"images/EM/69182_Dysuriaprepubfem.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">UTI may coexist with noninfectious etiologies. Unless the cause of dysuria is obvious on physical examination (eg, virginal vaginal ulcers, chemical irritation, diaper dermatitis, obvious local trauma, or viral exanthem) a urine specimen for rapid dipstick should be obtained in all patients. Urinalysis and urine culture should also be obtained if the urine dipstick suggests a UTI (refer to UpToDate topics on diagnosis of UTI in children).</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; UTI: urinary tract infection.<br />* Significant injury without a history should raise concern for sexual abuse. Refer to UpToDate topics on the clinical diagnosis of sexual abuse in children and adolescents.<br />&para; Sexual abuse is an important consideration and testing for <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> is often warranted. Other important causes include <em>Streptococcus pyogenes</em> infection, nonspecific vaginitis, and vaginal foreign body (eg, toilet paper or other objects). Refer to UpToDate topics on vulvovaginitis in the prepubertal child.<br />&Delta; In addition to Stevens-Johnson, varicella infection, Beh&ccedil;et syndrome, and reactive arthritis with urethritis and conjunctivitis, potential causes include Kawasaki disease or other inflammatory disorders (eg, inflammatory bowel disease). Refer to appropriate UpToDate topics.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topics and algorithms on the evaluation of symptomatic microscopic hematuria in children.</div><div id=\"graphicVersion\">Graphic 69182 Version 9.0</div></div></div>"},"69184":{"type":"graphic_table","displayName":"Benzodiazepine and other hypnotic drug kinetics","title":"Benzodiazepine and nonbenzodiazepine hypnotic pharmacokinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benzodiazepine and nonbenzodiazepine hypnotic pharmacokinetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Usual single&nbsp;adult dose&nbsp;(oral)</td> <td class=\"subtitle1\">Oral peak (hours)</td> <td class=\"subtitle1\">Half-life (hours) parent</td> <td class=\"subtitle1\">Metabolite activity*</td> <td class=\"subtitle1\">CYP3A4 interactions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Alprazolam</td> <td>Xanax</td> <td>0.25-0.5 mg</td> <td>1-2</td> <td>6-27</td> <td>Inactive</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Bromazepam<sup>&#182;</sup></td> <td>Lectopam</td> <td>2-6 mg</td> <td>1-2</td> <td>8-20</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Chlordiazepoxide</td> <td>Librium</td> <td>5-25 mg</td> <td>0.5-4</td> <td>5-30</td> <td>Active</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Clobazam</td> <td>Onfi</td> <td>10-20 mg</td> <td>0.5-4</td> <td>36-42</td> <td>Active (half-life 71-82 hours)</td> <td>Limited (interacts via CYP2C19)</td> </tr> <tr> <td class=\"indent1\">Clonazepam</td> <td>Klonopin</td> <td>0.25-0.5 mg</td> <td>1-2</td> <td>18-50</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Clorazepate</td> <td>Tranxene</td> <td>7.5-15 mg</td> <td>1-2</td> <td>Prodrug</td> <td>Active</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td>Valium</td> <td>2-10 mg</td> <td>0.5-1</td> <td>20-50</td> <td>Active</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Estazolam</td> <td>Prosom</td> <td>0.5-2 mg</td> <td>0.5-6</td> <td>10-24</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Flunitrazepam<sup>&#182;</sup></td> <td>Rohypnol</td> <td>0.5-2 mg</td> <td>1-2</td> <td>16-35</td> <td>Active</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Flurazepam</td> <td>Dalmane</td> <td>15-30 mg</td> <td>0.5-1</td> <td>2-4</td> <td>Active</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td>Ativan</td> <td>0.5-3 mg</td> <td>2-4</td> <td>10-20</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td>Versed</td> <td>0.25 to 1 mg/kg maximum 20 mg&nbsp;(oral syrup for pediatric sedation)</td> <td>1-2</td> <td>1.5-3</td> <td>Active</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Oxazepam</td> <td>Serax</td> <td>10-30 mg</td> <td>2-4</td> <td>5-20</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Temazepam</td> <td>Restoril</td> <td>7.5-30 mg</td> <td>1-2</td> <td>3-19</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Triazolam</td> <td>Halcion</td> <td>0.125-0.25 mg</td> <td>0.7-2</td> <td>2-3</td> <td>Inactive</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Nonbenzodiazepine hypnotics</td> </tr> <tr> <td class=\"indent1\">Eszopiclone</td> <td>Lunesta</td> <td>1-3 mg</td> <td>1</td> <td>6-9</td> <td>Active (less than parent)</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Zaleplon</td> <td>Sonata</td> <td>5-15 mg</td> <td>1</td> <td>1</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Zolpidem</td> <td>Ambien, Edluar, Zolpimist</td> <td>5-10 mg</td> <td>1-2</td> <td>1.5-8.4</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class=\"indent1\">Zopiclone<sup>&#182;</sup></td> <td>Imovane, Rhovane</td> <td>3.75-7.5 mg</td> <td>5-7</td> <td>&#60;2</td> <td>Active (less than parent)</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Other US FDA approved hypnotics</td> </tr> <tr> <td class=\"indent1\">Doxepin<sup>&#916;</sup></td> <td>Silenor</td> <td>3-6 mg</td> <td>3.5</td> <td>15</td> <td>Active (half-life 31 hours)</td> <td>Limited (interacts via CYP2D6)</td> </tr> <tr> <td class=\"indent1\">Ramelteon</td> <td>Rozerem</td> <td>8 mg</td> <td>0.5-1.5</td> <td>1-2.6</td> <td>Active (half-life 2-5 hours)</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Suvorexant</td> <td>Belsomra</td> <td>10-20 mg</td> <td>2</td> <td>12</td> <td>Inactive</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Duration of action of compounds having active metabolite(s) is significantly greater than predicted by half-life of parent.</div><div class=\"graphic_footnotes\">* Half-life of active metabolite(s) may exceed 50-100 hours.<br />¶ Not available in United States.<br />Δ Approach to diagnosis and management&nbsp;of overdose is reviewed separately.&nbsp;Refer to topic&nbsp;review of&nbsp;tricyclic antidepressant poisoning available in UpToDate.</div><div id=\"graphicVersion\">Graphic 69184 Version 7.0</div></div></div>"},"69186":{"type":"graphic_table","displayName":"Classification of neutropenias","title":"Classification of neutropenias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of neutropenias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"sublist2_start\">Infection</td> </tr> <tr> <td class=\"sublist2\">Bacterial</td> </tr> <tr> <td class=\"sublist2\">Parasitic</td> </tr> <tr> <td class=\"sublist2\">Rickettsial</td> </tr> <tr> <td class=\"sublist2\">Viral - eg, hepatitis B, Epstein-Barr virus, HIV, HCV</td> </tr> <tr> <td class=\"sublist2_start\">Collagen vascular diseases</td> </tr> <tr> <td class=\"sublist2\">Felty's syndrome</td> </tr> <tr> <td class=\"sublist2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist2_start\">Complement activation</td> </tr> <tr> <td class=\"sublist2\">Hemodialysis</td> </tr> <tr> <td class=\"sublist2\">Filtration leukapheresis</td> </tr> <tr> <td class=\"sublist2\">Acute respiratory distress syndrome</td> </tr> <tr> <td class=\"sublist2_start\">Drug-induced neutropenia</td> </tr> <tr> <td class=\"sublist2\">Clozapine</td> </tr> <tr> <td class=\"sublist2\">Thionamides</td> </tr> <tr> <td class=\"sublist2\">Sulfasalazine</td> </tr> <tr> <td class=\"sublist2_start\">Autoimmune</td> </tr> <tr> <td class=\"sublist2\">Benign of childhood and adult chronic form</td> </tr> <tr> <td class=\"sublist2\">Large granular lymphocyte syndrome</td> </tr> <tr> <td class=\"sublist2\">Thymoma</td> </tr> <tr> <td class=\"indent1\">Isoimmune or autoimmune neonatal neutropenia</td> </tr> <tr> <td class=\"indent1\">Transfusion reaction</td> </tr> <tr> <td class=\"indent1\">Chronic idiopathic neutropenia</td> </tr> <tr> <td class=\"indent1\">Pure white cell aplasia</td> </tr> <tr> <td class=\"indent1\">Hypersplenism</td> </tr> <tr> <td class=\"sublist2_start\">Nutritional deficiency</td> </tr> <tr> <td class=\"sublist2\">Alcoholism</td> </tr> <tr> <td class=\"sublist2\">Vitamin B12 or folate deficiency</td> </tr> <tr> <td class=\"sublist2\">Copper deficiency with low ceruloplasmin</td> </tr> <tr> <td class=\"indent1\">Diseases affecting the bone marrow*</td> </tr> <tr> <td class=\"indent1\">Postchemotherapy</td> </tr> <tr> <td class=\"indent1\">Hypoplasia (aplastic anemia, Fanconi anemia)</td> </tr> <tr> <td class=\"indent1\">Acute and chronic leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital<sup><sup>&#182;</sup></sup></td> </tr> <tr> <td class=\"indent1\">Severe congenital neutropenia (Kostmann's syndrome)</td> </tr> <tr> <td class=\"indent1\">Shwachman-Diamond-Oski syndrome</td> </tr> <tr> <td class=\"indent1\">Myelokathexis/neutropenia with tetraploid leukocytes</td> </tr> <tr> <td class=\"indent1\">Cyclic neutropenia</td> </tr> <tr> <td class=\"indent1\">Chediak-Higashi syndrome</td> </tr> <tr> <td class=\"indent1\">Reticular dysgenesis</td> </tr> <tr> <td class=\"indent1\">Dyskeratosis congenita</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Neutropenia usually does not occur as an isolated defect in these disorders.<br />&para; Partial list only. See Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007; 49:609 for a more complete classification.</div><div id=\"graphicVersion\">Graphic 69186 Version 7.0</div></div></div>"},"69187":{"type":"graphic_figure","displayName":"Primary VF outcome GISSI","title":"Primary VF after acute MI predicts early, but not late, mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary VF after acute MI predicts early, but not late, mortality</div><div class=\"cntnt\"><img style=\"width:445px; height:340px;\" src=\"images/CARD/69187_Primary_VF_outcome_GISSI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GISSI-2 trial of 9720 patients with acute myocardial infarction (MI), the occurrence of early (&#8804;4 hours) and late (&gt;4 to 48 hours) primary ventricular fibrillation (PVF) predicted a higher in-hospital morality compared to the absence of ventricular fibrillation. However, PVF, regardless of timing, did not affect the six month prognosis. In contrast, the prognosis was much poorer among patients with nonprimary VF which occurred &#8805;48 hours after the MI.</div><div class=\"graphic_reference\">Data from: Volpi A, Cavalli A, Santoro L, et al. on behalf of the GISSI-2 Investigators, Am J Cardiol 1998; 82:265.</div><div id=\"graphicVersion\">Graphic 69187 Version 2.0</div></div></div>"},"69188":{"type":"graphic_diagnosticimage","displayName":"Central calcification on CT II","title":"Pulmonary nodule with central calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary nodule with central calcification</div><div class=\"cntnt\"><img style=\"width:432px; height:252px;\" src=\"images/PULM/69188_Central_calcif_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right middle lobe nodule with characteristic target calcification diagnostic for a benign granuloma.</div><div id=\"graphicVersion\">Graphic 69188 Version 2.0</div></div></div>"},"69189":{"type":"graphic_picture","displayName":"Retroflexed view esophagogastric junction and proximal stomach","title":"Retroflexed view of the esophagogastric junction and the proximal stomach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retroflexed view of the esophagogastric junction and the proximal stomach</div><div class=\"cntnt\"><img style=\"width:434px; height:223px;\" src=\"images/GAST/69189_Retroflexed_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appearance of the endoscope and fundus during esophagogastroduodenoscopy. The endoscope is in a retroflexed configuration to achieve visualization of the fundus and the esophagogastric junction.</div><div id=\"graphicVersion\">Graphic 69189 Version 3.0</div></div></div>"},"69190":{"type":"graphic_picture","displayName":"Nevus homogeneous pattern","title":"Dermoscopic images of nevi with homogeneous patterns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic images of nevi with homogeneous patterns</div><div class=\"cntnt\"><img style=\"width:443px; height:548px;\" src=\"images/DERM/69190_Nevus_homogeneous_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Homogeneous brown pattern.<br> (B) Homogeneous pink pattern. It is not uncommon to see vessels in this variant (melanoma may enter in the differential diagnosis).<br> (C) Homogeneous blue pattern in a blue nevus.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 69190 Version 3.0</div></div></div>"},"69192":{"type":"graphic_table","displayName":"Differential diagnosis of pemphigoid","title":"Differential diagnosis of mucocutaneous lesions in pemphigoid disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of mucocutaneous lesions in pemphigoid disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Aphthous stomatitis</td> </tr> <tr> <td>Beh&#231;et syndrome</td> </tr> <tr> <td>Bullous impetigo</td> </tr> <tr> <td>Bullous lupus erythematosus</td> </tr> <tr> <td>Bullous mastocytosis</td> </tr> <tr> <td>Chronic eczema</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td>Dermatitis herpetiformis</td> </tr> <tr> <td>Drug-induced bullous disorder</td> </tr> <tr> <td>Epidermolysis bullosa acquisita</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Human immunodeficiency virus-associated mucosal lesions</td> </tr> <tr> <td>Primary hypereosinophilic syndrome </td> </tr> <tr> <td>Lichen planus</td> </tr> <tr> <td>Linear IgA bullous dermatosis</td> </tr> <tr> <td>Pemphigoid (herpes) gestationis</td> </tr> <tr> <td>Pemphigus</td> </tr> <tr> <td>Porphyria and pseudoporphyria</td> </tr> <tr> <td>Stevens-Johnson syndrome</td> </tr> <tr> <td>Toxic epidermal necrolysis</td> </tr> <tr> <td>Urticaria</td> </tr> <tr> <td class=\"sublist1_start\">Viral infection</td> </tr> <tr> <td class=\"sublist1\">&#8226; Herpes simplex virus</td> </tr> <tr> <td class=\"sublist1\">&#8226; Varicella-zoster virus</td> </tr> <tr> <td class=\"sublist1_start\">&nbsp;Wells' syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69192 Version 3.0</div></div></div>"},"69193":{"type":"graphic_table","displayName":"Overview benign bone tumors","title":"Overview of benign bone tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of benign bone tumors</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   &nbsp;\n   </td>\n   <td  class=\"subtitle1\">\n   Clinical features\n   </td>\n   <td  class=\"subtitle1\">\n   Most common locations\n   </td>\n   <td  class=\"subtitle1\">\n   Plain radiographic features\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"4\">\n   Bone-forming tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Osteoid osteoma\n   </td>\n   <td>\t<p>10 to 20 years</p>\n\t<p>M &#62; F</p>\n\t<p>Nocturnal pain promptly relieved by NSAIDs; limp, scoliosis</p>\n</td>\n   <td>Cortex of the metaphysis or diaphysis (less common) of the proximal femur, proximal tibia, distal femur, spine, proximal humerus, or phalanges</td>\n   <td>Small round intracortical lucency (nidus) with sclerotic margin; special imaging studies (bone scan, CT, or MRI) often needed for spine</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Osteoblastoma\n   </td>\n   <td>\t<p>Any age (usually 10 to 20 years)</p>\n\t<p>M &#62; F</p>\n\t<p>Chronic pain; less responsive to NSAIDs than osteoid osteoma; spine lesions may cause neurologic symptoms</p>\n</td>\n   <td>Posterior elements of the spine or sacrum; less commonly occurs in the metaphysis of the proximal femur or tibia</td>\n   <td>Variable (often requires CT or MRI for diagnosis)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"4\">\n   Cartilage-forming tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Osteochondroma (exostosis), including hereditary multiple exostosis (HME)\n   </td>\n   <td>\t<p>10 to 20 yrs</p>\n\t<p>M &#62; F</p>\n\t<p>Pain, functional problems, deformity, pathologic fracture, palpable near the ends of long bones</p>\n\t<p>Risk of malignant transformation to chondrosarcoma in adults (in HME)</p>\n</td>\n   <td>Metaphysis of the distal femur, proximal tibia, and proximal humerus</td>\n   <td>Bony spur arising from the surface of the cortex; the cortex of the spur is continuous with the cortex of underlying bone</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Solitary enchondroma\n   </td>\n   <td>\t<p>10 to 20 years</p>\n\t<p>M = F</p>\n\t<p>Widening of bone, deformity</p>\n</td>\n   <td>Diaphysis of the long bones of the hand, proximal humerus, and proximal femur</td>\n   <td>Oval, well-circumscribed central (medullary), lucent lesion with or without matrix calcifications or expansion of the cortex</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Enchondromatosis (Ollier syndrome, including Maffucci syndrome*)\n   </td>\n   <td>\t<p>&#60;10 years</p>\n\t<p>Intracranial enchondromas may cause headache and cranial nerve deficit</p>\n\t<p>Risk of malignant transformation to chondrosarcoma and increased risk of nonsarcomatous neoplasms</p>\n</td>\n   <td>Metaphysis, diaphysis of any bone</td>\n   <td>Oval, well-circumscribed central (medullary), lucent lesions with or without matrix calcifications or expansion of the cortex</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Periosteal (juxtacortical) chondroma\n   </td>\n   <td>\t<p>Children and adults</p>\n\t<p>Localized pain, palpable nontender hard mass that is fixed to bone</p>\n</td>\n   <td>Metaphysis or diaphysis of the proximal humerus, femur, or other long bones, including small bones of the hands and feet</td>\n   <td>Small, scalloped radiolucent lesion on outer surface of the cortex, may have intralesional calcification; minimal periosteal reaction</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Chondroblastoma\n   </td>\n   <td>\t<p>10 to 20 years</p>\n\t<p>M &#62; F</p>\n</td>\n   <td>Epiphysis (or apophysis) of the proximal humerus, distal femur, proximal tibia, calcaneus</td>\n   <td>Small, well-defined lesions with sclerotic border; may cross the growth plate</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Chondromyxoid fibroma\n   </td>\n   <td>\t<p>10 to 20 years</p>\n\t<p>M &#62; F</p>\n</td>\n   <td>Metaphysis of the proximal tibia, distal femur, or calcaneus</td>\n   <td>Eccentric, medullary, radiolucent, lobulated lesion in the metaphysis with sclerotic border</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"4\">\n   Fibrous lesions\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Fibrous dypslasia, including polyostotic fibrous dysplasia (McCune-Albright syndrome)\n   </td>\n   <td>\t<p>Teens to 20s</p>\n\t<p>M &#62; F</p>\n\t<p>Caf&#233;-au-lait macules, endocrine abnormalities (in McCune-Albright)</p>\n\t<p>Pathologic fracture (may be recurrent)</p>\n</td>\n   <td>Metaphysis or diaphysis of the proximal femur, ribs, tibia; mandible, skull, pelvis, proximal humerus, radius, ulna, distal femur, fibula</td>\n   <td>Lytic lesion in metaphysis or diaphysis with ground-glass appearance; thinning/scalloped cortical bone; expansion of bone and possible bowing</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Osteofibrous dysplasia (ossifying fibroma)\n   </td>\n   <td>\t<p>0 to 5 years</p>\n\t<p>Swelling, anterolateral bowing of lower leg; pathologic fracture</p>\n</td>\n   <td>Diaphysis of the tibia or fibula</td>\n   <td>Lytic thinning of diaphyseal cortical bone with interspersed sclerosis; sharply circumscribed margin</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Nonossifying fibroma (metaphyseal fibrous defect)\n   </td>\n   <td>\t<p>Teenagers</p>\n\t<p>Usually incidental finding</p>\n\t<p>Pathologic fracture (in large lesions)</p>\n</td>\n   <td>Metaphysis of the distal femur, distal tibia, proximal tibia</td>\n   <td>Well-defined small, eccentric, expansile lytic lesions in metaphysis; sclerotic scalloped borders</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"4\">\n   Cystic tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Unicameral bone cyst (simple bone cyst)\n   </td>\n   <td>\t<p>0 to 20 years</p>\n\t<p>M = F</p>\n\t<p>Localized pain, limp, failure to use extremity, pathologic fracture</p>\n</td>\n   <td>Proximal humerus, femur, or tibia</td>\n   <td>Well-marginated cystic lesion of metaphysis or metadiaphysis without reactive sclerosis; \"falling leaf\" sign</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Aneurysmal bone cyst\n   </td>\n   <td>\t<p>Adolescents</p>\n\t<p>F &#62; M</p>\n\t<p>Localized pain or swelling, limp, growth arrest (if lesion crosses the growth plate), neurologic symptoms (for spine lesions), pathologic fracture</p>\n</td>\n   <td>Posterior elements of the spine, or metaphysis of the distal femur, proximal tibia, proximal humerus, pelvis, fibula, ribs, clavicle, cervical spine</td>\n   <td>Aggressive, expansile, lytic metaphyseal lesions with an \"eggshell\" sclerotic rim; lesions may have a \"soap bubble\" appearance secondary to reinforcement of remaining trabeculae</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"4\">\n   Miscellaneous benign bone tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Langerhans cell histiocytosis\n   </td>\n   <td>\t<p>Any age (most common 5 to 10 years)</p>\n\t<p>M &#62; F</p>\n\t<p>Painful swelling of affected site, pathologic fracture, proptosis, thirst, refractory otitis media</p>\n</td>\n   <td>Skull, ribs, pelvis, long bones, mandible, vertebrae</td>\n   <td>Well-defined lytic lesion with or without sclerotic margins; variable periosteal reaction; flattening of vertebral body; \"floating\" teeth (with mandibular involvement)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Giant cell tumor\n   </td>\n   <td>\t<p>Young adults (peak incidence in 20s to 30s)</p>\n\t<p>F &#62; M</p>\n\t<p>Pain, swelling, limitation of joint movement, pathologic fracture</p>\n</td>\n   <td>Epiphysis of the distal femur, proximal tibia, distal radius, sacrum</td>\n   <td>Expansile, eccentric, lytic lesion in epiphysis and adjacent metaphysis, may extend to subchondral plate; absence of matrix calcification and periosteal reaction</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">CT: computed tomography; F: female; M: male; MRI: magnetic resonance imaging; NSAIDs: nonsteroidal antiinflammatory drugs.<br>* Enchondromatosis with hemangiomas.</div><div class=\"graphic_reference\">Data compiled from:<BR>1. Copley L, Dormans JP. Benign pediatric bone tumors. Evaluation and treatment. Pediatr Clin North Am 1996; 43:949.<BR>2. Springfield DS, Gebhardt MC. Bone and soft tissue tumors. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.493.<BR>3. Yochum TR, Rowe LJ.&nbsp;Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004.<BR>4. Wold LE, McLeod RA, Sim FH, Unni KK. Atlas of Orthopedic Pathology. Philadelphia: W.B. Saunders; 1990.<BR>5. Yildiz C, Erler K, Atesalp AS, Basbozkurt M. Benign bone tumors in children. Curr Opin Pediatr 2003; 15:58.</div><div id=\"graphicVersion\">Graphic 69193 Version 2.0</div></div></div>"},"69196":{"type":"graphic_figure","displayName":"Montelukast and exercise","title":"The FEV1 after exercise in patients who received montelukast (A) and salmeterol (B)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The FEV1 after exercise in patients who received montelukast (A) and salmeterol (B)</div><div class=\"cntnt\"><img style=\"width:383px; height:437px;\" src=\"images/PULM/69196_Montelukast_and_exercise.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mean response curves are shown for percentage change in FEV<SUB>1</SUB> from prechallenge FEV<SUB>1</SUB> at baseline (closed circles), days 1 to 3 (closed squares), week 4 (open squares), and week 8 (open circles) after study treatment.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in&nbsp;one second.</div><div class=\"graphic_reference\">Data from Edelman, et al. Ann Intern Med, 2000; 132:100.</div><div id=\"graphicVersion\">Graphic 69196 Version 3.0</div></div></div>"},"69197":{"type":"graphic_figure","displayName":"PA catheter leveling","title":"Position of pulmonary artery catheter pressure system","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Position of pulmonary artery catheter pressure system</div><div class=\"cntnt\"><img style=\"width:491px; height:303px;\" src=\"images/PULM/69197_PA_catheter_leveling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two methods for referencing the pressure system to the phlebostatic axis are shown. The system can be referenced by placing the air-fluid interface of either the in-line stopcock or the stopcock on top of the transducer at the phlebostatic level.</div><div class=\"graphic_reference\">Redrawn from Bridges, EJ, Woods, SL, Heart Lung 1993; 22:99.</div><div id=\"graphicVersion\">Graphic 69197 Version 1.0</div></div></div>"},"69200":{"type":"graphic_picture","displayName":"Subendothelial deposits in mixed cryo EM","title":"Subendothelial deposits in mixed cryoglobulinemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subendothelial deposits in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/69200_Cryoglobulinemia_EM_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in mixed cryoglobulinemia shows subendothelial deposits (D) under the glomerular basement membrane (GBM) with some of the granular material present within an infiltrating macrophage (arrows). The latter represents a phagocytic process that would remove the cryoprecipitate if no further deposition occurred.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69200 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"69201":{"type":"graphic_waveform","displayName":"ECG sustained monomorphic VT","title":"ECG of sustained monomorphic ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ECG of sustained monomorphic ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:431px; height:416px;\" src=\"images/CARD/69201_ECG_sustained_monomorphic_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the six precordial electrocardiogram (ECG) leads (V1-V6). The QRS complex is wide and bizarre and the rhythm is ventricular tachycardia (VT). The sixth (+) and seventh (*) QRS complexes show a change in morphology, resembling a normal QRS complex; these represent fusion beats, with partial (+) or complete (*) normalization of the QRS complex. The seventh QRS complex (*) is preceded by a distinct P wave, which is probably conducted, capturing the ventricle for one beat, but not terminating the VT; this is also known as a Dressler beat.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 69201 Version 3.0</div></div></div>"},"69202":{"type":"graphic_picture","displayName":"Buccal SCC resected","title":"Buccal SCC resected with 1 cm margins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buccal SCC resected with 1 cm margins</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/ONC/69202_Buccal_SCC_resected.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">SCC: squamous cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 69202 Version 3.0</div></div></div>"},"69203":{"type":"graphic_picture","displayName":"KS plaque like lesion","title":"Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:431px; height:234px;\" src=\"images/ONC/69203_KS_plaque_like_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AIDS-related Kaposi's sarcoma appearing as plaque-like lesions with breakdown of overlying skin.</div><div class=\"graphic_reference\">By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.</div><div id=\"graphicVersion\">Graphic 69203 Version 3.0</div></div></div>"},"69204":{"type":"graphic_diagnosticimage","displayName":"IVUS image coronary artery","title":"Intracoronary ultrasound image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracoronary ultrasound image</div><div class=\"cntnt\"><img style=\"width:440px; height:202px;\" src=\"images/CARD/69204_IVUS_image_coronary_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intracoronary image of the artery shows the different layers of the arterial wall including the intima (I), media (M) and adventitia (A). The corresponding histology of these layers is also shown.</div><div class=\"graphic_reference\">Courtesy of Neil Weissman, MD.</div><div id=\"graphicVersion\">Graphic 69204 Version 2.0</div></div></div>"},"69205":{"type":"graphic_diagnosticimage","displayName":"TEE descending aortic dissection","title":"Transesophageal echocardiogram of descending aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram of descending aortic dissection</div><div class=\"cntnt\"><img style=\"width:628px; height:228px;\" src=\"images/CARD/69205_TEE_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortic dissection is characterized by the formation of an \"intimal flap\" seen as a hyperechoic line extending across the vessel delimiting two distinct lumens (A). Color flow Doppler (B) depicts higher (orange) blood flow velocity and intraluminal velocity in the inferior of the two lumens, but does not provide definitive information regarding which is the true lumen and false lumen.</div><div class=\"graphic_reference\">Courtesy of W Manning, MD.</div><div id=\"graphicVersion\">Graphic 69205 Version 4.0</div></div></div>"},"69207":{"type":"graphic_table","displayName":"Features SIRS","title":"Defining features of systemic inflammatory response syndrome (SIRS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Defining features of systemic inflammatory response syndrome (SIRS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Two or more of the following conditions:</td> </tr> <tr> <td class=\"indent1\">Temperature &#62;38.3&#176;C or &#60;36.0&#176;C</td> </tr> <tr> <td class=\"indent1\">Heart rate of &#62;90 beats/minute</td> </tr> <tr> <td class=\"indent1\">Respiratory rate of &#62;20 breaths/minute or PaCO<sub>2</sub> of &#60;32 mmHg</td> </tr> <tr> <td class=\"indent1\">WBC count of &#62;12,000 cells/mL, &#60;4000 cells/mL, or &#62;10 percent immature (band) forms</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC count: white blood cell count.</div><div class=\"graphic_reference\">Data from: Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63.</div><div id=\"graphicVersion\">Graphic 69207 Version 4.0</div></div></div>"},"69208":{"type":"graphic_figure","displayName":"Ring pessary in situ","title":"Ring vaginal pessary in situ","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Ring vaginal pessary in situ</div><div class=\"cntnt\"><img style=\"width:477px; height:298px;\" src=\"images/OBGYN/69208_Ring_pessary_in_situ.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69208 Version 3.0</div></div></div>"},"69209":{"type":"graphic_table","displayName":"Death during induction AML","title":"Mortality during induction chemotherapy in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mortality during induction chemotherapy in acute myeloid leukemia</div><div class=\"cntnt\"><table style=\"width: 549px; height: 124px;\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Patient age</td>\n\n      <td class=\"subtitle1\">Performance status*</td>\n\n      <td class=\"subtitle1\"> Death by day +28 (percent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#60;50</td>\n\n      <td>&#60;3</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n      <td>50-59</td>\n      <td>&#60;3</td>\n      <td>7</td>\n    </tr>\n    <tr>\n\n      <td>60-69</td>\n\n      <td>&#60;3</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n      <td>70-79</td>\n      <td>&#60;3</td>\n      <td>13</td>\n    </tr>\n    <tr>\n      <td>&#62;79</td>\n      <td>&#60;3</td>\n      <td>30</td>\n    </tr>\n    <tr>\n\n      <td>&#60;50</td>\n\n      <td>&#8805;3</td>\n\n      <td>39</td>\n\n    </tr>\n    <tr>\n      <td>50-69</td>\n      <td>&#8805;3</td>\n      <td>46</td>\n    </tr>\n    <tr>\n      <td>&#62;69</td>\n      <td>&#8805;3</td>\n      <td>57</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Zubrod (ECOG) performance status at the onset of treatment. A score of &lt;3 is seen in a patient who is either asymptomatic or symptomatic and is in bed &lt;50 percent of the time. A score of 3 or greater means that the patient is symptomatic and in bed &gt;50 percent of the time.</div><div class=\"graphic_reference\">Data from Estey, EH. Cancer 2001; 92:1059.</div><div id=\"graphicVersion\">Graphic 69209 Version 1.0</div></div></div>"},"69210":{"type":"graphic_figure","displayName":"RBC size sideroblastic anemia","title":"Red cell size distribution curves in congenital sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Red cell size distribution curves in congenital sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:431px; height:430px;\" src=\"images/HEME/69210_RBC_size_sideroblastic_edt3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top panel) Size distribution curve from a 28-year-old man with autosomal recessive congenital sideroblastic anemia (Hb, 6.7 g/dL; MCV, 65 fL; RDW, 35). The pattern indicates a broad population of red cells, varying markedly in size, with the majority of the cells being microcytic.<br> (Bottom panel) Size distribution curve from a 60-year-old woman with X-linked sideroblastic anemia (Hb, 9.9 g/dL; MCV, 93 fL; RDW, 14). It indicates the presence of two populations of red cells: one is comprised of normocytic to macrocytic red cells (black arrow) derived from precursors expressing the normal ALAS2, while a lesser population contains only microcytic red cells (red arrow) derived from precursors expressing the mutant ALAS2.</div><div id=\"graphicVersion\">Graphic 69210 Version 7.0</div></div></div>"},"69211":{"type":"graphic_figure","displayName":"Survival advantage of arterial coronary bypass grafts","title":"Survival advantage of arterial coronary bypass grafts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival advantage of arterial coronary bypass grafts</div><div class=\"cntnt\"><img style=\"width:327px; height:254px;\" src=\"images/CARD/69211_Patient_survival_after_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated survival rates for patients with angina who underwent internal mammary artery (IMA, n = 749) or saphenous vein (n = 4888) coronary bypass grafts. Patient survival was significantly prolonged with IMA grafts (64 versus 53 percent at 15 years), a difference that increased over time.</div><div class=\"graphic_reference\">Data from Cameron A, Davis KB, Green G, Schaff HV. N Engl J Med 1996; 334:216.</div><div id=\"graphicVersion\">Graphic 69211 Version 3.0</div></div></div>"},"69212":{"type":"graphic_picture","displayName":"Muscle biopsy polymyositis","title":"Interstitial inflammation in polymyositis","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Interstitial inflammation in polymyositis</div><div class=\"cntnt\"><img style=\"width:599px; height:233px;\" src=\"images/RHEUM/69212_Muscle_biopsy_polymyositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left panel) and high (right panel) views of muscle biopsy in polymyositis. There is an intense interstitial mononuclear infiltrate with some myocyte degeneration.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD and William W Pendlebury, MD.</div><div id=\"graphicVersion\">Graphic 69212 Version 1.0</div></div></div>"},"69213":{"type":"graphic_figure","displayName":"Ilioinguinal iliohypogastric nerve block","title":"Ilioinguinal iliohypogastric nerve block","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Ilioinguinal iliohypogastric nerve block</div><div class=\"cntnt\"><img style=\"width:485px; height:449px;\" src=\"images/ANEST/69213_Ilioing_iliohypo_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound transducer is placed superior and medial to the iliac spine on a line (shown in blue) marked from the anterior superior iliac spine to the umbilicus. A needle is inserted in the skin (red dot) and, with ultrasound guidance, directed toward the ilioinguinal and iliohypogastic nerves, until a \"pop\" is felt as the needle pierces the external oblique fascia. Local anesthetic (0.25 to 0.5 percent bupivacaine or 0.5 to 0.75% ropivacaine) is administered.</div><div id=\"graphicVersion\">Graphic 69213 Version 6.0</div></div></div>"},"69214":{"type":"graphic_picture","displayName":"Disseminated cryptococcosis - papules","title":"Disseminated cryptococcosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated cryptococcosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69214_Dissem_crypt_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple umbilicated papules are present on the face of this patient with cryptococcosis. The lesions resemble molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69214 Version 3.0</div></div></div>"},"69215":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph pneumomediastinum","title":"Chest radiograph showing pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:599px; height:403px;\" src=\"images/EM/69215_CXR_pneumo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These AP and lateral views of the chest demonstrate pneumomediastinum (inferior arrows) with air tracking up into the soft tissues of the neck (superior arrows) in a patient with a tracheobronchial injury.</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div class=\"graphic_reference\">Courtesy of Pierre J Sasson, MD.</div><div id=\"graphicVersion\">Graphic 69215 Version 4.0</div></div></div>"},"69216":{"type":"graphic_picture","displayName":"Acute eponychia","title":"Acute eponychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eponychia</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/SURG/69216_Eponychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute eponychia is an infection of the proximal nail fold. This patient has an acute paronychia of the lateral nail fold in addition to an acute infection of the eponychium.</div><div id=\"graphicVersion\">Graphic 69216 Version 2.0</div></div></div>"},"69220":{"type":"graphic_picture","displayName":"Invasive beta catenin","title":"Advancing (invasive) edge of a gastric adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advancing (invasive) edge of a gastric adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:276px;\" src=\"images/ONC/69220_Invasive_beta_catenin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strongly positive nuclear strain of beta-catenin.</div><div id=\"graphicVersion\">Graphic 69220 Version 1.0</div></div></div>"},"69221":{"type":"graphic_table","displayName":"Pregnancy class acne meds","title":"Pregnancy risk categories of acne medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy risk categories of acne medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medications</td> <td class=\"subtitle1\">Pregnancy risk category</td> </tr> <tr> <td>Topical tretinoin</td> <td>C</td> </tr> <tr> <td>Adapalene</td> <td>C</td> </tr> <tr> <td>Tazarotene</td> <td>X</td> </tr> <tr> <td>Azelaic acid</td> <td>B</td> </tr> <tr> <td>Salicylic acid</td> <td>C</td> </tr> <tr> <td>Topical erythromycin</td> <td>B</td> </tr> <tr> <td>Topical clindamycin</td> <td>B</td> </tr> <tr> <td>Benzoyl peroxide</td> <td>C</td> </tr> <tr> <td>Benzoyl peroxide/clindamycin (Duac, Benzaclin, Acanya)</td> <td>C</td> </tr> <tr> <td>Benzoyl peroxide/erythromycin (Benzamycin)</td> <td>C</td> </tr> <tr> <td>Adapalene/benzoyl peroxide (Epiduo)</td> <td>C</td> </tr> <tr> <td>Topical tretinoin/clindamycin (Ziana)</td> <td>C</td> </tr> <tr> <td>Sodium sulfacetamide</td> <td>C</td> </tr> <tr> <td>Topical dapsone</td> <td>C</td> </tr> <tr> <td>Oral tetracycline, doxycycline, minocycline</td> <td>D</td> </tr> <tr> <td>Oral erythromycin</td> <td>B</td> </tr> <tr> <td>Oral trimethoprim-sulfamethoxazole</td> <td>D</td> </tr> <tr> <td>Oral azithromycin</td> <td>B</td> </tr> <tr> <td>Oral isotretinoin</td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A description of the US Food &amp; Drug Administration (FDA) pregnancy risk categories is provided in a separate table in UpToDate. In 2015, the United States Food &amp; Drug Administration (FDA) began overseeing the phase-out of pregnancy risk categories (A, B, C, D, and X) from prescription drug labeling and began requiring information from available human and animal studies of (1) known or potential maternal or fetal adverse reactions, and (2) dose adjustments needed during pregnancy and the postpartum period. Additional information is available at the FDA website: <A spellcheck=true href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm\">Pregnancy and Lactation Labeling Final Rule</A>. </div><div id=\"graphicVersion\">Graphic 69221 Version 2.0</div></div></div>"},"69223":{"type":"graphic_table","displayName":"Estrogen and progestin types and doses in hormonal contraceptive","title":"Selected hormonal contraceptives: Oral contraceptives (birth control pills) and other delivery methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected hormonal contraceptives: Oral contraceptives (birth control pills) and other delivery methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">United States trade name (manufacturer)</td> <td class=\"subtitle1\">Progestin (mg)*</td> <td class=\"subtitle1\">Estrogen (micrograms)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Monophasic combinations</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Beyaz 28 (Bayer)<sup>&#916;</sup><sup>&#9674;</sup></td> <td class=\"highlight_gray_text\" rowspan=\"5\">Drospirenone (3)</td> <td class=\"highlight_gray_text\" rowspan=\"5\">Ethinyl estradiol (20)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Gianvi 28 (Teva)<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Loryna 28 (Sandoz)<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Nikki 28 (Lupin)<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Yaz (Bayer)<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Aviane 28 (Teva Women's)</td> <td rowspan=\"6\">Levonorgestrel (0.1)</td> <td rowspan=\"6\">Ethinyl estradiol (20)</td> </tr> <tr> <td class=\"indent1\">Falmina 28 (Northstar)</td> </tr> <tr> <td class=\"indent1\">Lessina 28 (Teva Women's)</td> </tr> <tr> <td class=\"indent1\">Lutera 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Orsythia 28 (Qualitest)</td> </tr> <tr> <td class=\"indent1\">Sronyx 28 (Actavis)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Gildess Fe 1/20 (Qualitest)<sup>&#165;</sup><sup>&#135;</sup></td> <td class=\"highlight_gray_text\" rowspan=\"7\">Norethindrone acetate (1)</td> <td class=\"highlight_gray_text\" rowspan=\"7\">Ethinyl estradiol (20)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Junel Fe 1/20 28 (Teva Women's)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Larin Fe 1/20 (Teva Women's)<sup>&#165;</sup><sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Loestrin Fe 1/20 28 (Warner Chilcott)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Loestrin 24 Fe (Warner Chilcott)<sup>&#134;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Microgestin Fe 1/20 28 (Actavis)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Tarina Fe 1/20 (Afaxys)</td> </tr> <tr> <td class=\"indent1\">Apri 28 (Teva Women's)</td> <td rowspan=\"7\">Desogestrel (0.15)</td> <td rowspan=\"7\">Ethinyl estradiol (30)</td> </tr> <tr> <td class=\"indent1\">Desogen 28 (Merck)</td> </tr> <tr> <td class=\"indent1\">Emoquette 28 (Qualitest)</td> </tr> <tr> <td class=\"indent1\">Juleber 28 (Northstar)</td> </tr> <tr> <td class=\"indent1\">Ortho-Cept 28 (Janssen)</td> </tr> <tr> <td class=\"indent1\">Reclipsen 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Solia 28 (Prasco)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Ocella 28 (Teva Women's)</td> <td class=\"highlight_gray_text\" rowspan=\"4\">Drospirenone (3)</td> <td class=\"highlight_gray_text\" rowspan=\"4\">Ethinyl estradiol (30)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Syeda 28 (Sandoz)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Yasmin 28 (Bayer)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Zarah 28 (Watson)</td> </tr> <tr> <td class=\"indent1\">Altavera 28 (Sandoz)</td> <td rowspan=\"6\">Levonorgestrel (0.15)</td> <td rowspan=\"6\">Ethinyl estradiol (30)</td> </tr> <tr> <td class=\"indent1\">Chateal 28 (Afaxys)</td> </tr> <tr> <td class=\"indent1\">Kurvelo 28 (Lupin)</td> </tr> <tr> <td class=\"indent1\">Levora 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Marlissa 28 (Glenmark)</td> </tr> <tr> <td class=\"indent1\">Portia 28 (Teva Women's)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Gildess Fe 1.5/30 (Qualitest)<sup>&#165;</sup><sup>&#135;</sup></td> <td class=\"highlight_gray_text\" rowspan=\"6\">Norethindrone acetate (1.5)</td> <td class=\"highlight_gray_text\" rowspan=\"6\">Ethinyl estradiol (30)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Junel FE 1.5/30 (Teva Women's)<sup>&#165;</sup><sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Larin FE 1.5/30 (Northstar)<sup>&#165;</sup><sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Loestrin Fe 1.5/30 28 (Teva Women's)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Microgestin Fe 1.5/30 28 (Actavis)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Junel Fe 1.5/30 28 (Teva Women's)<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">Cryselle 28 (Teva Women's)<sup>&#165;</sup></td> <td rowspan=\"3\">Norgestrel<sup>&#165;</sup> (0.3)</td> <td rowspan=\"3\">Ethinyl estradiol (30)</td> </tr> <tr> <td class=\"indent1\">Elinest 28 (Northstar)</td> </tr> <tr> <td class=\"indent1\">Low-Ogestrel 28 (Actavis)<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Kelnor 28 (Teva Women's)</td> <td class=\"highlight_gray_text\" rowspan=\"2\">Ethynodiol diacetate (1)</td> <td class=\"highlight_gray_text\" rowspan=\"2\">Ethinyl estradiol (35)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Zovia 1/35E 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Balziva 28 (Teva's Women's)</td> <td rowspan=\"9\">Norethindrone (0.4)</td> <td rowspan=\"9\">Ethinyl estradiol (35)</td> </tr> <tr> <td class=\"indent1\">Briellyn 28 (Glenmark)</td> </tr> <tr> <td class=\"indent1\">Femcon Fe 28 chewable (Actavis)</td> </tr> <tr> <td class=\"indent1\">Gildagia 28 (Qualitest)</td> </tr> <tr> <td class=\"indent1\">Ovcon 35 28 (Actavis)<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Philith 28 (Northstar)</td> </tr> <tr> <td class=\"indent1\">Vyfemla (Lupin)</td> </tr> <tr> <td class=\"indent1\">Wymza Fe 28 chewable (Warner Chilcott)</td> </tr> <tr> <td class=\"indent1\">Zenchent Fe 28 chewable (Watson)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Brevicon 28 (Actavis)</td> <td class=\"highlight_gray_text\" rowspan=\"5\">Norethindrone (0.5)</td> <td class=\"highlight_gray_text\" rowspan=\"5\">Ethinyl estradiol (35)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Modicon 28 (Janssen)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Necon 0.5/35 28 (Actavis)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Nortrel 0.5/35 28 (Teva Women's)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Wera (Northstar)</td> </tr> <tr> <td class=\"indent1\">Alyacen 1/35 28 (Glenmark)</td> <td rowspan=\"8\">Norethindrone (1)</td> <td rowspan=\"8\">Ethinyl estradiol (35)</td> </tr> <tr> <td class=\"indent1\">Cyclafem 1/35 (Qualitest)</td> </tr> <tr> <td class=\"indent1\">Dasetta 1/35 28 (Northstar)</td> </tr> <tr> <td class=\"indent1\">Necon 1/35 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Norinyl 1+35 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Nortrel 1/35 28 (Teva Women's)<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Ortho-Novum 1/35 28 (Janssen)</td> </tr> <tr> <td class=\"indent1\">Pirmella 1/35 (Lupin)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Estarylla (Sandoz)</td> <td class=\"highlight_gray_text\" rowspan=\"6\">Norgestimate (0.25)</td> <td class=\"highlight_gray_text\" rowspan=\"6\">Ethinyl estradiol (35)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Mono-Linyah (Northstar)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">MonoNessa 28 (Actavis)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Ortho-Cyclen 28 (Janssen)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Previfem 28 (Vintage)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Sprintec 28 (Teva Women's)</td> </tr> <tr> <td class=\"indent1\"> <p>Cyestra-35 (Paladin)<sup>&#916;</sup>, Diane-35 (Bayer)<sup>&#916;</sup>, Novo-Cyproterone/Ethinyl estradiol (Novopharm)<sup>&#916;</sup></p> NOTE: Cyproterone hormonal contraceptive products are <strong>not</strong> available in United States; Canadian trade names shown</td> <td>Cyproterone (2)</td> <td>Ethinyl estradiol (35)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Zovia 1/50E 28 (Actavis)</td> <td>Ethynodiol diacetate (1)</td> <td>Ethinyl estradiol (50)</td> </tr> <tr> <td class=\"indent1\">Ogestrel 0.5/50 28 (Actavis)</td> <td>Norgestrel** (0.5)</td> <td>Ethinyl estradiol (50)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Necon 1/50 28 (Actavis)</td> <td class=\"divider_bottom highlight_gray_text\" rowspan=\"2\">Norethindrone (1)</td> <td class=\"divider_bottom highlight_gray_text\" rowspan=\"2\">Mestranol<sup>&#182;</sup> (50)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1 highlight_gray_text\">Norinyl 1+50 28 (Actavis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Multiphasic combinations</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Natazia (Bayer)</td> <td>Dienogest (0,2,3,0)</td> <td>Estradiol valerate (3,2,2,1)</td> </tr> <tr> <td class=\"indent1\">Lo Loestrin Fe (Actavis)<sup>&#182;&#182;</sup></td> <td>Norethindrone acetate (1,0)</td> <td>Ethinyl estradiol (10,10)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Azurette 28 (Actavis)</td> <td class=\"highlight_gray_text\" rowspan=\"6\">Desogestrel (0.15,0,0)</td> <td class=\"highlight_gray_text\" rowspan=\"6\">Ethinyl estradiol (20,0,10)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Kariva 28 (Teva Women's)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Kimidess 28 (Qualitest)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Mircette 28 (Teva Women's)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Pimtrea 28 (Northstar)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Viorele 28 (Glenmark)</td> </tr> <tr> <td class=\"indent1\">Estrostep Fe 28 (Actavis)<sup>&#916;</sup></td> <td rowspan=\"3\">Norethindrone acetate (1,1,1)</td> <td rowspan=\"3\">Ethinyl estradiol (20,30,35)</td> </tr> <tr> <td class=\"indent1\">Tilia Fe 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Tri-Legest Fe 28 (Teva Women's)<sup>&#135;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Ortho Tri-Cyclen Lo 28 (Janssen)</td> <td>Norgestimate (0.18,0.215,0.25)</td> <td>Ethinyl estradiol (25,25,25)</td> </tr> <tr> <td class=\"indent1\">Caziant 28 (Actavis)</td> <td rowspan=\"4\">Desogestrel (0.1,0.125,0.15)</td> <td rowspan=\"4\">Ethinyl estradiol (25,25,25)</td> </tr> <tr> <td class=\"indent1\">Cesia 28 (Prasco)</td> </tr> <tr> <td class=\"indent1\">Cyclessa 28 (Merck)</td> </tr> <tr> <td class=\"indent1\">Velivet (Teva Women's)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Enpresse-28 (Duramed)</td> <td class=\"highlight_gray_text\" rowspan=\"4\">Levonorgestrel (0.05,0.075,0.125)</td> <td class=\"highlight_gray_text\" rowspan=\"4\">Ethinyl estradiol (30,40,30)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Levonest 28 (Northstar)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Myzilra 28 (Qualitest)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Trivora 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Ortho Tri-Cyclen 28 (Janssen)<sup>&#916;</sup><sup>&#165;</sup></td> <td rowspan=\"5\">Norgestimate (0.18,0.215,0.25)</td> <td rowspan=\"5\">Ethinyl estradiol (35,35,35)</td> </tr> <tr> <td class=\"indent1\">Tri-Estarylla (Sandoz)</td> </tr> <tr> <td class=\"indent1\">TriNessa 28 (Actavis)</td> </tr> <tr> <td class=\"indent1\">Tri-Previfem 28 (Qualitest)</td> </tr> <tr> <td class=\"indent1\">Tri-Sprintec 28 (Teva Women's)</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Alyacen 7/7/7 28 (Glenmark)</td> <td class=\"highlight_gray_text\" rowspan=\"7\">Norethindrone (0.5,0.75,1)</td> <td class=\"highlight_gray_text\" rowspan=\"7\">Ethinyl estradiol (35,35,35)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Cyclafem 7/7/7 28 (Qualitest)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Dasetta 7/7/7 28 (Northstar)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Necon 7/7/7 28 (Actavis)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Nortrel 7/7/7 28 (Teva Women's)<sup>&#165;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Ortho-Novum 7/7/7 28 (Janssen)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Pirmella 7/7/7 (Lupin)</td> </tr> <tr> <td class=\"indent1\">Aranelle 28 (Teva Women's)</td> <td rowspan=\"2\">Norethindrone (0.5,1,0.5)</td> <td rowspan=\"2\">Ethinyl estradiol (35,35,35)</td> </tr> <tr> <td class=\"indent1\">Leena 28 (Actavis)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\">Tri-Norinyl 28 (Actavis)</td> <td>Norethindrone (0.5,1,0.5)</td> <td>Ethinyl estradiol (35,35,35)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Extended combinations<sup>&#916;&#916;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Amethia Lo 91 (Actavis), Camresse Lo 91 (Teva), LoSeasonique 91 (Teva)</td> <td>Levonorgestrel (0.1)</td> <td>Ethinyl estradiol (20,10)</td> </tr> <tr> <td class=\"indent1\">Quartette 91 (Teva)</td> <td>Levonorgestrel (0.15)</td> <td>Ethinyl estradiol (20,25,30,10)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Amethia 91 (Actavis), Camrese 91 (Teva), Daysee 91 (Lupin), Seasonique 91 (Teva)</td> <td>Levonorgestrel (0.15)</td> <td>Ethinyl estradiol (30,10)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Introvale 91, Jolessa 91 (Barr), Quasense 91 (Actavis)</td> <td>Levonorgestrel (0.15)</td> <td>Ethinyl estradiol (30)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Continuous combinations</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\">Amethyst 28 (Actavis), Ashlyna 28 (Glenmark)</td> <td>Levonorgestrel (0.09)</td> <td>Ethinyl estradiol (20)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Progestin-only</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">Camila 28 (Teva Women's)</td> <td class=\"divider_bottom highlight_gray_text\" rowspan=\"11\">Norethindrone (0.35)</td> <td class=\"divider_bottom highlight_gray_text\" rowspan=\"11\">None</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Debiltane (Northstar)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Errin 28 (Teva Women's)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Heather (Glenmark)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Jencycla (Lupin)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Jolivette 28 (Actavis)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Lyza 28 (Afaxys)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Nora-BE 28 (Actavis)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Norlyroc (Ohm Laboratories)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Nor-QD 28 (Actavis)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\">Ortho Micronor (Janssen)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other delivery methods</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Ortho Evra (Janssen), Xulane (Mylan) transdermal patch (weekly)</td> <td>Norelgestromin (releases 0.15 mg/day)</td> <td>Ethinyl estradiol (releases 35 mcg/day)</td> </tr> <tr> <td class=\"indent1\">NuvaRing vaginal ring (Organon)</td> <td>Etonogestrel (releases 0.12 mg/day)</td> <td>Ethinyl estradiol (releases 15 mcg/day)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Products with same or similar trade names available outside United States may contain different active ingredient(s) or component strengths. Consult local product information before use.</div><div class=\"graphic_footnotes\">Fe: contains iron.<br />* Different progestins are not equivalent on a milligram basis.<br />&para; Ethinyl estradiol and mestranol are not equivalent on a milligram basis; the results of some studies indicate that 30 to 35 mcg of ethinyl estradiol is equivalent to 50 mcg of mestranol.<br />&Delta; Also approved for acne.<br /><span class=\"lozenge\">&loz;</span> Also contains 451 mcg of levomefolate calcium per tablet. Beyaz is taken for 24 days followed by 4 days of levomefolate calcium alone.<br />&sect; Taken as active pills for 24 days and placebo for 4 days.<br />&yen; Also available in a 21-day regimen.<br />&Dagger; Also available in a 21-day regimen that does not contain iron.<br />&dagger; Loestrin 24 Fe is taken as active pills for 24 days followed by 4 days of iron tablets alone.<br />** The progestin norgestrel contains two isomers; only levonorgestrel is bioactive. The amount of norgestrel in each tablet is twice the amount of levonorgestrel.<br />&para;&para; Lo Loestrin Fe is taken as active pills for 26 days (24 days of the combination and 2 days of ethinyl estradiol only) followed by 2 days of iron tablets alone.<br />&Delta;&Delta; Introvale, Quasense, and Seasonale (Canada) are taken on a 91-day cycle: 84 days of active pills and 7 days of placebo. LoSeasonique, Quartette, and Seasonique are taken on a 91-day cycle, but instead of placebo, 10 mcg of ethinyl estradiol is taken for 7 days.</div><div class=\"graphic_reference\">Adapted with special permission from The Medical Letter on Drugs and Therapeutics, September 14, 2015; Vol. 57 (1477):e133-e134. <A href=\"http://www.medicalletter.org/\" target=_blank>www.medicalletter.org</A>.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Food &amp; Drug Administration Orange Book: Approved Drugs with Therapeutic Equivalence Equations. Available at: <A href=\"http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm\">www.accessdata.fda.gov/scripts/cder/ob/default.cfm</A> (Accessed on September 30, 2015).</LI>&#xD;&#xA;<LI>Lexicomp online. Copyright © 1978-2018 by Lexicomp, Inc. All rights reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 69223 Version 24.0</div></div></div>"},"69226":{"type":"graphic_diagnosticimage","displayName":"Cranial nerve lymphoma","title":"Cranial nerve involvement by non-Hodgkin's lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cranial nerve involvement by non-Hodgkin's lymphoma</div><div class=\"cntnt\"><img style=\"width:382px; height:452px;\" src=\"images/HEME/69226_Cranial_nerve_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gadolinium enhancement of the seventh cranial nerve (arrow) in this axial T1 MRI is highly suggestive of lymphomatous involvement.</div><div id=\"graphicVersion\">Graphic 69226 Version 3.0</div></div></div>"},"69228":{"type":"graphic_figure","displayName":"Body cast prevents lung injury","title":"Body cast protects against positive pressure ventilation","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Body cast protects against positive pressure ventilation</div><div class=\"cntnt\"><img style=\"width:470px; height:296px;\" src=\"images/PULM/69228_Body_cast_prevents_lung_inj.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of limited intrathoracic expansion by means of a body cast on ventilator-induced lung injury in rabbits. Rabbits were ventilated with 15, 30, and 45 cmH20 peak inspiratory pressure for one hour. Lung injury was assessed by changes in the capillary filtration coefficient (Kfc). The closed chest group had increasing lung injury at 30 and 45 cmH20 peak inspiratory pressures; this complication was completely prevented by the presence of a body cast, indicating that the injury is due to the high tidal volumes induced at these airway pressures (&quot;volutrauma&quot;) and not the high airway pressure itself.</div><div class=\"graphic_reference\">Redrawn from Hernandez, LA, Peevy, KJ, Moise, AA, Parker, JC, J Appl Physiol 1989; 66:2364.</div><div id=\"graphicVersion\">Graphic 69228 Version 1.0</div></div></div>"},"69230":{"type":"graphic_figure","displayName":"FEV1 after LVRS or lung transplant","title":"FEV1 after lung volume reduction surgery (LVRS) or lung transplantation in emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FEV1 after lung volume reduction surgery (LVRS) or lung transplantation in emphysema</div><div class=\"cntnt\"><img style=\"width:323px; height:224px;\" src=\"images/PULM/69230_FEV1_emphysema_lung_transpl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent of predicted FEV1 before and after volume reduction (VR), single lung transplantation (SLT), and bilateral lung transplantation (BLT). The FEV1 with volume reduction at six months was significantly increased compared to the baseline level but less than with both bilateral and single lung transplantation.</div><div class=\"graphic_reference\">Redrawn from Gaissert HA, Trulock EP, Cooper JD, et al, J Thorac Cardiovasc Surg 1996; 111:296.</div><div id=\"graphicVersion\">Graphic 69230 Version 2.0</div></div></div>"},"69231":{"type":"graphic_diagnosticimage","displayName":"Subcentimeter enhancing pancreatic neuroendocrine tumor","title":"Axial image of a contrast-enhanced CT scan demonstrating a subcentimeter enhancing pancreatic neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial image of a contrast-enhanced CT scan demonstrating a subcentimeter enhancing pancreatic neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:392px; height:340px;\" src=\"images/ONC/69231_Subcm_panc_neuro-endo_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 69231 Version 3.0</div></div></div>"},"69232":{"type":"graphic_picture","displayName":"Fight bite injury","title":"Fight bite injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fight bite injury</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/SURG/69232_Human_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the patient with a fight bite injury is examined with his or her fingers extended, the small skin laceration may no longer correspond to the fracture site and is frequently overlooked because of the innocuous clinical appearance (arrow).</div><div id=\"graphicVersion\">Graphic 69232 Version 3.0</div></div></div>"},"69234":{"type":"graphic_movie","displayName":"Aortic dissection transesophageal echocardiogram","title":"Aortic dissection transesophageal echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic dissection transesophageal echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/69234_aordis3tconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:327px; height:251px;\" src=\"images/CARD/69234_aordis3t.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram shows large intimal tear of the ascending aorta with an intimal flap separating the false and true lumens. Spontaneous echo contrast is seen in the false lumen, a result of stasis of blood.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 69234 Version 3.0</div></div></div>"},"69236":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance image of cleft soft palate","title":"Magnetic resonance image of cleft soft palate","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of cleft soft palate</div><div class=\"cntnt\"><img style=\"width:512px; height:256px;\" src=\"images/OBGYN/69236_Mag_reson_soft_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T2 weighted magnetic resonance imaging of fetus at 20 weeks gestational age with micrognathia and cleft soft palate (without cleft lip). Note how the tongue is high in the oropharynx and there is absence of the soft palate.<br />(B) Magnetic resonance&nbsp;imaging of normal fetal soft palate (arrow).</div><div class=\"graphic_footnotes\">T: tongue.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 69236 Version 4.0</div></div></div>"},"69237":{"type":"graphic_table","displayName":"Evaluation dermatoses pregnancy","title":"Evaluation of pruritic dermatoses in pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of pruritic dermatoses in pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Obtain a detailed medical, family, obstetrical, and current illness history.</td> </tr> <tr> <td class=\"sublist1_start\">Perform a physical examination focusing on the distribution and morphology of the lesions. </td> </tr> <tr> <td>Laboratory evaluation depends upon the physical findings. Laboratory studies (eg, bile acids, liver function tests, prothrombin time) are indicated when cholestasis is suspected because of the risks of maternal and fetal morbidity.</td> </tr> <tr> <td>Skin biopsy is indicated if the diagnosis is in question or to confirm pemphigoid gestationis or pustular psoriasis of pregnancy.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69237 Version 4.0</div></div></div>"},"69238":{"type":"graphic_picture","displayName":"Umbilical cord spiraling","title":"Umbilical cord spiraling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical cord spiraling</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/OBGYN/69238_Umbilical_cord_spiraling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cord spirals normally 1 turn per 3 cm.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 69238 Version 1.0</div></div></div>"},"69239":{"type":"graphic_diagnosticimage","displayName":"Congenital CMV cranial CT","title":"Computed tomography: Intracranial calcifications in congenital cytomegalovirus infection ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography: Intracranial calcifications in congenital cytomegalovirus infection </div><div class=\"cntnt\"><img style=\"width:356px; height:197px;\" src=\"images/PEDS/69239_CMV_cranial_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracranial&nbsp;computed tomography&nbsp;of an infant born with congenital&nbsp;cytomegalovirus disease and central nervous system involvement. Scan shows classic linear periventricular calcifications and&nbsp;cortical atrophy. The infant had microcephaly at birth and developmental disabilities and major motor impairment at eight years of age.</div><div id=\"graphicVersion\">Graphic 69239 Version 3.0</div></div></div>"},"69240":{"type":"graphic_picture","displayName":"Reactive arthritis - nails","title":"Reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reactive arthritis</div><div class=\"cntnt\"><img style=\"width:176px; height:171px;\" src=\"images/DERM/69240_Reactive_arthritis_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subungual hyperkeratosis and onycholysis in reactive arthritis.</div><div id=\"graphicVersion\">Graphic 69240 Version 1.0</div></div></div>"},"69241":{"type":"graphic_figure","displayName":"Latch on PI","title":"Latch-on","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Latch-on</div><div class=\"cntnt\"><img style=\"width:514px; height:554px;\" src=\"images/PI/69241_Latch_on_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During latch-on, a baby's mouth forms a tight seal around the nipple and most of the areola (the dark skin around the nipple). Signs that your baby has a good latch-on include:<br> <ul> <li>The top and bottom lips are wide open. </li> <li>The lower lip is turned outward against the breast. </li> <li>The chin is touching the breast, and the nose is close to the breast. </li> <li>The cheeks are full. </li> <li>The tongue comes out over the lower lip during latch-on and stays below the areola during nursing. </li> </ul></div><div id=\"graphicVersion\">Graphic 69241 Version 8.0</div></div></div>"},"69242":{"type":"graphic_figure","displayName":"STEP procedure","title":"Serial transverse enteroplasty procedure (STEP) for short bowel syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serial transverse enteroplasty procedure (STEP) for short bowel syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:348px;\" src=\"images/PEDS/69242_STEP_Procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The small arrows show the direction of insertion of the GIA stapler and the sites of the mesenteric defects. The staplers are placed in the 90&#176; and 270&#176; orientations using the mesentery as the 0&#176; reference point.</div><div class=\"graphic_reference\">Reproduced with permission from: Kim HB, Fauza D, Garza J, et al. Serial transverse enteroplasty (STEP): a novel bowel lengthening procedure. J Pediatr Surg 2003; 38:425. Copyright &#169;2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 69242 Version 3.0</div></div></div>"},"69243":{"type":"graphic_table","displayName":"Visual acuity","title":"Measuring visual acuity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Measuring visual acuity</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Visual acuity is typically measured monocularly rather than binocularly with the aid of a chart and an occluder to cover the eye not being tested. The examiner may also occlude an eye by sliding a tissue behind the patient's eyeglasses or instructing the patient to use his or her hand. The latter method is typically avoided in professional settings as it may inadvertently allow the patient to peek through his or her fingers, or press the eye and alter the measurement when that eye is evaluated.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>1.</strong> Place the chart at 20 feet (or 6 meters) and illuminate the chart adequately.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>2.</strong> If the patient uses glasses, then the test is performed using them.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>3.</strong> Place the occluder in front of the eye that is not being evaluated. The first evaluated eye is the one that is believed to see less or the one the patient says is seeing less.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>4.</strong> Start with the big letters and proceed to the smaller ones. The patient has to identify every letter on the line being presented and communicate it to the physician.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>5.</strong> If the measurement is reduced, then visual acuity can be tested using a pinhole occluder to confirm visual impairment. If performed, both measures should be registered with and without using the pinhole occluder.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>6.</strong> Change the occluder to the other eye and proceed again from the 4th step.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>7.</strong> After both eyes have been evaluated in distant visual acuity, proceed to evaluate near visual acuity by placing a modified Snellen chart for near vision (such as the Rosenbaum chart) at 15.7 inches (or 40 centimeters). Then repeat the test from the 2nd step.\n   </td>\n   </tr>\n   <tr>\n   <td>In some cases, binocular visual acuity will be measured, because usually binocular visual acuity is slightly better than monocular visual acuity.</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=61977&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Visual_acuity.htm</title></head></div><div class=\"graphic_reference\">Courtesy of Dr. Joe Kiff.</div><div id=\"graphicVersion\">Graphic 69243 Version 1.0</div></div></div>"},"69244":{"type":"graphic_table","displayName":"Dyspnea qualities disease state","title":"Qualities of dyspnea and associated disease states","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Qualities of dyspnea and associated disease states</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Descriptor</td>\n<td class=\"subtitle1\">Pathophysiologic mechanism</td>\n<td class=\"subtitle1\">Disease state</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Chest tightness or constriction</td>\n<td rowspan=\"2\">Bronchochonstriction, interstitial edema</td>\n<td>Asthma </td>\n</tr>\n<tr><td>Myocardial ischemia</td></tr>\n<tr>\n<td>Increased work or effort of breathing</td>\n<td>Airways obstruction, neuromuscular disease, reduced chest wall or pulmonary compliance</td>\n<td>COPD, moderate to severe asthma, myopathy, pulmonary fibrosis</td>\n</tr>\n<tr>\n<td>Air hunger, need to breathe, urge to breathe</td>\n<td>Increased drive to breathe</td>\n<td>HF, pulmonary embolism, moderate to severe asthma or COPD</td>\n</tr>\n<tr>\n<td>Rapid, shallow breathing</td>\n<td>Reduced chest wall or pulmonary compliance</td>\n<td>Interstitial fibrosis</td>\n</tr>\n<tr>\n<td>Suffocating, smothering</td>\n<td>Alveolar edema</td>\n<td>Pulmonary edema</td>\n</tr>\n<tr>\n<td>Heavy breathing, breathing more</td>\n<td>Inadequate oxygen delivery to the muscles</td>\n<td>Deconditioning</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69244 Version 1.0</div></div></div>"},"69245":{"type":"graphic_table","displayName":"Farmers lung antigens in HP","title":"Hypersensitivity pneumonitides associated with farming","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with farming</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Environmental source</td> <td class=\"subtitle1\">Major causative antigen</td> </tr> <tr> <td rowspan=\"2\">Moldy hay, grain, silage</td> <td>Thermophilic actinomycetes, such as Faenirecti virgula (also known as Micropolyspora faeni or Saccharopolyspora rectivirgula)</td> </tr> <tr> <td>Fungus, such as Aspergillus umbrosus</td> </tr> <tr> <td>Mold on pressed sugar cane (bagassosis, very rare cases)</td> <td>Thermoactinomyces sacchari, T. vulgaris</td> </tr> <tr> <td rowspan=\"2\">Tobacco plants (tobacco grower's lung; \"Blackfat\" tobacco)</td> <td>Aspergillus sp</td> </tr> <tr> <td>Scopulariopsis brevicaulis</td> </tr> <tr> <td rowspan=\"2\">Mushroom worker's lung</td> <td>Mushroom spores</td> </tr> <tr> <td>Thermophilic actinomycetes</td> </tr> <tr> <td rowspan=\"4\">Potato riddler's lung (moldy hay around potatoes)</td> <td>Thermophilic actinomycetes</td> </tr> <tr> <td>T. vulgaris</td> </tr> <tr> <td>F. rectivirgula</td> </tr> <tr> <td>Aspergillus sp</td> </tr> <tr> <td>Paprika slicer's lung (moldy paprika pods)</td> <td>Mucor stolonifer</td> </tr> <tr> <td>Wine maker's lung (mold on grapes)</td> <td>Botrytis cincrea</td> </tr> <tr> <td rowspan=\"2\">Cheese washer's lung (moldy cheese)</td> <td>Penicillium casei</td> </tr> <tr> <td>Aspergillus clavatus</td> </tr> <tr> <td>Coffee worker's lung</td> <td>Coffee-bean dust</td> </tr> <tr> <td>Tea grower's lung</td> <td>Tea plants</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69245 Version 3.0</div></div></div>"},"69246":{"type":"graphic_figure","displayName":"Epitope spreading","title":"Mechanism of epitope spreading","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of epitope spreading</div><div class=\"cntnt\"><img style=\"width:384px; height:534px;\" src=\"images/RHEUM/69246_Epitope_spreading.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic shows the putative mechanism of epitope spreading, a process whereby one autoantibody profile may evolve into another. At the top of the figure, multiple epitopes of a polypeptide antigen are shown as differently colored boxes. After the polypeptide antigen is processed intracellularly by an antigen presenting cell, a small peptide fragment (orange square) is presented to a Th 1 cell (blue cell). The T cell responds to the peptide by releasing cytokines which stimulates a B cell (green cell) to produce antibodies to the peptide fragment and express antigen specific immunoglobulins on the cell surface. Surface immunoglobulin subsequently recognizes the intact antigen and the antigen is internalized and processed by the B cell acting as an antigen presenting cell. A new peptide epitope (blue square) may then be presented via a HLA molecule to a T cell (red cell) with a different antigen specificity, thereby initiating the production of different antibodies to a new epitope of the same antigen.</div><div id=\"graphicVersion\">Graphic 69246 Version 1.0</div></div></div>"},"69249":{"type":"graphic_figure","displayName":"Ut perf bowel in suction","title":"Uterine fundal perforation with suction curette","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine fundal perforation with suction curette</div><div class=\"cntnt\"><img style=\"width:437px; height:307px;\" src=\"images/OBGYN/69249_Ut_perf_bowel_in_suction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration showing complicated uterine fundal perforation with suction curette: small bowel drawn into the uterine cavity.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69249 Version 1.0</div></div></div>"},"69251":{"type":"graphic_diagnosticimage","displayName":"Lateral CXR barium swallow","title":"Lateral chest x-ray following barium swallow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral chest x-ray following barium swallow</div><div class=\"cntnt\"><img style=\"width:304px; height:406px;\" src=\"images/CARD/69251_Lateral_CXR_barium_swallow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The esophagus is seen to course behind the heart (red arrows). Note the close proximity of the esophagus to the left atrium (LA) and left ventricle (LV).</div><div class=\"graphic_reference\">Courtesy of Sven Paulin, MD.</div><div id=\"graphicVersion\">Graphic 69251 Version 2.0</div></div></div>"},"69254":{"type":"graphic_figure","displayName":"Mastectomy incisions for lower outer quadrant tumors","title":"Mastectomy incisions for tumors of the lower outer quadrant of the breast","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Mastectomy incisions for tumors of the lower outer quadrant of the breast</div><div class=\"cntnt\"><img style=\"width:546px; height:350px;\" src=\"images/SURG/69254_Mastincislowerouterquad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incisions for cancer of the lower outer quadrants of the breast. The surgeon should design incisions that achieve margins of 1 to 2 cm from the tumor with cephalad margins that allow access for dissection of the axilla. The medial extent is the margin of the sternum. Laterally, the inferior extent of the incision is the latissimus.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69254 Version 7.0</div></div></div>"},"69255":{"type":"graphic_diagnosticimage","displayName":"TEE pulmonary arteries","title":"Pulmonary arteries on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteries on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:333px; height:243px;\" src=\"images/CARD/69255_TEE_pulmonary_arteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal (Oº) imaging demonstrates the main pulmonary artery (PA) and its bifurcation into the left (LPA) and right (RPA) pulmonary arteries. The ascending aorta (AAo) is also seen. There is a catheter in the superior vena cava (arrow.)</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 69255 Version 2.0</div></div></div>"},"69256":{"type":"graphic_figure","displayName":"Seminiferous epithelium","title":"Seminiferous epithelium","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Seminiferous epithelium</div><div class=\"cntnt\"><img style=\"width:541px; height:417px;\" src=\"images/ENDO/69256_Seminiferous_epithelium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the seminiferous epithelium. Tight junctions between Sertoli cells separate the tissue into two functional compartments: the basal compartment consists of the Leydig cells, the boundary tissue of the tubules including the peritubular myoid cells, and the outer layers of the tubules containing the spermatogonia; the adluminal compartment contains the inner portion of the tubules, including primary spermatocytes and more advanced stages of spermatogenesis. Developing germ cells are embedded in the Sertoli cell cytoplasm.</div><div class=\"graphic_reference\">Adapted from: Griffin JE, Wilson JD. In: Williams Textbook of Endocrinology, 7th ed, Wilson JD, Foster DW (Eds), WB Saunders, Philadelphia, 1985, p. 802.</div><div id=\"graphicVersion\">Graphic 69256 Version 2.0</div></div></div>"},"69260":{"type":"graphic_table","displayName":"Sx primary coccidioidomycosis","title":"Initial symptoms and signs of coccidioidal pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial symptoms and signs of coccidioidal pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Complaint</td> <td class=\"subtitle1\">Median percentage (range)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Constitutional</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>61 (30 to 99)</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> <td>59 (32 to 83)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Chest pain</td> <td>73 (52 to 95)</td> </tr> <tr> <td class=\"indent1\">Cough</td> <td>64 (44 to 89)</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> <td>21 (12 to 63)</td> </tr> <tr> <td class=\"indent1\">Hemoptysis</td> <td>5 (3 to 21)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Headache</td> <td>27 (17 to 74)</td> </tr> <tr> <td class=\"indent1\">Sore throat</td> <td>24 (14 to 41)</td> </tr> <tr> <td class=\"indent1\">Arthralgia</td> <td>23 (8 to 52)</td> </tr> <tr> <td class=\"indent1\">Erythema nodosum</td> <td>9 (3 to 23)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69260 Version 3.0</div></div></div>"},"69262":{"type":"graphic_diagnosticimage","displayName":"Inferior vena cavagram showing renal vein thrombosis","title":"Inferior vena cavagram showing renal vein thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inferior vena cavagram showing renal vein thrombosis</div><div class=\"cntnt\"><img style=\"width:272px; height:321px;\" src=\"images/NEPH/69262_Renal_vein_thrombosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior vena cavagram reveals large clot in area of left renal vein.</div><div class=\"graphic_reference\">From: Rose BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.</div><div id=\"graphicVersion\">Graphic 69262 Version 4.0</div></div></div>"},"69264":{"type":"graphic_waveform","displayName":"Hemodynamics in constriction","title":"Hemodynamics in severe constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamics in severe constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:329px; height:233px;\" src=\"images/CARD/69264_Hemodynamics_in_constrictio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left and right ventricular pressures are recorded in a patient with severe constrictive pericarditis using a conventional fluid-filled system with care to obtain near critical damping. Both equalization of diastolic pressures and a dip and plateau pattern are seen.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 69264 Version 2.0</div></div></div>"},"69265":{"type":"graphic_figure","displayName":"Euglycemic insulin clamp","title":"Euglycemic insulin clamp in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Euglycemic insulin clamp in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:402px; height:238px;\" src=\"images/ENDO/69265_Euglycemic_insulin_clamp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin dose-response curves during euglycemic clamp studies in normal subjects (upper curve), patients with type 2 diabetes (lower curve), and patients with type 2 diabetes who had been aggressively treated with insulin (middle curve). Patients with type 2 diabetes have marked insulin resistance, as evidenced by a much lower rate of glucose disposal at any insulin concentration. There was partial improvement in insulin responsiveness after aggressive insulin therapy. To convert plasma insulin values to pmol/L, multiply by 6.0.</div><div class=\"graphic_reference\">Data from: Scarlett JA, Gray RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982; 5:353.</div><div id=\"graphicVersion\">Graphic 69265 Version 4.0</div></div></div>"},"69268":{"type":"graphic_picture","displayName":"PJS colonic polyp Light","title":"Colonic Peutz-Jeghers polyp","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic Peutz-Jeghers polyp</div><div class=\"cntnt\"><img style=\"width:397px; height:288px;\" src=\"images/GAST/69268_PJS_colonic_polyp_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a colonic Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal colonic cell types.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 69268 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"69269":{"type":"graphic_diagnosticimage","displayName":"Splenic vein EUS","title":"Splenic vein and portal vein seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Splenic vein and portal vein seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:341px; height:603px;\" src=\"images/GAST/69269_Splenic_vein_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radial endoscopic ultrasound image showing the confluence (CON) of the splenic vein (SV) and the portal vein.<br />(Top) Anterior to the confluence, the pancreatic parenchyma and the pancreatic duct (PD) are shown.<br />(Bottom) Simplification of top image.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 69269 Version 4.0</div></div></div>"},"69270":{"type":"graphic_figure","displayName":"Triclonal pattern immunofix","title":"Triclonal gammopathy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Triclonal gammopathy</div><div class=\"cntnt\"><img style=\"width:463px; height:381px;\" src=\"images/HEME/69270_Triclonal_pattern_immunofix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the immunofixation pattern of a single serum specimen with antisera to heavy chain determinants of IgA, IgG, and IgM, and to kappa and lambda light chain determinants. It shows a discrete IgG band and a discrete kappa band with similar mobility, indicative of an IgG kappa monoclonal protein. There are also IgA lambda and IgM kappa monoclonal proteins.</div><div id=\"graphicVersion\">Graphic 69270 Version 1.0</div></div></div>"},"69272":{"type":"graphic_picture","displayName":"Rheumatoid nodule Low","title":"Rheumatoid nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid nodule</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/RHEUM/69272_Rheumatoid_nodule_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a nodule from a patient with rheumatoid arthritis showing an area of geographic stellate necrobiosis with extensive fibrin deposition surrounded by a palisading histiocytic rim.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 69272 Version 1.0</div></div></div>"},"69273":{"type":"graphic_table","displayName":"AC-T for breast cancer","title":"Doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (T) chemotherapy for adjuvant treatment of breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (T) chemotherapy for adjuvant treatment of breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> AC is given every 21 days for four cycles.<br /> Paclitaxel is given every seven days of a 28 day cycle for three cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5% dextrose in water (D5W). The presence of local erythematous streaking along the vein as well as facial flushing may be signs that administration is too rapid. If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Rapid infusions may produce nasal burning or congestion that is relieved by slowing the rate.</td> <td>Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>After completion of AC, administer:</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel*</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS or D5W to a final concentration of 0.3 to 1.2 mg/mL and administer over one hour.<sup>&#182;</sup></td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Not applicable. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment is not necessary for doxorubicin or paclitaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>A baseline assessment of LVEF is recommended, with periodic reassessment of during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin.<sup>[2]</sup> Further information on anthracycline-associated cardiotoxicity, including discussion about prevention and treatment, is available. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment cycle of paclitaxel. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>During treatment with doxorubicin or paclitaxel, assess line site periodically during infusion of chemotherapy for signs and symptoms of extravasation. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/microL and platelet count greater than 100,000/microL. If there is more than a three week delay in treatment, a dose reduction of 25% is recommended.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe neuropathy (grade 3 or 4) that persists for a week or longer, the dose of paclitaxel should be reduced by 20% for subsequent courses of paclitaxel; hold if severe toxicity persists after dose reduction.<sup>[4]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for hepatic or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin, cyclophosphamide, and paclitaxel in patients who have changes in kidney or liver function during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.<br />* Paclitaxel may also be administered at a dose of 175 mg/m<SUP>2</SUP> over&nbsp;three hours IV infusion on day 1 every 14 days times&nbsp;four doses.<br />¶ Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less. <br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sparano JA, et al. N Engl J Med 2008; 358:1663.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 69273 Version 22.0</div></div></div>"},"69276":{"type":"graphic_table","displayName":"Ethanol content in beverages and other products","title":"Ethanol content in beverages, medications, and household products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ethanol content in beverages, medications, and household products</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Ethanol content by volume, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Beverage*</td> </tr> <tr> <td class=\"indent1\">Nonalcoholic beer</td> <td>0.32</td> </tr> <tr> <td class=\"indent1\">Beer</td> <td>3.2-14</td> </tr> <tr> <td class=\"indent1\">Wine</td> <td>8-22</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Liquor</td> <td>20-95</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Medication</td> </tr> <tr> <td class=\"indent1\">Cold/allergy</td> <td>5-16</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cough medicine</td> <td>2-25</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Household products</td> </tr> <tr> <td class=\"indent1\">Aftershave lotion</td> <td>15-80</td> </tr> <tr> <td class=\"indent1\">Glass cleaners</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Mouthwashes</td> <td>15-25</td> </tr> <tr> <td class=\"indent1\">Perfumes or colognes</td> <td>25-95</td> </tr> <tr> <td class=\"indent1\">Alcohol-based hand sanitizers<sup>&#182;</sup></td> <td>60-95</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Typical content for beer, wine, and liquor is 5, 14, and 40 percent, respectively.<br />&para; May also contain isopropyl alcohol (isopropanol).</div><div class=\"graphic_reference\">Reproduced with permission from: Kleinschmidt, KC. Ethanol. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed, Shannon, MW, Borron, SW, Burns, MJ. Saunders Elsevier, Philadelphia, 2007. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2005 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 69276 Version 4.0</div></div></div>"},"69277":{"type":"graphic_waveform","displayName":"Basic case 5","title":"Basic case 5","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 5</div><div class=\"cntnt\"><img style=\"width:540px; height:79px;\" src=\"images/CARD/69277_Basic_case_5.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69277 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"69279":{"type":"graphic_diagnosticimage","displayName":"Acute histoplasmosis chest x-ray","title":"Acute histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute histoplasmosis</div><div class=\"cntnt\"><img style=\"width:325px; height:372px;\" src=\"images/ID/69279_Subacute_histoplasmosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray from a patient with acute pulmonary histoplasmosis shows enlargement of right hilar lymph nodes (arrow) and a patchy right upper lobe infiltrate (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 69279 Version 4.0</div></div></div>"},"69282":{"type":"graphic_picture","displayName":"Joints psoriatic arthritis PI","title":"Psoriatic arthritis on the joints of the fingers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psoriatic arthritis on the joints of the fingers</div><div class=\"cntnt\"><img style=\"width:360px; height:375px;\" src=\"images/PI/69282_Joints_psoriatic_arthr_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person has psoriatic arthritis affecting the middle and little fingers, on the joints furthest from the palm. The person's nails are also separating from the nail bed, which is also a symptom of psoriatic arthritis.</div><div class=\"graphic_reference\">Courtesy of Dafna D Gladman, MD.</div><div id=\"graphicVersion\">Graphic 69282 Version 3.0</div></div></div>"},"69283":{"type":"graphic_table","displayName":"Tumors reported to cause NICTH","title":"Tumors reported to cause nonislet cell tumor hypoglycemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumors reported to cause nonislet cell tumor hypoglycemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Carcinomas</td> </tr> <tr> <td>Adrenal cortex</td> </tr> <tr> <td>Bile duct</td> </tr> <tr> <td>Breast</td> </tr> <tr> <td>Cervix</td> </tr> <tr> <td>Colon</td> </tr> <tr> <td>Esophagus</td> </tr> <tr> <td>Larynx</td> </tr> <tr> <td>Lung</td> </tr> <tr> <td>Ovary</td> </tr> <tr> <td>Pancreas</td> </tr> <tr> <td>Prostate</td> </tr> <tr> <td>Stomach</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Other tumors</td> </tr> <tr> <td>Carcinoid</td> </tr> <tr> <td>Fibrosarcoma</td> </tr> <tr> <td>Fibrous tumor of the pleura</td> </tr> <tr> <td>Hemangiopericytoma</td> </tr> <tr> <td>Hepatoma</td> </tr> <tr> <td>Hypernephroma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Leiomyosarcoma</td> </tr> <tr> <td>Liposarcoma</td> </tr> <tr> <td>Meningioma</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Neurilemmoma</td> </tr> <tr> <td>Neurofibroma</td> </tr> <tr> <td>Neurofibrosarcoma</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Wilms tumor</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69283 Version 3.0</div></div></div>"},"69284":{"type":"graphic_waveform","displayName":"Aberrant conduction tutorial","title":"Aberrant interventricular conduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aberrant interventricular conduction</div><div class=\"cntnt\"><img style=\"width:422px; height:146px;\" src=\"images/CARD/69284_Aberrant_conduction_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aberrant conduction of the fourth beat (arrow) is diagnosed because the duration of the QRS complex is wider during a tachycardia than during the slower sinus rhythm.</div><div id=\"graphicVersion\">Graphic 69284 Version 2.0</div></div></div>"},"69285":{"type":"graphic_figure","displayName":"Recurrent AF after amiodarone propafenone and sotalol","title":"The rate of recurrent atrial fibrillation is lowest with amiodarone","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">The rate of recurrent atrial fibrillation is lowest with amiodarone</div><div class=\"cntnt\"><img style=\"width:541px; height:259px;\" src=\"images/CARD/69285_Recurrent_AF_amiodarone.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Canadian Trial of Atrial Fibrillation randomized 403 patients with at least one episode of atrial fibrillation (AF) during the prior six months to low-dose amiodarone, propafenone, or sotalol. After a mean follow-up of 16 months, the likelihood of being free from recurrent AF was highest with amiodarone (65 versus 37 percent for sotalol and propafenone) and the median time to recurrence was longer (&gt;468 versus 98 days).</div><div class=\"graphic_reference\">Data from: Roy D, Talajic M, Dorian P, et al. N Engl J Med 2000; 342:913.</div><div id=\"graphicVersion\">Graphic 69285 Version 3.0</div></div></div>"},"69286":{"type":"graphic_picture","displayName":"AC joint and shoulder internal rotation","title":"Internal rotation of shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal rotation of shoulder</div><div class=\"cntnt\"><img style=\"width:432px; height:320px;\" src=\"images/EM/69286_AC_joint_shoulder_int_rota.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with rotator cuff problems may also experience pain when their arm is adducted across the body, particularly if the shoulder is internally rotated, as in the photograph above.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 69286 Version 1.0</div></div></div>"},"69288":{"type":"graphic_movie","displayName":"VSD with prolapsed RCC of aortic valve","title":"VSD with prolapsed RCC of aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">VSD with prolapsed RCC of aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/69288_VSDprolapRCCaortmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:560px; height:425px;\" src=\"images/CARD/69288_VSDprolapRCCaortposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right coronary cusp of the aortic valve is seen prolapsing across the VSD and into the right ventricle. Note that the cusp is unusually elongated and more restricted in its motion when compared with the left coronary cusp.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; AO: aorta; MV: mitral valve; LA: left atrium; arrow: VSD.<BR>* Denotes right coronary cusp of the aortic valve.</div><div id=\"graphicVersion\">Graphic 69288 Version 4.0</div></div></div>"},"69289":{"type":"graphic_picture","displayName":"Q-switched laser skin whitening","title":"Skin whitening after Q-switched laser treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin whitening after Q-switched laser treatment</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/69289_Q_switched_laser_skin_white.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo demonstrates the expected skin whitening effect that appears immediately after treatment with a Q-switched laser.</div><div id=\"graphicVersion\">Graphic 69289 Version 1.0</div></div></div>"},"69291":{"type":"graphic_table","displayName":"Laboratory studies in child with status epilepticus","title":"Laboratory studies in child with status epilepticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory studies in child with status epilepticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient population</td> <td class=\"subtitle1\">Studies</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">All patients</td> <td>Serum electrolytes</td> </tr> <tr> <td>Serum calcium, phosphate, and magnesium</td> </tr> <tr> <td>Brain imaging (CT or MRI)*</td> </tr> <tr class=\"divider_bottom\"> <td>EEG</td> </tr> <tr class=\"divider_bottom\"> <td>Epilepsy patients maintained on anticonvulsants</td> <td>Anticonvulsant level</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Febrile patients</td> <td>CBC with differential</td> </tr> <tr> <td>Blood culture</td> </tr> <tr> <td>Urinalysis, urine culture</td> </tr> <tr class=\"divider_bottom\"> <td>CSF culture (once seizures stopped and if brain imaging excludes increased intracranial pressure)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Poisoned patient</td> <td>Urine screen for cocaine, amphetamines, and PCP</td> </tr> <tr> <td>Aspirin level</td> </tr> <tr> <td>Venous or arterial pH and pCO2</td> </tr> <tr class=\"divider_bottom\"> <td>EKG once seizures stop</td> </tr> <tr> <td rowspan=\"11\">Infants &#60;6 months of age<sup>&#182;</sup></td> <td>Blood gas</td> </tr> <tr> <td>Plasma ammonia</td> </tr> <tr> <td>Plasma amino acids</td> </tr> <tr> <td>PT, PTT</td> </tr> <tr> <td>Serum AST, ALT, LDH, Alkaline phosphatase</td> </tr> <tr> <td>Blood lactate and pyruvate</td> </tr> <tr> <td>Urinalysis</td> </tr> <tr> <td>Urine for reducing substances</td> </tr> <tr> <td>Urine organic acids</td> </tr> <tr> <td>Urine amino acids</td> </tr> <tr> <td>Check newborn urine screening results if infant from country where instituted</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; EEG: electroencephalogram; CBC: complete blood count; PCP: phencyclidine; EKG: electrocardiogram; PT: prothrombin time; PTT: partial thromboplastin time; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase.<br />* Neuroimaging is essential when status is the first presentation of epilepsy as well as in children whose recovery does not follow the expected course.<br />¶ Consultation with pediatric neurologist and/or metabolic specialist strongly encouraged.</div><div id=\"graphicVersion\">Graphic 69291 Version 6.0</div></div></div>"},"69292":{"type":"graphic_figure","displayName":"Neonatal testicular torsion","title":"Intravaginal and extravaginal testicular torsion","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Intravaginal and extravaginal testicular torsion</div><div class=\"cntnt\"><img style=\"width:539px; height:297px;\" src=\"images/PEDS/69292_Patho_NB_testis_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neonatal testicular torsion is generally due to extravaginal torsion and testicular torsion in older children and adolsecents is due to intravaginal torsion.</div><div id=\"graphicVersion\">Graphic 69292 Version 1.0</div></div></div>"},"69293":{"type":"graphic_picture","displayName":"TT bacterial biofilm","title":"Bacterial biofilm of tympanostomy tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial biofilm of tympanostomy tube</div><div class=\"cntnt\"><img style=\"width:390px; height:351px;\" src=\"images/PEDS/69293_TT_bacterial_biofilm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bacterial biofilms may form on mucosal surfaces and implanted prostheses, including tympanostomy tubes as depicted above; these bacterial aggregates are resistant to therapy with systemic antibiotics and to standard culture methods.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 69293 Version 2.0</div></div></div>"},"69294":{"type":"graphic_picture","displayName":"Cat scratch macular star","title":"Macular star from ocular involvement with cat scratch disease","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Macular star from ocular involvement with cat scratch disease</div><div class=\"cntnt\"><img style=\"width:564px; height:273px;\" src=\"images/RHEUM/69294_Cat_scratch_macular_star.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exudates are seen overlying the macula, and some are radiating outward from the foveal area. This is referred to as a macular star. The appearance is characteristic of cat scratch disease with ocular involvement.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 69294 Version 2.0</div></div></div>"},"69295":{"type":"graphic_picture","displayName":"Neutrophilic dermatosis hands","title":"Neutrophilic dermatosis of the dorsal hands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neutrophilic dermatosis of the dorsal hands</div><div class=\"cntnt\"><img style=\"width:389px; height:262px;\" src=\"images/DERM/69295_Neutrophilic_dermatosis_han.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Painful plaques that have progressed to ulceration. These developed in a 60-year-old female with seropositive rheumatoid arthritis. The histologic appearance was epithelial hyperplasia with intraepithelial sterile abscesses and dense dermal infiltrate of neutrophils with an absence of leucocytoclastic vasculitis.</div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD.</div><div id=\"graphicVersion\">Graphic 69295 Version 2.0</div></div></div>"},"69296":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis in IBD MRI","title":"Sacroiliitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis</div><div class=\"cntnt\"><img style=\"width:338px; height:748px;\" src=\"images/RHEUM/69296_Sacroiliitis_in_IBD_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Upper panel) Coronal T1-weighted MRI of the sacroiliac joints reveals decreased signal in the sacrum and the iliac in the region of the inferior left sacroiliac joint (arrows). (Middle panel) Coronal T2- weighted MRI reveals corresponding hyperintense signal in the inferior left sacroiliac joint (arrows). (Bottom panel) Axial T1- weighted MRI with fat saturation following intravenous gadolinium injection demonstrates intense enhancement of the left sacroiliac joint. These findings are most compatible with sacroiliitis in a patient with inflammatory bowel disease.</div><div class=\"graphic_reference\">Courtesy of Doug Brown, MD.</div><div id=\"graphicVersion\">Graphic 69296 Version 2.0</div></div></div>"},"69298":{"type":"graphic_figure","displayName":"Comparison of cephalosporin and penicillin structures","title":"Comparison of cephalosporin and penicillin structures","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Comparison of cephalosporin and penicillin structures</div><div class=\"cntnt\"><img style=\"width:513px; height:185px;\" src=\"images/ALLRG/69298_Ceph_vs_pen_structures_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cephalosporins and penicillins share a four-membered beta-lactam ring. Cephalosporins have a six-membered dihydrothiazine ring, while penicillins have a five-membered thiazolidine ring. The R1, and to a lesser extent, the R2 side groups on cephalosporins are important in generating allergenic epitopes.</div><div class=\"graphic_footnotes\">R: side chain group.</div><div class=\"graphic_reference\">Courtesy of Antonino Romano, MD.</div><div id=\"graphicVersion\">Graphic 69298 Version 10.0</div></div></div>"},"69299":{"type":"graphic_picture","displayName":"Melioidosis lung pathology","title":"Gross pathology of melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology of melioidosis</div><div class=\"cntnt\"><img style=\"width:390px; height:260px;\" src=\"images/ID/69299_Melioidosis_lung_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung findings in a gross pathology specimen of melioidosis at autopsy.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 69299 Version 2.0</div></div></div>"},"69301":{"type":"graphic_picture","displayName":"Infil UC micropap variant","title":"Infiltrating urothelial carcinoma, micropapillary variant","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma, micropapillary variant</div><div class=\"cntnt\"><img style=\"width:514px; height:200px;\" src=\"images/ONC/69301_Infil_UC_micropap_variant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: The micropapillary variant of UC is characterized by fine papillae with high-grade cytologic features. Necrosis (lower right) is commonly present (20x). B: The papillae are usually contained within tissue retraction spaces, simulating lymphatic spaces (40x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69301 Version 1.0</div></div></div>"},"69302":{"type":"graphic_picture","displayName":"MDI with counter PI","title":"MDI with counter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MDI with counter</div><div class=\"cntnt\"><img style=\"width:396px; height:325px;\" src=\"images/PI/69302_MDI_with_counter_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some metered dose inhalers have built-in dose counters. When the counter reads 0 (zero), there is no medicine left in the inhaler.</div><div id=\"graphicVersion\">Graphic 69302 Version 3.0</div></div></div>"},"69303":{"type":"graphic_table","displayName":"Sleep restriction rules","title":"Sleep restriction rules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sleep restriction rules</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Determine the patient's average sleep time from a sleep diary.</td> </tr> <tr> <td>2. Use this average sleep time as the new time allowed in bed each night.</td> </tr> <tr> <td>3. Set a consistent wake time based upon the type of insomnia and patient need.</td> </tr> <tr> <td>4. Have patient avoid daytime naps.</td> </tr> <tr> <td>5. If sleep efficiency increases above 90 percent (85 percent for patients over 65 years of age), then increase time in bed by 15 to 30 minutes.</td> </tr> <tr> <td>6. If sleep efficiency decreases below 85 percent (80 percent for patients over 65 years of age), then decrease time in bed by 15 to 30 minutes.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=68879&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Adapted from: Spielman AJ, Yang CM, Glovinsky PB. Insomnia: Sleep restriction therapy. In: Insomnia Diagnosis and Treatment, Sateia MJ, Buysse DJ (Eds), Informa UK Ltd, London 2010.</div><div id=\"graphicVersion\">Graphic 69303 Version 7.0</div></div></div>"},"69304":{"type":"graphic_diagnosticimage","displayName":"Osteonecrosis femoral head","title":"Osteonecrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteonecrosis</div><div class=\"cntnt\"><img style=\"width:318px; height:322px;\" src=\"images/RHEUM/69304_Osteonecrosis_femoral_head.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain film of the hip demonstrating features consistent with ischemic necrosis of the femoral head. These include lucent regions with associated sclerotic rims in the right femoral head (arrows), squared-off, straight margins, and mottled increased density due to destruction of the bony trabecula.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69304 Version 2.0</div></div></div>"},"69308":{"type":"graphic_table","displayName":"Adherence antiretroviral meds","title":"Strategies to improve adherence with antiretroviral medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to improve adherence with antiretroviral medications</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Initial intervention strategies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Establish trust and identify mutually acceptable goals for care.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Obtain explicit agreement on need for treatment and adherence.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Identify depression, low self-esteem, or drug use that may decrease adherence.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Treat prior to starting therapy, if possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Identify family, friends, health team members, or others who can help with adherence support.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Educate patient and family about the critical role of adherence in therapy outcome.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Identify the adherence target: 95 percent of prescribed doses.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Educate patient and family about the relationship between partial adherence and resistance.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Educate patient and family about resistance and constraint of later choices of antiretroviral drug; ie, explain that while a failure of adherence may be temporary, the effects on treatment choice may be permanent.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Develop a treatment plan that the patient and family understand and to which they feel committed.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Establish readiness to take medication by practice sessions or other means.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Consider a brief period of hospitalization at start of\ntherapy in selected circumstances, for patient education and to assess\ntolerability of medications chosen.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Medication strategies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose the simplest regimen possible, reducing dosing frequency and number of pills.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose a regimen with dosing requirements that best conform\nto the daily and weekly routines and variations in patient and family\nactivities.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose the best-tasting liquid medicine possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose drugs with the fewest side effects; inform patient regarding medication side effects; anticipate and treat side effects.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Simplify food requirements for medication administration.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prescribe drugs carefully to avoid adverse drug-drug interactions.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Follow-up intervention strategies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Monitor adherence at each visit, and in between visits by telephone or letter as needed.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide ongoing support, encouragement, and understanding of\nthe difficulties of the demands of trying to be &#62;95 percent adherent\nwith medication doses.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use patient education aids including pictures, calendars, stickers.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use pill boxes, reminders, alarms, pagers, timers.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide nurse, social worker, or other practitioner adherence clinic visits or telephone calls.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide access to support groups or one-on-one counseling for\npatients with depression or drug use issues that are known to decrease\nadherence.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide pharmacist-based adherence clinics.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Consider gastrostomy tube use in selected circumstances.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Consider a brief period of hospitalization during therapy in\nselected circumstances of apparent virologic failure to assess\nadherence and reinforce that medication adherence is fundamental to\nsuccessful antiretroviral therapy.</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=49756&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Adherence_antiretroviral_me.htm</title></head></div><div class=\"graphic_reference\">http://www.aidsinfo.nih.gov.</div><div id=\"graphicVersion\">Graphic 69308 Version 1.0</div></div></div>"},"69309":{"type":"graphic_table","displayName":"Pediatric dental rapid overview","title":"Pediatric dental trauma: Rapid overview*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric dental trauma: Rapid overview*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation</td> </tr> <tr> <td class=\"indent1\">When did the injury occur?</td> </tr> <tr> <td class=\"indent1\">Any loss of consciousness or altered mental status suggesting significant head trauma?</td> </tr> <tr> <td class=\"indent1\">Does the child have tooth pain or dental pain with touch, eating, or exposure to hot or cold?</td> </tr> <tr> <td class=\"indent1\">Is malocclusion present?</td> </tr> <tr> <td class=\"indent1\">Which teeth are injured? Are they primary or secondary teeth?<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Is tooth avulsion present (see \"Emergency treatment of dental avulsion\" below)?</td> </tr> <tr> <td class=\"indent1\">Are there signs of child abuse (eg, torn upper labial frenula or labial sulcus in a nonambulatory child, bruising behind the ear, bruising in the shape of a hand, pinchmarks, bruising in various stages of development)?<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Is there tenderness over the jaw or temporomandibular joint?</td> </tr> <tr> <td class=\"subtitle1_single\">Emergency treatment of dental avulsion</td> </tr> <tr> <td class=\"sublist2_start\">Reimplant any avulsed permanent teeth as soon as possible<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Handle the tooth by the crown</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Gently rinse the tooth with tap water or saline. Do NOT scrub or sterilize the tooth!</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Insert the tooth into the empty socket</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Keep the tooth in place through finger pressure or by having the child bite on a gauze pad or clean towel</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Obtain urgent pediatric dental consultation</li> </ul> </td> </tr> <tr> <td class=\"indent1\">If unable to reimplant immediately, store the tooth in Hank's balanced salt solution, cold milk, or a container of the child's saliva (NOT the child's mouth and not in water)</td> </tr> <tr> <td class=\"indent1\">Do NOT reimplant primary (baby) teeth<span style=\"font-size: 13px;\"><sup>&#916;</sup>. If uncertain if the tooth is primary or permanent, gently reimplant.</span></td> </tr> <tr> <td class=\"subtitle1_single\">Other dental injuries</td> </tr> <tr> <td class=\"indent1\">Remove very loose or dangling primary (baby) teeth<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"sublist2_start\">Urgently refer the following children to a dentist with pediatric expertise:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Extruded &#62;3mm or interfering with bite</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Laterally luxated (displaced) teeth that interfere with bite</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Intruded primary teeth</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Fractured teeth when dental pulp is exposed (bleeding from central core of the tooth)</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Fractured permanent teeth. If available, tooth fragments may be reattached (store in tap water to prevent discoloration).</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Suspected dental root or alveolar fracture</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Suspected jaw fracture (jaw tenderness and/or malocclusion) to obtain panorex radiograph</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other considerations</td> </tr> <tr> <td class=\"indent1\">Provide tetanus prophylaxis, as needed, for patients with contaminated wounds, deep intraoral lacerations, or avulsed teeth</td> </tr> <tr> <td class=\"indent1\">Provide antibiotic prophylaxis for bacterial endocarditis in susceptible patients</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on pediatric dental injuries.<br />&para; Refer to UpToDate topics on diagnosis and management of physical abuse in children.<br />&Delta; Permanent teeth do not typically erupt before six years of age.<br /></div><div id=\"graphicVersion\">Graphic 69309 Version 7.0</div></div></div>"},"69310":{"type":"graphic_figure","displayName":"Proximal sugar tong splint","title":"Proximal sugar tong splint","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Proximal sugar tong splint</div><div class=\"cntnt\"><img style=\"width:460px; height:525px;\" src=\"images/PEDS/69310_Proximal_sugar_tong_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Application of the proximal sugar tong splint is shown in three steps: <br />(A) Position the plaster. <br />(B) Secure the splint in place. <br />(C) Add a sling for support.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaw, DC, Heckman, JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391. Copyright © 1984 Elsevier.</div><div id=\"graphicVersion\">Graphic 69310 Version 2.0</div></div></div>"},"69312":{"type":"graphic_figure","displayName":"Brachial artery puncture","title":"Brachial artery puncture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachial artery puncture</div><div class=\"cntnt\"><img style=\"width:322px; height:240px;\" src=\"images/PULM/69312_Brachial_artery_puncture.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique of brachial artery puncture. The brachial artery is palpable in the antecubital fossa just medial to the biceps tendon. The needle should enter the brachial artery just above the antecubital crease.</div><div class=\"graphic_reference\">Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 69312 Version 1.0</div></div></div>"},"69313":{"type":"graphic_diagnosticimage","displayName":"Chronic thromboemboli PA","title":"Chronic thromboembolic disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic thromboembolic disease</div><div class=\"cntnt\"><img style=\"width:360px; height:315px;\" src=\"images/PULM/69313_Chronic_thromboemboli_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with chronic thromboembolic disease shows enlarged, irregular central pulmonary arteries with left lower lobe oligemia.</div><div class=\"graphic_reference\">Courtesy of Peter F Fedullo, MD.</div><div id=\"graphicVersion\">Graphic 69313 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"69317":{"type":"graphic_table","displayName":"Frequency appendiceal neoplasms","title":"Frequency of appendiceal neoplasms found in 7970 appendectomy specimens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of appendiceal neoplasms found in 7970 appendectomy specimens</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Neoplasm</td>\n\n      <td class=\"subtitle1\">N</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Carcinoid</td>\n\n      <td>42</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Benign tumors</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mucinous cystadenoma</td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Villous adenoma</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Malignant tumors</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">Primary</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Adenocarcinoma</td>\n\n      <td class=\"sublist_other\">8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Lymphoma</td>\n\n      <td class=\"sublist_other\">1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Secondary</td>\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Total</td>\n\n      <td>74</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from: Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7970 appendectomies. Dis Colon Rectum 1998; 41:75.</div><div id=\"graphicVersion\">Graphic 69317 Version 2.0</div></div></div>"},"69319":{"type":"graphic_figure","displayName":"Effect of workplace smoking policy","title":"Effect of workplace smoking policies on nicotine concentrations","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Effect of workplace smoking policies on nicotine concentrations</div><div class=\"cntnt\"><img style=\"width:511px; height:446px;\" src=\"images/PC/69319_Effect_workplace_smoking_po.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distribution of nicotine concentrations in workplaces as a function of smoking policy, and by office or other workplaces illustrates that a policy of banning smoking reduces nicotine concentrations.</div><div class=\"graphic_reference\">Data from Hammond, SK, Environ Health Perspect 1999; 107:329.</div><div id=\"graphicVersion\">Graphic 69319 Version 2.0</div></div></div>"},"69322":{"type":"graphic_figure","displayName":"Origin of dyspnea sensation","title":"Efferent and afferent signals that contribute to the sensation of dyspnea","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Efferent and afferent signals that contribute to the sensation of dyspnea</div><div class=\"cntnt\"><img style=\"width:497px; height:647px;\" src=\"images/PULM/69322_Origin_of_dyspnea_sensation_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The symptom of dyspnea likely arises from a range of sensory inputs, many of which lead to qualitatively distinct descriptive phrases used by patients. The sensation of respiratory effort arises from signals transmitted from the motor cortex to the sensory cortex (green arrow) when outgoing motor commands are sent to the ventilatory muscles (blue arrow). Motor output from the brain stem (blue arrow) may also be accompanied by signals transmitted to the sensory cortex, contributing to the sensation of effort (dotted green arrow).<br> The sensation of air hunger probably derives from a combination of stimuli that increase the drive to breathe such as insufficient oxygen or excess carbon dioxide (mediated by signals from chemoreceptors in the carotid body and aortic arch), acute hypercapnia or acidemia (mediated by signals from the peripheral and central chemoreceptors), airway and interstitial inflammation (mediated by pulmonary afferents), and vascular receptors. The intensity of air hunger is increased when there is a perceived mismatch between the outgoing efferent messages to the ventilatory muscles and incoming afferent signals from the lungs and chest wall.<br> Chest tightness, commonly associated with bronchospasm, is mediated by stimulation of vagal-irritant receptors. Afferent signals (red arrows) from airway, lung, and chest wall receptors most likely pass through the brain stem before being transmitted to sensory cortex, although it is also possible that some afferent information bypasses the brain stem and goes directly to sensory cortex (dotted arrow).</div><div class=\"graphic_footnotes\">Red arrows: afferent signals; Blue arrows: efferent signals; Green arrows: signals within the central nervous system; Dotted lines: hypothetical pathways; Circles: chemoreceptors; Squares: mechanoreceptors.</div><div id=\"graphicVersion\">Graphic 69322 Version 5.0</div></div></div>"},"69323":{"type":"graphic_figure","displayName":"Pericardium anatomy PI","title":"The pericardium of the heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The pericardium of the heart</div><div class=\"cntnt\"><img style=\"width:423px; height:436px;\" src=\"images/PI/69323_Pericardium_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pericardium is the sac that surrounds the heart. It normally functions to protect the heart and reduce friction between the heart and surrounding organs.</div><div id=\"graphicVersion\">Graphic 69323 Version 4.0</div></div></div>"},"69324":{"type":"graphic_diagnosticimage","displayName":"Pancreatic pseudocyst after blunt trauma","title":"Pancreatic pseudocyst after blunt trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic pseudocyst after blunt trauma</div><div class=\"cntnt\"><img style=\"width:430px; height:330px;\" src=\"images/EM/69324_Pan_pseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child was crushed between a snowmobile and a concrete wall and had acute swelling of the pancreas on computed tomography initially. Several weeks later, she developed signs of a pancreatic pseudocyst (arrows) shown as a large cystic mass posterior to the stomach (arrowhead). This cyst resolved after creation of a cyst-gastrostomy.</div><div class=\"graphic_reference\">Courtesy of David Wesson, MD.</div><div id=\"graphicVersion\">Graphic 69324 Version 4.0</div></div></div>"},"69325":{"type":"graphic_diagnosticimage","displayName":"Spiral fracture tibial shaft","title":"A spiral fracture of the tibial shaft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A spiral fracture of the tibial shaft</div><div class=\"cntnt\"><img style=\"width:233px; height:432px;\" src=\"images/EM/69325_Spiral_frac_tibial_shaft.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, WL. Fracture management for primary care, 2nd ed. Chapter 2: General principles of fracture care. Saunders, Philadelphia 1998. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright ©1998 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 69325 Version 3.0</div></div></div>"},"69328":{"type":"graphic_table","displayName":"Oral antibiotics human bites","title":"Empiric oral antibiotic therapy for human bites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric oral antibiotic therapy for human bites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dosing for adults</td> <td class=\"subtitle1\">Dosing for children</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Agent of choice:</p> Amoxicillin-clavulanate</td> <td>875/125 mg twice daily</td> <td>20 mg/kg per dose (amoxicillin component) two times daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternate empiric regimens include:<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">One of the following agents with activity against <em>Eikenella</em>:</td> </tr> <tr> <td class=\"sublist2\">Doxycycline<sup>&#916;<sup></sup></sup></td> <td class=\"sublist_other\">100 mg twice daily</td> <td class=\"sublist_other\">Not recommended in children &#60;8 years of age</td> </tr> <tr> <td class=\"sublist2\">Trimethoprim-sulfamethoxazole<sup>&#916;</sup></td> <td class=\"sublist_other\">1 double strength tablet twice daily</td> <td class=\"sublist_other\">4 to 5 mg/kg (trimethoprim component) per dose twice daily (maximum 160 mg trimethoprim per dose)</td> </tr> <tr> <td class=\"sublist2\">Penicillin VK</td> <td class=\"sublist_other\">500 mg four times daily</td> <td class=\"sublist_other\">12.5 mg/kg per dose four times daily (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"sublist2\">Cefuroxime</td> <td class=\"sublist_other\">500 mg twice daily</td> <td class=\"sublist_other\">10 mg/kg per dose twice daily (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Fluoroquinolones (one of the following):</td> </tr> <tr> <td class=\"sublist3\">Ciprofloxacin</td> <td class=\"sublist_other\">500 to 750 mg twice daily</td> <td class=\"sublist_other\">Use with caution in children &#60;18 years of age</td> </tr> <tr> <td class=\"sublist3\">Moxifloxacin</td> <td class=\"sublist_other\">400 mg once daily</td> <td class=\"sublist_other\">Use with caution in children &#60;18 years of age</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">One of the following agents with anaerobic activity:</td> </tr> <tr> <td class=\"sublist2\">Metronidazole</td> <td class=\"sublist_other\">500 mg three times daily</td> <td class=\"sublist_other\">10 mg/kg per dose three times daily (maximum 500 mg per dose)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Clindamycin<sup>&#916;</sup></td> <td class=\"sublist_other\">450 mg three times daily</td> <td class=\"sublist_other\">10 mg/kg per dose three times daily (maximum 450 mg per dose)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">The following agents have poor activity against <em>Eikenella</em> and should be avoided:</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Cephalexin</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Dicloxacillin</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Erythromycin</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency. Additional coverage for certain gram-positive pathogens may also be warranted (eg, if the patient has risk factors for colonization with community-acquired methicillin-resistant <EM>Staphylococcus aureus </EM>[MRSA]). Refer to UpToDate topic reviews of soft tissue infections due to human bites and MRSA treatment for recommendations.</div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* In patients with infected bite wounds, the clinician may increase the does to 45 mg/kg per dose (amoxicillin component) twice daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose).<br />¶ The preferred regimen for pencillin allergic pediatric patients is trimethoprim-sulfamethoxazole OR cefuroxime PLUS clindamycin (depending on liquid drug availability and palatability).<br />Δ May also be active against MRSA (check susceptibility testing).</div><div id=\"graphicVersion\">Graphic 69328 Version 6.0</div></div></div>"},"69330":{"type":"graphic_picture","displayName":"Anacardiaceae dermatitis","title":"Clinical manifestations of anacardiaceae dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical manifestations of anacardiaceae dermatitis</div><div class=\"cntnt\"><img style=\"width:373px; height:385px;\" src=\"images/PC/69330_Ancrdc_drmtt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Acute, streak-like edematous and erythematous dermatitis without vesicles after poison ivy brushed across the face. Courtesy of Fitzsimons Army Medical Center Dermatology slide teaching library.<br />(B) Acute, streak- like vesicular dermatitis after poison ivy (Toxicodendron radicans) contact. Courtesy of Fitzsimons Army Medical Center Dermatology slide teaching library.<br />(C) \"Black-spot\" poison ivy dermatitis: note the black discoloration in the central portion of the edematous plaques due to plant resin.<br />(D) Widespread erythema and edema associated with intense pruritus after carrying logs of the poisonwood tree (Metopium toxiferum) of the family Anacardiaceae.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &copy; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 69330 Version 4.0</div></div></div>"},"69331":{"type":"graphic_diagnosticimage","displayName":"Paravertebral mass MRI I","title":"Invasive neuroblastoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive neuroblastoma on MRI</div><div class=\"cntnt\"><img style=\"width:360px; height:214px;\" src=\"images/PULM/69331_Paravertebral_mass_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted section through the mass shows chest wall invasion (arrow) and extension into the spinal canal (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69331 Version 3.0</div></div></div>"},"69332":{"type":"graphic_table","displayName":"Stability of major allergens in dilute solutions","title":"Stability of major allergens in dilute solutions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stability of major allergens in dilute solutions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Extract</td> <td class=\"subtitle1\" rowspan=\"2\">Diluent</td> <td class=\"subtitle1\" colspan=\"3\">1:125 v/v</td> <td class=\"subtitle1\" colspan=\"3\">1:625 v/v</td> </tr> <tr> <td class=\"subtitle2\">3 months</td> <td class=\"subtitle2\">6 months</td> <td class=\"subtitle2\">12 months</td> <td class=\"subtitle2\">3 months</td> <td class=\"subtitle2\">6 months</td> <td class=\"subtitle2\">12 months</td> </tr> <tr> <td rowspan=\"2\">Grass</td> <td>HSA</td> <td>60</td> <td>76</td> <td>51</td> <td>79</td> <td>74</td> <td>54</td> </tr> <tr> <td>NSP</td> <td>54</td> <td>60</td> <td>16</td> <td>29</td> <td>24</td> <td>6</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Bermuda</td> <td>HSA</td> <td>73</td> <td>67</td> <td>43</td> <td>68</td> <td>51</td> <td>34</td> </tr> <tr> <td>NSP</td> <td>62</td> <td>53</td> <td>9</td> <td>26</td> <td>16</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Birch</td> <td>HSA</td> <td>93</td> <td>79</td> <td>75</td> <td>76</td> <td>63</td> <td>49</td> </tr> <tr> <td>NSP</td> <td>82</td> <td>41</td> <td>34</td> <td>41</td> <td>21</td> <td>13</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=82290&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Numbers represent percent of original potency.</div><div class=\"graphic_footnotes\">v/v: volume/volume; HSA: normal saline with 0.03% human serum albumin (HSA); NSP: normal saline phenol.</div><div class=\"graphic_reference\">Data from: Plunkett G. Stability of allergen extracts used in skin testing and immunotherapy. Curr Opin Otolaryngol Head Neck Surg 2008; 16:285.</div><div id=\"graphicVersion\">Graphic 69332 Version 6.0</div></div></div>"},"69333":{"type":"graphic_table","displayName":"Pediatric hypertensive emergencies by system","title":"Causes of pediatric hypertensive emergencies by system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pediatric hypertensive emergencies by system</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Renal </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Glomerular disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renal parenchymal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Obstructive uropathy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renovascular&nbsp;disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hemolytic uremic syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renal vascular trauma</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Polycystic kidney disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renal tumors (eg, Wilms tumor)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acute renal failure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Endocrine </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pheochromocytoma</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Congenital adrenal hyperplasia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Primary aldosteronism</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cushing syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hyperthyroidism</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Neurologic </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Increased intracranial pressure (eg, head trauma brain tumor)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Familial dysautonomia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Guillain-Barre syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Poliomyelitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cerebral hemorrhage or infarction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Cardiovascular </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Coarctation of the aorta</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Drug induced/toxicologic </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sympathomimetics (eg, cocaine, amphetamines, pseudoephedrine, PCP, ephedra-containing nutraceuticals, caffeine)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Serotonin syndrome </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anabolic steroids </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Corticosteroids</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Oral contraceptives</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clonidine withdrawal</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Miscellaneous </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Essential hypertension</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Neuroblastoma</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hypercalcemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acute intermittent porphyria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Neuroleptic malignant syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Neurofibromatosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tuberous sclerosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Volume overload </td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">1/27/2009--Requested permission (JD). 2/10/2009--Permission granted; signed agreement back to Arnetta, figure to Terrence (JD). 2/4/2010--Renewal requested (JD). 3/26/2010--Renewal granted; agreement mailed back to Arnetta (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=11764&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">PDA: patent ductus arteriosus; AV: arteriovenous; SLE: systemic lupus erythematosus; PCP: phencyclidine.</div><div class=\"graphic_reference\">Adapted with permission from Linakis JG, Constantine E. Hypertension. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Ed), Lippincott Williams &amp; Wilkins, Philadelphia, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69333 Version 12.0</div></div></div>"},"69334":{"type":"graphic_picture","displayName":"India ink marking a flat lesion","title":"India ink staining","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">India ink staining</div><div class=\"cntnt\"><img style=\"width:492px; height:207px;\" src=\"images/GAST/69334_India_ink_marking_a_flat_le.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flat lesion is visible at the three o'clock position during colonoscopy (left panel). The lesion has been stained circumferentially for later identification of the site (right panel).</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 69334 Version 1.0</div></div></div>"},"69335":{"type":"graphic_diagnosticimage","displayName":"PTC before hepaticojejunostomy","title":"Complete transection of the common bile duct after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete transection of the common bile duct after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:390px; height:234px;\" src=\"images/GAST/69335_PTC_before_hepaticojejunost.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous transhepatic cholangiogram demonstrating complete transection of the common bile duct and dilation of the biliary tree. This patient was treated with a hepaticojejunostomy.</div><div class=\"graphic_reference\">Photo courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 69335 Version 4.0</div></div></div>"},"69336":{"type":"graphic_figure","displayName":"Colpexin sphere pessary","title":"Colpexin sphere vaginal pessary in situ","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Colpexin sphere vaginal pessary in situ</div><div class=\"cntnt\"><img style=\"width:477px; height:298px;\" src=\"images/OBGYN/69336_Colpexin_sphere_pessary.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69336 Version 3.0</div></div></div>"},"69337":{"type":"graphic_figure","displayName":"Open oophorectomy a","title":"Open oophorectomy ","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Open oophorectomy </div><div class=\"cntnt\"><img style=\"width:509px; height:372px;\" src=\"images/OBGYN/69337_Open_oophorectomy_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The round ligament is divided and the retroperitoneal space entered.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69337 Version 2.0</div></div></div>"},"69338":{"type":"graphic_table","displayName":"Indications for invasive workup in acute pericarditis","title":"Indications for invasive workup in acute pericarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for invasive workup in acute pericarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pericardiocentesis:</td> </tr> <tr> <td>1. Cardiac tamponade</td> </tr> <tr> <td>2. Moderate to large effusions refractory to medical therapy and with severe symptoms</td> </tr> <tr> <td>3. Suspected bacterial or neoplastic pericarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Pericardial biopsy and pericardioscopy (targeted biopsy in specialized center):</td> </tr> <tr> <td>1. Relapsing cardiac tamponade</td> </tr> <tr> <td>2. Suspected bacterial or neoplastic pericarditis</td> </tr> <tr> <td>3. Worsening pericarditis (despite medical therapy) without a specific diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Massimo Imazio.</div><div id=\"graphicVersion\">Graphic 69338 Version 1.0</div></div></div>"},"69339":{"type":"graphic_figure","displayName":"Branchial arch derivatives","title":"Branchial arch derivatives","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Branchial arch derivatives</div><div class=\"cntnt\"><img style=\"width:607px; height:274px;\" src=\"images/ALLRG/69339_Brachial_arch_derivs_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral view of the head and neck region of a four-week embryo demonstrating the branchial arches participating in formation of the bones of the face and neck.<br />(B) Definitive structures formed from branchial arch mesenchyme.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler T. Langman's Medical Embryology, Ninth Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69339 Version 4.0</div></div></div>"},"69341":{"type":"graphic_figure","displayName":"Colectomy for mid-transverse colon cancer","title":"Colectomy for mid-transverse colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colectomy for mid-transverse colon cancer</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/69341_Colectomyformidtransversecoloncancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the extent of resection for a malignant lesion located in the mid-transverse colon.</div><div id=\"graphicVersion\">Graphic 69341 Version 3.0</div></div></div>"},"69342":{"type":"graphic_figure","displayName":"Ventilation lactate exercise","title":"Ventilatory and blood lactate response to exercise","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ventilatory and blood lactate response to exercise</div><div class=\"cntnt\"><img style=\"width:504px; height:306px;\" src=\"images/CARD/69342_Ventilation_lactate_exercis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventilatory and blood lactate response to exercise as a function of oxygen uptake (VO2) The anaerobic threshold (AT) indicates the onset of significant anaerobic metabolism and the production of lactate, which occurs at approximately 50 to 60 percent of VO2max.</div><div id=\"graphicVersion\">Graphic 69342 Version 1.0</div></div></div>"},"69343":{"type":"graphic_algorithm","displayName":"Approach to pallor in children","title":"The diagnostic approach to pallor in children","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">The diagnostic approach to pallor in children</div><div class=\"cntnt\"><img style=\"width:629px; height:769px;\" src=\"images/EM/69343_Approach_to_pallor_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Initial hemoglobin and red blood cell indices may be normal despite severe hemorrhage.<br />&para; Examples of possible conditions are provided within appropriate categories.</div><div id=\"graphicVersion\">Graphic 69343 Version 5.0</div></div></div>"},"69344":{"type":"graphic_figure","displayName":"Serology acute and chronic HBV","title":"Serologic responses to HBV infection","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Serologic responses to HBV infection</div><div class=\"cntnt\"><img style=\"width:543px; height:199px;\" src=\"images/GAST/69344_Serology_acute_and_chronic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the serologic responses to acute and chronic hepatitis B virus (HBV) infection in relation to the serum alanine aminotransferase (ALT) concentration. Left panel: Acute infection is characterized initially by the presence of HBeAg (hepatitis B e antigen), HBsAg (hepatitis B surface antigen), and HBV DNA beginning in the preclinical phase. IgM anti-HBc (hepatitis B core antigen) appears early in the clinical phase; the combination of this antibody and HBsAg makes the diagnosis of acute infection. Recovery is accompanied by normalization of the serum ALT, the disappearance of HBV DNA, HBeAg to anti-HBe seroconversion, and subsequently HBsAg to anti-HBs seroconversion and switch from IgM to IgG anti-HBc. Thus, previous HBV infection is characterized by anti-HBs and IgG anti-HBc. Right panel: Chronic infection is characterized by persistence of HBeAg (for a variable period), HBsAg, and HBV DNA in the circulation; anti-HBs is not seen (in approximately 20 percent of patients a non-neutralizing form of anti-HBs can be detected). Persistence of HBsAg for more than six months after acute infection is considered indicative of chronic infection.</div><div id=\"graphicVersion\">Graphic 69344 Version 2.0</div></div></div>"},"69348":{"type":"graphic_picture","displayName":"Electron micrograph of lupus membranous nephropathy","title":"Electron micrograph showing lupus membranous nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing lupus membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:375px; height:229px;\" src=\"images/NEPH/69348_SLE_Membranous_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of lupus membranous nephropathy. The subepithelial immune deposits (D) are characteristic of any form of membranous nephropathy, but the intraendothelial tubuloreticular inclusions (arrow) strongly suggest underlying lupus.</div><div class=\"graphic_footnotes\">GBM: glomerular basement membrane; Ep: epithelial cell.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69348 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"69349":{"type":"graphic_diagnosticimage","displayName":"Brain MRI eIF2B mutated individuals","title":"Typical cerebral MRI of eIF2B mutated individuals","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Typical cerebral MRI of eIF2B mutated individuals</div><div class=\"cntnt\"><img style=\"width:475px; height:588px;\" src=\"images/NEURO/69349_MRI_eIF2B_mutated.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cerebral MRI of Individuals 393-2 (A, B, C), 522 (D, E, F), 941-1 (G, H), and 1014 (I) performed at 1, 7, 23, and 16 years of age. In the hemispheric white matter, an abnormal diffuse signal, characterized by a hyposignal on T1-weighted sequences imaging (A, D) and hypersignal on T2 (B, E, G) and on fluid attenuated inversion recovery (FLAIR) sequences imaging (C, F, H, I), is observed. Individuals who had an infantile (C; arrow) and childhood (F; arrow) onset form have extensive CSF-like abnormal signal within the abnormal white matter on FLAIR sequences whereas in an individual with a juvenile/adult onset form these areas are restricted to the frontal white matter on FLAIR sequences (H; arrow). Individual 1014, who experienced secondary amenorrhea and episodes of headache, had a normal neurologic examination at 16 and no cavitations of the white matter on FLAIR sequences (I).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CSF: cerebrospinal fluid; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Fogli A, Schiffmann R, Bertini E. The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology 2004; 62:1509. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69349 Version 13.0</div></div></div>"},"69351":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus associated with Dandy Walker malformation","title":"Hydrocephalus associated with Dandy Walker malformation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus associated with Dandy Walker malformation</div><div class=\"cntnt\"><img style=\"width:514px; height:576px;\" src=\"images/PEDS/69351_Hydro_Dandy_Walker_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-month-old child with a Dandy Walker malformation, showing agenesis of the cerebellar vermis and a large posterior fossa cyst.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 69351 Version 2.0</div></div></div>"},"69353":{"type":"graphic_figure","displayName":"Central line IJ post anat","title":"External landmarks for the posterior approach to the internal jugular vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External landmarks for the posterior approach to the internal jugular vein</div><div class=\"cntnt\"><img style=\"width:434px; height:577px;\" src=\"images/EM/69353_Central_line_IJ_post_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 69353 Version 3.0</div></div></div>"},"69354":{"type":"graphic_figure","displayName":"Scintigraphic gastric emptying assessment","title":"Scintigraphic gastric emptying assessment in gastric stasis and gastric dumping","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Scintigraphic gastric emptying assessment in gastric stasis and gastric dumping</div><div class=\"cntnt\"><img style=\"width:539px; height:185px;\" src=\"images/GAST/69354_Scintigraphy_gastric_emptyi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scintigraphic study in gastric stasis (left panel) and gastric dumping (right panel) at&nbsp;two and&nbsp;four hours; the blue hatched lines at two and four hours refer to normal gastric retention. Compared with normals, the tracer is removed more slowly at&nbsp;two and four hours with gastric stasis, and more rapidly at two hours with gastric dumping.</div><div class=\"graphic_reference\">Data from: Thomforde GM, Camilleri M, Phillips SF, et al. J Nucl Med 1995; 36:93.</div><div id=\"graphicVersion\">Graphic 69354 Version 2.0</div></div></div>"},"69355":{"type":"graphic_diagnosticimage","displayName":"Lymphangitic cancer CT I","title":"Computed tomography appearance of lymphangitic carcinomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography appearance of lymphangitic carcinomatosis</div><div class=\"cntnt\"><img style=\"width:363px; height:243px;\" src=\"images/PULM/69355_Lymphangitic_cancer_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphangitic carcinomatosis from metastatic carcinoma of the cervix characterized by diffuse bilateral thickening of bronchovascular bundles. Peribronchial thickening results in visualization of more peripheral bronchi. The major fissures are slightly thickened. Several thickened interlobular septa are seen in the posterior aspect of the right lung. Small subpleural nodules in the left lower lobe represent perilymphatic nodules.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69355 Version 4.0</div></div></div>"},"69357":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - face","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/69357_Kaposis_sarcoma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous plaques are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69357 Version 3.0</div></div></div>"},"69359":{"type":"graphic_picture","displayName":"Herpes simplex keratitis","title":"Herpes simplex keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex keratitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/69359_Herpes_simplex_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69359 Version 4.0</div></div></div>"},"69360":{"type":"graphic_table","displayName":"Age-related changes in innate immunity","title":"Age-related changes in the innate immune system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-related changes in the innate immune system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Decrease with age</td> <td class=\"subtitle1\">Increase with age</td> <td class=\"subtitle1\">No change with age</td> </tr> <tr> <td>Hematopoietic stem cells</td> <td> <p>Total number in the bone marrow</p> <p>Proliferation capacity</p> <p>Homing capacity to the bone marrow</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Macrophages</td> <td> <p>Bone marrow precursors</p> <p>Oxidative burst</p> <p>Phagocytic capacity</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Neutrophils</td> <td> <p>Oxidative burst</p> <p>Phagocytic capacity</p> </td> <td>&nbsp;</td> <td> <p>Bone marrow precursors</p> <p>Peripheral blood numbers</p> </td> </tr> <tr class=\"divider_top\"> <td>Natural killer cells</td> <td>CD56<sup>bright</sup> natural killer cell number and percent</td> <td>Total number CD56<sup>dim</sup> natural killer cell number and percent</td> <td>Cytolytic activity</td> </tr> <tr class=\"divider_top\"> <td>Dendritic cells</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Number of myeloid and plasmacytoid dendritic cells</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69360 Version 2.0</div></div></div>"},"69361":{"type":"graphic_picture","displayName":"Uncircumcised penis PI","title":"Uncircumcised penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uncircumcised penis</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/PI/69361_Uncircumcised_penis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 69361 Version 1.0</div></div></div>"},"69362":{"type":"graphic_figure","displayName":"Chondroblastoma sites","title":"Skeletal distribution of chondroblastoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal distribution of chondroblastoma</div><div class=\"cntnt\"><img style=\"width:247px; height:605px;\" src=\"images/PEDS/69362_Chondroblastoma_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69362 Version 2.0</div></div></div>"},"69364":{"type":"graphic_figure","displayName":"Intra-abdominal hypertension and abdominal compartment syndrome","title":"Intra-abdominal hypertension and abdominal compartment syndrome","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Intra-abdominal hypertension and abdominal compartment syndrome</div><div class=\"cntnt\"><img style=\"width:484px; height:334px;\" src=\"images/SURG/69364_Intra_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intra-abdominal hypertension (IAH) is defined as a sustained intra-abdominal pressure &gt;12 mmHg. Abdominal compartment syndrome (ACS) is defined as a sustained intra-abdominal pressure &gt;20 mmHg that is associated with new organ dysfunction.</div><div class=\"graphic_reference\">Based on information from: Abdominal perfusion pressure. AdominalCompartmentSyndrome.org</div><div id=\"graphicVersion\">Graphic 69364 Version 4.0</div></div></div>"},"69365":{"type":"graphic_picture","displayName":"Pseudofolliculitis barbae 2","title":"Pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PC/69365_Pseudofolliculitis_barbae_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tight, curly hairs that have been sharpened by shaving penetrate the skin. Inflammatory papules and pustules that resemble acne are evident.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69365 Version 2.0</div></div></div>"},"69367":{"type":"graphic_diagnosticimage","displayName":"Hemochromatosis of liver CT","title":"Hemochromatosis of the liver as evaluated by CT scanning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis of the liver as evaluated by CT scanning</div><div class=\"cntnt\"><img style=\"width:362px; height:291px;\" src=\"images/GAST/69367_Hemochromatosis_of_liver_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan through the upper abdomen shows high attenuation throughout the liver (L), which normally has a similar attenuation to the spleen (white arrow). Other deposition diseases producing this appearance include amiodarone toxicity.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69367 Version 3.0</div></div></div>"},"69374":{"type":"graphic_table","displayName":"Differences in cervical CA relapse by histology and stage","title":"Cervical adenocarcinoma versus squamous cell cancer: Relapse rates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cervical adenocarcinoma versus squamous cell cancer: Relapse rates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease stage</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients with AdenoCA</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients with SCC</td> <td class=\"subtitle1\" colspan=\"2\">Five-year relapse rates for AdenoCA versus SCC, percent</td> </tr> <tr> <td class=\"subtitle2\">Pelvic</td> <td class=\"subtitle2\">Distant</td> </tr> <tr> <td>IB1</td> <td>113</td> <td>706</td> <td>6 versus 3 (p&#60;0.01)</td> <td>15 versus 7 (p = 0.01)</td> </tr> <tr> <td>IB2</td> <td>106</td> <td>797</td> <td>17 versus 13 (NSS)</td> <td>37 versus 21 (p&#60;0.01)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AdenoCA: adenocarcinoma; SCC: squamous cell carcinoma; NSS: not statistically significant.</div><div class=\"graphic_reference\">Data from: Eifel, P. Gynecol Oncol 1995; 59:38.</div><div id=\"graphicVersion\">Graphic 69374 Version 3.0</div></div></div>"},"69375":{"type":"graphic_table","displayName":"Opioid intoxication in children and adolescents - Rapid overview","title":"Opioid intoxication in children and adolescents: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid intoxication in children and adolescents: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features*</td> </tr> <tr> <td>Depressed mental status ranging from lethargy to coma</td> </tr> <tr> <td>Miotic pupils (often pinpoint)<sup>&#916;</sup></td> </tr> <tr> <td>Depressed respirations including apnea</td> </tr> <tr> <td>Bradycardia and hypotension</td> </tr> <tr> <td>Decreased to absent bowel sounds</td> </tr> <tr> <td>Track marks (adolescents with IV drug abuse)</td> </tr> <tr> <td class=\"subtitle1_single\">Ancillary studies<sup>&#9674;</sup></td> </tr> <tr> <td>Blood glucose and pulse oximetry in patients with coma and depressed respirations</td> </tr> <tr> <td>Serum ethanol level, especially in adolescents with recreational or suicidal overdose</td> </tr> <tr> <td>Serum acetaminophen if suicidal intent or ingestion of combination medications (eg, acetaminophen with oxycodone)</td> </tr> <tr> <td>Electrocardiogram in patients intoxicated with methadone (prolonged QTc) or propoxyphene (prolonged QRS)</td> </tr> <tr> <td>Chest radiograph in patients with persistent respiratory findings that suggest pulmonary aspiration or noncardiogenic pulmonary edema</td> </tr> <tr> <td>Urinalysis, serum electrolytes, blood urea nitrogen, creatinine, and creatine kinase in patients with prolonged immobilization or muscular rigidity at risk for rhabdomyolysis</td> </tr> <tr> <td>Rapid urine pregnancy test in postmenarchal girls</td> </tr> <tr> <td>Rapid urine testing for opioids in young children and infants with coma from unknown cause or in whom intentional poisoning by a caretaker is suspected</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Support airway and breathing using bag-mask ventilation with 100 percent inspired oxygen until naloxone is administered</td> </tr> <tr> <td class=\"sublist1_start\">Give naloxone for deep coma and respiratory depression as follows<sup>&#167;</sup>:</td> </tr> <tr> <td class=\"indent1\">- Children &#60;20 kg: 0.1 mg/kg IV or IO (maximum 2 mg per dose) <strong>except neonates</strong><sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">- Children over 20 kg: 2 mg IV or IO</td> </tr> <tr> <td class=\"indent1\">- Adolescents suspected of opioid addiction: 0.04 to 0.4 mg per dose repeated every 3-5 minutes and titrated to patient response</td> </tr> <tr> <td class=\"indent1\">- If no effect, repeat the naloxone dose every one to two minutes to a maximum total dose of 10 mg</td> </tr> <tr> <td class=\"indent1\"> <p>- Patients with recurrent toxicity may receive additional bolus doses or a continuous naloxone infusion. Begin the infusion rate at 2/3 of the total dose of naloxone needed to restore breathing, delivered every hour.</p> <ul> <li>If the patient develops respiratory depression despite the naloxone infusion (this may happen 20 to 30 minutes after starting infusion) administer a naloxone bolus (using half the original effective bolus dose) and repeat if necessary until adequate ventilation returns, then increase the infusion rate </li> <li>If the patient develops signs of opioid withdrawal, stop the infusion. If respiratory depression returns, start the infusion at half the original rate. </li> </ul> </td> </tr> <tr> <td>Give activated charcoal (1 gram/kg orally or by nasogastric tube, maximum dose 50 grams) to alert young children and adolescents who present within one hour of oral overdose<sup>&#135;</sup></td> </tr> <tr> <td>In cases of suspected child abuse, consult an experienced children protection team (if available) and report suspicion to the appropriate governmental agency</td> </tr> <tr> <td>Consult psychiatry for patients with substance abuse or suicidal intent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IO: intraosseous; AC: activated charcoal; ET: endotracheal tube; IM: intramuscular.<br />* The diagnosis of opioid intoxication is based upon clinical features and response to antidotal therapy.<br />&Delta; Small pupils are not always present in children and adolescents with opioid intoxication.<br /><span class=\"lozenge\">&loz;</span> Other ancillary studies may be indicated in selected patients in whom trauma, infection, or other etiologies besides poisoning are suspected. Refer to UpToDate topics on stupor and coma in children and pediatric occult toxic exposures.<br />&sect; Naloxone may also be given intramuscularly or intratracheally via endotracheal tube (ET) in children or adolescents with poor IV access. If an endotracheal tube is present, ET administration is preferred over intramuscular, if IV and IO routes not available. ET dose is approximately two to three times IV dose.<br />&yen; Naloxone administration is not recommended as part of initial resuscitation of neonates in the delivery room. Refer to UpToDate topics on neonatal resuscitation.<br />&Dagger; AC should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first or naloxone therapy is effective in maintaining an alert state. Endotracheal intubation should not be performed solely for the purpose of giving AC.</div><div id=\"graphicVersion\">Graphic 69375 Version 16.0</div></div></div>"},"69378":{"type":"graphic_table","displayName":"Bow-legs DDx","title":"Differential diagnosis of bowed legs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of bowed legs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Possible clues to the diagnosis</td> </tr> <tr> <td>Physiologic bowing</td> <td>Age &#60;2 years; bilateral and symmetric; involves the femurs and tibias; normal stature; no lateral thrust during ambulation; improves with age.</td> </tr> <tr> <td>Pathologic bowing</td> <td>Short stature, intercondylar distance &#62;6 cm when the legs are held with the patella facing forward and the medial malleoli touching.</td> </tr> <tr> <td class=\"sublist2_start\">Blount disease</td> <td class=\"sublist_other_start\">Asymmetry; focal angulation of proximal tibia; lateral thrust during ambulation; radiographs with medial beaking and downward slope of proximal tibial metaphysis and epiphysis.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Rickets</td> </tr> <tr> <td class=\"sublist2\">Nutritional rickets</td> <td class=\"sublist_other\">Breast-fed infant with inadequate supplementation of vitamin D; decreased serum calcium and/or vitamin D; widened physes and flared metaphyses.</td> </tr> <tr> <td class=\"sublist2\">X-linked dominant hypophosphatemic rickets (<a href=\"https://omim.org/entry/307800\" spellcheck=\"true\" target=\"_blank\">OMIM #307800</a>)</td> <td class=\"sublist_other\">Growth retardation, rachitic and osteomalacic bone disease; hypophosphatemia; renal defects in phosphate resorption and vitamin D metabolism; widened physes and flared metaphyses may or may not be present.</td> </tr> <tr> <td class=\"sublist2_start\">Skeletal dysplasia</td> <td class=\"sublist_other_start\">Characteristic clinical and radiographic features vary according to the dysplasia. Most children with skeletal dysplasia do not present solely with bowed legs. Some examples of additional manifestations are provided below.</td> </tr> <tr> <td class=\"sublist2\">Achondroplasia (<a href=\"https://www.omim.org/entry/100800\" spellcheck=\"true\" target=\"_blank\">OMIM #100800</a>)</td> <td class=\"sublist_other\">Short stature; rhizomelic shortening of the limbs; frontal bossing; midface hypoplasia; lumbar lordosis; elongated fibula; trident hand.</td> </tr> <tr> <td class=\"sublist2\">Pseudoachondroplasia (<a href=\"https://www.omim.org/entry/177170\" spellcheck=\"true\" target=\"_blank\">OMIM #177170</a>); associated with knock-knees in some patients</td> <td class=\"sublist_other\">Autosomal dominant inheritance; short-limb dwarfism with onset by&nbsp;two years; joint laxity; vertebral anomalies.</td> </tr> <tr> <td class=\"sublist2\">Metaphyseal chondrodysplasia (multiple types)</td> <td class=\"sublist_other\">Persistent bowing and short stature.</td> </tr> <tr> <td class=\"sublist2\">Multiple epiphyseal dysplasia syndrome (<a href=\"https://www.omim.org/entry/132400\" spellcheck=\"true\" target=\"_blank\">OMIM #132400</a>)</td> <td class=\"sublist_other\">Autosomal dominant inheritance; mild short-limb dwarfism; brachydactyly; small, irregular epiphyses on radiographs.</td> </tr> <tr> <td class=\"sublist2\">Cartilage hair hypoplasia (<a href=\"https://www.omim.org/entry/250250\" spellcheck=\"true\" target=\"_blank\">OMIM #250250</a>)</td> <td class=\"sublist_other\">Autosomal recessive inheritance; short-limb dwarfism; fine, sparse hair; sparse eyebrows, eyelashes, and beard; short hands.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Asymmetric growth</td> </tr> <tr> <td class=\"sublist2\">Fracture</td> <td class=\"sublist_other\">History of fracture.</td> </tr> <tr> <td class=\"sublist2\">Sepsis and DIC (eg, meningococcemia)</td> <td class=\"sublist_other\">History of infection.</td> </tr> <tr> <td class=\"sublist2\">Neoplasia (eg, focal fibrocartilaginous dysplasia of proximal tibial metaphysis)</td> <td class=\"sublist_other\">Progressive, unilateral deformity; radiolucent, well-circumscribed lesion, often with rim of reactive bone.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OMIM: Online Mendelian Inheritance in Man; DIC: disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6<SUP>th</SUP> ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.</LI>&#xD;&#xA;<LI>The knee and leg. In: Mihran O. Tachdjian. Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.87.</LI>&#xD;&#xA;<LI>OMIM Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/omim/).</LI></OL></div><div id=\"graphicVersion\">Graphic 69378 Version 4.0</div></div></div>"},"69379":{"type":"graphic_table","displayName":"Causes of FUO in children","title":"Causes of fever of unknown origin in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of fever of unknown origin in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious disease</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Bacterial endocarditis</td> </tr> <tr> <td class=\"indent1\"><em>Bartonella henselae</em></td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Liver abscess</td> </tr> <tr> <td class=\"indent1\">Mastoiditis (chronic)</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis</td> </tr> <tr> <td class=\"indent1\">Pelvic abscess</td> </tr> <tr> <td class=\"indent1\">Perinephric abscess</td> </tr> <tr> <td class=\"indent1\">Pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Salmonellosis</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Subdiaphragmatic abscess</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"indent1\">Arboviruses</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Enteroviruses</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (infectious mononucleosis)</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Hepatitis viruses</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Human immunodeficiency virus</span></td> </tr> <tr> <td class=\"subtitle2_single\">Chlamydial</td> </tr> <tr> <td class=\"indent1\">Lymphogranuloma venereum</td> </tr> <tr> <td class=\"indent1\">Psittacosis</td> </tr> <tr> <td class=\"subtitle2_single\">Rickettsial</td> </tr> <tr> <td class=\"indent1\">Q fever</td> </tr> <tr> <td class=\"indent1\">Rocky Mountain spotted fever</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\">Blastomycosis (nonpulmonary)</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis (disseminated)</td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"indent1\">Visceral larva migrans</td> </tr> <tr> <td class=\"subtitle2_single\">Unclassified</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rheumatologic diseases</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Vasculitis (eg, polyarteritis nodosa)</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies</td> </tr> <tr> <td>Hodgkin disease</td> </tr> <tr> <td>Leukemia/lymphoma</td> </tr> <tr> <td>Neuroblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Central diabetes insipidus</td> </tr> <tr> <td>Drug fever</td> </tr> <tr> <td>Ectodermal dysplasia</td> </tr> <tr> <td>Factitious fever</td> </tr> <tr> <td>Familial dysautonomia</td> </tr> <tr> <td>Granulomatous colitis</td> </tr> <tr> <td>Hemophagocytic lymphohistiocytosis</td> </tr> <tr> <td>Infantile cortical hyperostosis</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Kawasaki disease</td> </tr> <tr> <td>Kikuchi-Fujimoto disease</td> </tr> <tr> <td>Nephrogenic diabetes insipidus</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Periodic fever (eg, familial Mediterranean fever, PFAPA syndrome)</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr> <td>Thyrotoxicosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.</div><div class=\"graphic_reference\">Original table modified for this publication. Lorin MI, Feigin RD. Fever without localizing signs and fever of unknown origin. In: Textbook of Pediatric Infectious Disease, 4th ed, Feigin RD, Cherry JD (Eds), WB Saunders, Philadelphia 1998. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69379 Version 6.0</div></div></div>"},"69380":{"type":"graphic_picture","displayName":"Forme fruste of hypospadias with blind urethral pit","title":"Forme fruste of hypospadias with blind urethral pit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forme fruste of hypospadias with blind urethral pit</div><div class=\"cntnt\"><img style=\"width:256px; height:506px;\" src=\"images/PEDS/69380_Hypospadiasblindopening.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild glandular hypospadias with two apparent urethral openings. The feeding tube is inserted into the slightly hypospadiac urethra with the blind urethral pit at the normal location at the end of the glans.</div><div class=\"graphic_reference\">Courtesy of&nbsp;Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 69380 Version 4.0</div></div></div>"},"69381":{"type":"graphic_table","displayName":"Food frequency questionnaire","title":"Food frequency questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food frequency questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">How often does patient consume?</td> <td class=\"subtitle1\">Clinician&nbsp;evaluation</td> <td class=\"subtitle1\">Recommended amount</td> </tr> <tr> <td>Fish</td> <td>How often is fish consumed?</td> <td>One or more times per week; emphasize fatty fish and&nbsp;encourage variety</td> </tr> <tr> <td>Meat</td> <td>Lean, trimmed?</td> <td>&#60;3 to 6 oz per day, as appropriate</td> </tr> <tr> <td>Poultry</td> <td>Which part of the chicken?</td> <td>&#60;3 to 6 oz skinless white meat or thigh meat</td> </tr> <tr> <td>Legumes</td> <td>Meat alternatives, dried beans, etc</td> <td>Several times per week</td> </tr> <tr> <td>Fruit</td> <td>Variety? (Not just bananas)</td> <td>2 to 3 whole fruits per day</td> </tr> <tr> <td>Vegetables</td> <td>Variety? (Not just potatoes and corn)</td> <td>Volume should be&nbsp;<span style=\"font-size: 16px; font-family: Calibri;\">one-half</span> of the day's intake,&nbsp;2 to&nbsp;3 cups per day</td> </tr> <tr> <td>Grains</td> <td>How much from white flour, pasta?</td> <td>Choose whole grains most of the time</td> </tr> <tr> <td>Dairy</td> <td>What % milk fat? Cheese?</td> <td>Choose skim milk, lower-fat cheeses; exercise portion control</td> </tr> <tr> <td>Sodium</td> <td>Added salt, canned foods, processed foods, cheese, sauces, condiments, restaurants, and takeout</td> <td>2&nbsp;grams sodium diet (less for certain conditions); <strong>no </strong>added salt; less processed foods and cheese; decreased portions at restaurants; buy low-sodium options</td> </tr> <tr> <td>Nuts, seeds, good fats</td> <td>Ground flax, pumpkin, walnuts, other nuts and seeds, avocado, olive or canola oils</td> <td>Approximate amount&nbsp;per day:&nbsp;<span style=\"font-size: 16px; font-family: Calibri;\">one-fourth</span>&nbsp;cup nuts or one small handful, or&nbsp;2 tablespoons good oils, or&nbsp;2 tablespoons ground flaxseed</td> </tr> <tr> <td>Added fats</td> <td>Cream, cheese,&nbsp;butter, oils, sauces</td> <td>Choose small amounts of unsaturated, trans-fat-free additions</td> </tr> <tr> <td>Beverages</td> <td>Soda, juices, caloric beverages</td> <td>Avoid regular use of sweetened beverages; water down juices; caffeine in moderation; increase water instead of caloric beverages</td> </tr> <tr> <td rowspan=\"2\">Alcohol</td> <td rowspan=\"2\">Is intake appropriate?</td> <td>Men: &#60;2 drinks/day, women: &#60;1 drink/day;&nbsp;1 drink is defined as 12 oz of regular beer, 5 oz of wine (12 percent alcohol), or 1.5 oz of 80-proof distilled spirits</td> </tr> <tr> <td>Minimal amounts best for patient with elevated triglycerides, diabetes, or hypertension</td> </tr> <tr> <td>Water</td> <td>Is intake appropriate?</td> <td>Fluid intake guided by thirst except in patients with known impairment of the thirst mechanism</td> </tr> <tr> <td>Fried foods</td> <td>Ask about preparation</td> <td>Encourage broiling, baking, saut&#233;ing, boiling</td> </tr> <tr> <td>Restaurant fare or takeout</td> <td>How many times/week or month?</td> <td>Specify healthy food preparation methods and encourage patient to request more vegetables and ask for low-sodium options; portion control is essential</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69381 Version 9.0</div></div></div>"},"69384":{"type":"graphic_picture","displayName":"Eumycetoma foot A","title":"Eumycetoma abscesses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eumycetoma abscesses</div><div class=\"cntnt\"><img style=\"width:432px; height:257px;\" src=\"images/ID/69384_Eumycetoma_abscesses.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 69384 Version 1.0</div></div></div>"},"69386":{"type":"graphic_picture","displayName":"Apply pin to foreskin1","title":"Applying safety pin to foreskin","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Applying safety pin to foreskin</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/OBGYN/69386_Apply_pin_to_foreskin1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 69386 Version 1.0</div></div></div>"},"69387":{"type":"graphic_figure","displayName":"Anatomy of vasectomy PI","title":"Anatomy of vasectomy","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Anatomy of vasectomy</div><div class=\"cntnt\"><img style=\"width:530px; height:564px;\" src=\"images/PI/69387_Anat_of_vasectomy_PI_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A vasectomy is a surgery that is done on men who do not want to have children. The surgery makes it so that sperm can no longer leave a man's body. That way the man can no longer make a woman pregnant.<br />Sperm are made in the testicles and stored in the epididymis. During a vasectomy, a doctor cuts and blocks off the two tubes that carry sperm out of the epididymis. These tubes - one on the left and one on the right - are called the \"vas deferens\". After the surgery, the man's sperm get reabsorbed into the body. The sperm do not come out when the man ejaculates.</div><div id=\"graphicVersion\">Graphic 69387 Version 12.0</div></div></div>"},"69388":{"type":"graphic_waveform","displayName":"Intermediate case 16","title":"Intermediate case 16","html":"<div class=\"graphic normal\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Intermediate case 16</div><div class=\"cntnt\"><img style=\"width:539px; height:97px;\" src=\"images/CARD/69388_Intermediate_case_16.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69388 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"69389":{"type":"graphic_figure","displayName":"Gastric component of the LES","title":"Gastric component of the LES","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Gastric component of the LES</div><div class=\"cntnt\"><img style=\"width:455px; height:299px;\" src=\"images/GAST/69389_Gastric_comp_LES_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proximal margin of the lower esophageal sphincter (LES) extends up to and a short distance proximal to the squamocolumnar junction (not shown). The distal margin of the LES is more difficult to define, but careful anatomic studies suggest that it is composed of elements of the gastric musculature, the opposing clasp, and sling fibers of the gastric cardia.</div><div class=\"graphic_reference\">Adapted from: Liebermann-Meffert D, Allgöwer M, Schmid P, Blum AL. Muscular equivalent of the lower esophageal sphincter. Gastroenterology 1979; 76:31.</div><div id=\"graphicVersion\">Graphic 69389 Version 5.0</div></div></div>"},"69390":{"type":"graphic_table","displayName":"Assessing menstrual blood loss","title":"Questions to ask to help quantify blood loss during menses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to ask to help quantify blood loss during menses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>How often do you change your sanitary pad/tampon during peak flow days?</td> </tr> <tr> <td>How many pads/tampons do you use over a single menstrual period?</td> </tr> <tr> <td>Do you need to change the pad/tampon during the night?</td> </tr> <tr> <td>How large are any clots that are passed?</td> </tr> <tr> <td>Has a medical provider told you that you are anemic?</td> </tr> <tr> <td class=\"sublist1_start\">Women with a normal volume of menstrual blood loss tend to:</td> </tr> <tr> <td class=\"sublist1\">Change pads/tampons at &#8805;3 hour intervals</td> </tr> <tr> <td class=\"sublist1\">Use fewer than 21 pads/tampons per cycle</td> </tr> <tr> <td class=\"sublist1\">Seldom need to change the pad/tampon during the night</td> </tr> <tr> <td class=\"sublist1\">Have clots less than 1 inch in diameter</td> </tr> <tr> <td class=\"sublist1\">Not be anemic</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Warner PE, Critchley HD, Lumsden MA, et al. Menorrhagia I: Measured blood loss, clinical features, and outcome in women with heavy periods:&nbsp;A survey with follow-up data. Am J Obstet Gynecol 2004; 190:1216.</div><div id=\"graphicVersion\">Graphic 69390 Version 3.0</div></div></div>"},"69391":{"type":"graphic_figure","displayName":"CA-MRSA virulence factors","title":"Multiple factors probably contribute to the enhanced virulence of community-acquired methicillin-resistant <EM innerHtml>Staphylococcus aureus<SUP></SUP></EM> (CA-MRSA)","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Multiple factors probably contribute to the enhanced virulence of community-acquired methicillin-resistant <EM innerHtml>Staphylococcus aureus<SUP></SUP></EM> (CA-MRSA)</div><div class=\"cntnt\"><img style=\"width:526px; height:494px;\" src=\"images/ID/69391_CA-MRSA_virulence_factors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Virulence determinants include phenol-soluble modulins, alpha-hemolysin, and several of the other determinants shown. The expression of these factors is likely to be under regulatory control. Other factors, such as the host response and factors that facilitate transmission, have yet to be characterized.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Lowy FD. Secrets of a superbug. Nat Med 2007; 13:1418. Copyright © 2007.</div><div id=\"graphicVersion\">Graphic 69391 Version 3.0</div></div></div>"},"69392":{"type":"graphic_figure","displayName":"Geography hepatitis A","title":"Prevalence of antibodies against hepatitis A","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Prevalence of antibodies against hepatitis A</div><div class=\"cntnt\"><img style=\"width:586px; height:393px;\" src=\"images/ID/69392_Geography_hepatitis_A_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimates of prevalence of antibody to hepatitis A virus (anti-HAV IgG), a marker of previous HAV infection, are based on systematic literature review conducted for the period of 1990 to 2005. In addition, anti-HAV prevalence might vary within countries by subpopulation and locality. As used on this map, the terms &quot;high,&quot; &quot;medium,&quot; &quot;low,&quot; and &quot;very low&quot; endemicity reflect available evidence of how widespread HAV infection is within each country, rather than precise quantitative assessments.</div><div class=\"graphic_reference\">Original figure from: Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28:6653. Reproduced with the permission of Elsevier Inc. All rights reserved. Original figure modified and reproduced from: Centers for Disease Control and Prevention. Yellow Book 2012. Available at: <a href=\"http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-a.htm\" target=\"_blank\">http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-a.htm</a>.</div><div id=\"graphicVersion\">Graphic 69392 Version 2.0</div></div></div>"},"69393":{"type":"graphic_diagnosticimage","displayName":"Computed tomography scan of acute pyelonephritis","title":"Computed tomography scan of acute pyelonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography scan of acute pyelonephritis</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/NEPH/69393_Acute_pyelonephritis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan in a patient with acute pyelonephritis showing a large, hypodense region in the right kidney. There is no discrete abscess formation in this setting.</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 69393 Version 3.0</div></div></div>"},"69394":{"type":"graphic_table","displayName":"Drugs to sedate critically ill","title":"Drugs used to sedate critically-ill patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs used to sedate critically-ill patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Analgesics\n   </td>\n   </tr>\n   <tr>\n   <td>Fentanyl</td>\n   </tr>\n   <tr>\n   <td>Hydromorphone</td>\n   </tr>\n   <tr>\n   <td>Morphine sulfate</td>\n   </tr>\n   <tr>\n   <td>Remifentanil</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Sedative-hypnotics\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_single\">\n   Benzodiazepines\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Diazepam\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Lorazepam\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Midazolam\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Anesthetic-sedatives\n   </td>\n   </tr>\n   <tr>\n   <td>Propofol</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Alpha-2 agonists\n   </td>\n   </tr>\n   <tr>\n   <td>Dexmedetomidine</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Neuroleptics\n   </td>\n   </tr>\n   <tr>\n   <td>Haloperidol</td>\n   </tr>\n   <tr>\n   <td>Olanzapine</td>\n   </tr>\n   <tr>\n   <td>Quetiapine</td>\n   </tr>\n   <tr>\n   <td>Risperidone</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Barbiturates*\n   </td>\n   </tr>\n   <tr>\n   <td>Methohexital</td>\n   </tr>\n   <tr>\n   <td>Thiopental</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* Not recommended as usual agents for ICU sedation. See Text.</div><div id=\"graphicVersion\">Graphic 69394 Version 1.0</div></div></div>"},"69396":{"type":"graphic_picture","displayName":"Ocular changes in atopic keratoconjunctivitis","title":"Ocular changes in atopic keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ocular changes in atopic keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/RHEUM/69396_AKC_ocular_changes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe ocular surface changes in acute keratoconjunctivitis include corneal neovascularization and conjunctival fibrosis and xerosis with secondary keratinization.</div><div id=\"graphicVersion\">Graphic 69396 Version 3.0</div></div></div>"},"69397":{"type":"graphic_table","displayName":"Causes of splenomegaly","title":"Major causes of splenomegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of splenomegaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Congestive</td> </tr> <tr> <td>Cirrhosis</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Thrombosis of portal, hepatic, or splenic veins</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Lymphoma, usually indolent variants</td> </tr> <tr> <td>Acute and chronic leukemias</td> </tr> <tr> <td>Polycythemia vera</td> </tr> <tr> <td>Multiple myeloma and its variants</td> </tr> <tr> <td>Essential thrombocythemia</td> </tr> <tr> <td>Primary myelofibrosis</td> </tr> <tr> <td>Primary splenic tumors</td> </tr> <tr> <td>Metastatic solid tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td>Viral <span style=\"font-size: 13px;\">&ndash;</span> Hepatitis, infectious mononucleosis, cytomegalovirus</td> </tr> <tr> <td>Bacterial <span style=\"font-size: 13px;\">&ndash;</span> <em>Salmonella</em>, <em>Brucella</em>, tuberculosis</td> </tr> <tr> <td>Parasitic&nbsp;<span style=\"font-size: 13px;\">&ndash;</span>&nbsp;Malaria, schistosomiasis, toxoplasmosis, leishmaniasis</td> </tr> <tr> <td>Infective endocarditis</td> </tr> <tr> <td>Fungal</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammation</td> </tr> <tr> <td>Sarcoid</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Rheumatoid arthritis (Felty syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Infiltrative, nonmalignant</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Niemann-Pick disease</td> </tr> <tr> <td>Amyloid</td> </tr> <tr> <td>Other lysosomal&nbsp;storage diseases (eg, mucopolysaccharidoses)</td> </tr> <tr> <td>Langerhans cell histiocytosis</td> </tr> <tr> <td>Hemophagocytic lymphohistiocytosis</td> </tr> <tr> <td>Rosai-Dorfman disease</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic (hypersplenic) states</td> </tr> <tr> <td>Acute and chronic hemolytic anemias, all etiologies</td> </tr> <tr> <td>Sickle cell disease (children)</td> </tr> <tr> <td>Following use of recombinant human granulocyte colony-stimulating&nbsp;factor</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69397 Version 5.0</div></div></div>"},"69399":{"type":"graphic_picture","displayName":"Incorrect tennis backhand","title":"Incorrect tennis backhand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incorrect tennis backhand</div><div class=\"cntnt\"><img style=\"width:252px; height:432px;\" src=\"images/EM/69399_Tennisbackhandincorrect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous contraction of wrist extensors, insufficient follow-through, and leading with the elbow (red arrow) are three common faults with the beginner's backhand.</div><div class=\"graphic_reference\">Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69399 Version 12.0</div></div></div>"},"69402":{"type":"graphic_picture","displayName":"Hepatic cystadenocarcinoma","title":"Hepatic cystadenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic cystadenocarcinoma</div><div class=\"cntnt\"><img style=\"width:365px; height:279px;\" src=\"images/GAST/69402_Hepatobilcystadenocarcinom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: CT scan, during a percutaneous aspiration. Note irregular thick cyst wall with nonhomogenous content. Panel B: Gross pathological examination, revealing a thick wall with multiple papillary projections. Panel C: Histologic examination: Scanning magnification showing complex glandular structures embedded in the stroma of the wall (hematoxylin and eosin, original magnification: x 400). Panel D: Higher power demonstrates glands with a cribriform growth pattern and nuclei displaying mild atypia (hematoxylin and eosin, original magnification: x 2000).</div><div class=\"graphic_reference\">Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright © 2001 American College of Surgeons.</div><div id=\"graphicVersion\">Graphic 69402 Version 4.0</div></div></div>"},"69403":{"type":"graphic_picture","displayName":"Pipelle and Vabra instruments","title":"Office endometrial biopsy instruments","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Office endometrial biopsy instruments</div><div class=\"cntnt\"><img style=\"width:502px; height:288px;\" src=\"images/OBGYN/69403_Pipelle_and_Vabra_instrumen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pipelle endometrial suction curette. (B) Vabra aspirator.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69403 Version 2.0</div></div></div>"},"69404":{"type":"graphic_figure","displayName":"Positve predictive of value stress test results","title":"Positive predictive value of findings from stress testing after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Positive predictive value of findings from stress testing after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:549px; height:301px;\" src=\"images/CARD/69404_Pred_value_tests_post_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis of studies reporting risk stratification after a myocardial infarction (MI). The positive predictive value (PPV) of different types of stress tests (ECG, myocardial perfusion imaging, echocardiography) for cardiac death rate or the combined end point of cardiac death or MI was lower in patients treated with a thrombolytic agent. Markers of left ventricular function (eg, peak left ventricular ejection fraction) were better predictors of outcome than markers of ischemia.</div><div class=\"graphic_reference\">Data from Shaw LJ, Peterson ED, Kesler K, et al. Am J Cardiol 1996; 78:1327.</div><div id=\"graphicVersion\">Graphic 69404 Version 3.0</div></div></div>"},"69405":{"type":"graphic_picture","displayName":"Sarcoidosis - facial","title":"Papular sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69405_Sarcoidosis_facial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small papules are present on the nose and cheeks of this patient with cutaneous sarcoidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.</div><div id=\"graphicVersion\">Graphic 69405 Version 5.0</div></div></div>"},"69406":{"type":"graphic_picture","displayName":"Fordyce spots - buccal","title":"Fordyce spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fordyce spots</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69406_Fordyce_spots_buccal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small yellow papules are present on the buccal mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69406 Version 3.0</div></div></div>"},"69407":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of first trimester umbilical cord cyst","title":"Prenatal ultrasound image of first trimester umbilical cord cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of first trimester umbilical cord cyst</div><div class=\"cntnt\"><img style=\"width:330px; height:511px;\" src=\"images/OBGYN/69407_US_first_tri_umbil_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First-trimester umbilical cord cyst.<br> (Panel A) Two cysts within the amniotic cavity are identified in relation to the umbilical cord.<br> (Panel B) Note the extraamniotic yolk sac.</div><div id=\"graphicVersion\">Graphic 69407 Version 2.0</div></div></div>"},"69408":{"type":"graphic_table","displayName":"Dermoscopy sensitivity and specificity","title":"Sensitivity and specificity for melanoma diagnosis of different dermoscopic algorithms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity for melanoma diagnosis of different dermoscopic algorithms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Algorithm/method</td> <td class=\"subtitle1\" colspan=\"2\">Sensitivity (percent)</td> <td class=\"subtitle1\" colspan=\"2\">Specificity (percent)</td> </tr> <tr> <td class=\"subtitle2\">Amelanotic melanoma</td> <td class=\"subtitle2\">Pigmented melanoma</td> <td class=\"subtitle2\">Experts</td> <td class=\"subtitle2\">Nonexperts</td> </tr> <tr> <td rowspan=\"6\"><strong>Quantitative</strong></td> <td>ABCD rule<sup>[1-8]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">78-98</td> <td class=\"centered\">70-90</td> <td class=\"centered\">45-80</td> </tr> <tr> <td>Menzies method<sup>[1,3,4,7,9,10]</sup></td> <td class=\"centered\">54</td> <td class=\"centered\">86-95</td> <td class=\"centered\">71-78</td> <td class=\"centered\">38-76</td> </tr> <tr> <td>7-point checklist<sup>[1-5,7,9,11-13]</sup></td> <td class=\"centered\">41</td> <td class=\"centered\">62-95</td> <td class=\"centered\">71-87</td> <td class=\"centered\">35-97</td> </tr> <tr> <td>Revised 7-point checklist<sup>[13]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">88</td> <td class=\"centered\">75</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>3-point checklist<sup>[9,14,15]</sup></td> <td class=\"centered\">50</td> <td class=\"centered\">79-91</td> <td class=\"centered\">71-72</td> <td class=\"centered\">72</td> </tr> <tr> <td>CASH algorithm<sup>[3,16]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">87-98</td> <td class=\"centered\">68</td> <td class=\"centered\">67</td> </tr> <tr class=\"divider_top\"> <td><strong>Qualitative</strong></td> <td>Pattern analysis<sup>[1,2,5,7,13]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">82-85</td> <td class=\"centered\">79-88</td> <td class=\"centered\">61-79</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Argenziano G, Soyer H, Chimenti S, et al, Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679. </LI>&#xD;&#xA;<LI>Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759. </LI>&#xD;&#xA;<LI>Henning JS, Stein JA, Yeung J, et al. CASH algorithm for dermoscopy revisited. Arch Dermatol 2008; 144:554. </LI>&#xD;&#xA;<LI>Blum A, Rassner G, Garbe C. Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. J Am Acad Dermatol 2003; 48:672. </LI>&#xD;&#xA;<LI>Carli P, Quercioli E, Sestini S, et al. Pattern analysis, not simplified algorithms, is the most reliable method for teaching dermoscopy for melanoma diagnosis to residents in dermatology. Br J Dermatol 2003; 148:981. </LI>&#xD;&#xA;<LI>Stolz W, Riemann A, Cognetta A, et al. ABCD rule of dermoscopy: a new practical method for early recognition of maligant melanoma. Eur J Dermatol 1994; 4:521. </LI>&#xD;&#xA;<LI>Pagnanelli G, Soyer HP, Argenziano G, et al. Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts. Br J Dermatol 2003; 148:698. </LI>&#xD;&#xA;<LI>Dolianitis C, Kelly J, Wolfe R, Simpson P. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. Arch Dermatol 2005; 141:1008. </LI>&#xD;&#xA;<LI>Menzies SW, Kreusch J, Byth K, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008; 144:1120. </LI>&#xD;&#xA;<LI>Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996; 132:1178. </LI>&#xD;&#xA;<LI>Haenssle HA, Korpas B, Hansen-Hagge C, et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. J Am Acad Dermatol 2010; 62:785. </LI>&#xD;&#xA;<LI>Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134:1563. </LI>&#xD;&#xA;<LI>Argenziano G, Catricala C, Ardigo M, et al. Seven-Point Checklist of Dermoscopy Revisited. Br J Dermatol 2010. </LI>&#xD;&#xA;<LI>Zalaudek I, Argenziano G, Soyer HP, et al. Three-point checklist of dermoscopy: an open internet study. Br J Dermatol 2006; 154:431. </LI>&#xD;&#xA;<LI>Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006; 24:1877. </LI>&#xD;&#xA;<LI>Henning JS, Dusza SW, Wang SQ, et al. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol 2007; 56:45. </LI></OL>Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 69408 Version 4.0</div></div></div>"},"69411":{"type":"graphic_figure","displayName":"Combination Rx and proteinuria","title":"Superior antiproteinuric effect with combination antihypertensive therapy","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Superior antiproteinuric effect with combination antihypertensive therapy</div><div class=\"cntnt\"><img style=\"width:510px; height:280px;\" src=\"images/NEPH/69411_Combination_Rx_and_proteinu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in protein excretion over a one-year period in patients with type 2 diabetes mellitus randomly assigned to verapamil SR, trandolapril, or combination. Protein excretion was significantly less at nine and 12 months in the combination therapy group, as compared with either of the single-drug groups.</div><div class=\"graphic_reference\">Data from: Bakris GL, Weir MR, DeQuattro V, et al. Kidney Int 1998; 54:1283.</div><div id=\"graphicVersion\">Graphic 69411 Version 2.0</div></div></div>"},"69413":{"type":"graphic_picture","displayName":"Partial third nerve palsy","title":"Partial third nerve palsy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Partial third nerve palsy</div><div class=\"cntnt\"><img style=\"width:512px; height:515px;\" src=\"images/NEURO/69413_Partial_right_third_nerv_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has ptosis of the right upper eyelid. Note that the right eye does not elevate well, indicating a superior division third nerve palsy.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 69413 Version 4.0</div></div></div>"},"69416":{"type":"graphic_picture","displayName":"Kikuchi disease lymph node histopathology 1","title":"Lymph node from a patient with Kikuchi disease","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Lymph node from a patient with Kikuchi disease</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/ID/69416_Kikuchis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Haematoxylin &amp; eosin stained lymph node at 40x magnification, showing areas of necrosis.</div><div class=\"graphic_reference\">Courtesy of Dr. Anthony Landgren.</div><div id=\"graphicVersion\">Graphic 69416 Version 2.0</div></div></div>"},"69418":{"type":"graphic_table","displayName":"Etiologies of right ventricular pathology","title":"Etiologies of right ventricular pathology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of right ventricular pathology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Volume overload</td> </tr> <tr> <td>Atrial septal defect</td> </tr> <tr> <td class=\"sublist1_start\">Valvular regurgitation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Tricuspid regurgitation (including Ebstein's anomaly)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Pulmonic regurgitation</td> </tr> <tr> <td class=\"subtitle1_single\">Pressure overload</td> </tr> <tr> <td>Pulmonary hypertension due to chronic left ventricular failure, chronic lung disease, etc</td> </tr> <tr> <td>Primary pulmonary hypertension</td> </tr> <tr> <td>Eisenmenger syndrome</td> </tr> <tr> <td>Acute or chronic thromboembolic disease</td> </tr> <tr> <td class=\"sublist1_start\">Right ventricular outflow obstruction</td> </tr> <tr> <td class=\"sublist1\">&#8226; Valvular pulmonic stenosis</td> </tr> <tr> <td class=\"sublist1\">&#8226; Infundibular stenosis or obstruction</td> </tr> <tr> <td class=\"sublist2\">- Tetralogy of Fallot</td> </tr> <tr> <td class=\"sublist2\">- Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"sublist2\">- Other causes (eg, tricuspid valve tissue, aneurysm of the sinus of Valsalva, or aneurysm of the membranous septum)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Subinfundibular obstruction</td> </tr> <tr> <td class=\"sublist2\">- Double chambered right ventricle</td> </tr> <tr> <td class=\"sublist1_start\">Pulmonary artery stenosis</td> </tr> <tr> <td class=\"sublist1\">&#8226; Supravalvular</td> </tr> <tr> <td class=\"sublist1\">&#8226; Branch</td> </tr> <tr> <td class=\"sublist1\">&#8226; Peripheral</td> </tr> <tr> <td>Stenotic right ventricular to pulmonary artery conduit</td> </tr> <tr> <td>Dextro-transposition of the great arteries after atrial baffle procedure (systemic right ventricle)</td> </tr> <tr> <td>Congenitally corrected transposition of the great arteries (systemic right ventricle)</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiomyopathic processes</td> </tr> <tr> <td>Right ventricular ischemia or infarction</td> </tr> <tr> <td>Dilated cardiomyopathy</td> </tr> <tr> <td>Arrhythmogenic right ventricular cardiomyopathy</td> </tr> <tr> <td>Endomyocardial fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors</td> </tr> <tr> <td>Cardiac myxomas</td> </tr> <tr> <td>Other primary cardiac tumors (eg, sarcomas, fibromas, rhabdomyomas)</td> </tr> <tr> <td>Metastatic lesions (eg, melanoma, renal cell carcinoma)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Ebstein's anomaly (abnormalities of tricuspid valve and right ventricle)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69418 Version 1.0</div></div></div>"},"69419":{"type":"graphic_picture","displayName":"Nasopharyngeal airways","title":"Nasopharyngeal airways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal airways</div><div class=\"cntnt\"><img style=\"width:268px; height:339px;\" src=\"images/EM/69419_Nasopharyn_airways.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69419 Version 2.0</div></div></div>"},"69420":{"type":"graphic_diagnosticimage","displayName":"EAS defect EUS","title":"Endoscopic ultrasound of external anal sphincter tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound of external anal sphincter tear</div><div class=\"cntnt\"><img style=\"width:325px; height:313px;\" src=\"images/GAST/69420_EAS_defect_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endorectal ultrasound image showing a moderate sized defect in the external anal sphincter (EAS).</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 69420 Version 3.0</div></div></div>"},"69422":{"type":"graphic_figure","displayName":"Calculation vascular resistance","title":"Calculation of systemic and pulmonary vascular resistance","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Calculation of systemic and pulmonary vascular resistance</div><div class=\"cntnt\"><img style=\"width:509px; height:170px;\" src=\"images/PULM/69422_Calculation_vascular_resist.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Or mean pulmonary artery wedge pressure (mmHg).<br> &#8226; Use measured cardiac output if no shunt is present.</div><div id=\"graphicVersion\">Graphic 69422 Version 2.0</div></div></div>"},"69423":{"type":"graphic_table","displayName":"Pneum ILD temsirolimus","title":"Suggested guidelines for evaluating and managing respiratory side effects associated with temsirolimus treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested guidelines for evaluating and managing respiratory side effects associated with temsirolimus treatment</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Adverse event\n   </td>\n   <td  class=\"subtitle1\">\n   Evaluation\n   </td>\n   <td  class=\"subtitle1\">\n   Management\n   </td>\n   </tr>\n   <tr>\n   <td>Dyspnea</td>\n   <td>\t<p>PFTs</p>\n\t<p>Chest X-ray</p>\n\t<p>Chest CT scan</p>\n\t<p>CBC</p>\n</td>\n   <td>\t<p>If imaging does not reveal ILD, provide supportive care and treat other factors contributing to dyspnea (eg, anemia)</p>\n\t<p>If imaging suggests interstitial lung disease, see below for management</p>\n</td>\n   </tr>\n   <tr>\n   <td>ILD in asymptomatic patients</td>\n   <td>\t<p>PFTs</p>\n\t<p>Chest CT scan</p>\n</td>\n   <td>No specific therapy or drug interruption if PFTs are normal and radiographic changes are mild</td>\n   </tr>\n   <tr>\n   <td>ILD in patients with mild symptoms</td>\n   <td>\t<p>PFTs</p>\n\t<p>Chest CT scan</p>\n</td>\n   <td>\t<p>May require temporary treatment interruption, depending on severity of PFT and CT abnormalities</p>\n\t<p>Will need ongoing monitoring of PFTs and chest CT</p>\n</td>\n   </tr>\n   <tr>\n   <td>ILD in patients with underlying lung disease or moderate symptoms/PFT/CT abnormalities</td>\n   <td>\t<p>PFTs</p>\n\t<p>Chest CT scan </p>\n\t<p>Diagnostic testing for opportunistic infection</p>\n</td>\n   <td>\t<p>May require temsirolimus discontinuation</p>\n\t<p>Will need frequent monitoring of PFTs and chest CT</p>\n</td>\n   </tr>\n   <tr>\n   <td>ILD in patients with severe or progressive symptoms/PFT abnormalities</td>\n   <td>\t<p>PFTs</p>\n\t<p>Chest CT scan</p>\n\t<p>Diagnostic testing for opportunistic infection</p>\n</td>\n   <td>\t<p>Discontinue temsirolimus</p>\n\t<p>Administer high dose glucocorticoids</p>\n</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">CBC: complete blood count; CT: computed tomography; DLCO: diffusing capacity for carbon monoxide; ILD: radiographic evidence of interstitial lung disease; PFTs: pulmonary function tests.</div><div class=\"graphic_reference\">Adapted from: Bellmunt, J, Szczylik, C, Feingold, J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19:1387.</div><div id=\"graphicVersion\">Graphic 69423 Version 1.0</div></div></div>"},"69424":{"type":"graphic_diagnosticimage","displayName":"Stage II sarcoidosis CT","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:372px; height:287px;\" src=\"images/PULM/69424_Stage_II_sarcoidosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage II sarcoidosis according to Siltzbach's classification. Multiple miliary peribronchiolar nodules are scattered diffusely throughout both lungs. In addition, both hilar regions are enlarged due to lymph node enlargement.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69424 Version 3.0</div></div></div>"},"69425":{"type":"graphic_figure","displayName":"Kudo Pit Pattern Classification","title":"Kudo Pit Pattern Classification of colonic mucosal lesions","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Kudo Pit Pattern Classification of colonic mucosal lesions</div><div class=\"cntnt\"><img style=\"width:518px; height:373px;\" src=\"images/GAST/69425_Kudopitpatternclassification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pit pattern classification for colonic mucosal lesions.</div><div id=\"graphicVersion\">Graphic 69425 Version 6.0</div></div></div>"},"69426":{"type":"graphic_table","displayName":"ESC recommendations carotid sinus massage","title":"European Society of Cardiology recommendations for carotid sinus massage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology recommendations for carotid sinus massage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Level<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Indications</td> </tr> <tr> <td class=\"indent1\">CSM is indicated in patients &#62;40 years with syncope of unknown aetiology after initial evaluation</td> <td>I</td> <td>B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CSM should be avoided in patients with previous TIA or stroke within the past three months and in patients with carotid bruits (except if carotid Doppler studies excluded significant stenosis)</td> <td>III</td> <td>C</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diagnostic criteria</td> </tr> <tr> <td class=\"indent1\">CSM is diagnostic if syncope is reproduced in the presence of asystole longer than 3 s and/or a fall in systolic BP &#62;50 mmHg</td> <td>I</td> <td>B</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; CSM: carotid sinus massage; TIA: transient ischaemic attack.<br />* Class of recommendation.<br />¶ Level of evidence.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 69426 Version 8.0</div></div></div>"},"69427":{"type":"graphic_picture","displayName":"Amanita smithiana and Tricholoma magnivelare mushroom","title":"Amanita smithiana and Tricholoma magnivelare (Matsutake or pine) mushroom","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Amanita smithiana and Tricholoma magnivelare (Matsutake or pine) mushroom</div><div class=\"cntnt\"><img style=\"width:584px; height:329px;\" src=\"images/EM/69427_Aman_smithian_tricholoma_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Amanita smithiana mushrooms cause acute gastroenteritis and delayed renal failure due to the action of the toxin allenic norleucine and may be mistaken for Tricholoma magnivelare (Matsutake or pine mushroom). Their appearance is similar to the amatoxin-containing Amanita genus mushrooms such as Amanita phalloides, A. verna, A. virosa, and A. bisporigea.<br> (B) Tricholoma magnivelare (Matsutake or pine mushroom) is a prized gourmet mushroom.</div><div class=\"graphic_reference\">Courtesy of Patrick West, MD.</div><div id=\"graphicVersion\">Graphic 69427 Version 2.0</div></div></div>"},"69428":{"type":"graphic_diagnosticimage","displayName":"Spinal cord compression MRI","title":"MRI image of a patient with an epidural spinal cord compression","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">MRI image of a patient with an epidural spinal cord compression</div><div class=\"cntnt\"><img style=\"width:485px; height:224px;\" src=\"images/ONC/69428_Spinal_cord_compression_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal (left panel) and axial (right panel) gadolinium-enhanced spinal MRI scan of a 69-year-old woman with a remote history of breast cancer, interscapular back pain for one month, and a normal neurologic examination. The scans demonstrate a large epidural lesion compressing the spinal cord (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of David Schiff, MD.</div><div id=\"graphicVersion\">Graphic 69428 Version 5.0</div></div></div>"},"69429":{"type":"graphic_figure","displayName":"External jugular cannulation","title":"External jugular vein cannulation","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">External jugular vein cannulation</div><div class=\"cntnt\"><img style=\"width:507px; height:226px;\" src=\"images/PEDS/69429_External_jugular_cannulatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cannulation of the external jugular vein usually requires that the infant or child be placed in a 30 degree head-down (Trendelenburg) position to maximize venous filling.</div><div id=\"graphicVersion\">Graphic 69429 Version 1.0</div></div></div>"},"69431":{"type":"graphic_table","displayName":"Causes of tinnitus","title":"Causes of tinnitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of tinnitus</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Sensorineural hearing loss </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Presbycusis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Late-onset congenital hearing loss</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Noise-induced hearing loss</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Ototoxicity</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Idiopathic</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Vascular insufficiency </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Small vessel disease</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hypercoagulable states</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hypercholesterolemia</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Diabetic vasculopathy</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hypertension</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sickle cell anemia</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Other anemia</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Bone disease</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Fibrous dysplasia</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Paget's disease</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Osteogenesis imperfecta</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Otosclerosis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Central nervous system anomalies</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sarcoid</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Pseudotumor cerebri</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Vascular malformations</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Tumor</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Stroke</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Multiple sclerosis</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Infections </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Rubella</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Neurosyphilis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Lyme disease</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Meningitis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Chronic otitis media</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Measles</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Cytomegalovirus</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Metabolic disorders </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Thyroid disease</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Diabetes mellitus</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Chronic renal failure</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hyperparathyroidism</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Autoimmune disease </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Autoimmune inner ear disease (not always associated with systemic autoimmune disease)</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Rheumatoid arthritis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Systemic lupus erythematosus</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Cochlear injury </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Salicylates</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Antibiotics</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Loop diuretics</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Platinum-based chemotherapy</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Meniere syndrome</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Trauma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Drugs </td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>See Cochlear injury and see separate table</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 69431 Version 2.0</div></div></div>"},"69433":{"type":"graphic_figure","displayName":"Measures isovolumic relaxation","title":"Measures of isovolumic relaxation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Measures of isovolumic relaxation</div><div class=\"cntnt\"><img style=\"width:504px; height:350px;\" src=\"images/CARD/69433_Measures_isovolumic_relax.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69433 Version 2.0</div></div></div>"},"69434":{"type":"graphic_picture","displayName":"Nocardia in sputum","title":"<em>Nocardia</em> in sputum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Nocardia</em> in sputum</div><div class=\"cntnt\"><img style=\"width:365px; height:234px;\" src=\"images/ID/69434_Nocardia2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of sputum (x1000) shows inflammatory cells and thin, faintly staining, beaded gram-positive and branching filaments. This Gram stain is consistent with either <EM>Nocardia</EM> or <EM>Actinomyces</EM>. <EM>Nocardia</EM> grew aerobically from this specimen on Sabouraud agar. <EM>Nocardia </EM>can also be differentiated from <EM>Actinomyces</EM> with the acid-fast stain.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 69434 Version 4.0</div></div></div>"},"69435":{"type":"graphic_movie","displayName":"VSD after MI TEE with color Doppler","title":"Ventricular septal defect after myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular septal defect after myocardial infarction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/69435_teepostmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:261px; height:408px;\" src=\"images/CARD/69435_teepostm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a two-dimensional echocardiogram shows a ventricular septal defect (VSD) near the left ventricular apex. Blood flows through the VSD from left to right ventricle during systole but not diastole.</div><div class=\"graphic_reference\">Courtesy of Neil Weissman, MD.</div><div id=\"graphicVersion\">Graphic 69435 Version 2.0</div></div></div>"},"69437":{"type":"graphic_picture","displayName":"Giant cell arteritis fundus","title":"Giant cell arteritis fundus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant cell arteritis fundus</div><div class=\"cntnt\"><img style=\"width:360px; height:271px;\" src=\"images/NEURO/69437_Giant_cell_arteritis_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pallid disc swelling in GCA.</div><div class=\"graphic_reference\">Courtesy of Madhura Tamhankar, MD and Nicholas J Volpe, MD.</div><div id=\"graphicVersion\">Graphic 69437 Version 1.0</div></div></div>"},"69438":{"type":"graphic_table","displayName":"Neonatal morbidity after failed forceps vacuum cesarean delivery","title":"Neonatal morbidity after intrapartum cesarean delivery, with or without a trial of operative vaginal delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neonatal morbidity after intrapartum cesarean delivery, with or without a trial of operative vaginal delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Morbidity</td> <td class=\"subtitle1\">Cesarean delivery after attempts at operative vaginal birth*</td> <td class=\"subtitle1\">Cesarean delivery&nbsp;with no attempts at operative vaginal birth*</td> </tr> <tr> <td>Subdural or cerebral hemorrhage</td> <td>25.7</td> <td>6.8</td> </tr> <tr> <td>Facial nerve injury</td> <td>12.8</td> <td>2.8</td> </tr> <tr> <td>Convulsions</td> <td>68.8</td> <td>19.9</td> </tr> <tr> <td>CNS depression</td> <td>17.1</td> <td>9.4</td> </tr> <tr> <td>Mechanical ventilation</td> <td>156.1</td> <td>101.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Number of cases per 10,000 infants.</div><div class=\"graphic_reference\">Data from: Towner D, Castro MA, Eby-Wilkens E, et al. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709.</div><div id=\"graphicVersion\">Graphic 69438 Version 5.0</div></div></div>"},"69439":{"type":"graphic_picture","displayName":"Hemangioblastoma immunohistochemistry","title":"Hemangioblastoma immunohistochemistry","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Hemangioblastoma immunohistochemistry</div><div class=\"cntnt\"><img style=\"width:724px; height:244px;\" src=\"images/ONC/69439_Hemangioblastoma_NSE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs of immunoperoxidase staining for neuron specific enolase (NSE) on the left and inhibin on the right. The neoplastic stromal cells immunoreact with NSE in the cytoplasm around nuclei and at the borders of the vacuoles. Inhibin shows strongly cytoplasmic reactivity.</div><div id=\"graphicVersion\">Graphic 69439 Version 4.0</div></div></div>"},"69440":{"type":"graphic_table","displayName":"Foods better tolerated PI","title":"Foods and beverages that are better tolerated by irritable bowel syndrome patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and beverages that are better tolerated by irritable bowel syndrome patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Water, Ginger Ale, Sprite, and Gatorade.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Soy milk or rice milk.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Soy or rice based products.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plain pasta, plain noodles, white rice. No sauces or gravies.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Potato: boiled or baked. No French Fries.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Breads: French, Italian, whole white, English muffins, and white rolls.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plain fish, plain chicken, plain turkey, or plain ham.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Eggs: soft-boiled, poached.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cereals: Plain Cornflakes, Rice Krispies, Corn or Rice Chex, Cheerios; dry or with soymilk or rice milk.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Salads: lettuce, hard-boiled egg slices, oil and vinegar dressing.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cooked peas, carrots (avoid raw vegetables).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Margarine, jams, jellies, peanut butter.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>In small amounts: applesauce, cantaloupe, watermelon, honeydew melon.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>In small amounts: fruit cocktail, peaches, pears (canned, non-dietetic).</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Substitutes and alternatives are available for the foods and beverages that induce gastrointestinal symptoms. Listed above are examples of some of the foods and beverages that IBS patents have found to be well tolerated. It is important to use daily vitamins (multivitamin, calcium with vitamin D, folic acid, vitamin B complex, and vitamin C) when on a restricted diet.</div><div class=\"graphic_reference\">Data from: MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.</div><div id=\"graphicVersion\">Graphic 69440 Version 2.0</div></div></div>"},"69442":{"type":"graphic_diagnosticimage","displayName":"Osteochondritis dissecans knee","title":"Osteochondritis dissecans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondritis dissecans</div><div class=\"cntnt\"><img style=\"width:360px; height:288px;\" src=\"images/PEDS/69442_Osteochondritis_dissecans_k.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a 16-year-old with a 1-year history of knee pain. The radiograph demonstrates a well-circumscribed, dense fragment of subchondral bone demarcated from the surrounding femoral condyle or affected area by a crescent-shaped line (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Carleton University Sports Medicine Clinic.</div><div id=\"graphicVersion\">Graphic 69442 Version 2.0</div></div></div>"},"69443":{"type":"graphic_table","displayName":"Arsenic chelating agents","title":"Adverse effects of chelating agents used for arsenic poisoning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse effects of chelating agents used for arsenic poisoning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chelating agent</td> <td class=\"subtitle1\">Adverse effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">BAL</td> </tr> <tr> <td class=\"indent1\">Endpoint: 24-hour urinary arsenic &#60;50 &#181;g/L or until another agent is substituted</td> <td> <p>Hypertension</p> <p>Febrile reaction, diaphoresis</p> <p>Nausea, vomiting, salivation</p> <p>Lacrimation, rhinorrhea</p> <p>Headache</p> <p>Painful injection, injection site sterile abscess</p> <p>Hemolysis in G6PD-deficient patients</p> <p>Chelation of essential metals (prolonged course)</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Succimer</td> </tr> <tr> <td class=\"indent1\">Endpoint: 24-hour urinary arsenic &#60;50 &#181;g/L</td> <td> <p>Nausea, vomiting, diarrhea</p> <p>Abdominal gas, pain</p> <p>Transient elevations in hepatic amino transferases, and alkaline phosphatase</p> <p>Rash, pruritus</p> <p>Sore throat, rhinorrhea</p> <p>Drowsiness, paresthesias</p> <p>Thrombocytosis, eosinophilia</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">DMPS</td> </tr> <tr> <td class=\"indent1\">Endpoint: 24 hour urinary arsenic&#60;50 &#181;g/L</td> <td> <p>Allergic reactions</p> <p>Increased copper and zinc excretion</p> <p>Nausea</p> <p>Pruritus</p> <p>Vertigo</p> <p>Weakness</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Ford MD. Arsenic. In: Goldfrank's Toxicological Emergencies, Goldfrank L, Flomenbaum N, Howland MA, Hoffman R, Nelson L (Eds), Mcgraw-Hill, New York 2002. p.1183. Copyright &#169; 2002 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 69443 Version 3.0</div></div></div>"},"69444":{"type":"graphic_picture","displayName":"Palpation of palmar fascia","title":"Palpation of the palmar fascia for nodularity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the palmar fascia for nodularity</div><div class=\"cntnt\"><img style=\"width:346px; height:293px;\" src=\"images/RHEUM/69444_Palpation_of_palmar_fascia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is placed in the palm-up position. Each of the four digits are passively stretched in extension, noting any differences in flexibility and thickening (cords) or nodularity of the palmar fascia.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 69444 Version 5.0</div></div></div>"},"69446":{"type":"graphic_diagnosticimage","displayName":"CXR pulmonary artery HT PA","title":"Pulmonary hypertension","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:292px; height:360px;\" src=\"images/CARD/69446_CXR_pulmonary_artery_HT_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain frontal chest radiograph from a 50-year-old male demonstrates prominence of the interstitial pulmonary markings with enlargement of the right and left ventricle and the right atrium (arrow). Additionally, large central, but attenuated peripheral pulmonary arteries are noted (arrowhead), all features characteristic of pulmonary hypertension.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69446 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"69449":{"type":"graphic_picture","displayName":"Finger varus valgus stress","title":"Varus and valgus stress of finger","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Varus and valgus stress of finger</div><div class=\"cntnt\"><img style=\"width:468px; height:309px;\" src=\"images/EM/69449_Finger_varus_valgus_stress.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Collateral ligaments are evaluated by placing a varus and valgus stress on the DIP and PIP joints. In the photograph above, the PIP joint is assessed.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 69449 Version 1.0</div></div></div>"},"69450":{"type":"graphic_picture","displayName":"Cutaneous lichen amyloid close-up","title":"Cutaneous lichen amyloidosis in a patient with MEN2: Close-up","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen amyloidosis in a patient with MEN2: Close-up</div><div class=\"cntnt\"><img style=\"width:468px; height:311px;\" src=\"images/ENDO/69450_Cutaneous_lichen_amyloid4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.</div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69450 Version 4.0</div></div></div>"},"69451":{"type":"graphic_table","displayName":"Causes of occult gastrointestinal bleeding","title":"Causes of occult gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of occult gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inflammatory/mechanical trauma</td> </tr> <tr> <td class=\"indent1\">Reflux esophagitis</td> </tr> <tr> <td class=\"indent1\">Cameron lesions </td> </tr> <tr> <td class=\"indent1\">Erosive gastritis</td> </tr> <tr> <td class=\"indent1\">Gastric ulcer</td> </tr> <tr> <td class=\"indent1\">Duodenal ulcer</td> </tr> <tr> <td class=\"indent1\">Celiac sprue</td> </tr> <tr> <td class=\"indent1\">Whipple disease</td> </tr> <tr> <td class=\"indent1\">Meckel diverticulum with ulceration</td> </tr> <tr> <td class=\"indent1\">Idiopathic cecal ulcer</td> </tr> <tr> <td class=\"indent1\">Crohn disease</td> </tr> <tr> <td class=\"indent1\">Ulcerative colitis</td> </tr> <tr> <td class=\"subtitle1_single\">Mass lesions</td> </tr> <tr> <td class=\"indent1\">Carcinoma (any site)</td> </tr> <tr> <td class=\"indent1\">Large polyps (any site)</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Vascular ectasia(s)</td> </tr> <tr> <td class=\"indent1\">Portal hypertensive gastropathy</td> </tr> <tr> <td class=\"indent1\">Portal hypertensive enteropathy and colopathy</td> </tr> <tr> <td class=\"indent1\">Gastric antral vascular ectasia</td> </tr> <tr> <td class=\"indent1\">Hemangiomas</td> </tr> <tr> <td class=\"indent1\">Blue rubber bleb nevus syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Hookworm</td> </tr> <tr> <td class=\"indent1\">Strongyloidiasis</td> </tr> <tr> <td class=\"indent1\">Ascariasis</td> </tr> <tr> <td class=\"indent1\">Tuberculous enterocolitis</td> </tr> <tr> <td class=\"indent1\">Amebiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Long-distance running</td> </tr> <tr> <td class=\"indent1\">Factitious</td> </tr> <tr> <td class=\"indent1\">Hemoptysis</td> </tr> <tr> <td class=\"indent1\">Epistaxis</td> </tr> <tr> <td class=\"indent1\">Oropharyngeal</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69451 Version 3.0</div></div></div>"},"69452":{"type":"graphic_diagnosticimage","displayName":"Pancreatic fistula series","title":"Pancreatic fistula","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Pancreatic fistula</div><div class=\"cntnt\"><img style=\"width:502px; height:376px;\" src=\"images/GAST/69452_Pancreatic_fistula_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 45-year-old man was admitted with acute alcoholic pancreatitis. Computed tomography (CT) scan on day 7 showed necrosis of body and tail of the pancreas (upper left panel). On day 28 he developed high fever. Fine-needle aspiration confirmed the suspicion of infected pancreatic necrosis. This was treated with percutaneous drainage and lavage (upper right panel). A sinogram through the drainage catheter revealed a pancreatic duct leak from the neck of the pancreas with retrograde and antegrade filling of the pancreatic duct (lower left panel). The external pancreatic fistula was successfully treated with endoscopic retrograde cholangiopancreatography (ERCP), dilatation of the stricture in the pancreatic head and stenting of the pancreatic duct (lower right panel).</div><div class=\"graphic_reference\">Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.</div><div id=\"graphicVersion\">Graphic 69452 Version 3.0</div></div></div>"},"69453":{"type":"graphic_picture","displayName":"Lichen simplex chronicus","title":"Lichen simplex chronicus of the vulva (skin lichenification from chronic scratching)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen simplex chronicus of the vulva (skin lichenification from chronic scratching)</div><div class=\"cntnt\"><img style=\"width:379px; height:283px;\" src=\"images/OBGYN/69453_Lichen_simplex_chronicus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lichenification and swelling in localized plaque of lichen simplex chronicus.<br />(B) Marked lichenification, erosions, and crusting in lichen simplex chronicus of left labium major.</div><div class=\"graphic_reference\">Reproduced with permission from: Fisher BK, Margesson LJ. Genital Skin Disorders: Diagnosis and Treatment. Mosby, St. Louis, Missouri 1998. p.158. Copyright &copy; 1998 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 69453 Version 3.0</div></div></div>"},"69454":{"type":"graphic_figure","displayName":"Hypertension and ESRD","title":"Relation between hypertension and development of ESRD","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Relation between hypertension and development of ESRD</div><div class=\"cntnt\"><img style=\"width:708px; height:420px;\" src=\"images/NEPH/69454_Hypertension_and_ESRD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of end-stage renal disease (ESRD), due to any cause, according to blood pressure category in 332,544 men screened for the Multiple Risk Factor Intervention Trial (MRFIT) trial. The adjusted relative risk increased from 1.0 in those with optimal blood pressure (&lt;120/&lt;80) to 1.9 with high-normal blood pressure, 3.1 with mild hypertension, 6.0 with moderate hypertension, and 11.2 with severe hypertension. Patients with stage 1 hypertension or lower blood pressure were at very low risk of ESRD at 16 years (≤0.34 percent).</div><div class=\"graphic_reference\">Redrawn from: Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13.</div><div id=\"graphicVersion\">Graphic 69454 Version 5.0</div></div></div>"},"69456":{"type":"graphic_figure","displayName":"Stages neurodegeneration PD","title":"Stages in the development of Parkinson disease-related pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stages in the development of Parkinson disease-related pathology</div><div class=\"cntnt\"><img style=\"width:433px; height:547px;\" src=\"images/NEURO/69456_Staging_neurodegen_PD_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parkinson disease presymptomatic and symptomatic phases. <strong>(Panel A)</strong> The presymptomatic phase is marked by the appearance of Lewy neurites/bodies in the brains of asymptomatic persons. In the symptomatic phase, the individual neuropathological threshold is exceeded (black arrow). The increasing slope and intensity of the colored areas below the diagonal indicate the growing severity of the pathology in vulnerable brain regions (panel B). The severity of the pathology is indicated by darker degrees of shading in the colored arrow left. <strong>(Panel B)</strong> Diagram showing the ascending pathological process (white arrows). The shading intensity of the colored areas corresponds to that in panel A.</div><div class=\"graphic_reference\">Reproduced from: Braak H, Ghebremedhi E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121; with kind permission from Springer Science + Business Media B.V. Copyright © 2004.</div><div id=\"graphicVersion\">Graphic 69456 Version 14.0</div></div></div>"},"69457":{"type":"graphic_table","displayName":"Class opioids pain mgmt","title":"Classification of opioids for pain management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of opioids for pain management</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Opioid type</td>\r\n            <td class=\"subtitle1\">Medications</td>\r\n            <td class=\"subtitle1\">Notes about therapy</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"11\">Pure agonists</td>\r\n            <td>Codeine</td>\r\n            <td rowspan=\"11\">\r\n            <p>Mainstay of therapy for moderate to severe cancer pain.</p>\r\n            <p>No clinically relevant ceiling effect to analgesia; as dose is raised, analgesic effects increase until analgesia is achieved or dose-limiting side effects supervene.</p>\r\n            <p>Meperidine and propoxyphene are not preferred due to potential effects of toxic metabolites.</p>\r\n            <p>Methadone must be used with caution; only clinicians who are knowledgeable about the risks posed by long and variable half-life, unpredictable potency, and potential for QTc prolongation should use this drug without guidance.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hydrocodone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Dihydrocodeine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Morphine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hydromorphone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Fentanyl</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Oxycodone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Oxymorphone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Levorphanol</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Methadone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Meperidine</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"7\">Agonist-antagonists</td>\r\n            <td class=\"sublist1_start\">Partial agonists:</td>\r\n            <td rowspan=\"7\">\r\n            <p>Agonist-antagonists include mu-receptor agonists with lower intrinsic efficacy (partial agonists) and drugs that have agonist effects at one opioid receptor and antagonist effects at another (mixed agonist-antagonists).</p>\r\n            <p>Most were developed to be less attractive to individuals with the disease of addiction; this characteristic does not rationalize widespread use for cancer pain.</p>\r\n            <p>All have a ceiling effect for analgesia.</p>\r\n            <p>All have the potential to induce acute abstinence in patients with physical dependency to agonist opioids.</p>\r\n            <p>Some (pentazocine and butorphanol) have a high risk of psychotomimetic side effects.</p>\r\n            <p>Buprenorphine is available in a transdermal patch and may be of use in relatively opioid-na&#239;ve cancer patients.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Buprenorphine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Mixed agonist-antagonists:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Butorphanol</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Dezocine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Nalbuphine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Pentazocine</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"5\">Pure antagonists</td>\r\n            <td>Alvimopan</td>\r\n            <td rowspan=\"5\">\r\n            <p>Compete with endogenous and exogenous opioids at mu-receptor sites.</p>\r\n            <p>Administered for prevention or reversal of opioid effects.</p>\r\n            <p>Alvimopan and methylnaltrexone have been developed specifically to treat opioid-induced bowel dysfunction.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Methylnaltrexone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Naloxone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Naltrexone</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Nalmafene</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Mixed mechanism drugs</td>\r\n            <td>Tramadol</td>\r\n            <td rowspan=\"2\">Centrally acting analgesics that have agonist actions at the mu-receptor and block reuptake of monoamines.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tapentadol</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 69457 Version 4.0</div></div></div>"},"69458":{"type":"graphic_table","displayName":"Colic management PI","title":"Tips for reducing colic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for reducing colic</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Try these interventions first:</td> </tr> <tr> <td class=\"indent1\">Change your baby's bottle or nipple. Feed him or her in a sitting-up position and burp him or her often.</td> </tr> <tr> <td class=\"indent1\">Carry your baby more during the day in your arms, a sling, or a front carrier.</td> </tr> <tr> <td class=\"indent1\">Put your baby in his or her car seat, and put the car seat in a safe place near a dishwasher, clothes dryer, or other source of \"white noise.\"</td> </tr> <tr> <td class=\"indent1\">Take your baby for a ride in the car.</td> </tr> <tr> <td class=\"indent1\">Give your baby a pacifier.</td> </tr> <tr> <td class=\"indent1\">Put your baby in a baby swing.</td> </tr> <tr> <td class=\"indent1\">Massage your baby's belly.</td> </tr> <tr> <td class=\"indent1\">Swaddle your baby.</td> </tr> <tr> <td class=\"indent1\">Put a white noise or heartbeat machine near your baby.</td> </tr> <tr> <td class=\"indent1\">Put a warm water bottle on your baby's belly (make sure the water is not too hot).</td> </tr> <tr> <td class=\"indent1\">Give your baby a warm bath.</td> </tr> <tr> <td class=\"subtitle1_single\">If the above interventions do not work, you can try:</td> </tr> <tr> <td class=\"indent1\">Changing your baby's formula from cow's milk to predigested.</td> </tr> <tr> <td class=\"indent1\">If you breastfeed, try avoiding certain food groups, such as dairy (milk-based), eggs, nuts, and wheat. To do this, stop eating one of these types of foods for 1 week, and see if your baby's colic improves. If it does, keep that type of food out of your diet. If the colic does not improve, you can restart that food and try stopping another one.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69458 Version 6.0</div></div></div>"},"69459":{"type":"graphic_picture","displayName":"CPAM type 1 gross pathology","title":"Gross pathology of a type 1 congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology of a type 1 congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:420px; height:276px;\" src=\"images/PEDS/69459_CCAM_type_1_gross_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross pathology specimen from the lung of the patient with congenital pulmonary airway malformation (CPAM) type 1. A single, large, thin-walled, septate cyst is demonstrated.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD, and Claire Langston, MD</div><div id=\"graphicVersion\">Graphic 69459 Version 5.0</div></div></div>"},"69460":{"type":"graphic_table","displayName":"Hormone regimens in adult transgender persons","title":"Hormone regimens in adult transgender persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormone regimens in adult transgender persons</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose range</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">MTF transgender persons*</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\"><strong>Estrogen</strong><sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Oral: estradiol (17 beta-estradiol valerate)</td> <td>2 to 6 mg/day</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Transdermal: estradiol patch</td> <td>0.1 to 0.4 mg per 24 hours, changed once or twice weekly, depending on specific preparation type</td> <td>Lower risk of thromboembolism compared with oral estrogen options.</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Parenteral:</td> </tr> <tr> <td class=\"indent3\">Estradiol valerate</td> <td>5 to 20 mg IM every two weeks</td> <td rowspan=\"2\">Abuse potential; due to prolonged time to onset of effect and steady-state, greater risk of accumulation and overdose.</td> </tr> <tr> <td class=\"indent3\">Estradiol cypionate</td> <td>2 to 10 mg IM every week</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\"><strong>Antiandrogens</strong>*</td> </tr> <tr> <td class=\"indent2\">Spironolactone</td> <td>100 to 400 mg/day oral</td> <td>Monitor blood pressure and electrolytes.</td> </tr> <tr> <td class=\"indent2\">Cyproterone acetate<sup>&#916;</sup></td> <td>50 to 100 mg/day oral</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Finasteride</td> <td>2.5 to 5 mg per day oral</td> <td>Possible add-on to slow male pattern baldness.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\"><strong>GnRH agonists</strong></td> </tr> <tr> <td class=\"indent2\">Leuprolide</td> <td>3.75 to 7.5 mg IM depot monthly</td> <td>Inhibits gonadotropin secretion.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Goserelin</td> <td>3.6 mg subcutaneous implant monthly</td> <td>Expensive.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">FTM transgender persons</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\"><strong>Testosterone</strong><sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent2\">Oral: testosterone undecanoate<sup>&#916;</sup> </td> <td>160 to 240 mg/day oral</td> <td>Oral preparation is not available in United States due to rare reports of hepatocellular carcinoma with long-term use. Short half-life requires multiple daily doses (up to four times daily).</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Parenteral</td> </tr> <tr> <td class=\"indent3\">Testosterone enanthate or cypionate</td> <td> <p>50 to 100 mg IM every week</p> <p>OR</p> 100 to 200 mg IM every two weeks</td> <td>Weekly injections produce less peak-trough variation in effect (eg, mood); injection site reaction may occur.</td> </tr> <tr> <td class=\"indent3\">Testosterone undecanoate<sup>&#916;</sup><sup>&#167;</sup> </td> <td>1000 mg IM every 10 to 12 weeks</td> <td> <p>Not available in the United States.</p> Produces stable physiologic testosterone levels over 10 to 13 weeks.</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Transdermal</td> </tr> <tr> <td class=\"indent3\">Testosterone gel 1%</td> <td>2.5 to 10 grams of gel per day (equivalent to 25 to 100 mg/day testosterone)</td> <td>Less variation in serum testosterone levels than injectable preparations; gel formulations can result in interpersonal transfer if contact occurs before fully dried (rare).</td> </tr> <tr> <td class=\"indent3\">Testosterone patch</td> <td>2.5 to 7.5 mg/day transdermal</td> <td>Transdermal patch may produce lower serum testosterone levels and more skin irritation compared with gels.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Suggestions shown in table are based upon case descriptions and experience. Regimen and dose must be carefully individualized based upon patient age, goals of therapy, whether pre- or post-gonadectomy, co-morbid medical conditions and risks. Refer to topic.</div><div class=\"graphic_footnotes\">MTF: male-to-female; FTM: female-to-male; IM: intramuscular; GnRH agonist: gonadotropin-releasing hormone agonist.<br />* Dose of estrogen should be adjusted according to serum 17 beta-estradiol levels (ie, 100 to 200 pg/mL) and effect. Lower doses of estradiol are generally sufficient for feminization goals when combined with an anti-androgen, GnRH agonist, or after gonadectomy. Anti-androgen therapy is discontinued after gonadectomy.<br />¶ Synthetic estrogens (eg, ethinyl estradiol) are not recommended due to elevated risk of thromboembolic disease, cardiovascular mortality, and inability to regulate dose by measurement of serum levels.<br />Δ Not available in the United States. Available widely elsewhere.<br /><FONT class=lozenge>◊</FONT> Doses of testosterone should be adjusted according to serum testosterone levels (ie, normal male range 320 to 1000 ng/dL) and effect. Time to onset of effect of parenteral preparations may be less than with transdermal preparations. Supplemental agents such as depot medroxyprogesterone 150 mg every three months or oral medroxyprogesterone 5 to 10 mg/day or oral lynestrenol 5 to 10 mg/day (not available in the United States) have been used as an add-on option when starting testosterone therapy to induce cessation of menses.<br />§ 1000 mg initially, followed by an injection at six weeks, then at 12-week intervals.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.</LI>&#xD;&#xA;<LI>Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med 2011; 364:1251.</LI>&#xD;&#xA;<LI>Spack NP. Management of transgenderism. JAMA 2013; 309:478.</LI>&#xD;&#xA;<LI>Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy 2012; 32:54.</LI></OL></div><div id=\"graphicVersion\">Graphic 69460 Version 7.0</div></div></div>"},"69461":{"type":"graphic_diagnosticimage","displayName":"Fibula fracture above lateral malleolus","title":"Fibula fracture above the lateral malleolus  ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibula fracture above the lateral malleolus  </div><div class=\"cntnt\"><img style=\"width:262px; height:432px;\" src=\"images/EM/69461_Weber_C_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fracture is above the joint line and involves disruption of the syndesmosis.&nbsp;Such injuries&nbsp;require orthopedic referral.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 69461 Version 4.0</div></div></div>"},"69465":{"type":"graphic_picture","displayName":"Three examples of thrush (oral candidiasis) in an infant","title":"Three examples of thrush (oral candidiasis) in an infant","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Three examples of thrush (oral candidiasis) in an infant</div><div class=\"cntnt\"><img style=\"width:514px; height:391px;\" src=\"images/PEDS/69465_Thrush_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the white plaques on the inner lip and tongue (panel A) and on the buccal mucosa (panels B and C).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69465 Version 5.0</div></div></div>"},"69466":{"type":"graphic_picture","displayName":"Crusted scabies finger","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:309px; height:309px;\" src=\"images/DERM/69466_Crusted_scabies_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous plaques on the hands and thickened, dystrophic nails. The lesions are teeming with mites.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69466 Version 5.0</div></div></div>"},"69467":{"type":"graphic_table","displayName":"Features of drug induced LE","title":"Features of spontaneous and drug-induced lupus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of spontaneous and drug-induced lupus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Idiopathic SLE</td> <td class=\"subtitle1\">Drug-induced lupus</td> </tr> <tr> <td>Gender predisposition (F:M)</td> <td>9:1</td> <td>1:1</td> </tr> <tr> <td>Acetylation type</td> <td>Slow = Fast</td> <td>Slow (described for hydralazine and procainamide)</td> </tr> <tr> <td>Symptom onset</td> <td>Gradual</td> <td>Abrupt</td> </tr> <tr> <td>Usual age</td> <td>20 to 40</td> <td>Drug-dependent, tends to be older population than idiopathic (&#62;50)*</td> </tr> <tr> <td>Race</td> <td>All</td> <td>Less likely to occur in black patients</td> </tr> <tr> <td>Fever/malaise</td> <td>40 to 85 percent</td> <td>40 to 50 percent</td> </tr> <tr> <td>Arthralgias/arthritis</td> <td>75 to 95 percent</td> <td>80 to 95 percent</td> </tr> <tr> <td>Rash (all)</td> <td>50 to 70 percent</td> <td>10 to 30 percent</td> </tr> <tr> <td>Rash (discoid)</td> <td>20 percent</td> <td>Rare<sup>&#182;</sup></td> </tr> <tr> <td>Rash (malar/acute cutaneous)</td> <td>42 percent</td> <td>2 percent</td> </tr> <tr> <td>Raynaud's</td> <td>35 to 50 percent</td> <td>&#60;25 percent</td> </tr> <tr> <td>Pleuritis/pleural effusion</td> <td>16 to 60 percent</td> <td>10 to 50 percent (procainamide)</td> </tr> <tr> <td>Pulmonary infiltrates</td> <td>0 to 10 percent</td> <td>5 to 40 percent (procainamide)</td> </tr> <tr> <td>Pericarditis</td> <td>6 to 45 percent</td> <td>2 to 18 percent</td> </tr> <tr> <td>Hepatomegaly/splenomegaly</td> <td>10 to 45 percent</td> <td>5 to 25 percent</td> </tr> <tr> <td>Renal involvement</td> <td>30 to 50 percent</td> <td>0 to 5 percent</td> </tr> <tr> <td>CNS/neurologic involvement</td> <td>25 to 70 percent</td> <td>0 to 2 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Hematologic</td> <td>Common</td> <td>Unusual</td> </tr> <tr> <td class=\"subtitle1\">Laboratory feature</td> <td class=\"subtitle1\">Idiopathic SLE</td> <td class=\"subtitle1\">Drug-induced lupus</td> </tr> <tr> <td>ANA</td> <td>95 to 98 percent</td> <td>95 to 100 percent</td> </tr> <tr> <td>Anti-dsDNA</td> <td>50 to 80 percent</td> <td>&#60;5 percent (rare)</td> </tr> <tr> <td>Anti-Smith</td> <td>20 to 30 percent</td> <td>&#60;5 percent (rare)</td> </tr> <tr> <td>Anti-RNP</td> <td>40 to 50 percent</td> <td>20 percent</td> </tr> <tr> <td>Anti-Ro/SS-A</td> <td>30 to 40 percent</td> <td>Uncertain<sup>&#167;</sup></td> </tr> <tr> <td>Anti-histone</td> <td>60 to 80 percent</td> <td>90 to 95 percent<sup>&#916;</sup></td> </tr> <tr> <td>Low complement levels</td> <td>40 to 65 percent</td> <td>Rare</td> </tr> <tr> <td>Anemia</td> <td>30 to 90 percent</td> <td>0 to 46 percent</td> </tr> <tr> <td>Leukopenia</td> <td>35 to 66 percent</td> <td>2 to 33 percent</td> </tr> <tr> <td>Positive Coombs' test</td> <td>18 to 65 percent</td> <td>0 to 33 percent<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; ANA: anti-nuclear antibody; LE: lupus erythematosus; RNP: ribonucleoprotein; dsDNA: double-stranded deoxyribonucleic acid.<br />* Minocycline-induced disease tends to occur in young females, consistent with greater use of the medication than other groups.<br />¶ Case reports of drug-induced discoid lupus with anti-TNF drug exposure.<br />§ Insufficient data are available to provide an accurate estimate for (systemic) drug-induced lupus. The antibodies are present in 70 to 90 percent of patients with drug-induced subacute cutaneous lupus.<br />Δ Overall presence of anti-histone antibodies in drug-induced lupus; prevalence varies markedly between implicated drugs (may be less with minocycline or tumor necrosis factor inhibitors, and data are lacking for many agents). (Merola JF. Lupus-like syndromes related to drugs. In: Lupus Erythematosus: Clinical Evaluation and Treatment, Schur PH, Massarotti E. (Eds), Springer, New York, pp. 211-221).<br /><FONT class=lozenge>◊</FONT> Most common with&nbsp;methyldopa exposure.</div><div id=\"graphicVersion\">Graphic 69467 Version 7.0</div></div></div>"},"69469":{"type":"graphic_picture","displayName":"Chigger bites - leg","title":"Chigger bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chigger bites</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/69469_Chigger_bites_leg_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small erythematous papules are present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69469 Version 4.0</div></div></div>"},"69470":{"type":"graphic_table","displayName":"Physical examination in the hypertensive patient","title":"Important aspects of the physical examination in the hypertensive patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination in the hypertensive patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Accurate measurement of blood pressure</td> </tr> <tr> <td class=\"subtitle1_single\">General appearance</td> </tr> <tr> <td>Distribution of body fat</td> </tr> <tr> <td>Skin lesions</td> </tr> <tr> <td>Muscle strength</td> </tr> <tr> <td>Alertness</td> </tr> <tr> <td class=\"subtitle1_single\">Fundoscopy</td> </tr> <tr> <td>Hemorrhage</td> </tr> <tr> <td>Papilledema</td> </tr> <tr> <td>Cotton wool spots</td> </tr> <tr> <td>Arteriolar narrowing and arteriovenous nicking</td> </tr> <tr> <td class=\"subtitle1_single\">Neck</td> </tr> <tr> <td>Palpation and auscultation of carotids</td> </tr> <tr> <td>Thyroid</td> </tr> <tr> <td class=\"subtitle1_single\">Heart</td> </tr> <tr> <td>Size</td> </tr> <tr> <td>Rhythm</td> </tr> <tr> <td>Sounds</td> </tr> <tr> <td class=\"subtitle1_single\">Lungs</td> </tr> <tr> <td>Rhonchi</td> </tr> <tr> <td>Rales</td> </tr> <tr> <td class=\"subtitle1_single\">Abdomen</td> </tr> <tr> <td>Renal masses</td> </tr> <tr> <td>Bruits over aorta or renal arteries</td> </tr> <tr> <td>Femoral pulses</td> </tr> <tr> <td class=\"subtitle1_single\">Extremities</td> </tr> <tr> <td>Peripheral pulses</td> </tr> <tr> <td>Edema</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic assessment</td> </tr> <tr> <td>Visual disturbance</td> </tr> <tr> <td>Focal weakness</td> </tr> <tr> <td>Confusion</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69470 Version 4.0</div></div></div>"},"69473":{"type":"graphic_figure","displayName":"Diagram explaining constipation and fecal incontinence PI","title":"Constipation and bowel retraining","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Constipation and bowel retraining</div><div class=\"cntnt\"><img style=\"width:537px; height:483px;\" src=\"images/PI/69473_Encopresis_diagram_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fecal incontinence in children is when a toilet-trained child has bowel movements in the wrong place. Constipation is the most common cause. This diagram shows how constipation can make bowel movements build up and how treatment works.</div><div id=\"graphicVersion\">Graphic 69473 Version 5.0</div></div></div>"},"69474":{"type":"graphic_table","displayName":"CF oral formulas","title":"Commercially available oral supplements used for individuals with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commercially available oral supplements used for individuals with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Supplement</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">Fat<br /> (grams per 8 oz formula)</td> <td class=\"subtitle1\">Type of fat</td> <td class=\"subtitle1\">Kcal/mL</td> </tr> <tr> <td>Ensure*</td> <td>Abbott</td> <td>6</td> <td>Soy, canola, corn oil</td> <td>1.06</td> </tr> <tr> <td>Boost*</td> <td>Nestle</td> <td>4</td> <td>Canola, high oleic sunflower, corn oil</td> <td>1.0</td> </tr> <tr> <td>Pediasure</td> <td>Abbott</td> <td>9</td> <td>High oleic safflower, soy, MCT oil</td> <td>1.0</td> </tr> <tr> <td>Pediasure 1.5</td> <td>Abbott</td> <td>16</td> <td>High oleic safflower, soy, MCT oil</td> <td>1.5</td> </tr> <tr> <td>Carnation Breakfast Essentials* (powder mixed with 8 oz. whole milk)</td> <td>Nestle</td> <td>8</td> <td>Butter fat</td> <td>1.06</td> </tr> <tr> <td>Ensure Plus*</td> <td>Abbott</td> <td>11</td> <td>Canola, corn oil</td> <td>1.5</td> </tr> <tr> <td>Boost Plus*</td> <td>Nestle</td> <td>14</td> <td>Canola, high oleic sunflower, corn oil</td> <td>1.5</td> </tr> <tr> <td>Resource 2.0</td> <td>Nestle</td> <td>21</td> <td>Canola oil</td> <td>2.0</td> </tr> <tr> <td>Boost Kids Essentials 1.5</td> <td>Nestle</td> <td>18</td> <td>Soybean oil, high oleic sunflower oil, MCT oil</td> <td>1.5</td> </tr> <tr> <td>Boost Kids Essentials 1.0</td> <td>Nestle</td> <td>9</td> <td>High oleic sunflower oil, soybean oil, MCT oil</td> <td>1.0</td> </tr> <tr> <td>Scandishake*</td> <td>Aptalis</td> <td>23</td> <td>Partially hydrogenated coconut oil, sunflower oil, and MCT oil</td> <td>2.5</td> </tr> <tr> <td>Boost&nbsp;Breeze</td> <td>Nestle</td> <td>0</td> <td>None</td> <td>1.06</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCT: medium-chain triglycerides; kcal: kilocalories.<br />* Appropriate selections for adolescents and adults.</div><div class=\"graphic_reference\">Data in this table from the manufacturers' websites.</div><div id=\"graphicVersion\">Graphic 69474 Version 13.0</div></div></div>"},"69475":{"type":"graphic_picture","displayName":"Mycobacterium avium adenitis","title":"<EM>Mycobacterium avium </EM>adenitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Mycobacterium avium </EM>adenitis</div><div class=\"cntnt\"><img style=\"width:203px; height:274px;\" src=\"images/PEDS/69475_Mycobac_avium_adenitis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>M. avium </EM>cervical lymphadenitis in the parotid and submandibular regions. The parotid node underwent incomplete excision and began to relapse. The submandibular node began to spontaneously drain and formed an overlying scab.</div><div id=\"graphicVersion\">Graphic 69475 Version 4.0</div></div></div>"},"69476":{"type":"graphic_diagnosticimage","displayName":"MRCP in a patient with primary sclerosing cholangitis","title":"Magnetic resonance cholangiopancreatography in a patient with primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance cholangiopancreatography in a patient with primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:432px; height:402px;\" src=\"images/GAST/69476_MRCP_prim_scleros_cholang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thick slab coronal magnetic resonance image of the liver in a patient with primary sclerosing cholangitis. The image sequence shows all bile ducts with a bright white signal. Note the beaded duct in the left lobe (arrow) as well as the many dilated intrahepatic ducts.</div><div class=\"graphic_footnotes\">GB: gallbladder.</div><div id=\"graphicVersion\">Graphic 69476 Version 3.0</div></div></div>"},"69477":{"type":"graphic_table","displayName":"Medical Rx pain endometriosis","title":"Medical treatment for pelvic pain in endometriosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical treatment for pelvic pain in endometriosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Advantages</td> </tr> <tr> <td>Avoids risk of damaging pelvic organs during surgery</td> </tr> <tr> <td>Avoids risk of postoperative adhesion formation</td> </tr> <tr> <td>Treats implants not visualized during surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Disadvantages</td> </tr> <tr> <td>Side effects of medications</td> </tr> <tr> <td>High recurrence rates after discontinuation</td> </tr> <tr> <td>No effect on existing adhesions</td> </tr> <tr> <td>No effect on endometriomas</td> </tr> <tr> <td>Treatments involving suppression of ovulation also prevent pregnancy during the treatment period</td> </tr> <tr> <td>No effect on infertility</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69477 Version 3.0</div></div></div>"},"69478":{"type":"graphic_waveform","displayName":"Intermediate case 17 answer","title":"Monomorphic ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Monomorphic ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:506px; height:295px;\" src=\"images/CARD/69478_Intermediate_case_17_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This wide complex arrhythmia shows a right bundle branch block morphology with a positive QRS in lead V1. The QS waves in V5 and V6 suggest that the tachycardia originates in the vicinity of an apical-lateral infarct. The diagnosis of VT, rather than supraventricular tachycardia (SVT) with aberration, is supported by the wide R wave in V1 (versus an rSR' pattern which can be seen with SVT or occasionally VT), the very wide QRS (&gt;160 msec, 200 msec here), and the QS waves in V5 and V6. Atrial activity cannot be readily identified in this ECG.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 69478 Version 2.0</div></div></div>"},"69479":{"type":"graphic_table","displayName":"Corticosteroid coverage surgery","title":"Corticosteroid coverage for surgery in patients taking exogenous corticosteroids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Corticosteroid coverage for surgery in patients taking exogenous corticosteroids</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>For minor procedures or surgery under local anesthesia (eg, inguinal hernia repair), take usual morning steroid dose. No extra supplementation is necessary.</td> </tr> <tr> <td>For moderate surgical stress (eg, lower extremity revascularization, total joint replacement), take usual morning steroid dose. Give 50 mg hydrocortisone intravenously just before the procedure and 25 mg of hydrocortisone every&nbsp;eight hours for 24 hours. Resume usual dose thereafter.</td> </tr> <tr> <td>For major surgical stress (eg, esophagogastrectomy, total proctocolectomy, open heart surgery), take usual&nbsp;morning steroid dose. Give 100 mg of intravenous hydrocortisone before induction of anesthesia and 50 mg every&nbsp;eight hours for 24 hours. Taper dose by half per day to maintenance level.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69479 Version 5.0</div></div></div>"},"69481":{"type":"graphic_picture","displayName":"Forward step up PI","title":"Forward step up","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forward step up</div><div class=\"cntnt\"><img style=\"width:411px; height:515px;\" src=\"images/PI/69481_Forward_step_up_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place left foot onto a step, then step up with right foot. Move left foot back down to floor then step down with right. Repeat this sequence 10 times then change order of feet (step first with the left, followed by the right); this is one set. Perform three sets.</div><div id=\"graphicVersion\">Graphic 69481 Version 4.0</div></div></div>"},"69482":{"type":"graphic_diagnosticimage","displayName":"Primary chylopericardium CT","title":"Primary chylopericardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary chylopericardium</div><div class=\"cntnt\"><img style=\"width:337px; height:246px;\" src=\"images/CARD/69482_Primary_chylopericardium_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan from a patient with primary chylopericardium. The thoracic duct (large arrow) is connected to the pericardial cavity (small arrow heads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced by permission from: Akamatsu H, Amano J, Sakamoto T, Suzuki A. Ann Thorac Surg 1994; 58:262.</div><div id=\"graphicVersion\">Graphic 69482 Version 4.0</div></div></div>"},"69483":{"type":"graphic_figure","displayName":"Variations in the cystic and hepatic ducts","title":"Variations in the cystic and hepatic ducts","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Variations in the cystic and hepatic ducts</div><div class=\"cntnt\"><img style=\"width:585px; height:315px;\" src=\"images/SURG/69483_Variations_ducts_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variations in the cystic and hepatic ducts are depicted here:<br> (A) Low union.<br> (B) High union.<br> (C) Swerving course.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69483 Version 4.0</div></div></div>"},"69484":{"type":"graphic_table","displayName":"Anticoagulant trials acute CVT","title":"Placebo-controlled randomized trials of anticoagulants in acute cerebral venous thrombosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Placebo-controlled randomized trials of anticoagulants in acute cerebral venous thrombosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Einh&#228;upl et al 1991, intravenous heparin versus placebo</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Heparin versus placebo</td> <td class=\"subtitle2\" colspan=\"2\">Outcome at three months</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">Heparin group (n = 10)</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Total recovery</td> <td class=\"sublist_other\" colspan=\"2\">8 patients</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Residual motor deficit</td> <td class=\"sublist_other\" colspan=\"2\">2 patients</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">Placebo group (n = 10)</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Total recovery</td> <td class=\"sublist_other\" colspan=\"2\">1 patient</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Minor residual deficit</td> <td class=\"sublist_other\" colspan=\"2\">6 patients</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Deaths</td> <td class=\"sublist_other\" colspan=\"2\">3 patients</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">De Bruijn and Stam 1999, subcutaneous nadroparin versus placebo</td> </tr> <tr> <td class=\"subtitle2\">Outcome difference</td> <td class=\"subtitle2\">Nadroparin (n = 30)</td> <td class=\"subtitle2\">Placebo (n = 29)</td> <td class=\"subtitle2\">Risk difference</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">At three weeks</td> </tr> <tr> <td class=\"sublist2\">Deaths</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">BI score &#60;15</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Death or BI &#60;15</td> <td class=\"sublist_other\">6 (20 percent)</td> <td class=\"sublist_other\">7 (24 percent)</td> <td class=\"sublist_other\">4 percent (95% CI, &ndash;25 to 17 percent)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">At 12 weeks</td> </tr> <tr> <td class=\"sublist2\">Deaths</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Dependent (OHS 3 to 5)</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Death or dependent</td> <td class=\"sublist_other\">4 (13 percent)</td> <td class=\"sublist_other\">6 (21 percent)</td> <td class=\"sublist_other\">7 percent (95% CI, &ndash;26 to 12 percent)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BI: Barthel Index; OHS: Oxford Handicap Score.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Einh&auml;upl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597.</li>&#xD;&#xA;    <li>de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69484 Version 5.0</div></div></div>"},"69485":{"type":"graphic_diagnosticimage","displayName":"Hip effusion MRI","title":"Magnetic resonance image of left hip effusion","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of left hip effusion</div><div class=\"cntnt\"><img style=\"width:528px; height:263px;\" src=\"images/PEDS/69485_Hip_effusion_MRI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial and (B) coronal image of left hip effusion. The bright collection seen around the femoral neck (arrows) is a left hip effusion. The images were obtained using a fast spin echo-inversion recovery (FSE-IR) sequence, which is fluid sensitive.</div><div class=\"graphic_reference\">Courtesy of Michael Rosenthal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69485 Version 4.0</div></div></div>"},"69486":{"type":"graphic_table","displayName":"NB resuscitation equipment","title":"Neonatal resuscitation supplies and equipment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neonatal resuscitation supplies and equipment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Suction equipment</td> </tr> <tr> <td>Bulb syringe</td> </tr> <tr> <td>Mechanical suction, tubing, and catheters</td> </tr> <tr> <td>Meconium aspirator</td> </tr> <tr> <td>8F feeding tube and 20 cc syringe</td> </tr> <tr> <td class=\"subtitle1_single\">Intubation equipment</td> </tr> <tr> <td>Laryngoscope with straight blades (number 0 and 1 for preterm and term infants, respectively)</td> </tr> <tr> <td>Face masks (preterm and term infant sizes)</td> </tr> <tr> <td>Oxygen source with flowmeter</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Dextrose solution 10 percent</td> </tr> <tr> <td>Epinephrine (0.1 mg/mL)</td> </tr> <tr> <td>Isotonic solution</td> </tr> <tr> <td>Naloxone hydrochloride (0.4 mg/mL)</td> </tr> <tr> <td>Needles</td> </tr> <tr> <td>Syringes</td> </tr> <tr> <td class=\"sublist1_start\">Umbilical vessel catheterization supplies</td> </tr> <tr> <td class=\"sublist1\">Sterile gloves, scalpel, antiseptic prep solution, umbilical catheter, tape, three-way stopcock</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Radiant warmer</td> </tr> <tr> <td>Warm towels</td> </tr> <tr> <td>Cardiac monitor</td> </tr> <tr> <td>Pulse oximeter and probe</td> </tr> <tr> <td>Oropharyngeal airways</td> </tr> <tr> <td class=\"subtitle1_single\">Additional equipment for delivery of preterm infants</td> </tr> <tr> <td>Compressed air source</td> </tr> <tr> <td>Oxygen blender</td> </tr> <tr> <td>Plastic wrap</td> </tr> <tr> <td>Transport incubator</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Kattwinkel J. Textbook of neonatal resuscitation, 5th ed, American Academy of Pediatrics, 2006. Copyright © 2006 American Academy of Pediatrics.</div><div id=\"graphicVersion\">Graphic 69486 Version 14.0</div></div></div>"},"69487":{"type":"graphic_waveform","displayName":"Intermediate case 8 with answer","title":"Mobitz type I (Wenckebach) AV block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobitz type I (Wenckebach) AV block</div><div class=\"cntnt\"><img style=\"width:450px; height:98px;\" src=\"images/CARD/69487_Intermediate_case_8_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm with Mobitz type I (Wenckebach) atrioventricular block. Note the progressive prolongation of the PR interval with the sixth P wave not being conducted (arrow). This is followed by resumption of AV conduction as the seventh P wave is conducted with a relatively short PR interval that then begins to increase with the next P wave.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger.</div><div id=\"graphicVersion\">Graphic 69487 Version 2.0</div></div></div>"},"69489":{"type":"graphic_table","displayName":"Confusion assessment method","title":"Confusion assessment method (CAM) for the diagnosis of delirium*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Confusion assessment method (CAM) for the diagnosis of delirium*</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Feature\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Assessment\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>1. Acute onset and fluctuating course</td>\r\n  \r\n   <td>\t<p>Usually obtained from a family member or nurse and shown by positive responses to the following questions:</p>\n\t<p>\t\"Is there evidence of an acute change in mental status from the patient's baseline?\"; </p>\n\t<p>\t\"Did the abnormal behavior fluctuate during the day, that is, tend to come and go, or increase and decrease in severity?\"</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>2. Inattention</td>\r\n  \r\n   <td>\t<p>Shown by a positive response to the following:</p>\n\t<p>\t \"Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said?\"</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3. Disorganized thinking</td>\r\n  \r\n   <td>\t<p>Shown by a positive response to the following: </p>\n\t<p>\t\"Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject?\"</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"7\">\r\n  \r\n   4. Altered level of consciousness\r\n  \r\n   </td>\r\n  \r\n   <td>Shown by any answer other than \"alert\" to the following:</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\"Overall, how would you rate this patient's level ofconsciousness?\"</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Normal = alert</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperalert = vigilant</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Drowsy, easily aroused = lethargic</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Difficult to arouse = stupor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Unarousable = coma</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">*The diagnosis of delirium requires the presence of features 1 AND 2 plus either 3 OR 4.</div><div id=\"graphicVersion\">Graphic 69489 Version 1.0</div></div></div>"},"69490":{"type":"graphic_table","displayName":"Beta thal intermedia variants","title":"Thalassemia variants that may present as beta thalassemia intermedia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thalassemia variants that may present as beta thalassemia intermedia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>General principles:</strong> The pathophysiology of beta (&#946;)&nbsp;thalassemia depends absolutely on the amount of excess unpaired alpha globin chains. Therefore, any genetic variant that increases or decreases the amount of these unpaired alpha chains (eg, by altering the rate of alpha or beta chain production or by substituting for the missing beta chains) will modify the phenotype. Disorders that present as &#946; thalassemia intermedia, rather than as the major or minor variants, are listed below:</td> </tr> <tr> <td>Homozygosity for mild forms of &#946;+ thalassemia</td> </tr> <tr> <td>Compound heterozygosity for &#946;+/&#946;&ordm; thalassemia</td> </tr> <tr> <td>Compound heterozygosity for &#946; thalassemia and another beta chain variant (eg, &#946;-thal/HbE)</td> </tr> <tr> <td>Coinheritance of homozygous &#946; thalassemia with genes for increased gamma chain synthesis (ie, HPFH)</td> </tr> <tr> <td>Coinheritance of homozygous &#946;+ thalassemia with alpha thalassemia (eg, &#946;+/&#946;+ with -a/-a, --/aa, -a/aa, or --/-a)</td> </tr> <tr> <td>Coinheritance of heterozygous &#946; thalassemia and triplicated or quadruplicated alpha genes (eg, aa/aaa or aa/aaaa)</td> </tr> <tr> <td>Dominant forms of &#946; thalassemia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">β+ thalassemia: reduced production of beta chains (may be mild, moderate, or severely reduced); βº thalassemia: no production of beta chains; HbE: hemoglobin E; HPFH: hereditary persistence of fetal hemoglobin.</div><div class=\"graphic_reference\">Table provided by Stanley L. Schrier, MD.</div><div id=\"graphicVersion\">Graphic 69490 Version 7.0</div></div></div>"},"69492":{"type":"graphic_figure","displayName":"Thoracic lymph nodes - Posterior view","title":"Thoracic lymph nodes - Posterior view","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Thoracic lymph nodes - Posterior view</div><div class=\"cntnt\"><img style=\"width:492px; height:560px;\" src=\"images/SURG/69492_Thoracic-lymph-nodes-posterior-view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the posterior view of the thoracic lymph nodes. Note the relationship of the nodes to the esophagus, trachea, heart, and great vessels.</div><div id=\"graphicVersion\">Graphic 69492 Version 2.0</div></div></div>"},"69493":{"type":"graphic_picture","displayName":"Molluscum pathology","title":"Molluscum bodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum bodies</div><div class=\"cntnt\"><img style=\"width:418px; height:292px;\" src=\"images/DERM/69493_Molluscum_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eosinophilic cytoplasmic inclusion bodies are visualized on hematoxylin and eosin staining of a molluscum contagiosum lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69493 Version 2.0</div></div></div>"},"69494":{"type":"graphic_table","displayName":"Rapid overview Epidural hematoma in children","title":"Rapid overview: Epidural hematoma (EDH) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Epidural hematoma (EDH) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Head trauma, especially to the temporal or occipital region</td> </tr> <tr> <td class=\"sublist2_start\">Possible signs and symptoms include:</td> </tr> <tr> <td class=\"sublist2\">History of loss of consciousness</td> </tr> <tr> <td class=\"sublist2\">History of altered mental status per caregiver</td> </tr> <tr> <td class=\"sublist2\">Severe headache</td> </tr> <tr> <td class=\"sublist2\">Vomiting</td> </tr> <tr> <td class=\"sublist2\">Lethargy (GCS 9-14) or coma (GCS &#8804;8)</td> </tr> <tr> <td class=\"sublist2\">Irritability, pallor, cephalohematoma (infants &#8804;12 months)</td> </tr> <tr> <td class=\"sublist2\">Lucid interval for minutes up to several hours followed by clinical deterioration (classic temporal EDH)</td> </tr> <tr> <td class=\"sublist2\">Ataxia, dizziness with potential for abrupt catastrophic deterioration (posterior fossa EDH)</td> </tr> <tr> <td class=\"sublist2\">Lateralizing signs (anisocoria, hemiparesis, hemiplegia) and Cushing triad (hypertension, bradycardia, respiratory depression) are late findings that indicate cerebral herniation</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">The primary goal is to make the diagnosis of EDH BEFORE neurologic deterioration in an asymptomatic or mildly affected child to permit timely surgical intervention</td> </tr> <tr> <td class=\"indent1\">Determine GCS*. Identify pupillary abnormalities and lateralizing motor findings.</td> </tr> <tr> <td class=\"indent1\">Obtain emergent unenhanced head CT</td> </tr> <tr> <td class=\"indent1\">Obtain neurosurgical consultation for all patients with GCS &#8804;12 or with identified EDH</td> </tr> <tr> <td class=\"sublist2_start\">Initial laboratory studies (patients with EDH in need of surgical evacuation):</td> </tr> <tr> <td class=\"sublist2\">Complete blood count with platelets</td> </tr> <tr> <td class=\"sublist2\">Coagulation studies (PT, PTT with INR)</td> </tr> <tr> <td class=\"sublist2\">Type and cross match for blood transfusion</td> </tr> <tr> <td class=\"sublist2\">Other studies (eg, AST, ALT, and urinalysis) may be indicated in multiple trauma patients<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Lumbar puncture is <strong>contraindicated</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist2_start\">Surgical evacuation is the definitive management for EDH in children with altered mental status, signs of increased intracranial pressure, or focal neurologic findings. Such patients require emergent consultation with a neurosurgeon.</td> </tr> <tr> <td class=\"sublist2_start\">During stabilization, manage the patient according to principles of advanced trauma life support<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Immobilize cervical spine</td> </tr> <tr> <td class=\"sublist2\">Treat hypoxemia</td> </tr> <tr> <td class=\"sublist2\">Assess and manage airway, breathing, circulation, and disability </td> </tr> <tr> <td class=\"sublist2\">Perform endotracheal intubation in children with GCS &#8804;8 or rapidly worsening mental status. Ventilate to maintain pCO2 between 35 and 40 mmHg</td> </tr> <tr> <td class=\"sublist2\">Provide fluid resuscitation, as needed, to prevent hypotension<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2_start\">If signs of herniation, provide hyperosmolar therapy (preferably in consultation with a neurosurgeon):</td> </tr> <tr> <td class=\"sublist2\">3 percent hypertonic saline solution in a volume of 2 to 6 mL/kg IV per dose (maximum 300 mL), as a rapid bolus infusion. May repeat if needed or initiate infusion. Closely monitor serum sodium concentration and osmolarity (maintain &#60;360 mOsm/L).</td> </tr> <tr> <td class=\"sublist2\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist2\">Mannitol 20 percent solution, 0.5 to 1 gram/kg IV per dose, as a rapid bolus infusion. May repeat after 6 hours as needed to increase serum osmolarity (maintain &#60;320 mOsm/L).</td> </tr> <tr> <td class=\"indent1\">Perform mild hyperventilation (PaCO2 30-35 mmHg) for children whose signs of herniation do not respond to hyperosmolar therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDH: epidural hematoma; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; AST: aspartate transferase; ALT: alanine transferase; CT: computed tomography; GCS: Glasgow coma scale.<br />* Utilize the pediatric Glasgow coma scales when indicated. Refer to UpToDate graphics on Glasgow coma scales.<br />¶ Refer to UpToDate topics on trauma in the unstable child.</div><div id=\"graphicVersion\">Graphic 69494 Version 6.0</div></div></div>"},"69495":{"type":"graphic_table","displayName":"Major causes of weight loss","title":"Major causes of weight loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of weight loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Involuntary weight loss with increased appetite</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Uncontrolled diabetes mellitus</td> </tr> <tr> <td>Malabsorption syndromes</td> </tr> <tr> <td>Marked increase in physical activity</td> </tr> <tr> <td class=\"subtitle1_single\">Involuntary weight loss with decreased appetite</td> </tr> <tr> <td class=\"sublist1_start\">Medical disorders</td> </tr> <tr> <td class=\"sublist1\">Malignancy (particularly gastrointestinal, lung, lymphoma, renal, and prostate cancers)</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal diseases (including peptic ulcer disease, malabsorption, diabetic enteropathy, dysphagia, inflammatory bowel disease, hepatitis, Zenker's diverticulum, paraesophageal hernia)</td> </tr> <tr> <td class=\"sublist1\">Endocrine diseases (hyperthyroidism, diabetes, adrenal insufficiency)</td> </tr> <tr> <td class=\"sublist1\">Infectious diseases (HIV, viral hepatitis, tuberculosis, chronic fungal or bacterial disease, chronic helminth infection, lung abscess)</td> </tr> <tr> <td class=\"sublist1\">Severe heart, lung, or kidney disease (cardiac cachexia from heart failure; pulmonary cachexia from severe obstructive or restrictive lung disease; renal failure, nephrotic sydrome, chronic glomerulonephritis)</td> </tr> <tr> <td class=\"sublist1\">Neurological diseases (stroke, dementia, dysphagia, Parkinson disease, amyotrophic lateral sclerosis)</td> </tr> <tr> <td class=\"sublist1\">Noninfectious chronic inflammatory diseases (sarcoidosis, severe rheumatoid arthritis, giant cell vasculitis)</td> </tr> <tr> <td class=\"sublist1_start\">Psychiatric disorders</td> </tr> <tr> <td class=\"sublist1\">Affective disorders (depression, bipolar disorder, generalized anxiety disorder)</td> </tr> <tr> <td class=\"sublist1\">Food-related delusional manifestations of other psychiatric disorders</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Alcohol</td> </tr> <tr> <td class=\"sublist1\">Opiates</td> </tr> <tr> <td class=\"sublist1\">Amphetamines and cocaine</td> </tr> <tr> <td class=\"sublist1\">Drug withdrawal syndromes (withdrawal after chronic high-dose psychotropic medications or cannabis)</td> </tr> <tr> <td class=\"sublist1\">Adverse effects of prescription drugs (topiramate, zonisamide, SSRIs, levodopa, digoxin, metformin, exenatide, liraglutide, NSAIDS, and anticancer and antiretroviral drugs)</td> </tr> <tr> <td class=\"sublist1\">Herbal and other nonprescription drugs (5-hydroxytryptophan, aloe, caffeine, cascara, chitosan, chromium, dandelion, ephedra, garcinia, glucomannan, guarana, guar gum, herbal diuretics, nicotine, pyruvate, St. John's wort)</td> </tr> <tr> <td class=\"subtitle1_single\">Voluntary weight loss</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Prescription drugs used for treating obesity (rimonabant, orlistat, phentermine, sibutramine, metformin, bupropion)</td> </tr> <tr> <td class=\"sublist1\">Prescription drugs occasionally abused for weight loss effects (amphetamines and derivatives, thyroid hormone)</td> </tr> <tr> <td class=\"sublist1\">Herbal and other nonprescription drugs (5-hydroxytryptophan, aloe, caffeine, cascara, chitosan, chromium, dandelion, ephedra, garcinia, glucomannan, guarana, guar gum, herbal diuretics, nicotine, pyruvate, St. John's wort)</td> </tr> <tr> <td>Dieting</td> </tr> <tr> <td>Anorexia nervosa and bulimia nervosa</td> </tr> <tr> <td>Chronic vigorous exercise, usually combined with dieting (eg, distance runners, ballet dancers, gymnasts)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69495 Version 5.0</div></div></div>"},"69496":{"type":"graphic_table","displayName":"Late complications female circ","title":"Long-term complications of female circumcision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-term complications of female circumcision</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Urinary</td>\n</tr>\n<tr>\n<td>Urethral strictures</td>\n</tr>\n<tr>\n<td> Meatal obstruction</td>\n</tr>\n<tr>\n<td> Chronic urinary tract infection</td>\n</tr>\n<tr>\n<td> Meatitis</td>\n</tr>\n<tr>\n<td> Urinary crystals</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Scarring</td>\n</tr>\n<tr>\n<td>Fibrosis</td>\n</tr>\n<tr>\n<td> Keloids</td>\n</tr>\n<tr>\n<td> Partial fusion</td>\n</tr>\n<tr>\n<td> Complete fusion</td>\n</tr>\n<tr>\n<td> Hematocolpos</td>\n</tr>\n<tr>\n<td> Inclusion/sebaceous cyst</td>\n</tr>\n<tr>\n<td> Vulvar abscess</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Pain</td>\n</tr>\n<tr>\n<td>Neuromas</td>\n</tr>\n<tr>\n<td> Chronic vaginal infections</td>\n</tr>\n<tr>\n<td> Dyspareunia</td>\n</tr>\n<tr>\n<td> Vaginismus</td>\n</tr>\n<tr>\n<td> Dysmenorrhea</td>\n</tr>\n<tr>\n<td> Menorrhagia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Infertility</td>\n</tr>\n<tr>\n<td>Vaginal stenosis</td>\n</tr>\n<tr>\n<td> Infibulated scar</td>\n</tr>\n<tr>\n<td> Dyspareunia</td>\n</tr>\n<tr>\n<td> Apareunia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69496 Version 1.0</div></div></div>"},"69497":{"type":"graphic_figure","displayName":"Rapid rise in BP after ending chronic antihypertensive therapy","title":"Rapid rise in blood pressure after discontinuation of chronic antihypertensive therapy","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Rapid rise in blood pressure after discontinuation of chronic antihypertensive therapy</div><div class=\"cntnt\"><img style=\"width:462px; height:422px;\" src=\"images/NEPH/69497_Cessation_antihypertensive.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a trial performed by the Medical Research Council Working Party of Mild Hypertension, 2765 patients were randomly assigned to bendrofluazide, propranolol, or placebo. Both systolic and diastolic pressures fell more with drug therapy than placebo (phase 1). At six years, patients in the drug therapy groups were reassigned to continued therapy or placebo (phase 2). The fall in both systolic and diastolic pressures was maintained in those on continued therapy, while switching to placebo led, within&nbsp;9 to 12&nbsp;months, to a rise in blood pressure to a level similar to the values in patients treated with placebo from the beginning.</div><div class=\"graphic_reference\">Data from Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Br Med J (Clin Res Ed)&nbsp;1986; 293:988.</div><div id=\"graphicVersion\">Graphic 69497 Version 3.0</div></div></div>"},"69498":{"type":"graphic_table","displayName":"Systemic disease spine pain","title":"Categories of systemic disease associated with spine pain, and clues to their diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of systemic disease associated with spine pain, and clues to their diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">Cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Prior history of cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Older age</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Unexplained weight loss</td>\n\t  </tr>\n\t  <tr>\n\t    <td>No relief with bed rest</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Pain exceeding one month</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Failure to improve with spine therapies</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Spinal infections</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Intravenous drug use</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Urinary tract infection</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Skin infection</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Compression fractures</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Older age</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Trauma</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Prolonged glucocorticoid use</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Rheumatologic disorders</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ankylosing spondylitis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Beh&#231;et disease</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Crohn disease</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Psoriatic arthritis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Rheumatoid arthritis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ulcerative colitis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Whipple disease</td>\n\t  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69498 Version 1.0</div></div></div>"},"69501":{"type":"graphic_table","displayName":"Indication contraind LVRS","title":"Potential indications and contraindications for LVRS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications and contraindications for LVRS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Contraindications</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Clinical</td> <td>Age &#60;75 years</td> <td>Age &#8805;75 years</td> </tr> <tr> <td>Ex-smoker (&#62;6 months)</td> <td>Current smoking</td> </tr> <tr> <td>Clinical picture consistent with emphysema</td> <td>Surgical constraints (eg, previous thoracic procedure, pleurodesis, chest wall deformity)</td> </tr> <tr class=\"divider_bottom\"> <td>Dyspnea despite maximal medical therapy and pulmonary rehabilitation</td> <td>Pulmonary hypertension (PA systolic &#62;45 mmHg, PA mean &#62;35 mmHg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Comorbid illness*</td> <td>&nbsp;</td> <td>Clinically significant bronchiectasis</td> </tr> <tr> <td>&nbsp;</td> <td>Clinically significant coronary heart disease</td> </tr> <tr> <td>&nbsp;</td> <td>Heart failure with an ejection fraction &#60;45 percent</td> </tr> <tr> <td>&nbsp;</td> <td>Uncontrolled hypertension</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Obesity<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Physiology</td> <td>FEV1 after bronchodilator &#60;45 percent predicted</td> <td>FEV1 &#8804;20 percent predicted with either DLCO &#8804;20 percent predicted or homogeneous emphysema</td> </tr> <tr> <td>Hyperinflation (TLC &#62;100 percent predicted, RV &#62;150 percent)</td> <td>PaO2 &#8804;45 mmHg on room air</td> </tr> <tr> <td>Post rehabilitation 6-minute walk distance &#62;140 meters</td> <td>PaCO2 &#8805;60 mmHg</td> </tr> <tr class=\"divider_bottom\"> <td>Low post rehabilitation maximal achieved cycle ergometry watts<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"4\">Imaging</td> <td>Chest radiograph - hyperinflation</td> <td>&nbsp;</td> </tr> <tr> <td>HRCT confirming severe emphysema, ideally with upper lobe predominance</td> <td>Homogeneous emphysema with FEV1 &#8804;20 percent predicted</td> </tr> <tr> <td>&nbsp;</td> <td>Significant pleural or interstitial changes on HRCT</td> </tr> <tr> <td>&nbsp;</td> <td>Nonupper lobe predominant emphysema and high post rehabilitation maximal achieved cycle ergometry watts<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in one second; TLC: total lung capacity; RV: residual volume; PaO2: arterial partial pressure of oxygen; PaCO2: arterial partial pressure of carbon dioxide; HRCT: high resolution computed tomography.<br />* Comorbid illnesses may be considered relative contraindications depending on degree of severity.<br />&para; The NETT trial required a body mass index less than 31.1 kg/m2 for men and less than 32.3 kg/m2 for women. It is not known whether more severe obesity would adversely affect perioperative risk.<br />&Delta; Low post rehabilitation maximal achieved cycle ergometry watts (W) is defined as at or below the sex specific 40th percentile (25 W for women and 40 W for men).<br /><span class=\"lozenge\">&loz;</span> High post rehabilitation maximal achieved cycle ergometry watts (W) is defined as above the sex specific 40th percentile (25 W for women and 40 W for men). This is a relative contraindication.</div><div class=\"graphic_reference\">Data from: www.thoracic.org/COPD.</div><div id=\"graphicVersion\">Graphic 69501 Version 2.0</div></div></div>"},"69502":{"type":"graphic_table","displayName":"Etiology of osteonecrosis","title":"Etiologic factors associated with osteonecrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic factors associated with osteonecrosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Traumatic</td>\n</tr>\n<tr>\n<td>Femoral neck fracture</td>\n</tr>\n<tr>\n<td>Dislocation or fracture-dislocation</td>\n</tr>\n<tr>\n<td>Minor trauma</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Nontraumatic</td>\n</tr>\n<tr>\n<td>Corticosteroid administration, rarely hypersecretion of cortisol</td>\n</tr>\n<tr>\n<td>Alcohol use</td>\n</tr>\n<tr>\n<td>Sickle cell hemoglobinopathies</td>\n</tr>\n<tr>\n<td>Caisson (dysbarism) disease</td>\n</tr>\n<tr>\n<td>Systemic lupus erythematosus</td>\n</tr>\n<tr>\n<td>Gaucher's disease</td>\n</tr>\n<tr>\n<td>Chronic renal failure or hemodialysis</td>\n</tr>\n<tr>\n<td>Pancreatitis</td>\n</tr>\n<tr>\n<td>Pregnancy</td>\n</tr>\n<tr>\n<td>Hyperlipidemia</td>\n</tr>\n<tr>\n<td>Radiation</td>\n</tr>\n<tr>\n<td>Organ transplantation</td>\n</tr>\n<tr>\n<td>Intravascular coagulation</td>\n</tr>\n<tr>\n<td>Thrombophlebitis</td>\n</tr>\n<tr>\n<td>Cigarette smoking</td>\n</tr>\n<tr>\n<td>Hyperuricemia/gout</td>\n</tr>\n<tr>\n<td>Human immunodeficiency virus infection</td>\n</tr>\n<tr>\n<td>Idiopathic</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69502 Version 1.0</div></div></div>"},"69504":{"type":"graphic_picture","displayName":"Langerhans histiocytosis skin 2","title":"Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/69504_Langerhans_histio_skin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-pink papules with scale are present in the diaper area of this infant with Langerhans cell histiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69504 Version 6.0</div></div></div>"},"69505":{"type":"graphic_algorithm","displayName":"Management of chronic epicondylitis algorithm","title":"Management of chronic epicondylitis algorithm","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Management of chronic epicondylitis algorithm</div><div class=\"cntnt\"><img style=\"width:595px; height:748px;\" src=\"images/EM/69505_Epicondylitis_chronic_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PRP: platelet-rich plasma; U/S: ultrasound.</div><div id=\"graphicVersion\">Graphic 69505 Version 4.0</div></div></div>"},"69507":{"type":"graphic_figure","displayName":"Vascular supply of the pons","title":"Vascular supply of the pons","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vascular supply of the pons</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/NEURO/69507_BA_pontine_penetrators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major penetrating arteries from the basilar artery are depicted. A) Large paired median arteries. B) Paramedian arteries lying slightly laterally. C) Arteries that branch at a right angle from the long circumferential artery (the superior cerebellar artery) into the lateral pontine tegmentum.</div><div class=\"graphic_reference\">Reproduced with permission from: Caplan LR. Posterior circulation disease. Clinical findings, diagnosis, and management. Blackwell Science, Boston 1996. Copyright &#169; 1996 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 69507 Version 3.0</div></div></div>"},"69509":{"type":"graphic_form","displayName":"MDAS II","title":"Memorial Delirium Assessment Scale (MDAS) cont.","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Memorial Delirium Assessment Scale (MDAS) cont.</div><div class=\"cntnt\"><img style=\"width:604px; height:786px;\" src=\"images/ONC/69509_MDAS_II.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Breitbart, W, Rosenfield, B, Roth, A, Smith, M, Cohen, K, Passik, S. The memorial delirium assessment scale. J Pain Symptom Manage 1997; 13:128. Copyright ©1997 The US Cancer Pain Relief Committee.</div><div id=\"graphicVersion\">Graphic 69509 Version 2.0</div></div></div>"},"69510":{"type":"graphic_picture","displayName":"HCV hepatitis","title":"Histopathology of chronic hepatitis C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of chronic hepatitis C</div><div class=\"cntnt\"><img style=\"width:408px; height:286px;\" src=\"images/PEDS/69510_HCV_hepatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Portal inflammation and lymphoid aggregate (*), and surrounding macro- and micro-steatosis. B) High-power view showing portal inflammation with lymphocyte-mediated bile duct damage (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Badizadegan, K, Jonas, MM, Ott, MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28:1416. Copyright &#169;1998 Wiley-Blackwell.</div><div id=\"graphicVersion\">Graphic 69510 Version 1.0</div></div></div>"},"69511":{"type":"graphic_picture","displayName":"Obstructed megaureter","title":"Intraoperative picture of an obstructed megaureter with an aperistalic distal segment (black arrows)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraoperative picture of an obstructed megaureter with an aperistalic distal segment (black arrows)</div><div class=\"cntnt\"><img style=\"width:432px; height:315px;\" src=\"images/PEDS/69511_Obstructed_megaureter_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 69511 Version 4.0</div></div></div>"},"69513":{"type":"graphic_figure","displayName":"Anatomic landmarks during direct laryngoscopy","title":"Anatomic landmarks during direct laryngoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic landmarks during direct laryngoscopy</div><div class=\"cntnt\"><img style=\"width:313px; height:608px;\" src=\"images/EM/69513_ETIlandmarks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic landmarks for direct laryngoscopy.<br />(A) After initial retraction of the tongue with a straight blade, the epiglottis may remain draped posteriorly, partially or completely covering the glottic opening.<br />(B) Retraction of the epiglottis with the tip of the straight blade allows visualization of the glottis and surrounding structures.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69513 Version 13.0</div></div></div>"},"69515":{"type":"graphic_diagnosticimage","displayName":"Colovesical fistula BE","title":"Barium enema of colovesical fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium enema of colovesical fistula</div><div class=\"cntnt\"><img style=\"width:324px; height:360px;\" src=\"images/GAST/69515_Colovesical_fistula_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium enema in a 54-year-old woman with pneumaturia and left lower quadrant pain reveals a fistulous tract arising in the mid-sigmoid colon (arrow), passing into an abscess cavity (arrowhead), and then into the bladder where contrast is also seen (dashed arrow).</div><div id=\"graphicVersion\">Graphic 69515 Version 3.0</div></div></div>"},"69518":{"type":"graphic_table","displayName":"Platelet aggregation","title":"Patterns of platelet aggregation in selected disorders of platelet function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of platelet aggregation in selected disorders of platelet function</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   Disorder\n   </td>\n   <td  class=\"subtitle1\" colspan=\"4\">\n   Aggregation response\n   </td>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   Other features\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2\">\n   Primary ADP\n   </td>\n   <td  class=\"subtitle2\">\n   Secondary ADP\n   </td>\n   <td  class=\"subtitle2\">\n   Collagen\n   </td>\n   <td  class=\"subtitle2\">\n   Ristocetin\n   </td>\n   </tr>\n   <tr>\n   <td>vWD</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>Highly variable</td>\n   <td>Platelet morphology normal; vWD panel is usually abnormal</td>\n   </tr>\n   <tr>\n   <td>Bernard-Soulier syndrome</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>0</td>\n   <td>Giant platelets, thrombocytopenia-vWD panel normal</td>\n   </tr>\n   <tr>\n   <td>Glanzmann's thrombasthenia</td>\n   <td>0</td>\n   <td>0</td>\n   <td>0</td>\n   <td>+++</td>\n   <td>Normal platelet morphology</td>\n   </tr>\n   <tr>\n   <td>Storage pool disease</td>\n   <td>++++</td>\n   <td>0 to ++</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>Platelet morphology normal (except in gray platelet subgroup); electron microscopy abnormal</td>\n   </tr>\n   <tr>\n   <td>Secretion defect</td>\n   <td>++++</td>\n   <td>0 to ++</td>\n   <td>++++</td>\n   <td>++++</td>\n   <td>Normal morphology by light and electron microscopy</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">Acquired (eg, aspirin) or inherited COX-1 defects can be tested using arachidonic acid as the agonist. Results will show absent aggregation response to arachidonic acid as well as reduced secondary aggregation to ADP. Thromboxane receptor defects can be tested for using U-46619 in conjunction with this.</div><div class=\"graphic_footnotes\">++++: normal response; +++: slightly reduced response; ++: reduced response; +: markedly reduced response; 0: no response; ADP: adenosine diphosphate; vWD: von Willebrand disease.</div><div class=\"graphic_reference\">Modified with permission from: Rodgers, GM. Qualitative platelet disorders and von Willebrand's disease. In: Practical Diagnosis of Hematologic Disorders, 2nd ed., Kjeldsberg, C, Foucar, K, McKenna, RW, et al. (Eds), ASCP Press, Chicago 1995. Copyright &#169; 1995-2010 American Society for Clinical Pathology and ASCP Press.</div><div id=\"graphicVersion\">Graphic 69518 Version 1.0</div></div></div>"},"69519":{"type":"graphic_figure","displayName":"Types of parastomal hernias","title":"Types of parastomal hernias","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Types of parastomal hernias</div><div class=\"cntnt\"><img style=\"width:510px; height:450px;\" src=\"images/SURG/69519_PSH_four_types_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four types of parastomal hernias:<br> (A) Subcutaneous - bulges into the subcutaneous tissue.<br> (B) Interstitial - burrows into a muscular plane.<br> (C) Perstomal - enters the space between layers of prolapsed bowel.<br> (D) Intrastomal - enters the plane between the emerging and the everted part of the bowel forming the ostomy.</div><div id=\"graphicVersion\">Graphic 69519 Version 3.0</div></div></div>"},"69520":{"type":"graphic_figure","displayName":"CAV lesion types","title":"Cardiac allograft vasculopathy lesion types","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac allograft vasculopathy lesion types</div><div class=\"cntnt\"><img style=\"width:405px; height:231px;\" src=\"images/CARD/69520_CAVlesiontypes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic abnormalities in transplant coronary vascular disease.<br />Type A lesion: Discrete, tubular, or multiple stenoses.<br />Type B<SUB>1</SUB> lesion: Abrupt onset with distal diffuse concentric narrowing and obliterated vessels.<br />Type B<SUB>2</SUB> lesion: Gradual, concentric tapering with distal portion having some residual lumen.<br />Type C lesion: Narrowed irregular distal branches with terminations that are often nontapered and squared off, ending abruptly.</div><div class=\"graphic_reference\">Reproduced from: Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12:334. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69520 Version 4.0</div></div></div>"},"69521":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of cranium in osteogenesis imperfecta type 2","title":"Ultrasound of cranium in osteogenesis imperfecta type 2","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Ultrasound of cranium in osteogenesis imperfecta type 2</div><div class=\"cntnt\"><img style=\"width:503px; height:519px;\" src=\"images/OBGYN/69521_US_cranium_osteogene_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osteogenesis imperfecta type 2 with demineralization of the cranial vault.<br />(A) Cranial vault appears normally mineralized.<br />(B) Mild transducer pressure over the cranial vault results in flattening of the skull.<br />(C) Caput membranacae or membranous coverings of the intracranial content occurs when the demineralization is so significant that no appreciable calvarium bone ossification has occurred. Note the absence of a bright wall line representing ossified bone, which should normally encircle the intracranial contents.</div><div id=\"graphicVersion\">Graphic 69521 Version 6.0</div></div></div>"},"69523":{"type":"graphic_picture","displayName":"Meissner corpuscles","title":"Meissner corpuscles","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Meissner corpuscles</div><div class=\"cntnt\"><img style=\"width:504px; height:436px;\" src=\"images/NEURO/69523_Meissner_corpuscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Meissner corpuscles are typically located at the apex of dermal papillae and are more frequently observed in glabrous skin (arrow).</div><div class=\"graphic_reference\">Courtesy of&nbsp;A. Gordon Smith, MD</div><div id=\"graphicVersion\">Graphic 69523 Version 3.0</div></div></div>"},"69524":{"type":"graphic_algorithm","displayName":"Fetal and infant deaths and live births","title":"Algorithm for reporting live births, and infant and fetal deaths","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Algorithm for reporting live births, and infant and fetal deaths</div><div class=\"cntnt\"><img style=\"width:605px; height:786px;\" src=\"images/PEDS/69524_Fetal_infant_deaths_live.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The National Association for Public Health Statistics and Information system algorithm for reporting live births, infant deaths, fetal deaths, and induced terminations of pregnancy.</div><div class=\"graphic_footnotes\">* Jurisdictional reporting requirements will vary. For most jurisdictions, a Report of Fetal Death is required when the birth weight is 350 grams or greater, or the gestational age is 20 weeks or greater.</div><div class=\"graphic_reference\">Reproduced with permission from: the National Association for Public Health Statistics and Information Systems (<a href=\"http://www.naphsis.org/\" target=\"_blank\">www.naphsis.org</a>).</div><div id=\"graphicVersion\">Graphic 69524 Version 2.0</div></div></div>"},"69525":{"type":"graphic_diagnosticimage","displayName":"Carotid stenosis by CDUS","title":"Carotid artery stenosis assessed by duplex ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carotid artery stenosis assessed by duplex ultrasonography</div><div class=\"cntnt\"><img style=\"width:369px; height:265px;\" src=\"images/NEURO/69525_Carotid_artery_sten_CDU_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid duplex ultrasonography of the right internal carotid artery.<br />(Left) The high peak systolic flow velocity indicates the presence of 80 to 90 percent stenosis in the right internal carotid artery proximal to the measurement.<br />(Right) Ultrasonic image of the right internal carotid artery distal to the stenosis; the foot pad (arrow) represents the site at which the flow velocity is measured. These findings were confirmed by MR angiography.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 69525 Version 6.0</div></div></div>"},"69526":{"type":"graphic_figure","displayName":"VF sup quadrantanopia","title":"Visual fields: Superior quadrantanopia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Visual fields: Superior quadrantanopia</div><div class=\"cntnt\"><img style=\"width:514px; height:239px;\" src=\"images/NEURO/69526_VF_sup_quadrantanopia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Goldmann visual field showing a left superior homonymous quadrantanopia.</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69526 Version 13.0</div></div></div>"},"69528":{"type":"graphic_figure","displayName":"Lymph nodes head and neck","title":"Lymph nodes of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Lymph nodes of the head and neck</div><div class=\"cntnt\"><img style=\"width:568px; height:480px;\" src=\"images/ONC/69528_Lymphnodesheadandneck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing schematically depicts the major lymph nodes in the head and neck area that are likely to be enlarged on physical examination in patients with various local or systemic diseases. The major nodal groups are shown here in bold, with the areas draining into these nodal groups noted when appropriate. While enlargement of both the left and right supraclavicular lymph nodes may reflect disease in the thorax, left supraclavicular nodal enlargement, because of its drainage pattern, may also reflect the presence of abdominal involvement (ie, Virchow node).</div><div id=\"graphicVersion\">Graphic 69528 Version 4.0</div></div></div>"},"69529":{"type":"graphic_picture","displayName":"Prost adenoCA hormone ablation","title":"Prostatic adenocarcinoma after androgen ablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostatic adenocarcinoma after androgen ablation</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/ONC/69529_Prost_adenoCA_hormone_ablat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an hematoxylin- and eosin-stained tissue section of a prostate gland following androgen deprivation therapy. The scattered tumor cells have undergone cytoplasmic vacuolization and other degenerative changes (arrows). In a benign gland (arrowheads), the secretory epithelium also shows atrophic changes while basal cells are prominent.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 69529 Version 2.0</div></div></div>"},"69531":{"type":"graphic_table","displayName":"Cost utility league table","title":"Cost-utility league table (example data for cost-effectiveness analyses)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cost-utility league table (example data for cost-effectiveness analyses)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td colspan=\"2\"><strong><em>For illustration purposes only</em></strong></td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td class=\"subtitle1\">Medical intervention</td>\r\n                    <td class=\"subtitle1\">Incremental cost-effectiveness ratio<br />\r\n                    ($ per discounted quality-adjusted life year gained)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Screening siblings and children of patients with hereditary hemochromatosis<sup>[1]</sup></td>\r\n                    <td>$508-$3665</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Low-molecular weight heparin for deep vein thrombosis<sup>[2]</sup></td>\r\n                    <td>$7820</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Colorectal cancer screening<sup>[3]</sup></td>\r\n                    <td>$10,000-$25,000</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Aspirin for secondary prevention of coronary heart disease<sup>[4]</sup></td>\r\n                    <td>$11,000</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Flexible sigmoidoscopy evaluation of rectal bleeding in young persons<sup>[5]</sup></td>\r\n                    <td>$11,461</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Combination antiretroviral therapy<sup>[6]</sup></td>\r\n                    <td>$23,000</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Radiofrequency ablation for supraventricular tachycardia<sup>[7]</sup></td>\r\n                    <td>$27,900</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Intensive glycemic control for type 2 diabetes<sup>[8]</sup></td>\r\n                    <td>$41,384</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Center hemodialysis<sup>[9]</sup></td>\r\n                    <td>$55,000-$80,000</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prolonged hospitalization following uncomplicated acute MI<sup>[10]</sup></td>\r\n                    <td>$105,629</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Nissen fundoplication<sup>[11]</sup></td>\r\n                    <td>&#62;$1,000,000</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=17649&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132:1.</li>&#xD;&#xA;    <li>Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789.</li>&#xD;&#xA;    <li>Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:96.</li>&#xD;&#xA;    <li>Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800.</li>&#xD;&#xA;    <li>Lewis JD, Brown A, Localio AR, Schwartz JS. Initial evaluation of rectal bleeding in young persons: a cost-effectiveness analysis. Ann Intern Med 2002; 136:99.</li>&#xD;&#xA;    <li>Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824.</li>&#xD;&#xA;    <li>Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000; 133:864.</li>&#xD;&#xA;    <li>The CDCDC-eG. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542.</li>&#xD;&#xA;    <li>Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417.</li>&#xD;&#xA;    <li>Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342:749.</li>&#xD;&#xA;    <li>Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112:1078.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69531 Version 3.0</div></div></div>"},"69532":{"type":"graphic_table","displayName":"Health risks from obesity","title":"Health risks associated with obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Health risks associated with obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Coronary artery disease, hypertension</td> </tr> <tr> <td>Hyperlipidemia</td> </tr> <tr> <td>Type II diabetes mellitus</td> </tr> <tr> <td>Asthma, obesity hypoventilation syndrome, obstructive sleep apnea</td> </tr> <tr> <td>Gastroesophageal reflux, esophagitis</td> </tr> <tr> <td>Fatty liver, cholelithiasis, non-alcoholic steatohepatitis (NASH), cirrhosis</td> </tr> <tr> <td>Stress urinary incontinence</td> </tr> <tr> <td>Venous stasis disease, deep vein thrombosis, pulmonary embolus, superficial thrombophlebitis</td> </tr> <tr> <td>Hernias (inguinal, ventral, umbilical, incisional)</td> </tr> <tr> <td>Irregular menstruation, hirsutism, gynecomastia, infertility, polycystic ovary syndrome</td> </tr> <tr> <td>Cancer (colon, prostate, uterine, breast)</td> </tr> <tr> <td>Infection (cellulitis, panniculitis, postoperative wound infections)</td> </tr> <tr> <td>Degenerative joint disease, osteoarthritis</td> </tr> <tr> <td>Pseudotumor cerebri (idiopathic intracranial hypertension)</td> </tr> <tr> <td>Clinical depression</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Vivian Sanchez, MD and Edward Mun, MD.</div><div id=\"graphicVersion\">Graphic 69532 Version 2.0</div></div></div>"},"69533":{"type":"graphic_table","displayName":"Mechanisms of diabetic diarrhea","title":"Putative mechanisms of diabetic diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Putative mechanisms of diabetic diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Due to autonomic neuropathy</td>\n</tr>\n<tr>\n<td>Abnormal small intestinal motility</td>\n</tr>\n<tr>\n<td>Bacterial overgrowth</td>\n</tr>\n<tr>\n<td>Abnormal colonic motility</td>\n</tr>\n<tr>\n<td>Anorectal dysfunction - lowered rectal sensory threshold, weak internal anal sphincter</td>\n</tr>\n<tr>\n<td>Increased intestinal secretion</td>\n</tr>\n<tr>\n<td>Exocrine pancreatic insufficiency (?)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Due to associated factors</td>\n</tr>\n<tr>\n<td>Dietetic foods - sorbitol</td>\n</tr>\n<tr>\n<td>Concurrent celiac sprue - similar genetic predisposition</td>\n</tr>\n<tr>\n<td>Bile acid malabsorption (?)</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=19388&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Intestinal_dysmotility_diab.htm</title></head></div><div id=\"graphicVersion\">Graphic 69533 Version 2.0</div></div></div>"},"69536":{"type":"graphic_figure","displayName":"Vaginal agenesis rudiment horns","title":"Vaginal agenesis with rudimentary uterine horns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal agenesis with rudimentary uterine horns</div><div class=\"cntnt\"><img style=\"width:374px; height:285px;\" src=\"images/OBGYN/69536_Vaginalagenesisrudimenth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Of note, in cases of vaginal agenesis, the uterus may be normal or exhibit a variety of malformations.</div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69536 Version 14.0</div></div></div>"},"69537":{"type":"graphic_table","displayName":"Grading GMH/IVH by cranial imaging","title":"Severity of germinal matrix and intraventricular hemorrhage on cranial ultrasonography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of germinal matrix and intraventricular hemorrhage on cranial ultrasonography</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description on parasagittal view</td> </tr> <tr> <td>I</td> <td>Germinal matrix hemorrhage (GMH)&nbsp;only or germinal matrix hemorrhage plus intraventricular hemorrhage&nbsp;less than 10% of ventricular area</td> </tr> <tr> <td>II</td> <td>GMH and intraventricular hemorrhage; 10 to 50% of ventricular area</td> </tr> <tr> <td>III</td> <td>GMH and intraventricular hemorrhage involving more than 50% of ventricular area; lateral ventricles are usually distended</td> </tr> <tr> <td>IV</td> <td><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Hemorrhagic infarction in periventricular white matter ipsilateral to&nbsp;intraventricular hemorrhage&nbsp;(also called periventricular hemorrhagic infarction)</span></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Papile LA, et al. J Pediatr 1978; 92:529 and Inder TE, et al. Preterm Intraventricular Hemorrhage/Posthemorrhagic hydrocephalus. In: Volpe's Neurology of the Newborn, 6th, Volpe JJ (Ed), 2018. p.637. </div><div id=\"graphicVersion\">Graphic 69537 Version 10.0</div></div></div>"},"69540":{"type":"graphic_picture","displayName":"Horizontal neck lines","title":"Horizontal neck lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horizontal neck lines</div><div class=\"cntnt\"><img style=\"width:385px; height:432px;\" src=\"images/DERM/69540_Horiz_neck_lines_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal bands are present on the upper neck.</div><div id=\"graphicVersion\">Graphic 69540 Version 2.0</div></div></div>"},"69541":{"type":"graphic_picture","displayName":"AL amyloidosis bruising and ecchymoses","title":"Easy bruising and ecchymoses of the skin in AL amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Easy bruising and ecchymoses of the skin in AL amyloidosis</div><div class=\"cntnt\"><img style=\"width:430px; height:573px;\" src=\"images/HEME/69541_Amyloidosis_bruising.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69541 Version 2.0</div></div></div>"},"69543":{"type":"graphic_table","displayName":"Osmotic cervical dilators","title":"Osmotic cervical dilators","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Osmotic cervical dilators</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name </td> <td class=\"subtitle1\">Material </td> <td class=\"subtitle1\">Size (dry diameter x length) (mm) </td> <td class=\"subtitle1\">Dilation </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Natural </td> </tr> <tr> <td class=\"indent1\">Laminaria (Laminaria japonica, Laminaria digitata) </td> <td>Dried compressed seaweed stalk</td> <td> <p>2 to 10 x </p> <p>60 to 85</p> </td> <td> <p>4 hours: 25 percent increase in diameter</p> <p>Overnight: 90 percent increase in diameter<sup>[1]</sup></p> </td> <td>Multiple laminaria are generally used.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Synthetic </td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Dilapan-S </td> <td rowspan=\"4\">Polyacrylate-based hydrogel rod </td> <td rowspan=\"4\"> <p>3 x 55</p> <p>4 x 55</p> <p>4 x 65</p> </td> <td class=\"sublist1_start\">4 hours: </td> <td rowspan=\"4\">A previous version, Dilapan, had a tendency to break under high mechanical force; there have been no reports of breakage with Dilapan-S.<sup>[3]</sup> </td> </tr> <tr> <td class=\"sublist1\"> <p>3 mm size: dilates to 8 mm</p> <p>4 mm size: dilates to 8.5 mm</p> </td> </tr> <tr> <td class=\"sublist1_start\">16 to 20 hours: </td> </tr> <tr> <td class=\"sublist1\"> <p>3 mm size: dilates to 10 mm</p> <p>4 mm size: dilates to 11.3 mm<sup>[2]</sup></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">The manufacture of lamicel, a polyvinyl alcohol polymer sponge soaked in 500 mg magnesium sulfate, was discontinued in 2008.</div><div class=\"graphic_reference\">Data from:<br />1. Krammer J, O'Brien WF. Mechanical methods of cervical ripening. Clin Obstet Gynecol 1995; 38:280.<br />2. Bokstrom H, Wiqvist N. Preoperative dilatation of the cervix at legal abortion with a synthetic, fast-swelling hygroscopic tent. Acta Obstet Gynecol Scand 1989; 68:313.<br />3. Allen RH, Goldberg AB. Cervical dilation before first-trimester surgical abortion (&lt;14 weeks' gestation). SFP Guideline 20071. Contraception 2007; 76:139.<br />4. Nicolaides KH, Welch CC, Koullapis EN, Filshie GM. Cervical dilatation by Lamicel-studies on the mechanism of action. Br J Obstet and Gynaecol 1983; 90:1060.<br />5. Nicolaides KH, Welch MacPherson MB, Johnson IR, et al. Br J Obstet Gynaecol 1983; 90:475.</div><div id=\"graphicVersion\">Graphic 69543 Version 2.0</div></div></div>"},"69544":{"type":"graphic_picture","displayName":"Resectoscope parts","title":"Hysteroscopy: Resectoscope parts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: Resectoscope parts</div><div class=\"cntnt\"><img style=\"width:428px; height:284px;\" src=\"images/OBGYN/69544_Resectoscope_parts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 69544 Version 1.0</div></div></div>"},"69547":{"type":"graphic_table","displayName":"Progn subtypes append adenoca","title":"Survival of different subtypes of appendiceal adenocarcinomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival of different subtypes of appendiceal adenocarcinomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Mean age</td> <td class=\"subtitle1\">Lymph nodes involved, percent</td> <td class=\"subtitle1\">Advanced at diagnosis*, percent</td> <td class=\"subtitle1\">Five-year survival, percent</td> </tr> <tr> <td>Mucinous</td> <td>613</td> <td>60</td> <td>26</td> <td>63</td> <td>44</td> </tr> <tr> <td>Colonic</td> <td>411</td> <td>62</td> <td>31</td> <td>37</td> <td>52</td> </tr> <tr> <td>Signet&nbsp;ring</td> <td>70</td> <td>58</td> <td>64</td> <td>76</td> <td>20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Defined as extension to adjacent organs or metastatic at the time of diagnosis.</div><div class=\"graphic_reference\">Data from: McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: A population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94:3307.</div><div id=\"graphicVersion\">Graphic 69547 Version 3.0</div></div></div>"},"69551":{"type":"graphic_picture","displayName":"Reduction mastopexy","title":"Reduction mastopexy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Reduction mastopexy</div><div class=\"cntnt\"><img style=\"width:503px; height:690px;\" src=\"images/SURG/69551_Reductionmastopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction mastopexy lumpectomy.<br> (A) Skin incision design showing keyhole incision pattern.<br> (B) Initial skin incision.<br> (C) Manual examination of dissected tissues facilitating excision of specimen.<br> (D) Specimen excision.<br> (E) Fibroglandular defect after specimen excision.<br> (F) Wound approximation.<br> (G) Final wound closure.<br> (H) Postoperative result.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69551 Version 7.0</div></div></div>"},"69552":{"type":"graphic_table","displayName":"Morbidity rates for extremely preterm infants","title":"Rates of common morbidities among survivors in selected studies for infants 22 to 25 weeks gestation during the initial NICU admission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of common morbidities among survivors in selected studies for infants 22 to 25 weeks gestation during the initial NICU admission</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"5\" width=\"11%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study</td> <td class=\"subtitle1\" colspan=\"5\">Rate (percent) by gestational week</td> <td class=\"subtitle1\" rowspan=\"2\">Comment</td> </tr> <tr> <td class=\"subtitle2\">22</td> <td class=\"subtitle2\">23</td> <td class=\"subtitle2\">24</td> <td class=\"subtitle2\">25</td> <td class=\"subtitle2\">Total</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Severe intraventricular hemorrhage (&#8805;grade 3)</td> </tr> <tr> <td class=\"indent1\">NEPS1<sup>[1]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">11</td> <td class=\"centered\">16</td> <td class=\"centered\">10</td> <td class=\"centered\">12</td> <td>Infants with CUS* scans at &#8805;3 weeks</td> </tr> <tr> <td class=\"indent1\">NEPS2<sup>[2]</sup></td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">&nbsp;0</td> <td class=\"centered\">&nbsp;14</td> <td class=\"centered\">10&nbsp;</td> <td class=\"centered\">10</td> <td>CUS before hospital discharge or death</td> </tr> <tr> <td class=\"indent1\">Ishii<sup>[3]</sup></td> <td class=\"centered\">24</td> <td class=\"centered\">22</td> <td class=\"centered\">15</td> <td class=\"centered\">12</td> <td class=\"centered\">16</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">EXPRESS<sup>[4]</sup></td> <td class=\"centered\">20*</td> <td class=\"centered\">19</td> <td class=\"centered\">10</td> <td class=\"centered\">12</td> <td class=\"centered\">13</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">38</td> <td class=\"centered\">36</td> <td class=\"centered\">26</td> <td class=\"centered\">21</td> <td class=\"centered\">25</td> <td>Infants with CUS scans within first 28 days</td> </tr> <tr> <td class=\"indent1\">Stoll<sup><span style=\"font-size: 13px;\">[6]</span></sup></td> <td class=\"centered\">35&nbsp;</td> <td class=\"centered\">&nbsp;38</td> <td class=\"centered\">24&nbsp;</td> <td class=\"centered\">&nbsp;17</td> <td class=\"centered\">&nbsp;23</td> <td>Infants with CUS scans within first 28 days</td> </tr> <tr> <td class=\"indent1\">EPIPAGE<sup>[7]</sup></td> <td class=\"centered\">NS</td> <td class=\"centered\">0</td> <td class=\"centered\">&nbsp;22&nbsp;</td> <td class=\"centered\">14&nbsp;</td> <td class=\"centered\">16</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anderson<sup><span style=\"font-size: 13px;\">[10]</span></sup></td> <td class=\"centered\">38&nbsp;</td> <td class=\"centered\">16&nbsp;</td> <td class=\"centered\">13&nbsp;</td> <td class=\"centered\">12</td> <td class=\"centered\">13&nbsp;</td> <td> <p>Survival of live births to one year&nbsp;</p> <p>Based on ICD-9-CM codes</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Periventricular leukomalacia</td> </tr> <tr> <td class=\"indent1\">NEPS1<sup>[1]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">0</td> <td class=\"centered\">14</td> <td class=\"centered\">8</td> <td class=\"centered\">10</td> <td>Infants with CUS<sup><span style=\"font-size: 13px;\">&#182;</span></sup> scans at &#8805;3 weeks</td> </tr> <tr> <td class=\"indent1\">NEPS2<sup>[2]</sup></td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">&nbsp;5</td> <td class=\"centered\">3</td> <td>CUS before hospital discharge or death</td> </tr> <tr> <td class=\"indent1\">Ishii<sup>[3]</sup></td> <td class=\"centered\">2.7</td> <td class=\"centered\">4.1</td> <td class=\"centered\">3.9</td> <td class=\"centered\">5.4</td> <td class=\"centered\">4.5</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">EXPRESS<sup>[4]</sup></td> <td class=\"centered\">0*</td> <td class=\"centered\">9.4</td> <td class=\"centered\">6.2</td> <td class=\"centered\">5.4</td> <td class=\"centered\">6.2</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">6</td> <td class=\"centered\">4</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td>Infants with CUS scans within first 28 days</td> </tr> <tr> <td class=\"indent1\">Stoll<sup><span style=\"font-size: 13px;\">[6]</span></sup></td> <td class=\"centered\">0</td> <td class=\"centered\">8</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">6</td> <td>Infants with CUS scans within first 28 days</td> </tr> <tr> <td class=\"indent1\">EPIPAGE<sup><span style=\"font-size: 13px;\">[7]</span></sup></td> <td class=\"centered\">NS</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anderson<sup><span style=\"font-size: 13px;\">[10]</span></sup></td> <td class=\"centered\">7&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td> <p>Survival of live births to one year&nbsp;</p> <p>Based on ICD-9-CM codes</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Necrotizing enterocolitis (NEC)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"6\">Carlo<sup>[8]</sup></td> <td class=\"sublist1_start\">Both medically and surgically treated NEC</td> </tr> <tr> <td class=\"indent2\">ANS</td> <td class=\"centered\">0</td> <td class=\"centered\">12</td> <td class=\"centered\">10</td> <td class=\"centered\">10</td> <td class=\"centered\">10</td> <td>ANS subgroup treated with antenatal steroids (ANS)</td> </tr> <tr> <td class=\"indent2\">No ANS</td> <td class=\"centered\">12</td> <td class=\"centered\">15</td> <td class=\"centered\">10</td> <td class=\"centered\">6</td> <td class=\"centered\">9</td> <td>No ANS subgroup did not receive antenatal steroids</td> </tr> <tr> <td class=\"indent1\">NEPS<sup>[1]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">0</td> <td class=\"centered\">8.6</td> <td class=\"centered\">0</td> <td class=\"centered\">3</td> <td>Surgically treated NEC</td> </tr> <tr> <td class=\"indent1\">NEPS<sup>[2]</sup></td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">&nbsp;17</td> <td class=\"centered\">6&nbsp;</td> <td class=\"centered\">&nbsp;9</td> <td class=\"centered\">8&nbsp;</td> <td>Bell stages II and III</td> </tr> <tr> <td class=\"indent1\">Ishii<sup>[3]</sup></td> <td class=\"centered\">1.4</td> <td class=\"centered\">&nbsp;6.5</td> <td class=\"centered\">3</td> <td class=\"centered\">3.7</td> <td class=\"centered\">4</td> <td>Both medically and surgically treated NEC</td> </tr> <tr> <td class=\"indent1\">EXPRESS<sup>[4]</sup></td> <td class=\"centered\">0*</td> <td class=\"centered\">1.9</td> <td class=\"centered\">9.4</td> <td class=\"centered\">6</td> <td class=\"centered\">6.2</td> <td>Both medically and surgically treated NEC</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">1.7</td> <td class=\"centered\">&nbsp;8.3</td> <td class=\"centered\">9.2</td> <td class=\"centered\">6.2</td> <td class=\"centered\">7.6</td> <td>Surgically treated NEC</td> </tr> <tr> <td class=\"indent1\">Stoll<sup><span style=\"font-size: 13px;\">[6]</span></sup></td> <td class=\"centered\">&nbsp;0</td> <td class=\"centered\">&nbsp;16</td> <td class=\"centered\">&nbsp;11</td> <td class=\"centered\">&nbsp;9</td> <td class=\"centered\">&nbsp;11</td> <td>Bell stages II and III</td> </tr> <tr> <td class=\"indent1\">EPIPAGE<sup><span style=\"font-size: 13px;\">[7]</span></sup></td> <td class=\"centered\">NS&nbsp;</td> <td class=\"centered\">&nbsp;100</td> <td class=\"centered\">5&nbsp;</td> <td class=\"centered\">&nbsp;6</td> <td class=\"centered\">&nbsp;30</td> <td>&nbsp;<span style=\"font-size: 10px; font-family: GuardianTextEgypGR-Regular; color: #1a171c;\"></span> <p>Bell stages II and III</p> </td> </tr> <tr> <td class=\"indent1\">Anderson<sup><span style=\"font-size: 13px;\">[10]</span></sup></td> <td class=\"centered\">14</td> <td class=\"centered\">19</td> <td class=\"centered\">14&nbsp;</td> <td class=\"centered\">11&nbsp;</td> <td class=\"centered\">13</td> <td> <p>Survival of live births to one year&nbsp;</p> <p>Based on ICD-9-CM codes</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Bronchopulmonary dysplasia</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"6\">Carlo<sup>[8]</sup></td> <td class=\"sublist1_start\">Oxygen use at 36 weeks PMA</td> </tr> <tr> <td class=\"indent2\">ANS</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">66</td> <td class=\"centered\">55</td> <td class=\"centered\">60</td> <td>ANS sugroup treated with antenatal steroids (ANS)</td> </tr> <tr> <td class=\"indent2\">No ANS</td> <td class=\"centered\">58</td> <td class=\"centered\">70</td> <td class=\"centered\">54</td> <td class=\"centered\">47</td> <td class=\"centered\">54</td> <td>No ANS subgroup did not receive antenatal steroids</td> </tr> <tr> <td class=\"indent1\">EPICure<sup>[9]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">&nbsp; 86*</td> <td class=\"centered\">77</td> <td class=\"centered\">70</td> <td class=\"centered\">73</td> <td>Oxygen use at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">NEPS<sup>[1]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">67</td> <td class=\"centered\">54</td> <td class=\"centered\">47</td> <td class=\"centered\">52</td> <td>Use of oxygen or assisted ventilation at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">NEPS2<sup>[2]</sup></td> <td class=\"centered\">67&nbsp;</td> <td class=\"centered\">58&nbsp;</td> <td class=\"centered\">57&nbsp;</td> <td class=\"centered\">34&nbsp;</td> <td class=\"centered\">45&nbsp;</td> <td>Receipt of &#8805;30 percent oxygen or respiratory support&nbsp;at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">Ishii<sup>[3]</sup></td> <td class=\"centered\">21</td> <td class=\"centered\">30</td> <td class=\"centered\">38</td> <td class=\"centered\">34</td> <td class=\"centered\">33</td> <td>Receipt of &#8805;30 percent oxygen at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">EXPRESS<sup>[4]</sup></td> <td class=\"centered\">&nbsp;40<sup>&#182;</sup></td> <td class=\"centered\">26</td> <td class=\"centered\">31</td> <td class=\"centered\">29</td> <td class=\"centered\">41</td> <td>Receipt of &#8805;30 percent oxygen at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">85</td> <td class=\"centered\">73</td> <td class=\"centered\">69</td> <td class=\"centered\">55</td> <td class=\"centered\">63</td> <td>Oxygen use at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[6]</sup></td> <td class=\"centered\">100&nbsp;</td> <td class=\"centered\">&nbsp;89</td> <td class=\"centered\">&nbsp;73</td> <td class=\"centered\">56&nbsp;</td> <td class=\"centered\">66</td> <td>Oxygen use at 36 weeks PMA or at discharge</td> </tr> <tr> <td class=\"indent1\">EPIPAGE<sup><span style=\"font-size: 13px;\">[7]</span></sup></td> <td class=\"centered\">&nbsp;NS</td> <td class=\"centered\">&nbsp;100</td> <td class=\"centered\">&nbsp;37&nbsp;</td> <td class=\"centered\">&nbsp;28</td> <td class=\"centered\">30</td> <td>Receipt of 30 percent oxygen&nbsp;and/or mechanical ventilation&nbsp;or continuous positive airway pressure at 36 weeks PMA</td> </tr> <tr> <td class=\"indent1\">Anderson<sup>[10]</sup></td> <td class=\"centered\">66</td> <td class=\"centered\">58</td> <td class=\"centered\">53</td> <td class=\"centered\">46</td> <td class=\"centered\">50</td> <td> <p>Survival of live births to one year&nbsp;</p> <p>Based on ICD-9-CM codes</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Severe retinopathy of prematurity (ROP)</td> </tr> <tr> <td class=\"indent1\">EPICure<sup>[9]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">26*</td> <td class=\"centered\">20</td> <td class=\"centered\">10</td> <td class=\"centered\">15</td> <td>Treated with cryotherapy or laser</td> </tr> <tr> <td class=\"indent1\">NEPS1<sup>[1]</sup></td> <td class=\"centered\">n/a</td> <td class=\"centered\">33</td> <td class=\"centered\">17</td> <td class=\"centered\">9</td> <td class=\"centered\">14</td> <td>Treated with cryotherapy</td> </tr> <tr> <td class=\"indent1\">NEPS2<sup>[2]</sup></td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">33</td> <td class=\"centered\">34&nbsp;</td> <td class=\"centered\">&nbsp;19</td> <td class=\"centered\">25&nbsp;</td> <td>&nbsp;ROP &#8805;Stage 3</td> </tr> <tr> <td class=\"indent1\">Ishii<sup>[3]</sup></td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">31</td> <td class=\"centered\">32</td> <td class=\"centered\">30</td> <td>Treated with cryotherapy or laser</td> </tr> <tr> <td class=\"indent1\">EXPRESS<sup>[4]</sup></td> <td class=\"centered\">&nbsp;80<sup>&#182;</sup></td> <td class=\"centered\">62</td> <td class=\"centered\">48</td> <td class=\"centered\">32</td> <td class=\"centered\">42</td> <td>ROP &#62;Stage 2</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">50</td> <td class=\"centered\">40</td> <td class=\"centered\">35</td> <td class=\"centered\">17</td> <td class=\"centered\">27</td> <td>Infants in hospital at 28 days requiring intervention/surgery</td> </tr> <tr> <td class=\"indent1\">Stoll<sup><span style=\"font-size: 13px;\">[6]</span></sup></td> <td class=\"centered\">25&nbsp;</td> <td class=\"centered\">&nbsp;44</td> <td class=\"centered\">33&nbsp;</td> <td class=\"centered\">18&nbsp;</td> <td class=\"centered\">26&nbsp;</td> <td>Infants in hospital at 28 days with ROP &#8805;stage 3</td> </tr> <tr> <td class=\"indent1\">EPIPAGE<sup><span style=\"font-size: 13px;\">[7]</span></sup></td> <td class=\"centered\">&nbsp;NS</td> <td class=\"centered\">&nbsp;0</td> <td class=\"centered\">17&nbsp;</td> <td class=\"centered\">9&nbsp;</td> <td class=\"centered\">11&nbsp;</td> <td>ROP &#8805;Stage 3</td> </tr> <tr> <td class=\"indent1\">Anderson<sup><span style=\"font-size: 13px;\">[10]</span></sup></td> <td class=\"centered\">28</td> <td class=\"centered\">36&nbsp;</td> <td class=\"centered\">26</td> <td class=\"centered\">18</td> <td class=\"centered\">24&nbsp;</td> <td> <p>Survival of live births to one year&nbsp;</p> <p>ROP requiring surgery, based on ICD-9-CM codes</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Late-onset infection</td> </tr> <tr> <td class=\"indent1\">Stoll<sup>[5]</sup></td> <td class=\"centered\">58</td> <td class=\"centered\">62</td> <td class=\"centered\">55</td> <td class=\"centered\">46</td> <td class=\"centered\">52</td> <td>Among infants who survived &#62;3 days after birth</td> </tr> <tr> <td class=\"indent1\">Stoll<sup><span style=\"font-size: 13px;\">[6]</span></sup></td> <td class=\"centered\">29&nbsp;</td> <td class=\"centered\">&nbsp;50</td> <td class=\"centered\">&nbsp;40</td> <td class=\"centered\">&nbsp;31</td> <td class=\"centered\">36&nbsp;</td> <td>Among infants who survived &#62;3 days after birth</td> </tr> <tr> <td class=\"indent1\">NEPS2<sup>[2]</sup></td> <td class=\"centered\">20&nbsp;</td> <td class=\"centered\">&nbsp;23</td> <td class=\"centered\">22&nbsp;</td> <td class=\"centered\">39&nbsp;</td> <td class=\"centered\">29</td> <td>&nbsp;Among infants who survived &#62;3 days after birth</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANS: antenatal steroid therapy; CUS: cranial ultrasound; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; NICU: Neonatal Intensive Care Unit;&nbsp;NS: No survivors; PMA: postmenstrual age. <br />* ≤23 weeks.<br />¶ ≤22 weeks.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Markestad T, Kaaresen PI, Rønnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115:1289.</LI>&#xD;&#xA;<LI>Stensvold HF, Klingenberg C, Stoen R, et al. Neonatal morbidity and 1-year survival of extremely preterm infants. Pediatrics 2017. </LI>&#xD;&#xA;<LI>Ishii N, Kono Y, Yonemoto N, et al. Outcomes of infants born at 22 and 23 weeks' gestation. Pediatrics 2013; 132:62.</LI>&#xD;&#xA;<LI>EXPRESS Group, Fellman V, Hellström-Westas L, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301:2225.</LI>&#xD;&#xA;<LI>Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.</LI>&#xD;&#xA;<LI>Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA 2015; 314:1039.</LI>&#xD;&#xA;<LI>Ancel PY, Goffinet F, et al. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: Results of the EPIPAGE-2 Cohort Study. JAMA Pediatrics 2015; 169:230. </LI>&#xD;&#xA;<LI>Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.</LI>&#xD;&#xA;<LI>Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659.</LI>&#xD;&#xA;<LI>Anderson JG, Baer RJ, Partridge JC, et al. Survival and Major Morbidity of Extremely Preterm Infants: A Population-Based Study. Pediatrics 2016; 138:e20154434. </LI></OL></div><div id=\"graphicVersion\">Graphic 69552 Version 17.0</div></div></div>"},"69553":{"type":"graphic_diagnosticimage","displayName":"MRI of normal medial collateral ligament","title":"MRI of normal medial collateral ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of normal medial collateral ligament</div><div class=\"cntnt\"><img style=\"width:380px; height:368px;\" src=\"images/EM/69553_MCL_normal_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal MCL appears as a linear low signal \"strap\" on all sequences, extending from the medial epicondyle of the femur to a point on the tibia approximately 7 cm below the tibial plateau.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MCL: medial collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 69553 Version 3.0</div></div></div>"},"69554":{"type":"graphic_picture","displayName":"Amyloid goiter Light","title":"Amyloid goiter: Microscopic section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloid goiter: Microscopic section</div><div class=\"cntnt\"><img style=\"width:378px; height:251px;\" src=\"images/ENDO/69554_Amyloid_goiter_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section (hematoxylin and eosin, magnification x 100) of the thyroid of a patient with an amyloid goiter showing deposition of amyloid, focal lymphocytic thyroiditis, and a single thyroid follicle.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69554 Version 2.0</div></div></div>"},"69555":{"type":"graphic_figure","displayName":"Immunologic synapse","title":"Immunologic synapse","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Immunologic synapse</div><div class=\"cntnt\"><img style=\"width:538px; height:526px;\" src=\"images/ENDO/69555_Immunologicsynapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">APCs are illustrated as presenting a peptide bound to human leukocyte antigen (HLA) forming an \"immunologic synapse\" with the T cell immunoreceptor. CD8-positive T cells bind to MHC class I APCs, and CD4-positive T cells bind to MHC class II-positive APCs. Notice the presence of secondary messenger systems such as the CD28 and B7 molecules (CD80/B7.1 and&nbsp;CD86/B7.2), which also come into apposition to allow a T cell response. Local adhesion molecules are thought to help stabilize the synapse.</div><div class=\"graphic_footnotes\"><FONT color=black>MHC: major histocompatibility complex; CD: cluster of differentiation; ICAM-1: intercellular adhesion molecule 1; LFA-1: lymphocyte function-associated antigen 1; TCR: T cell receptor.</FONT></div><div id=\"graphicVersion\">Graphic 69555 Version 5.0</div></div></div>"},"69557":{"type":"graphic_figure","displayName":"Pathogenesis of bronchopulmonary dysplasia","title":"Pathogenesis of bronchopulmonary dysplasia (BPD)","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of bronchopulmonary dysplasia (BPD)</div><div class=\"cntnt\"><img style=\"width:517px; height:527px;\" src=\"images/PEDS/69557_BPD-pathogenesis-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exposure to antenatal pulmonary insults during the saccular state of lung development result in developmental arrest or delay in pulmonary maturation (&quot;new&quot; bronchopulmonary dysplasia [BPD]), whereas postnatal insults cause structural pulmonary injury (&quot;old&quot; BPD).</div><div class=\"graphic_reference\">Adapted&nbsp;from: Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357:1946.</div><div id=\"graphicVersion\">Graphic 69557 Version 6.0</div></div></div>"},"69558":{"type":"graphic_table","displayName":"Endocrine risk cancer survivors","title":"Endocrine complications based on specific tumors and their treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endocrine complications based on specific tumors and their treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Representative tumor, location</td> <td class=\"subtitle1\">Therapy</td> <td class=\"subtitle1\">Highest endocrine risk</td> </tr> <tr> <td>Hodgkin's lymphoma</td> <td>Chemotherapy, mantle irradiation</td> <td>Primary hypothyroidism, primary hypogonadism</td> </tr> <tr> <td>Rhabdomyosarcoma or neuroblastoma, pelvis</td> <td>Excision, chemotherapy, focal radiation</td> <td>Primary gonadal failure</td> </tr> <tr> <td>ALL</td> <td>Chemotherapy and 18 GY cranial radiation</td> <td>Growth hormone deficiency (GHD), early onset puberty, rapid tempo of puberty, osteoporosis</td> </tr> <tr> <td>AML</td> <td>Chemotherapy to achieve remission, bone marrow transplant (12 GY total body radiation)</td> <td>Primary hypothyroidism, primary hypogonadism, reduced epiphyseal growth (direct effect of radiation), GHD, central hypothyroidism</td> </tr> <tr> <td>Medulloblastoma, posterior fossa</td> <td>Surgical excision, chemotherapy, craniospinal irradiation, and posterior fossa \"boost\" to 50 Gy</td> <td>Reduced spinal growth, central or primary or mixed hypothyroidism, GHD, precocious puberty and/or gonadotropin deficiency, ACTH deficiency</td> </tr> <tr> <td>Craniopharyngioma, suprasellar</td> <td>Biopsy, excision and &nbsp;focal radiation 30 to 50 Gy</td> <td>Panhypopituitarism, diabetes insipidus, precocious puberty or gonadotropin deficiency</td> </tr> <tr> <td>Rhabdomyosarcoma, nasopharyngeal</td> <td>Excision, focal radiation 30 to 50 Gy, and chemotherapy</td> <td>Panhypopituitarism, central or primary or mixed hypothyroidism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia.</div><div id=\"graphicVersion\">Graphic 69558 Version 3.0</div></div></div>"},"69559":{"type":"graphic_figure","displayName":"Gold improves synovitis in RA","title":"Gold therapy improves synovitis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Gold therapy improves synovitis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:503px; height:260px;\" src=\"images/RHEUM/69559_Gold_improves_synovitis_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of a double-blind, randomized trial in which 27 patients who had RA for less then five years were followed for 30 months during a standard course and then maintenance therapy with gold sodium thiomalate (GSTM); they were compared to group of patients treated with placebo. The joint score (maximum value 44) was stable in the placebo group and fell in the patients receiving GSTM. The benefit with GSTM requires three months and sometimes as long as nine months to become apparent.</div><div class=\"graphic_reference\">Data from Sigler, JW, Bluhm, GB, Duncan, H, et al, Ann Intern Med 1974; 80:21.</div><div id=\"graphicVersion\">Graphic 69559 Version 1.0</div></div></div>"},"69561":{"type":"graphic_figure","displayName":"Emergency pericardiocentesis apical approach","title":"Emergency pericardiocentesis apical approach","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Emergency pericardiocentesis apical approach</div><div class=\"cntnt\"><img style=\"width:521px; height:499px;\" src=\"images/EM/69561_Emergency-pericardiocentesis-apical-approach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69561 Version 6.0</div></div></div>"},"69562":{"type":"graphic_table","displayName":"Clinical findings in caudal regression syndrome","title":"Clinical findings in caudal regression syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in caudal regression syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Musculoskeletal</td> </tr> <tr> <td>Flexion contractures of the knees and hips</td> </tr> <tr> <td>Hip dislocation</td> </tr> <tr> <td>Pelvic deformity</td> </tr> <tr> <td>Equinovarus, calcaneovarus</td> </tr> <tr> <td>Absent fibula</td> </tr> <tr> <td>Scoliosis, kyphoscoliosis</td> </tr> <tr> <td>Absence of or bifid/fused ribs</td> </tr> <tr> <td>Syndactyly, polydactyly, absent radii</td> </tr> <tr> <td>Pierre Robin syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td>Anorectal malformations</td> </tr> <tr> <td>Tracheoesophageal fistulae</td> </tr> <tr> <td>Abdominal wall defects</td> </tr> <tr> <td>Malrotation of gut</td> </tr> <tr> <td>Duodenal/colonic atresia</td> </tr> <tr> <td>Inguinal hernia</td> </tr> <tr> <td class=\"subtitle1_single\">Genitourinary</td> </tr> <tr> <td>Renal agenesis and dysplasia</td> </tr> <tr> <td>Nonspecific hydronephrosis</td> </tr> <tr> <td>Dilated ureters</td> </tr> <tr> <td>Ectopic ureters</td> </tr> <tr> <td>Vesicoureteral reflux</td> </tr> <tr> <td>Fused kidneys</td> </tr> <tr> <td>Absent bladder</td> </tr> <tr> <td>Vesical/cloacal exstrophy</td> </tr> <tr> <td>Rectovaginal and rectourethral fistulae</td> </tr> <tr> <td>Transposition of external genitalia</td> </tr> <tr> <td>Hypospadias</td> </tr> <tr> <td>Ureteral atresia</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous</td> </tr> <tr> <td>Myelomeningocele</td> </tr> <tr> <td>Hydrocephalus</td> </tr> <tr> <td>Ventriculomegaly</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Congenital heart defects</td> </tr> <tr> <td>Facial clefts</td> </tr> <tr> <td>Strabismus</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=83656&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Boulas M. Recognition of caudal regression syndrome. Adv Neonatal Care 2009; 9:61. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69562 Version 9.0</div></div></div>"},"69564":{"type":"graphic_picture","displayName":"Pagets dis with carcinoma","title":"Extramammary Paget disease of the vulva with adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramammary Paget disease of the vulva with adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:400px; height:300px;\" src=\"images/OBGYN/69564_Paget_dis_with_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69564 Version 1.0</div></div></div>"},"69566":{"type":"graphic_algorithm","displayName":"Barcelona Rx algorithm HCC","title":"Barcelona clinic liver cancer staging classification and treatment algorithm","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Barcelona clinic liver cancer staging classification and treatment algorithm</div><div class=\"cntnt\"><img style=\"width:588px; height:475px;\" src=\"images/ONC/69566_Barcelona_Rx_algorithm_HCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; PST: performance status test.<br />* Cadaveric liver transplantation or living donor liver transplantation.</div><div class=\"graphic_reference\">Modified with permission from: Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. J Natl Cancer Inst 2008; 100:698. Copyright © 2008 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 69566 Version 13.0</div></div></div>"},"69569":{"type":"graphic_table","displayName":"Identified structures EUS","title":"Normal pancreatico-biliary anatomy: Structures identified with radial scanning EUS according to approximate transducer positions within the GI tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal pancreatico-biliary anatomy: Structures identified with radial scanning EUS according to approximate transducer positions within the GI tract</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Transducer location</td> <td class=\"subtitle1\">Major structures identified with EUS</td> </tr> <tr> <td>Gastric body</td> <td>Confluence of splenic and portal vein, body/tail of pancreas, PD, left kidney, left RV, left RA, celiac axis, aorta, SMA</td> </tr> <tr> <td>Gastric antrum</td> <td>Confluence of splenic and portal vein, pancreas, liver, gallbladder</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Duodenal</td> </tr> <tr> <td class=\"sublist1\">- Bulb</td> <td class=\"sublist_other\">Pancreas, PD, liver, gallbladder, CBD, PV</td> </tr> <tr> <td class=\"sublist1\">- Ampullary region</td> <td class=\"sublist_other\">Head of pancreas, PD, CBD, PV, ampulla</td> </tr> <tr> <td class=\"sublist1\">- Post-ampullary region</td> <td class=\"sublist_other\">Head/uncinate process of the pancreas, IVC, aorta, SMA, SMV, PD, right kidney</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PD: pancreatic duct; RV: renal vein; RA: renal artery; SMA: superior mesenteric artery; SMV: superior mesenteric vein; CBD: common bile duct; PV: portal vein; IVC: inferior vena cava.</div><div id=\"graphicVersion\">Graphic 69569 Version 3.0</div></div></div>"},"69570":{"type":"graphic_table","displayName":"Periop complix from IBD meds","title":"Complications of medical therapy for IBD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of medical therapy for IBD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Perioperative complications</td> </tr> <tr> <td rowspan=\"3\">Prednisone</td> <td>Addisonian crisis</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Adrenal insufficiency</td> </tr> <tr> <td rowspan=\"3\">Sulfasalazine</td> <td>Neutropenia</td> </tr> <tr> <td>Blood dyscrasias</td> </tr> <tr> <td>Hypersensitivity</td> </tr> <tr> <td rowspan=\"5\">Azathioprine and 6-mercaptopurine</td> <td>Leukopenia</td> </tr> <tr> <td>Thrombocytopenia</td> </tr> <tr> <td>Macrocytic anemia </td> </tr> <tr> <td>Bone marrow suppression </td> </tr> <tr> <td>Hepatotoxicity</td> </tr> <tr> <td rowspan=\"3\">Mesalamine</td> <td>Diarrhea</td> </tr> <tr> <td>Nausea/vomiting</td> </tr> <tr> <td>Headache</td> </tr> <tr> <td rowspan=\"2\">Metronidazole </td> <td>Convulsive disorders</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td rowspan=\"2\">Cyclosporine</td> <td>Nephrotoxicity</td> </tr> <tr> <td>Hepatotoxicity</td> </tr> <tr> <td rowspan=\"7\">TNF-alpha inhibitors</td> <td>Injection site reactions</td> </tr> <tr> <td>Infusion reactions</td> </tr> <tr> <td>Infections</td> </tr> <tr> <td>Demyelinating disease</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Induction of autoimmunity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; TNF: tumor necrosis factor.</div><div id=\"graphicVersion\">Graphic 69570 Version 2.0</div></div></div>"},"69572":{"type":"graphic_picture","displayName":"Defibulation 2","title":"Defibulation (reversal of female genital infibulation)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibulation (reversal of female genital infibulation)</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/69572_Defibulation_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 2: Make an anterior incision between the two Allis clamps with Mayo scissors, being certain not to cut into a buried clitoris.</div><div id=\"graphicVersion\">Graphic 69572 Version 2.0</div></div></div>"},"69573":{"type":"graphic_figure","displayName":"Light and skin interaction in laser therapy","title":"Interaction between light and skin during laser therapy","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Interaction between light and skin during laser therapy</div><div class=\"cntnt\"><img style=\"width:481px; height:450px;\" src=\"images/DERM/69573_Light-skin-interaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light that reaches the skin surface can be reflected away from the skin, absorbed by light absorbing molecules (chromophores) within the skin, scattered in various directions within the skin, or transmitted through the skin to underlying tissues.</div><div id=\"graphicVersion\">Graphic 69573 Version 7.0</div></div></div>"},"69574":{"type":"graphic_table","displayName":"Autoimmune disorders with adrenal insufficiency","title":"Incidence of other autoimmune diseases in 365 patients with autoimmune adrenal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of other autoimmune diseases in 365 patients with autoimmune adrenal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Incidence (percent)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Thyroid disease</td> </tr> <tr> <td class=\"sublist1\">Hypothyroidism</td> <td class=\"sublist_other_centered\">8</td> </tr> <tr> <td class=\"sublist1\">Nontoxic goiter</td> <td class=\"sublist_other_centered\">7</td> </tr> <tr> <td class=\"sublist1\">Hyperthyroidism</td> <td class=\"sublist_other_centered\">7</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Gonadal failure</td> </tr> <tr> <td class=\"sublist1\">Ovarian</td> <td class=\"sublist_other_centered\">20</td> </tr> <tr> <td class=\"sublist1\">Testicular</td> <td class=\"sublist_other_centered\">2</td> </tr> <tr> <td>Type 1 diabetes mellitus</td> <td class=\"centered\">11</td> </tr> <tr> <td>Hypoparathyroidism</td> <td class=\"centered\">10</td> </tr> <tr> <td>Pernicious anemia</td> <td class=\"centered\">5</td> </tr> <tr> <td>None</td> <td class=\"centered\">53</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Compiled from multiple reports.</div><div id=\"graphicVersion\">Graphic 69574 Version 3.0</div></div></div>"},"69575":{"type":"graphic_table","displayName":"Multiple daily insulin inject","title":"Multiple daily insulin injections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multiple daily insulin injections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Regimen </td> <td class=\"subtitle1\">Breakfast </td> <td class=\"subtitle1\">Lunch </td> <td class=\"subtitle1\">Dinner </td> <td class=\"subtitle1\">Bedtime </td> </tr> <tr> <td>1*</td> <td>RA + N</td> <td>&nbsp;</td> <td>RA</td> <td>N</td> </tr> <tr> <td>2*</td> <td>RA</td> <td>RA</td> <td>RA</td> <td>N</td> </tr> <tr> <td>3*</td> <td>RA</td> <td>RA</td> <td>RA</td> <td>G or D</td> </tr> <tr> <td>4</td> <td>RA + G or D</td> <td>RA</td> <td>RA</td> <td>&nbsp;</td> </tr> <tr> <td>5</td> <td>RA + G or D</td> <td>RA</td> <td>RA + G or D</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RA: any rapid-acting analog (lispro, aspart, or glulisine); N: NPH (neutral protamine hagedorn)&nbsp;insulin; G: glargine; D: detemir.<br />* In any of regimens 1 to 3, rapid-acting analog (lispro, aspart, or glulisine) can be replaced with regular insulin.</div><div id=\"graphicVersion\">Graphic 69575 Version 4.0</div></div></div>"},"69581":{"type":"graphic_picture","displayName":"Blueberry muffin lesions","title":"Blueberry muffin lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blueberry muffin lesions</div><div class=\"cntnt\"><img style=\"width:432px; height:300px;\" src=\"images/PEDS/69581_Blueberry_muffin_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This infant with congenital rubella syndrome presented with &quot;blueberry muffin&quot; skin lesions. These lesions indicate cutaneous hematopoiesis and may occur in other intrauterine infections and hematologic disorders.</div><div class=\"graphic_reference\">Courtesy of Centers for Disease Control and Prevention Public Health Image Library.</div><div id=\"graphicVersion\">Graphic 69581 Version 3.0</div></div></div>"},"69582":{"type":"graphic_figure","displayName":"Structure of the spleen","title":"Structure of the spleen","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Structure of the spleen</div><div class=\"cntnt\"><img style=\"width:476px; height:342px;\" src=\"images/SURG/69582_Structure_of_the_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The splenic arteries progressively branch to form peripheral arterioles which open freely into the splenic pulp. Blood flows through the reticular tissue and is collected in the terminal venules which coalesce to form the larger veins. The veins do not accompany the arteries within the spleen. The splenic pulp is important for opsonization of encapsulated organisms.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary, 27th ed. Baltimore: Lippincott Williams &amp; Wilkins 2000. Copyright &#169; 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69582 Version 1.0</div></div></div>"},"69584":{"type":"graphic_picture","displayName":"Classic Kaposi sarcoma - papules and plaques","title":"Classic Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/69584_CKS_papules_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous papules and plaques are present on the distal upper extremity of this patient with classic Kaposi sarcoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69584 Version 5.0</div></div></div>"},"69586":{"type":"graphic_movie","displayName":"Colonic stent","title":"Endoscopic placement of a colonic stent","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic placement of a colonic stent</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/69586_colonstentconv.mp4\" style=\"width:398px;height:348px\"></div><img style=\"width:320px; height:318px;\" src=\"images/CARD/69586_colonstent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A colonic stent has been deployed through an obstructing colon cancer. The distal end of the stent is visible in the colonic lumen.</div><div class=\"graphic_reference\">Courtesy of Todd H Baron, MD.</div><div id=\"graphicVersion\">Graphic 69586 Version 3.0</div></div></div>"},"69589":{"type":"graphic_table","displayName":"Umbilical cord gases in preterm newborns","title":"Reference range for umbilical artery blood gas values in preterm newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference range for umbilical artery blood gas values in preterm newborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Umbilical arterial blood</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">5th to 95th percentile</td> </tr> <tr> <td>pH</td> <td class=\"centered\">7.28</td> <td class=\"centered\">7.14 to 7.4</td> </tr> <tr> <td>PCO<sub>2</sub> (mmHg)</td> <td class=\"centered\">50.2</td> <td class=\"centered\">32 to 69.2</td> </tr> <tr> <td>HCO<sub>3</sub> (mEq/L)</td> <td class=\"centered\">22.4</td> <td class=\"centered\">16 to 27.1</td> </tr> <tr> <td>Base excess (mEq/L)</td> <td class=\"centered\">&ndash;2.5</td> <td class=\"centered\">&ndash;7.6 to 1.3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values represent findings from umbilical artery cord blood analysis after vaginal delivery of 1015 unselected preterm infants delivered at Shands Hospital, University of Florida, 1992-1993.</div><div class=\"graphic_reference\">Data from: Riley RJ, Johnson JWC. Collecting and analyzing cord blood gases. Clin Obstet Gynecol 1993; 36:13.</div><div id=\"graphicVersion\">Graphic 69589 Version 3.0</div></div></div>"},"69591":{"type":"graphic_table","displayName":"Tx guidelines comorbidities","title":"Treatment regimen based on clinical practice guidelines for a hypothetical 79-year-old woman with hypertension, diabetes mellitus, osteoporosis, osteoarthritis, and COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimen based on clinical practice guidelines for a hypothetical 79-year-old woman with hypertension, diabetes mellitus, osteoporosis, osteoarthritis, and COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Medications*</td> <td class=\"subtitle1\">Other</td> </tr> <tr class=\"divider_bottom\"> <td>7:00 AM</td> <td> <p>Ipratropium metered dose inhaler</p> 70 mg/week of alendronate</td> <td> <p>Check feet</p> <p>Sit upright for 30 minutes on day when alendronate is taken</p> Check blood sugar</td> </tr> <tr class=\"divider_bottom\"> <td>8:00 AM</td> <td> <p>500 mg of calcium and 200 IU of vitamin D</p> <p>12.5 mg of hydrochlorothiazide</p> <p>40 mg of lisinopril</p> <p>10 mg of glyburide</p> <p>81 mg of aspirin</p> <p>850 mg of metformin</p> <p>250 mg of naproxen</p> 20 mg of omeprazole</td> <td> <p>Eat breakfast</p> <p>2.4 g/day of sodium</p> <p>90 mmol/day of potassium</p> <p>Low intake of dietary saturated fat and cholesterol</p> <p>Adequate intake of magnesium and calcium</p> <p>Medical nutrition therapy for diabetes<sup>&#182;</sup></p> DASH<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>12:00 PM</td> <td>&nbsp;</td> <td> <p>Eat lunch</p> <p>2.4 g/day of sodium</p> <p>90 mmol/day of potassium</p> <p>Low intake of dietary saturated fat and cholesterol</p> <p>Adequate intake of magnesium and calcium</p> <p>Medical nutrition therapy for diabetes<sup>&#182;</sup></p> DASH<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>1:00 PM</td> <td> <p>Ipratropium metered dose inhaler</p> 500 mg of calcium and 200 IU of vitamin D</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>7:00 PM</td> <td> <p>Ipratropium metered dose inhaler</p> <p>850 mg of metformin</p> <p>500 mg of calcium and 200 IU of vitamin D</p> <p>40 mg of lovastatin</p> 250 mg of naproxen</td> <td> <p>Eat dinner</p> <p>2.4 g/day of sodium</p> <p>90 mmol/day of potassium</p> <p>Low intake of dietary saturated fat and cholesterol</p> <p>Adequate intake of magnesium and calcium</p> <p>Medical nutrition therapy for diabetes<sup>&#182;</sup></p> DASH<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>11:00 PM</td> <td>Ipratropium metered dose inhaler</td> <td>&nbsp;</td> </tr> <tr> <td>As needed</td> <td>Albuterol metered dose inhaler</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADA: American Diabetes Association; COPD: chronic obstructive pulmonary disease; DASH: Dietary Approaches to Stop Hypertension.<br />* Taken orally unless otherwise indicated. The medication complexity score of the regimen for this hypothetical woman is 14, with 19 doses of medications per day, assuming 2 as needed doses of albuterol metered dose inhaler plus 70 mg/wk of alendronate.<br />¶ DASH and ADA dietary guidelines may be synthesized, but the help of a registered dietitian is specifically recommended. Eat foods containing carbohydrate from whole grains, fruits, vegetables, and low-fat milk. Avoid protein intake of more than 20 percent of total daily energy; lower protein intake to about 10 percent of daily calories if overt nephropathy is present. Limit intake of saturated fat (&lt;10 percent of total daily energy) and dietary cholesterol (&lt;200 to 300 mg). Limit intake of <EM>trans</EM>unsaturated fatty acids. Eat two to three servings of fish per week. Intake of polyunsaturated fat should be about 10 percent of total daily energy.</div><div class=\"graphic_reference\">Reproduced with permission from: Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA 2005; 294:716. Copyright &copy; 2005 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69591 Version 12.0</div></div></div>"},"69592":{"type":"graphic_picture","displayName":"Primary vitreoretinal lymphoma fundoscopy","title":"Fundoscopy of a patient with primary vitreoretinal lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fundoscopy of a patient with primary vitreoretinal lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:502px;\" src=\"images/HEME/69592_Prim_vitreo_lymph_fund_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are many small, round, yellow-orange lesions (arrows) at the retinal pigment epithelium level in the deep retina.</div><div class=\"graphic_reference\">Reproduced with permission from: Chan CC, Rubenstein JL, Coupland, SE, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 2011; 16:1589. Copyright &#169; 2011 AlphaMed Press. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69592 Version 1.0</div></div></div>"},"69594":{"type":"graphic_table","displayName":"WHO classif panc cyst neopl","title":"World Health Organization classification of pancreatic cystic neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization classification of pancreatic cystic neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Serous cystic tumor</td> </tr> <tr> <td class=\"sublist1_start\">Serous cystadenoma</td> </tr> <tr> <td class=\"sublist1\">Serous microcystic adenoma</td> </tr> <tr> <td class=\"sublist1\">Serous oligocystic adenoma</td> </tr> <tr> <td>Serous cystadenocarcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Mucinous cystic neoplasm</td> </tr> <tr> <td>Mucinous cystadenoma</td> </tr> <tr> <td>Mucinous cystic neoplasm with moderate dysplasia</td> </tr> <tr> <td class=\"sublist1_start\">Mucinous cystadenocarcinoma</td> </tr> <tr> <td class=\"sublist1\">Noninvasive</td> </tr> <tr> <td class=\"sublist1\">Invasive</td> </tr> <tr> <td class=\"subtitle1_single\">Intraductal papillary mucinous neoplasm</td> </tr> <tr> <td>Intraductal papillary mucinous adenoma</td> </tr> <tr> <td>Intraductal papillary mucinous neoplasm with moderate dysplasia</td> </tr> <tr> <td class=\"sublist1_start\">Intraductal papillary mucinous carcinoma</td> </tr> <tr> <td class=\"sublist1\">Noninvasive</td> </tr> <tr> <td class=\"sublist1\">Invasive</td> </tr> <tr> <td class=\"subtitle1_single\">Solid pseudopapillary neoplasm</td> </tr> <tr> <td>Solid pseudopapillary neoplasm</td> </tr> <tr> <td>Solid pseudopapillary carcinoma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Zamboni G, Kloeppel G, Hruban RH, et al. Mucinous cystic neoplasms of the pancreas. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen LA, Hamilton SR (Eds), IARC Press, Lyon, France 2000. p.234.</div><div id=\"graphicVersion\">Graphic 69594 Version 3.0</div></div></div>"},"69595":{"type":"graphic_picture","displayName":"Diaphragm fitting kit","title":"Diaphragm fitting kit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragm fitting kit</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/OBGYN/69595_Diaphragm_fitting_kit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69595 Version 1.0</div></div></div>"},"69597":{"type":"graphic_figure","displayName":"Demand oxygen pulse delivery","title":"Demand oxygen pulse delivery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Demand oxygen pulse delivery</div><div class=\"cntnt\"><img style=\"width:412px; height:268px;\" src=\"images/PULM/69597_Demand_pulsed_oxygen_delive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The demand module is interposed between the pressurized oxygen source and the patient. As the patient inhales, inspiratory airflow is detected by pressure changes in the nasal cannula. A solenoid in the module is rapidly opened and closed, enabling a pulse of oxygen to be delivered at the beginning of inhalation.</div><div class=\"graphic_reference\">Data from: Tiep BL. Electronic pulse oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.</div><div id=\"graphicVersion\">Graphic 69597 Version 3.0</div></div></div>"},"69598":{"type":"graphic_table","displayName":"Evaluation bronchiectasis 2","title":"Evaluation of bronchiectasis-2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of bronchiectasis-2</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Specific examples/features</td> <td class=\"subtitle1\">Diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immunodeficiency states</td> </tr> <tr> <td class=\"indent1\">IgG deficiency</td> <td>Congenital (Bruton's type) agammaglobulinemia; selective deficiency of subclasses (IgG2, IgG4); acquired immune globulin deficiency; common variable hypogammaglobulinemia; Nezelof's syndrome; \"bare lymphocyte\" syndrome</td> <td>Quantitative immunoglobulin levels; immunoglobulin subclass levels; impaired response to immunization with pneumococcal vaccine</td> </tr> <tr> <td class=\"indent1\">IgA deficiency</td> <td>Selective IgA deficiency &#177; ataxia-telegiectasia syndrome</td> <td>Quantitative immunoglobulin levels</td> </tr> <tr> <td class=\"indent1\">Leukocyte dysfunction</td> <td>Chronic granulomatous disease (NADPH oxidase dysfunction)</td> <td>Dihydrorhodamine 123 (DHR) oxidation test; nitroblue tetrazolium test; genetic testing</td> </tr> <tr> <td class=\"indent1\">Other rare humoral immunodeficiencies (CXCR4 mutation, CD40 deficiency, CD40 ligand deficiency, and others)</td> <td>WHIM; hypergammaglobulinemia M</td> <td>Neutrophil count; quantitative immunoglobulin levels</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Abnormal secretion clearance</td> </tr> <tr> <td class=\"indent1\">Ciliary defects of airway mucosa</td> <td>Kartagener's syndrome; ciliary dyskinesis</td> <td>Chest image showing situs inversus; nasal nitric oxide; bronchial biopsy; ciliary motility studies; electron microscopy of sperm or respiratory mucosa</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis (mucoviscidosis)</td> <td>Typical early childhood syndrome; later presentation with predominantly sinopulmonary symptoms</td> <td>Sweat chloride; genetic testing</td> </tr> <tr> <td class=\"indent1\">Young's syndrome</td> <td>Obstructive azoospermia with sinopulmonary infections</td> <td>Sperm count</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous disorders</td> </tr> <tr> <td class=\"indent1\">Alpha-1 antitrypsin deficiency</td> <td>Absent or abnormal antitrypsin synthesis and function</td> <td>Alpha-1 antitrypsin serum level; alpha-1 antitrypsin genotyping</td> </tr> <tr> <td class=\"indent1\">Recurrent aspiration pneumonia</td> <td>Alcoholism; neurologic disorders; lipoid pneumonia</td> <td>History; chest imaging</td> </tr> <tr> <td class=\"indent1\">Rheumatic disease</td> <td>Associated with rheumatoid arthritis and Sjogren's syndrome</td> <td>Rheumatoid factor; antiSSA/antiSSB; salivary gland MRI or biopsy</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> <td>Crohn's disease; ulcerative colitis</td> <td>History; lower gastrointestinal endoscopy; imaging studies; colonic biopsy</td> </tr> <tr> <td class=\"indent1\">Inhalation of toxic fumes and dusts</td> <td>Ammonia; nitrogen dioxide, or other irritant gases; smoke; talc; silicates</td> <td>Exposure history; chest imaging</td> </tr> <tr> <td class=\"indent1\">Chronic rejection following organ transplantation</td> <td>Bone marrow, lung and heart lung transplantation; associated with obliterative bronchiolitis</td> <td>History; PFT; chest CT imaging with inspiratory and expiratory views</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography; NADPH: reduced nicotinamide adenine dinucleotide phosphate; PFT: pulmonary function testing; WHIM: syndrome of warts, hypogammaglobulinemia, infections, and myelokathexis.</div><div id=\"graphicVersion\">Graphic 69598 Version 5.0</div></div></div>"},"69599":{"type":"graphic_picture","displayName":"PDA closure Gianturco coils","title":"Gianturco coils used to close patent ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gianturco coils used to close patent ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:427px; height:279px;\" src=\"images/CARD/69599_PDAclosureGlanturcocoils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gianturco coils have been utilized for percutaneous occlusion of patent arteriosus ductus. Coils come in a variety of sizes. They are usually made of stainless steel and contain fibers to increase their thrombogenicity.</div><div class=\"graphic_reference\">Courtesy of Kevin Hill, MD.</div><div id=\"graphicVersion\">Graphic 69599 Version 4.0</div></div></div>"},"69600":{"type":"graphic_diagnosticimage","displayName":"Influenza pneumonia CT","title":"Influenza virus pneumonia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Influenza virus pneumonia </div><div class=\"cntnt\"><img style=\"width:415px; height:243px;\" src=\"images/ID/69600_Infpneuaftercelltrans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Influenza virus pneumonia. High-resolution computed tomography scan in a 34-year-old man who developed influenza virus pneumonia following hematopoietic stem cell transplantation shows small foci of consolidation, patchy ground-glass opacities, and a few centrilobular nodules in the right lower lobe. Also noted are postoperative changes related to previous right upper lobectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Infections. In: High-resolution CT of the lung, 4th Ed, Webb WR, Müller NL, Naidich DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69600 Version 13.0</div></div></div>"},"69601":{"type":"graphic_table","displayName":"Oral CMF for breast cancer","title":"Oral cyclophosphamide, methotrexate, and fluorouracil chemotherapy for breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral cyclophosphamide, methotrexate, and fluorouracil chemotherapy for breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 8 days.<br /> <strong>Total cycles:</strong> 6. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cyclophosphamide*</td> <td>100 mg/m<sup>2</sup> orally daily</td> <td>Cyclophosphamide tablets should be swallowed whole, and not cut or crushed before administration.</td> <td>Days 1 through 14</td> </tr> <tr> <td>Methotrexate</td> <td>40 mg/m<sup>2</sup> IV</td> <td>Methotrexate is available in a 25 mg/mL solution that needs no further dilution. It can be administered as a slow IV push.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil</td> <td>600 mg/m<sup>2</sup> per day IV</td> <td>Fluorouracil is available in 50 mg/mL solution that needs no further dilution prior to administration as IV push.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients should maintain adequate hydration (2 to 3 L/day), void frequently, and avoid taking cyclophosphamide at bedtime to reduce the risk of bladder irritation. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>No specific premedication regimen is indicated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of fluorouracil may be needed for patients with liver impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal or hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modication in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count on days 1 and 8 of each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes, renal, and liver function once per cycle on day 1. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If the ANC is &#60;1000 cells/microL or platelets are &#60;75,000/microL on day 1 of each cycle, therapy should be delayed until counts recover, at which time 75% of the calculated dose should be administered, or 100% of the dose if the ANC is &#62;2000 cells/microL and the platelet count is &#8805;100,000/microL. If the ANC on day 8 is &#60;1000 cells/microL or platelets &#60;75,000/microL, the day 8 doses of methotrexate and fluorouracil should be omitted.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold fluorouracil for grade 2 or worse diarrhea and restart at a lower dose after complete resolution. </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicty of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>Hold fluorouracil for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Cyclophosphamide tablets should be swallowed whole, and not cut or crushed before administration.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fisher B, et al. J Clin Oncol 1990; 8:1483.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on July 3, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed July 3, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 69601 Version 15.0</div></div></div>"},"69603":{"type":"graphic_picture","displayName":"Fatty cast","title":"Fatty cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fatty cast</div><div class=\"cntnt\"><img style=\"width:360px; height:280px;\" src=\"images/NEPH/69603_Fatty_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing a fatty cast. The fat droplets (or globules) can be distinguished from red cells (which also have a round appearance) by their variable size (from much smaller to much larger than a red cell), dark outline, and &quot;Maltese cross&quot; appearance under polzarized light.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 69603 Version 1.0</div></div></div>"},"69605":{"type":"graphic_picture","displayName":"HS abscess","title":"Hidradenitis suppurativa with an abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa with an abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/DERM/69605_HS_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&#160;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 69605 Version 4.0</div></div></div>"},"69606":{"type":"graphic_picture","displayName":"Neurofibromata and cafe-au-lait macules","title":"Neurofibromata and café-au-lait macules in a patient with neurofibromatosis 1 (NF1)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neurofibromata and café-au-lait macules in a patient with neurofibromatosis 1 (NF1)</div><div class=\"cntnt\"><img style=\"width:310px; height:334px;\" src=\"images/PEDS/69606_Cafe-au-lait_macules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin-colored and pink-tan, soft papules and nodules on the back are neurofibromata. These lesions first appeared during late childhood. The large, soft, ill-defined, subcutaneous nodule on the right lower back&nbsp;is a&nbsp;plexiform neuroma. The café-au-lait macules appeared earlier in childhood. A large one is visible on the middle lower back.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York. p.461. Copyright © 1997 The McGraw-Hill Companies.</div><div id=\"graphicVersion\">Graphic 69606 Version 3.0</div></div></div>"},"69607":{"type":"graphic_table","displayName":"Pediatric ulcerative colitis activity index","title":"Pediatric ulcerative colitis activity index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric ulcerative colitis activity index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Item </td> <td class=\"subtitle1\">Points </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdominal pain </td> </tr> <tr> <td class=\"indent1\">No pain </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Pain can be ignored </td> <td>5</td> </tr> <tr> <td class=\"indent1\">Pain cannot be ignored </td> <td>10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rectal bleeding </td> </tr> <tr> <td class=\"indent1\">None </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Small amount only, in &#60;50% of stools </td> <td>10</td> </tr> <tr> <td class=\"indent1\">Small amount with most stools </td> <td>20</td> </tr> <tr> <td class=\"indent1\">Large amount (&#62;50% of the stool content) </td> <td>30</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Stool consistency of most stools </td> </tr> <tr> <td class=\"indent1\">Formed </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Partially formed </td> <td>5</td> </tr> <tr> <td class=\"indent1\">Completely unformed </td> <td>10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Number of stools per 24 hours </td> </tr> <tr> <td class=\"indent1\">0 to 2 </td> <td>0</td> </tr> <tr> <td class=\"indent1\">3 to 5 </td> <td>5</td> </tr> <tr> <td class=\"indent1\">6 to 8 </td> <td>10</td> </tr> <tr> <td class=\"indent1\">&#62;8 </td> <td>15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nocturnal stools (any episode causing wakening) </td> </tr> <tr> <td class=\"indent1\">No </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Yes </td> <td>10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Activity level </td> </tr> <tr> <td class=\"indent1\">No limitation of activity </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Occasional limitation of activity </td> <td>5</td> </tr> <tr> <td class=\"indent1\">Severe restricted activity </td> <td>10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sum of PUCAI (0 to 85) </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PUCAI scores are interpreted as follows:<br /><UL>&#xD;&#xA;<LI>0 to 9&nbsp;– Remission</LI>&#xD;&#xA;<LI>10 to 34&nbsp;– Mild disease</LI>&#xD;&#xA;<LI>35 to 64&nbsp;– Moderate disease</LI>&#xD;&#xA;<LI>65 to 85&nbsp;– Severe disease</LI></UL></div><div class=\"graphic_footnotes\">PUCAI: pediatric ulcerative colitis activity index.</div><div class=\"graphic_reference\">Reproduced with permission from: Turner, D, Otley, AR, Mack, D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007; 133:423. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 69607 Version 6.0</div></div></div>"},"69608":{"type":"graphic_figure","displayName":"TcR V genes in Hashimotos","title":"T-cell receptor V gene use in Hashimoto's thyroiditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T-cell receptor V gene use in Hashimoto's thyroiditis</div><div class=\"cntnt\"><img style=\"width:392px; height:425px;\" src=\"images/ENDO/69608_TcR_V_genes_in_Hashimotos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Many different V genes coding for the TcR are present in T cells from the thyroid of patients with Hashimoto's thyroiditis, suggesting that many antigens are involved in the pathogenesis of the disease.</div><div class=\"graphic_footnotes\">TcR: T-cell receptor.</div><div class=\"graphic_reference\">Redrawn with permission from Davies, TF, Concepcion, ES, Ben-Nun, A, et al. autoimmune thyroid disease: Direct assessment by thyroid aspiration. J Clin Endocrinol Metab 1993; 76:660.</div><div id=\"graphicVersion\">Graphic 69608 Version 2.0</div></div></div>"},"69611":{"type":"graphic_figure","displayName":"Anterior anatomy of knee joint","title":"Anterior anatomy of the knee joint","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Anterior anatomy of the knee joint</div><div class=\"cntnt\"><img style=\"width:526px; height:514px;\" src=\"images/RHEUM/69611_Anterior_knee_anatomy_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing represents an anterior view of the knee with the patella removed and demonstrates the relationship between the bones, menisci, and major ligaments.</div><div id=\"graphicVersion\">Graphic 69611 Version 9.0</div></div></div>"},"69612":{"type":"graphic_table","displayName":"Tests in episcleritis scleritis","title":"Possible laboratory investigations for patients with episcleritis or scleritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible laboratory investigations for patients with episcleritis or scleritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Blood and serologic testing</td> </tr> <tr> <td>Complete blood count</td> </tr> <tr> <td>Erythrocyte sedimentation rate</td> </tr> <tr> <td>Antinuclear antibody</td> </tr> <tr> <td>Syphilis serologies</td> </tr> <tr> <td>Rheumatoid factor</td> </tr> <tr> <td>Angiotensin-converting enzyme levels</td> </tr> <tr> <td>Antineutrophil cytoplasmic antibody</td> </tr> <tr> <td>Serum uric acid concentration</td> </tr> <tr> <td class=\"subtitle1_single\">Urinalysis</td> </tr> <tr> <td class=\"subtitle1_single\">Skin tests</td> </tr> <tr> <td>Tuberculin skin test</td> </tr> <tr> <td>Allergy tests</td> </tr> <tr> <td class=\"subtitle1_single\">Radiologic testing</td> </tr> <tr> <td>Chest radiograph</td> </tr> <tr> <td>Sacroiliac joint radiographs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">These recommendations should be modified as dictated by the findings of a thorough history, review of systems, and physical examination.</div><div id=\"graphicVersion\">Graphic 69612 Version 2.0</div></div></div>"},"69613":{"type":"graphic_diagnosticimage","displayName":"Guide for AP cervical spine x-ray","title":"Guide for AP cervical spine x-ray","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Guide for AP cervical spine x-ray</div><div class=\"cntnt\"><img style=\"width:454px; height:667px;\" src=\"images/EM/69613_Guide_AP_cerv_spine_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Mower WR, Hoffman JR, Mahadevan SV. Cervical spine fractures. In: Harwood-Nuss Clinical Practice of Emergency Medicine, 5th ed, Wolfson AB (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69613 Version 7.0</div></div></div>"},"69614":{"type":"graphic_diagnosticimage","displayName":"US of Bakers cyst","title":"Ultrasound of needle entry into popliteal cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of needle entry into popliteal cyst</div><div class=\"cntnt\"><img style=\"width:287px; height:386px;\" src=\"images/RHEUM/69614_US_Bakers_cyst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal US scan showing a large Baker's cyst and needle at upper right corner.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div class=\"graphic_reference\">Courtesy of Juhani Koski, MD.</div><div id=\"graphicVersion\">Graphic 69614 Version 2.0</div></div></div>"},"69615":{"type":"graphic_figure","displayName":"Augmented limb leads","title":"Augmented limb leads","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Augmented limb leads</div><div class=\"cntnt\"><img style=\"width:479px; height:212px;\" src=\"images/CARD/69615_Unipolar_limb_leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The potential difference between the reference electrode and an exploring electrode constitutes the&nbsp;augmented lead. The three exploring electrodes are the right arm (R), the left arm (L), and the left leg (F). The electrical signals for the unipolar leads are \"augmented\" by disconnecting the exploring electrode from the reference electrode. Since the reference electrode has zero potential, the&nbsp;augmented potential represents only that measured by the three electrodes. The three augmented leads are designated aVR, aVL, and aVF. An impulse directed toward a limb lead records a positive or upright deflection in that lead.</div><div id=\"graphicVersion\">Graphic 69615 Version 2.0</div></div></div>"},"69616":{"type":"graphic_diagnosticimage","displayName":"Aortic dissection on magnetic resonance imaging","title":"Aortic dissection on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic dissection on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:360px; height:252px;\" src=\"images/SURG/69616_Aortic_dissection_MRI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse (axial) spin-echo CMR in a patient with an aortic dissection at the level of the aortic arch. The true lumen (TL), false lumen (FL), and intimal flap can be easily identified. The trachea and superior vena cava (SVC) are also seen.</div><div class=\"graphic_footnotes\">CMR: cardiovascular magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 69616 Version 6.0</div></div></div>"},"69617":{"type":"graphic_movie","displayName":"Myopia nearsightedness","title":"Myopia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myopia</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/69617_myopiaconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:318px; height:198px;\" src=\"images/CARD/69617_myopia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myopia is also known as nearsightedness. The image of an object twenty feet or more away (optical infinity) is focused in front of the retina resulting in blurry distance vision.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 69617 Version 4.0</div></div></div>"},"69620":{"type":"graphic_figure","displayName":"Saethre-Chotzen syndrome","title":"Saethre-Chotzen syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saethre-Chotzen syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:250px;\" src=\"images/PEDS/69620_Saethre-Chotzen_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Craniosynostosis (mild). Ptosis with facial asymmetry and septal deviation. Low-set hairline and simple syndactyly of index and middle finger.</div><div id=\"graphicVersion\">Graphic 69620 Version 1.0</div></div></div>"},"69622":{"type":"graphic_table","displayName":"Characteristics of pancreatic neuroendocrine tumors","title":"Characteristics of pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor<br /> (secreted product)</td> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Pancreatic localization<br /> (percent)</td> <td class=\"subtitle1\">Malignancy<br /> (percent)</td> <td class=\"subtitle1\">MEN1 associated<br /> (percent)</td> <td class=\"subtitle1\">Incidence in MEN1<br /> (percent)</td> </tr> <tr> <td>Insulinoma (insulin)</td> <td>Whipple triad*</td> <td>&#62;97</td> <td>&#60;10</td> <td>5 to 10</td> <td>21</td> </tr> <tr> <td>Gastrinoma (gastrin)</td> <td>Zollinger-Ellison syndrome<sup>&#182;</sup></td> <td>25 to 60</td> <td>60 to 90</td> <td>20 to 30</td> <td>54</td> </tr> <tr> <td>VIPoma (vasoactive intestinal polypeptide)</td> <td>Verner-Morrison syndrome<sup>&#916;</sup></td> <td>&#62;90</td> <td>40 to 70</td> <td>6</td> <td>17</td> </tr> <tr> <td>Glucagonoma (glucagon)</td> <td>Glucagonoma syndrome<sup>&#9674;</sup></td> <td>&#62;95</td> <td>50 to 80</td> <td>1 to 20</td> <td>3</td> </tr> <tr> <td>Somatostatinoma (somatostatin)</td> <td>Somatostatinoma syndrome<sup>&#167;</sup></td> <td>55</td> <td>&#62;70</td> <td>45 to 50</td> <td>&#60;5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEN1: multiple endocrine neoplasia type 1.<br />* Hypoglycemic symptoms, low blood glucose levels, reversible upon glucose intake.<br />¶ Diarrhea, hypergastrinemia, gastric acid hypersecretion, peptic ulcer diathesis.<br />Δ WDHA syndrome: watery diarrhea, hypokalemia, achlorhydria.<br /><FONT class=lozenge>◊</FONT> 4D syndrome: necrolytic migrating erythematous dermatitis, diabetes, deep vein thrombosis, depression.<br />§ (Questionable) elevated somatostatin serum levels, diabetes, hypochlorhydria, cholelithiasis, dia-/steatorrhea, anemia, weight loss.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jensen RT. Pancreatic endocrine tumors: Recent advances. Ann Oncol 1999; 10:170. </li>&#xD;&#xA;    <li>Ehehalt F, Saeger HD, Schmidt CM, Gr&uuml;tzmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009; 14:456. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69622 Version 5.0</div></div></div>"},"69623":{"type":"graphic_picture","displayName":"Contact dermatitis chronic","title":"Chronic allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/69623_Contact_dermatitis_chronic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin is dry, scaly, and thick, as a result of hyperkeratosis, acanthosis, and lymphomononuclear cell infiltration.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69623 Version 3.0</div></div></div>"},"69624":{"type":"graphic_picture","displayName":"Renal Bx - congenital NS of the Finnish type","title":"Renal Bx - congenital NS of the Finnish type","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Renal Bx - congenital NS of the Finnish type</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/PEDS/69624_Renal_Bx_congenital_NS_Finn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal biopsy from an infant with congenital nephrotic syndrome (NS) of the Finnish type due to mutations in the <EM>NPHS1</EM> gene that encodes nephrin, a transmembrane protein located at the slit diaphragm of the glomerular podocytes. Histologic changes include the characteristic findings of mild mesangial hypercellularity and increased mesangial matrix in the glomeruli, and irregular microcystic dilatation of proximal tubules.</div><div id=\"graphicVersion\">Graphic 69624 Version 4.0</div></div></div>"},"69626":{"type":"graphic_figure","displayName":"Megakaryocyte ploidy","title":"Megakaryocyte ploidy varies inversely with the platelet count","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte ploidy varies inversely with the platelet count</div><div class=\"cntnt\"><img style=\"width:424px; height:321px;\" src=\"images/HEME/69626_Megakaryocyte_ploidy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mice were made thrombocytopenic by the injection of antiplatelet antibody or thrombocytotic by the transfusion of platelets and 48 hours later compared with normal animals. Changes in the platelet count were associated with inverse changes in bone marrow mean megakaryocyte ploidy (r = 0.98).</div><div class=\"graphic_reference\">Data from: Kuter DJ, Greenberg SM, Rosenberg RD. Analysis of megakaryocyte ploidy in rat bone marrow cultures. Blood 1989; 74:1952.</div><div id=\"graphicVersion\">Graphic 69626 Version 2.0</div></div></div>"},"69627":{"type":"graphic_diagnosticimage","displayName":"CT enlarged lymph node","title":"CT scan of enlarged intra-abdominal lymph nodes with hypodense centers (solid arrows) and chylous ascites (double-line arrow) (patient 33)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of enlarged intra-abdominal lymph nodes with hypodense centers (solid arrows) and chylous ascites (double-line arrow) (patient 33)</div><div class=\"cntnt\"><img style=\"width:432px; height:427px;\" src=\"images/ID/69627_CT_enlarged_lymph_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Phillips, P, Bonner, S, Gataric, N, et al. Nontuberculous Mycobacterial Immune Reconstitution Syndrome in HIV-infected patients spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483. Copyright © 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 69627 Version 2.0</div></div></div>"},"69629":{"type":"graphic_picture","displayName":"Silver stain in membranous nephropathy","title":"Silver stain in membranous nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silver stain in membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:396px; height:273px;\" src=\"images/NEPH/69629_MembranousSilver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph silver stain of membranous nephropathy shows a spike appearance (arrows). The spikes represent new basement membrane growing between the subepithelial immune deposits, which are visible on electron microscopy but not with this stain.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69629 Version 3.0</div></div></div>"},"69630":{"type":"graphic_figure","displayName":"Anterior circulation stroke","title":"Occlusion of middle and anterior cerebral arteries","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Occlusion of middle and anterior cerebral arteries</div><div class=\"cntnt\"><img style=\"width:609px; height:703px;\" src=\"images/NEURO/69630_Anterior_circulation_stroke.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Netter, FH, Caplan, LR. Cerebrovascular Disease, Section III, Plate 8. In: The Netter Collection of Medical Illustrations, Vol 1, Nervous System, Part II, Neurologic and Neuromuscular Disorders, Netter, FH, Jones, HR, Dingle, RV (Eds), MediMedia USA, Inc 1986. Copyright &#169;1986 Elsevier.</div><div id=\"graphicVersion\">Graphic 69630 Version 1.0</div></div></div>"},"69631":{"type":"graphic_diagnosticimage","displayName":"Gastroschisis 3D ultrasound","title":"Gastroschisis 3D ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastroschisis 3D ultrasound</div><div class=\"cntnt\"><img style=\"width:324px; height:516px;\" src=\"images/OBGYN/69631_Gastroschisis_3D_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a three-dimensional ultrasound examination of a fetus with a gastroschisis at 16 weeks of gestation. The free loops of bowel are seen floating in the amniotic fluid. The umbilical cord is seen superior and to the left of the defect.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 69631 Version 3.0</div></div></div>"},"69632":{"type":"graphic_diagnosticimage","displayName":"Tracheal burn","title":"Severe tracheal burn injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe tracheal burn injury</div><div class=\"cntnt\"><img style=\"width:388px; height:532px;\" src=\"images/PULM/69632_Tracheal_burn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows tracheostomy tube and severe stenosis of the intrathoracic trachea. Computed tomographic scan shows marked narrowing of the intrathoracic trachea.</div><div id=\"graphicVersion\">Graphic 69632 Version 2.0</div></div></div>"},"69633":{"type":"graphic_figure","displayName":"Structure of selectins","title":"Structure of selectins","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Structure of selectins</div><div class=\"cntnt\"><img style=\"width:570px; height:308px;\" src=\"images/RHEUM/69633_Structure_of_selectins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The protein structure of selectins is characterized by variable numbers of short consensus repeats (related to complement regulatory proteins), an epithelial growth factor-like domain, and a C-type (calcium-dependent) lectin domain. Three selectins are known to exist: P-selectin, E-selectin, and L-selectin.</div><div id=\"graphicVersion\">Graphic 69633 Version 2.0</div></div></div>"},"69635":{"type":"graphic_table","displayName":"Phases of aortic regurgitation","title":"Echocardiographic phases of chronic aortic regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic&nbsp;phases of chronic aortic regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Compensated</td> <td class=\"subtitle1\">Transitional</td> <td class=\"subtitle1\">Decompensated*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Dimensions</td> </tr> <tr> <td class=\"indent1\">End-diastolic dimension (mm) </td> <td>&#60;60</td> <td>60 to 70</td> <td>&#62;75</td> </tr> <tr> <td class=\"indent1\">End-systolic dimension (mm) </td> <td>&#60;45</td> <td>45 to 50</td> <td>&#62;55</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Volumes</td> </tr> <tr> <td class=\"indent1\">End-diastolic volume (mL/m<sup>2</sup>)</td> <td>&#60;120</td> <td>130 to 160</td> <td>&#62;170</td> </tr> <tr> <td class=\"indent1\">End-systolic volume (mL/m<sup>2</sup>)</td> <td>&#60;50</td> <td>50 to 60</td> <td>&#62;60</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Left ventricular function</td> </tr> <tr> <td class=\"indent1\">Ejection fraction (percent) </td> <td>&#62;55</td> <td>51 to 55</td> <td>&#8804;50</td> </tr> <tr> <td class=\"indent1\">Fractional shortening (percent)</td> <td>&#62;32</td> <td>30 to 31</td> <td>&#60;29</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with intermediate values between transitional and decompensated disease (end-diastolic dimension 70 to 75 mm and end-systolic dimension 50 to 55 mm) can be referred for exercise testing. Those with an abnormal response are referred for valve replacement, while those with a normal response to exercise are closely monitored.</div><div class=\"graphic_footnotes\">* Patients with decompensated aortic regurgitation are referred for aortic valve replacement. Lower threshold values can be considered in patients of small stature.</div><div id=\"graphicVersion\">Graphic 69635 Version 3.0</div></div></div>"},"69636":{"type":"graphic_picture","displayName":"Proper positioning for pediatric ventilation and intubation ","title":"Proper positioning for ventilation and intubation for children older than two years of age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper positioning for ventilation and intubation for children older than two years of age</div><div class=\"cntnt\"><img style=\"width:319px; height:505px;\" src=\"images/EM/69636_Position_laryngoscopy_pedia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The oral (O), tracheal (T), and pharyngeal (P) axes are in divergent planes. <br />(B) A towel under the occiput brings the external auditory canal anterior to the shoulder, aligning the T and P axes. <br />(C) The extension of the head on the neck, with the mouth and nose facing the ceiling, aligns the O axis with the T and P axes.</div><div id=\"graphicVersion\">Graphic 69636 Version 6.0</div></div></div>"},"69640":{"type":"graphic_figure","displayName":"Salmonella secretion system","title":"Salmonella type III secretion system","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Salmonella type III secretion system</div><div class=\"cntnt\"><img style=\"width:457px; height:410px;\" src=\"images/ID/69640_Salmonella_secretion_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note hollow needle-like structure, 80 nm long and 13 nm wide.</div><div class=\"graphic_reference\">Drawing adapted from: Cossart, P, Boquet, P, Normark, S, Rappuoli, R. Cellular Microbiology. ASM Press 2000.</div><div id=\"graphicVersion\">Graphic 69640 Version 1.0</div></div></div>"},"69644":{"type":"graphic_table","displayName":"Occupational asthma","title":"Evaluation and management of work aggravated asthma and occupational asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and management of work aggravated asthma and occupational asthma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Evaluation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Potential for workplace-related symptoms:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Recognized sensitizers (eg, isocyanates, plant or animal products).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Irritants* or physical stimuli (eg, cold/heat, dust, humidity).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Coworkers may have similar symptoms.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Patterns of symptoms (in relation to work exposures):</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Improvement occurs during vacations or days off (may take a week or more).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Symptoms may be immediate (&#60;1 hour), delayed (most commonly, 2-8 hours after exposure), or nocturnal.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Initial symptoms may occur after high-level exposure (eg, spill).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Documentation of work-relatedness of airflow limitation:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Serial charting for 2-3 weeks (2 weeks at work and up to 1 week off work, as needed to identify or exclude work-related changes in PEF):</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Record when symptoms and exposures occur.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Record when a bronchodilator is used.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Measure and record peak flow (or FEV<sub>1</sub>) every 2 hours while awake.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Immunologic tests.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Referral for further confirmatory evaluation (eg, bronchial challenges).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Management</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Work-aggravated asthma:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Work with onsite health care providers or managers/supervisors.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Discuss avoidance, ventilation, respiratory protection, tobacco smoke-free environment.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Occupationally induced asthma:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Recommend complete cessation of exposure to initiating agent.</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in 1 second; PEF: peak expiratory flow.<br> * Material Safety Data Sheets may be helpful for identifying respiratory irritants, but many sensitizers are not listed.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 69644 Version 1.0</div></div></div>"},"69646":{"type":"graphic_diagnosticimage","displayName":"TEE aortic valve","title":"Aortic valve on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Aortic valve on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:547px; height:405px;\" src=\"images/CARD/69646_TEE_aortic_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Horizontal (0) imaging shows the aortic valve (AoV during systole with the leaflets widely opened. Panel B: Short axis view of the normal trileaflet aortic valve at 37º transducer rotation during systole. Panel C: With the same transducer position, the short axis view during diastole is seen and the right (RCC), left (LCC), and non-coronary cusps (NCC) are well delineated.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 69646 Version 2.0</div></div></div>"},"69647":{"type":"graphic_figure","displayName":"Anatomy of Koch's triangle","title":"Schematic representation of Koch's triangle and environment","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Schematic representation of Koch's triangle and environment</div><div class=\"cntnt\"><img style=\"width:519px; height:300px;\" src=\"images/CARD/69647_Anatomy_of_Kochs_triangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Around the compact atrioventricular (AV) node is an extended zone with transitional cells.</div><div class=\"graphic_footnotes\">LBB: left bundle branch; RBB: right bundle branch.</div><div id=\"graphicVersion\">Graphic 69647 Version 2.0</div></div></div>"},"69650":{"type":"graphic_table","displayName":"Lipid lowering drugs child","title":"Lipid-lowering medications in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lipid-lowering medications in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Initial daily dose</td> <td class=\"subtitle1\">Upper daily dose studied in clinical trials (children aged &#8805;10 years)<sup>[1]</sup></td> <td class=\"subtitle1\">Maximum daily dose (adult)</td> <td class=\"subtitle1\">Available strengths (US)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Statins</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">&nbsp;</td> <td>Atorvastatin</td> <td>5 to 10 mg</td> <td>20 mg</td> <td>80 mg</td> <td>10, 20, 40, 80 mg</td> </tr> <tr> <td>Fluvastatin</td> <td>20 mg</td> <td>80 mg</td> <td>80 mg</td> <td>20, 40 mg, 80 mg (extended release)</td> </tr> <tr> <td>Lovastatin</td> <td>10 mg</td> <td>40 mg</td> <td>80 mg</td> <td> <p>10, 20, 40 mg</p> 20, 40, 60 mg (extended release)</td> </tr> <tr> <td>Pravastatin</td> <td>10 mg</td> <td> <p>40 mg (age 14 to 18 years)</p> 20 mg (age 8 to 13 years)</td> <td>80 mg</td> <td>10, 20, 40, 80 mg</td> </tr> <tr> <td>Rosuvastatin</td> <td>5 mg</td> <td>20 mg</td> <td>40 mg</td> <td>5, 10, 20, 40 mg</td> </tr> <tr class=\"divider_bottom\"> <td>Simvastatin<sup>​</sup></td> <td> <p>10 mg (age &#8805;10 years)</p> 5 mg (age 10 years)</td> <td>40 mg</td> <td>40 mg</td> <td>5, 10, 20, 40, 80<sup>&#182;</sup> mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Cholesterol absorption inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Ezetimibe</td> <td>10 mg</td> <td>10 mg</td> <td>10 mg</td> <td>10 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Fibric acid derivates</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td>Gemfibrozil</td> <td>1200 mg<sup>*</sup></td> <td>Data lacking</td> <td>1200 mg</td> <td>600 mg</td> </tr> <tr class=\"divider_bottom\"> <td>Fenofibrate</td> <td>40 mg</td> <td>Data lacking</td> <td>130 to 200 mg (maximum dose depends on preparation; see Lexicomp drug reference)</td> <td>40, 43, 48, 50, 54, 67, 100, 120, 134, 145, 160, 200 mg (available strengths vary by preparation; see Lexicomp drug reference)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Bile acid sequestrants</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td>Cholestyramine</td> <td>2 to 4 g or 240 mg/kg per day</td> <td> <p>8 g</p> 4 g (age &#60;10 years)</td> <td>16 g</td> <td>4 g per packet or scoop</td> </tr> <tr> <td>Colestipol</td> <td>2.5 to 5 g</td> <td>12 g</td> <td>20 g</td> <td> <p>5 g per packet or scoop</p> 1 g tablet</td> </tr> <tr class=\"divider_bottom\"> <td>Colesevelam</td> <td>1.25 g</td> <td>3.75 g</td> <td>3.75 g</td> <td> <p>3.75 g per packet</p> 625 mg tablet</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Omega-3 fish oils</td> </tr> <tr> <td>&nbsp;</td> <td>Omega-3 acid ethyl esters</td> <td>1 g</td> <td>Data lacking</td> <td>4 g</td> <td>1 g (many strengths available)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Always review drug interactions upon initiation and alteration of treatment. Specific interactions may be determined using the drug interactions tool (Lexi-Interact Online) included with UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.<br />Children and adolescents are generally NOT managed with more than one class of lipid lowering agents due to increased risk of side effects. Combinations of statins and fibrates should be administered under the supervision of a pediatric lipid specialist.</div><div class=\"graphic_footnotes\">mg: milligrams; g: grams.<br />* An initial 600 mg daily dose of gemfibrozil may be considered. Data in children are lacking.<br /><SUP>¶</SUP>​ The US Food and Drug Administration has placed a black box label on simvastatin at a dose of 80 mg per day because it is associated with muscle toxicity in adults. If a daily dose of 40 mg of simvastatin is insufficient to achieve LDL-C control, a change to a more potent statin (eg, atorvastatin or rosuvastatin) is suggested. Doses of simvastatin that exceed 40 mg per day should be given under the supervision of a pediatric lipid specialist, and are generally not required, as more potent statins are available. </div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Data from: Daniels DR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report-2011. National Heart Lung and Blood Institute. Available at: <A href=\"https://www.nhlbi.nih.gov/node/80139\">https://www.nhlbi.nih.gov/node/80139</A> (Accessed April 4, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 69650 Version 9.0</div></div></div>"},"69652":{"type":"graphic_table","displayName":"Hypotensive herbal ingredients","title":"Hypotensive herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypotensive herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Agrimony</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Asafoetida</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Avens</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Calamus</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Celery</td>\n<td>Hypotensive, human and in vivo</td>\n</tr>\n<tr>\n<td>Cohoswh, black</td>\n<td>Hypotensive, human</td>\n</tr>\n<tr>\n<td>Cornsilk</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Cowslip</td>\n<td>Hypotensive, then hypertensive in vivo</td>\n</tr>\n<tr>\n<td>Devil's Claw</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Elecampane</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Fenugreek</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Fucus</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Fumitory</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Garlic</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Ginger</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Ginseng, Panax</td>\n<td>Hypotensive, human and in vivo</td>\n</tr>\n<tr>\n<td>Goldenseal</td>\n<td>Hypotensive, alkaloid effect</td>\n</tr>\n<tr>\n<td>Hawthorn</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Horehound, white</td>\n<td>Vasodilator, oil</td>\n</tr>\n<tr>\n<td>Horseradish</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Mistletoe</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Nettle</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Parsley</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Plantain</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Pokeroot</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Prickly Ash, northern</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Prickly Ash, southern</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Sage</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Shepherd's purse</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Squill</td>\n<td>Vasodilator, oil</td>\n</tr>\n<tr>\n<td>St. John's Wort</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Vervain</td>\n<td>Hypotensive</td>\n</tr>\n<tr>\n<td>Wild carrot</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n<tr>\n<td>Yarrow</td>\n<td>Hypotensive, in vivo</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p. 277.</div><div id=\"graphicVersion\">Graphic 69652 Version 2.0</div></div></div>"},"69653":{"type":"graphic_figure","displayName":"Y-linked inheritance--pedigree","title":"Example of a pedigree showing Y-linked inheritance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing Y-linked inheritance</div><div class=\"cntnt\"><img style=\"width:311px; height:249px;\" src=\"images/PC/69653_Y-linked_inheritance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Y-linked. Inheritance follows that of the Y-chromosome: all males are affected. Females are not.</div><div id=\"graphicVersion\">Graphic 69653 Version 3.0</div></div></div>"},"69654":{"type":"graphic_table","displayName":"Acute liver failure","title":"Transplantation of allogeneic hepatocyte in 37 patients with acute liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transplantation of allogeneic hepatocyte in 37 patients with acute liver failure</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Diagnosis, [reference]\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Age\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Procedure and Outcome\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Acetaminophen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [1]\r\n  \r\n   </td>\r\n  \r\n   <td>16 years</td>\r\n  \r\n   <td>Intraportal (4x10<sup>7</sup> cells), NH<sub>3</sub> &#8595;, encephalopathy grade 4 unchanged. Died on d2.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [7]\r\n  \r\n   </td>\r\n  \r\n   <td>26 years</td>\r\n  \r\n   <td>Intrasplenic (1.2x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, d2 OLT, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   INH\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [1]\r\n  \r\n   </td>\r\n  \r\n   <td>12 years</td>\r\n  \r\n   <td>Intraportal (1x10<sup>8</sup> cells x 3). NH<sub>3</sub> &#8595;, encephalopathy grade 4 unchanged. Died on d7.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Phenytoin\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [1]\r\n  \r\n   </td>\r\n  \r\n   <td>10 years</td>\r\n  \r\n   <td>Intraportal (2.8x10<sup>9</sup> cells x 3), NH<sub>3</sub> &#8595;, encephalopathy grade 4 unchanged. Died of viral meningitis on d7.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Dilantin\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [2]\r\n  \r\n   </td>\r\n  \r\n   <td>13 years</td>\r\n  \r\n   <td>Intraportal (1x10<sup>9</sup> cells). encephalopathy grade 4 unchanged. Died on d4.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [7]\r\n  \r\n   </td>\r\n  \r\n   <td>27 years</td>\r\n  \r\n   <td>Intrasplenic (2.8x10<sup>7</sup>), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, d10 OLT, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Tegretol\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>14.8 years</td>\r\n  \r\n   <td>Intraportal (2.5x10<sup>9</sup> cells). NH<sub>3</sub> &#8595;, encephalopathy grade 4 improved. OLT on d1. Full recovery, 6 year follow-up.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Idiopathic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [1]\r\n  \r\n   </td>\r\n  \r\n   <td>3 years</td>\r\n  \r\n   <td>Intraportal (4x10<sup>9</sup> cells x 9 infusions). NH<sub>3</sub> &#8595; and encephalopathy improved. Full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [1]\r\n  \r\n   </td>\r\n  \r\n   <td>5 years</td>\r\n  \r\n   <td>Intraportal (2x10<sup>9</sup> cells x 7 infusions). NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved. OLT on d4. Full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [4]\r\n  \r\n   </td>\r\n  \r\n   <td>3.5 months</td>\r\n  \r\n   <td>Intraportal (1.8x10<sup>8</sup> cells). Encephalopathy unchanged. OLT on d1. Full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [5]\r\n  \r\n   </td>\r\n  \r\n   <td>8 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup> fetal liver cells/kg bw). Encephalopathy grade 3 improved, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Viral\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>4 years</td>\r\n  \r\n   <td>Intraportal (1.7x10<sup>9</sup> cells x 2). NH<sub>3</sub> &#8595;, encephalopathy grade 3 improved. Intracranial hemorrhage on d2.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Halothane\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [2]\r\n  \r\n   </td>\r\n  \r\n   <td>43 years</td>\r\n  \r\n   <td>Encephalopathy grade 4 improved. Died on day 35 from sepsis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Polysubstance Abuse\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>32 years</td>\r\n  \r\n   <td>Intrasplenic (1.3x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved to grade 2. Died on d14 from sepsis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>35 years</td>\r\n  \r\n   <td>Intrasplenic (1x10<sup>10</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved. Died on d20 from sepsis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>21 years</td>\r\n  \r\n   <td>Intrasplenic (9x10<sup>8</sup> cells x 2 and 2.5x10<sup>7</sup> x 1), encephalopathy grade 4 unchanged, d1 brain death.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>35 years</td>\r\n  \r\n   <td>S/P OLT, intraportal (5.4x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved. Died on d18 from sepsis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>35 years</td>\r\n  \r\n   <td>Intraportal, (3.7x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, full recovery with more than 1 year follow up.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>51 years</td>\r\n  \r\n   <td>Intraportal (3.9x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, died of mesenteric thrombosis on d3.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>32 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup> fetal hep./kg), encephalopathy grade 4 unchanged. Died after 30 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>29 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup> fetal hep/kg), encephalopathy grade 4 unchanged. Died after 37 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>20 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup> fetal hep/kg), encephalopathy grade 4 unchanged, Died after 48 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>20 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup>fetal hep/kg, encephalopathy grade 4 improved, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>24 years</td>\r\n  \r\n   <td>Intraperitoneal (6x10<sup>7</sup> fetal hep/kg), encephalopathy grade 3 improved, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Chloroform, EtOH\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>55 years</td>\r\n  \r\n   <td>Intrasplenic (3.9x10<sup>10</sup> cells), encephalopathy grade 4 unchanged, multisystem organ failure 6 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Etiology unknown\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [8]\r\n  \r\n   </td>\r\n  \r\n   <td>23 years</td>\r\n  \r\n   <td>Intrasplenic, (2.86x10<sup>8</sup> and 1.52x10<sup>8</sup> cells), NH<sub>3</sub> &#8595;, and encephalopathy grade 3 improved, OLT on d5, multisystem organ failure on d13.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Reyes syndrome\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>48 years</td>\r\n  \r\n   <td>Intraportal, (7.5x10<sup>8</sup> cells), NH<sub>3</sub> &#8595;, encephalopathy grade 4 unchanged, brain death on d1.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   &#60;i&#62;Amanita phalloides&#60;/i&#62;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [8]\r\n  \r\n   </td>\r\n  \r\n   <td>64 years</td>\r\n  \r\n   <td>Intraportal, (4.9x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, full recovery, off immuno 12 weeks.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Post-surgical trisegmentectomy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [2]\r\n  \r\n   </td>\r\n  \r\n   <td>69 years</td>\r\n  \r\n   <td>Intrasplenic, (3.6x10<sup>8</sup> cells and 1.7x10<sup>8</sup> cells), encephalopathy grade 4 unchanged, died on day 2.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Herpes II\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>29 years</td>\r\n  \r\n   <td>Intraportal + intrasplenic (1x10<sup>10</sup> cells), encephalopathy grade 4 unchanged, O2 &#8595;. Died after 18 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [4]\r\n  \r\n   </td>\r\n  \r\n   <td>37 years</td>\r\n  \r\n   <td>Intrasplenic, (1.2x10<sup>8</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved. Died on d5 from sepsis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   HBV\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [6]\r\n  \r\n   </td>\r\n  \r\n   <td>65 years</td>\r\n  \r\n   <td>Intraportal + intrasplenic, (3x10<sup>10</sup> cells), encephalopathy grade 3 improved, NH<sub>3</sub> &#8595; &#38; O<sub>2</sub> &#8595;, multisystem organ failure on d52.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [2]\r\n  \r\n   </td>\r\n  \r\n   <td>28 years</td>\r\n  \r\n   <td>Intrasplenic, (1.69x10<sup>8</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 4 improved, OLT d3, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [2]\r\n  \r\n   </td>\r\n  \r\n   <td>43 years</td>\r\n  \r\n   <td>Intraportally, (2.43x10<sup>8</sup> cells x 3 ), encephalopathy 4, OLT on d1, full recovery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [5]\r\n  \r\n   </td>\r\n  \r\n   <td>40 years</td>\r\n  \r\n   <td>Intraperitoneal, (6x10<sup>7</sup> cells/kg body weight), encephalopathy grade 4 unchanged. Died after 13 hours.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   HBV + cocaine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [9]\r\n  \r\n   </td>\r\n  \r\n   <td>37 years</td>\r\n  \r\n   <td>Intrasplenic, (8.8x10<sup>8</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 2 improved, full recovery with 7 year follow up.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   HBV + lymphoma\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   [3]\r\n  \r\n   </td>\r\n  \r\n   <td>54 years</td>\r\n  \r\n   <td>Intraportal, (6.6x10<sup>9</sup> cells), NH<sub>3</sub> &#8595; and encephalopathy grade 2 improved, multisystem organ death d7.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">1. Soriano HE, Wood RP, Kang DC, et al. Hepatocellular transplantation HCT) in children with fulminant liver failure. Hepatology 1997; 30:239A.<BR>2. Strom SC, Roy-Chowdhury J, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999; 19:39.<BR>3. Fisher RA, Strom SC. Human hepatocyte Transplantation: Worldwide results. Transplantation 2006; 82:441.<BR>4. Sterling RK, Fisher RA. Liver Transplantation: Living Donor, Hepatocyte, and Xenotransplantation. In: Current Future Treatment Therapies for Liver Disease. Clinics in Liver Disease. Gish R, ed. Philadelphia: WB Saunders, 2001.<BR>5. Habibullah CM, Syed IH, Qamar A, Taher-Uz Z. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58:951.<BR>6. Bilir BM, Guinette D, Karrer F, et al. Hepatocyte transplantation in acute liver failure. Liver Transp 2000; 6:32.<BR>7. Fisher RA, Strom SC. Human Hepatocyte Transplantation: Biology and Therapy. In the Hepatocyte Review. Berry MN, Edwards AM, eds. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000.<BR>8. Ott M, Barthold M, Alexandrova K, et al. Clinical applications of human hepatocytes isolated under CGMP conditions. 40th annual meeting of the European Association for the study of the liver. 2005: Ab 716.<BR>9. Fisher RA, Bu D, Thompson M, et al. Defining hepatocellular chimerism of a liver failure patient bridged with hepatocyte infusion. Transplantation 2000; 69:303.</div><div id=\"graphicVersion\">Graphic 69654 Version 2.0</div></div></div>"},"69655":{"type":"graphic_table","displayName":"Influenza testing methods","title":"Influenza testing methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Influenza testing methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22.5%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"22.5%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Time to results</td> <td class=\"subtitle1\">Acceptable specimens</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Conventional RT-PCR (gel-based PCR, real-time RT-PCR, and multiplex PCR) and other molecular assays (influenza viral RNA or nucleic acid detection)</td> <td>Varies (generally 1 to 8 hours)</td> <td>NP swab, NP or bronchial washing, nasal or endotracheal aspirate, sputum, throat swab*</td> <td>High sensitivity and very high specificity; highly recommended; can differentiate between influenza types (A or B) and subtypes</td> </tr> <tr class=\"divider_bottom\"> <td>Rapid molecular assays (influenza viral RNA or nucleic acid detection)<sup>&#182;</sup></td> <td>&#60;20 minutes</td> <td>NP swab, nasal swab</td> <td>High sensitivity and specificity; highly recommended; can differentiate between influenza types (A or B), but not subtypes</td> </tr> <tr> <td>Immunofluorescence<sup>&#916;</sup></td> <td>&nbsp;</td> <td>NP swab or washing, bronchial washing, nasal or endotracheal aspirate</td> <td>Moderately high sensitivity and high specificity; recommended</td> </tr> <tr> <td class=\"indent1\">Direct fluorescent antibody staining</td> <td>1 to 4 hours</td> <td>&ndash;</td> <td>Detects and distinguishes between influenza A and B and between A/B and other respiratory viruses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Indirect fluorescent antibody staining</td> <td>1 to 4 hours</td> <td>&ndash;</td> <td>Detects and distinguishes between influenza A and B and between A/B and other respiratory viruses</td> </tr> <tr class=\"divider_bottom\"> <td>Digital immunoassay (rapid immunochromatographic antigen detection test)<sup>&#9674;</sup>&nbsp;</td> <td>10 to 15 minutes</td> <td> <p>CLIA waived test: NP swab, nasal wash</p> <p>Non-CLIA waived test: NP wash, NP aspirate</p> </td> <td>Moderately high sensitivity and high specificity; can differentiate between influenza types (A or B) and subtypes<sup>&#167;</sup></td> </tr> <tr> <td>Rapid influenza diagnostic tests<sup>&#9674;</sup></td> <td>&nbsp;</td> <td>NP swab, nasal washing, nasal aspirate, throat swab*</td> <td>Low to moderate sensitivity and high specificity; recommended; during periods of peak influenza activity, negative rapid antigen tests do not reliably exclude influenza</td> </tr> <tr> <td class=\"indent1\">Antigen detection (EIA)</td> <td>&#60;15 minutes</td> <td>&ndash;</td> <td>Depending on which EIA test is used, will either detect influenza A only, will detect and distinguish between influenza A and B, or will detect but not distinguish between influenza A and B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neuraminidase detection assay</td> <td>&#60;15 minutes</td> <td>&ndash;</td> <td>Detects but does not distinguish between influenza A and B</td> </tr> <tr> <td>Viral culture</td> <td>&nbsp;</td> <td>NP swab, NP or bronchial washing, nasal or endotracheal aspirate, sputum, throat swab*; specimens placed in viral transport media</td> <td>Moderately high sensitivity and highest specificity; this test is important for confirming screening test results and for public health surveillance, but it is not useful for timely clinical management</td> </tr> <tr> <td class=\"indent1\">Shell viral culture</td> <td>24 to 72 hours</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Isolation in cell culture</td> <td>3 to 10 days</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Serologic tests (hemagglutinin inhibition, ELISA, complement-fixation, and neutralization)<sup>&#165;</sup></td> <td>&nbsp;</td> <td>Serum</td> <td>Available only in reference laboratories; not useful for timely clinical management; recommended only for retrospective diagnosis, surveillance, or research purposes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT-PCR: reverse-transcriptase polymerase chain reaction; RNA: ribonucleic acid; NP: nasopharyngeal; CLIA: Clinical Laboratory Improvement Amendments; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay; FDA: US Food and Drug Administration.<br />* Throat swabs are inferior to NP specimens for the detection of influenza viruses, but may be used if NP specimens cannot be obtained.<br />¶ Alere i Influenza A&amp;B was FDA cleared for use with both nasal swabs (direct) and NP or nasal swabs in viral transport media. It was CLIA-waived for use with nasal swabs (direct) only. Roche Cobas Influenza A/B was cleared and CLIA-waived by FDA for use with NP swabs only.<br />Δ Requires fluorescence microscope.<br /><FONT class=lozenge>◊</FONT> Includes moderately complex and CLIA-waived tests.<br />§ Additional clinical experience is necessary to confirm utility at the point of care.<br />¥ Requires paired acute- and convalescent-phase serum samples.</div><div class=\"graphic_reference\">Adapted with permission from: Harper SA, Bradley JS, Englund JA, et al. Seasonal Influenza in Adults and Children--Diagnosis, Treatment, Chemoprophylaxis and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America for Seasonal Influenza in Adults and Children. Clin Infect Dis 2009; 48:1003. Copyright &copy; 2009 University of Chicago Press.<br />Additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>United States Centers for Disease Control and Prevention. Clinical description and lab diagnosis of influenza. Available at: <a href=\"https://www.cdc.gov/flu/professionals/diagnosis/index.htm\" target=\"_blank\">https://www.cdc.gov/flu/professionals/diagnosis/index.htm</a>. Accessed on October 9, 2017. </li>&#xD;&#xA;    <li>Dunn JJ, Ginocchio CC. Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections? J Clin Microbiol 2015; 53:1790.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69655 Version 14.0</div></div></div>"},"69657":{"type":"graphic_picture","displayName":"Postinfectious GN light high","title":"Postinfectious glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinfectious glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:259px;\" src=\"images/PEDS/69657_PostinfectiousGNLightHig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power light micrograph showing marked cellular proliferation and neutrophilic infiltration (arrows) within the glomerular tuft in postinfectious glomerulonephritis. Few open capillary lumens can be seen.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69657 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"69658":{"type":"graphic_table","displayName":"Horners syndrome in children","title":"Etiology of Horner's syndrome in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of Horner's syndrome in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">\"Congenital\" (diagnosed within four weeks after birth)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Birth trauma related</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Congenital infections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neuroblastoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Idiopathic</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Acquired</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neuroblastoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rhabdomyosarcoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Brainstem vascular malformations (AVM)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Brainstem tumors (glioma)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Demyelination (brainstem)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Carotid artery thrombosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neck trauma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Post surgical:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Jugular cannulation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Thoracic surgery</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Neck surgery</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Idiopathic</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69658 Version 1.0</div></div></div>"},"69660":{"type":"graphic_picture","displayName":"Battles sign","title":"Battle sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Battle sign</div><div class=\"cntnt\"><img style=\"width:360px; height:316px;\" src=\"images/EM/69660_Battles_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroauricular or mastoid ecchymosis (ie, Battle sign) typically appears one to three days after a basilar skull fracture is sustained.</div><div class=\"graphic_reference\">Basilar Skull Fracture. In: Color Atlas of Emergency Trauma, Mandavia, DP, Newton, EJ, Demetriades, D, Cambridge University Press, Cambridge, UK 2003. Reprinted with the permission of Cambridge University Press. Copyright © 2003.</div><div id=\"graphicVersion\">Graphic 69660 Version 3.0</div></div></div>"},"69661":{"type":"graphic_table","displayName":"Infection risk of blood products","title":"Risk of viral and bacterial infection following transfusion of blood products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of viral and bacterial infection following transfusion of blood products</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Components prepared from whole blood*</td> </tr> <tr> <td>Hepatitis B virus<sup>[1]</sup></td> <td>1:1 million</td> </tr> <tr> <td>Hepatitis C virus<sup>[2]</sup></td> <td>1:1.2 million</td> </tr> <tr> <td>HTLV<sup>[2,3]</sup></td> <td>1:2.7 million</td> </tr> <tr> <td>HIV<sup>[2]</sup></td> <td>1:1.5 million</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Solvent/detergent-treated plasma products</td> </tr> <tr> <td>Hepatitis C virus</td> <td>Inactivated</td> </tr> <tr> <td>Hepatitis B virus</td> <td>Inactivated</td> </tr> <tr> <td>HIV</td> <td>Inactivated</td> </tr> <tr> <td>Hepatitis A virus</td> <td>Not fully&nbsp;inactivated<sup>&#182;</sup></td> </tr> <tr> <td>Parvovirus B19</td> <td>Not fully&nbsp;inactivated<sup>&#182;</sup></td> </tr> <tr> <td>Hepatitis E virus</td> <td>Not fully inactivated<sup>&#182;</sup>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Platelets</td> </tr> <tr> <td colspan=\"2\">With automated bacterial culturing methods in place, septic transfusion reactions are estimated to occur at a rate of 1:50,000 to 1:80,000 transfused platelet apheresis units. This is an underestimate, since it relies on passive surveillance data<sup>[4]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Cytomegalovirus (CMV) infection</td> </tr> <tr> <td colspan=\"2\">The risk of CMV infection is rare in recipients with selected conditions (eg, bone marrow or solid organ transplants) who are at risk for severe morbidity from CMV infection and who receive CMV reduced-risk products. Two methods to supply CMV reduced-risk products that appear to have equal efficacy are CMV seronegative cellular components (red blood cells, platelets) <strong>or</strong> leukoreduced components.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Numbers reported in this table are <STRONG>estimates</STRONG> for the United States, where blood is routinely screened for infection with syphilis, hepatitis B&nbsp;virus,&nbsp;hepatitis&nbsp;C virus, HIV-1, HIV-2, HTLV-I, HTLV-II, West Nile virus, and<EM> T. cruz</EM>i. CMV serotesting is not routine. Only enough products are tested to provide a sufficient inventory of CMV-negative products. Platelets are tested for bacterial contamination. Refer to UpToDate topics on risks of blood transfusion for further details.</div><div class=\"graphic_footnotes\">HTLV: human T-lymphotropic virus; HIV: human immunodeficiency virus.<br />* These estimates apply to red blood cells, platelets, and plasma, with the exception of HTLV, for which there is no risk from plasma.<br />¶ Plasma products are tested for parvovirus B19, <FONT color=red><FONT color=black>hepatitis A virus, and hepatitis E virus</FONT>&nbsp;</FONT>nucleic acid before being used for further manufacturing into&nbsp;solvent/detergent-treated plasma. Transmission of these agents should not occur (or should be extraordinarily rare)&nbsp;under these conditions.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: Does it improve blood safety? Transfusion 2013; 53:2449.</LI>&#xD;&#xA;<LI>Zou S, Stramer SL, Dodd RY. Donor testing and risk: Current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.&nbsp;Transfus Med Rev 2012; 26:119.</LI>&#xD;&#xA;<LI>Stramer SL, Notari EP, Zou S, et al. HTLV antibody screening of blood donors: Rates of false positive results and evaluation of a potential donor re-entry algorithm. Transfusion 2011; 51:692.</LI>&#xD;&#xA;<LI>Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: Application to apheresis platelets in the United States. Transfusion 2013; 53:1603.&nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 69661 Version 19.0</div></div></div>"},"69662":{"type":"graphic_picture","displayName":"Raccoon eyes","title":"Raccoon eyes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Raccoon eyes</div><div class=\"cntnt\"><img style=\"width:217px; height:149px;\" src=\"images/EM/69662_Raccoon_eyes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral periorbital ecchymoses in a child with a basilar skull fracture.</div><div class=\"graphic_reference\">Courtesy of Joan E Shook, MD.</div><div id=\"graphicVersion\">Graphic 69662 Version 4.0</div></div></div>"},"69663":{"type":"graphic_figure","displayName":"Lifetime risk CVD at age 50","title":"Lifetime risk of cardiovascular disease","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Lifetime risk of cardiovascular disease</div><div class=\"cntnt\"><img style=\"width:520px; height:377px;\" src=\"images/CARD/69663_LifetimeriskCVDatage50.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative lifetime incidence of cardiovascular disease, adjusted for the competing risk of death, according to the aggregate risk factor (RF) burden in men and women in the Framingham Heart Study at age 50 who did not have clinical cardiovascular disease. The lifetime risk ranged from 5 percent in men and 8 percent in women with all optimal risk factors to 69 percent in men and 50 percent in women with ≥2 major risk factors. Intermediate values were obtained in patients with intermediate risk factor burdens. The definitions of optimal, not optimal, and major risk factors are presented in the text.</div><div class=\"graphic_reference\">Data from Lloyd-Jones DM, Leip EP, Larson MG, et al. Circulation 2006; 113:791.</div><div id=\"graphicVersion\">Graphic 69663 Version 2.0</div></div></div>"},"69664":{"type":"graphic_figure","displayName":"Port sites for laparoscopic pancreatectomy","title":"Port sites for laparoscopic pancreatectomy","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Port sites for laparoscopic pancreatectomy</div><div class=\"cntnt\"><img style=\"width:520px; height:493px;\" src=\"images/SURG/69664_Lap_pancreatectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For laparscopic pancreatectomy, an 11 mm port is placed to the left of the umbilicus for the camera. An additional 5 mm working port is placed between the left anterior axillary line and midclavicular line just cephalad to the umbilicus. On the right, a 12 mm port is placed opposite the 10 mm port for the harmonic scalpel and endoscopic gastrointestinal anastomosis stapler. Additional 5 mm ports are placed in the right lower quadrant and in the subxiphoid area, which is used to retract the stomach and liver.</div><div id=\"graphicVersion\">Graphic 69664 Version 5.0</div></div></div>"},"69668":{"type":"graphic_diagnosticimage","displayName":"Colon mass disseminated histo","title":"Colonic mass in disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic mass in disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:232px; height:271px;\" src=\"images/ID/69668_Colon_mass_disseminated_his.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium enema shows a mass lesion in a patient with disseminated histoplasmosis who presented with fever and weight loss. <EM>H. capsulatum</EM> can cause ulcers, masses, inflammation resembling Crohn's disease, peritonitis, and mesenteric lymphadenitis.</div><div class=\"graphic_reference\">Courtesy of George Sarosi, MD.</div><div id=\"graphicVersion\">Graphic 69668 Version 3.0</div></div></div>"},"69671":{"type":"graphic_table","displayName":"Oral agents for mild to moderate diabetic foot infections","title":"Oral agents for empiric treatment of mild to moderate diabetic foot infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral agents for empiric treatment of mild to moderate diabetic foot infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regimens with activity against streptococci and staphylococci (MSSA)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Cephalexin <strong>or</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Dicloxacillin <strong>or</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Amoxicillin-clavulanate <strong>or</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Clindamycin</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regimens with activity against streptococci and MRSA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Clindamycin* <strong>or</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Linezolid <strong>or</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>Cephalexin <strong>or</strong> dicloxacillin</p> <p><strong>PLUS</strong></p> Trimethoprim-sulfamethoxazole <strong>or</strong> doxycycline</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regimens with activity against streptococci, MRSA, aerobic gram-negative bacilli<sup>&#182;</sup> and anaerobes</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <p>Trimethoprim-sulfamethoxazole</p> <p><strong>PLUS</strong></p> <p>Amoxicillin-clavulanate</p> <p><strong>-OR-</strong></p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>Clindamycin*</p> <p><strong>PLUS</strong></p> Ciprofloxacin<sup>&#182;</sup> <strong>or</strong> levofloxacin<sup>&#182;</sup> <strong>or</strong> moxifloxacin</td> </tr> <tr> <td colspan=\"2\"><strong>Antibiotic dosing for adults with normal renal function</strong><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> <td>500 mg every 6 hours</td> </tr> <tr> <td class=\"indent1\">Dicloxacillin</td> <td>500 mg every 6 hours</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td>300 to 450 mg every 6 to 8 hours</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>600 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td>2 double-strength tablets (trimethoprim 160 mg and sulfamethoxazole 800 mg per tablet) every 12 hours</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally every 12 hours</td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate</td> <td>875/125 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> <td>500 mg every 12 hours (or, if there is concern for <em>Pseudomonas aeruginosa</em>, 750 mg every 12 hours)</td> </tr> <tr> <td class=\"indent1\">Levofloxacin</td> <td>500 mg every 24 hours (or, if there is concern for <em>P. aeruginosa</em>, 750 mg every 24 hours)</td> </tr> <tr> <td class=\"indent1\">Moxifloxacin<sup>&#9674;</sup></td> <td>400 mg every 24 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <em>Staphylococcus aureus</em>; MRSA: methicillin-resistant <em>S. aureus</em>.<br />* Check susceptibility testing.<br />&para; Only the regimens containing ciprofloxacin or levofloxacin have expected activity against <em>Pseudomonas aeruginosa</em>. Empiric coverage for <em>P. aeruginosa</em> may not be necessary unless the patient has a particular risk for involvement with this organism, such as a macerated wound or one with significant water exposure. When there is concern for <em>P. aeruginosa</em>, higher dosing of ciprofloxacin or levofloxacin is appropriate, as described in the dosing section above.<br />&Delta; Many of these agents require adjustment of the dose in the setting of renal dysfunction.<br /><span class=\"lozenge\">&loz;</span> Moxifloxacin is not recommended for the treatment of <em>P. aeruginosa</em>.</div><div class=\"graphic_reference\">Data courtesy of authors with additional data from: Lipsky BA, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.</div><div id=\"graphicVersion\">Graphic 69671 Version 8.0</div></div></div>"},"69673":{"type":"graphic_table","displayName":"Causes cardiogenic shock","title":"Causes of cardiogenic shock","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cardiogenic shock</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Acute myocardial infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Pump failure</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Large infarction, generally involving &#8805;40 percent of the left ventricle</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\">Smaller infarction with preexisting left ventricular dysfunction or a prior infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Infarction extension or expansion</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Reinfarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Mechanical complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Acute mitral regurgitation caused by rupture of a papillary muscle or chordae tendinae or severe papillary muscle dysfunction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Ventricular septal defect caused by rupture of the interventricular septum</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Left ventricular free wall rupture</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pericardial tamponade due to rupture of the left ventricular free wall or hemorrhagic pericardial effusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right ventricular infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Other conditions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>End-stage cardiomyopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocarditis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Septic shock with severe myocardial depression</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Left ventricular outflow tract obstruction</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Aortic stenosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hypertrophic obstructive cardiomyopathy</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Obstruction to left ventricular filling</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Mitral stenosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Left atrial myxoma</td>\n    </tr>\n    <tr>\n\n      <td>Acute mitral regurgitation (chordal rupture)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute aortic insufficiency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial contusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prolonged cardiopulmonary bypass</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Hollenberg SM, Kavinsky CJ, Parrillo JE. Ann Intern Med 1999; 131:47.</div><div id=\"graphicVersion\">Graphic 69673 Version 2.0</div></div></div>"},"69674":{"type":"graphic_table","displayName":"Malignancy pulmonary nodule men","title":"Likelihood ratios for malignancy in solitary pulmonary nodules in men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood ratios for malignancy in solitary pulmonary nodules in men</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Finding</td> <td class=\"subtitle1\" colspan=\"2\">Probability of this finding among men with:</td> <td class=\"subtitle1\" rowspan=\"2\">Likelihood ratio for malignancy*</td> </tr> <tr> <td class=\"subtitle2\">Malignant nodules</td> <td class=\"subtitle2\">Benign nodules</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Diameter of nodule, cm</td> </tr> <tr> <td class=\"indent1\">&#60;1.5</td> <td>0.026</td> <td>0.232</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">1.5-2.2</td> <td>0.255</td> <td>0.501</td> <td>0.5</td> </tr> <tr> <td class=\"indent1\">2.3-3.2</td> <td>0.343</td> <td>0.203</td> <td>1.7</td> </tr> <tr> <td class=\"indent1\">3.3-4.2 </td> <td>0.193</td> <td>0.045</td> <td>4.3</td> </tr> <tr> <td class=\"indent1\">4.3-5.2</td> <td>0.118</td> <td>0.018</td> <td>6.6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">5.3-6.0</td> <td>0.065</td> <td>0.002</td> <td>29.4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Patient's age, yr</td> </tr> <tr> <td class=\"indent1\">&#8804;35</td> <td>0.011</td> <td>0.155</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">36-44</td> <td>0.111</td> <td>0.329</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">45-49</td> <td>0.096</td> <td>0.136</td> <td>0.7 </td> </tr> <tr> <td class=\"indent1\">50-59</td> <td>0.2</td> <td>0.138</td> <td>1.5 </td> </tr> <tr> <td class=\"indent1\">60-69</td> <td>0.454</td> <td>0.22</td> <td>2.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">70-83</td> <td>0.129</td> <td>0.023</td> <td>5.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Smoking history</td> </tr> <tr> <td class=\"indent1\">Never smoked</td> <td>0.03</td> <td>0.21</td> <td>0.15</td> </tr> <tr> <td class=\"indent1\">Pipe or cigar only</td> <td>0.05</td> <td>0.15</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">Ever smoked cigarettes</td> <td>0.92</td> <td>0.63</td> <td>1.5</td> </tr> <tr> <td class=\"indent1 sublist1_start\" colspan=\"4\">Current smoker or quit within past 9 yr</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">Average number of cigarettes per day:</td> </tr> <tr> <td class=\"sublist2\">1-9</td> <td class=\"sublist_other\">0.03</td> <td class=\"sublist_other\">0.1</td> <td class=\"sublist_other\">0.3</td> </tr> <tr> <td class=\"sublist2\">10-20</td> <td class=\"sublist_other\">0.27</td> <td class=\"sublist_other\">0.27</td> <td class=\"sublist_other\">1</td> </tr> <tr> <td class=\"sublist2\">21-40</td> <td class=\"sublist_other\">0.38</td> <td class=\"sublist_other\">0.19</td> <td class=\"sublist_other\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">&#8805;41</td> <td class=\"sublist_other\">0.24</td> <td class=\"sublist_other\">0.06</td> <td class=\"sublist_other\">3.9</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Quit smoking, yr</td> </tr> <tr> <td class=\"indent1\">&#8804;3</td> <td>0.07</td> <td>0.05</td> <td>1.4</td> </tr> <tr> <td class=\"indent1\">4-6</td> <td>0.04</td> <td>0.04</td> <td>1</td> </tr> <tr> <td class=\"indent1\">7-12</td> <td>0.04</td> <td>0.07</td> <td>0.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;13</td> <td>0.02</td> <td>0.19</td> <td>0.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Overall prevalence</td> </tr> <tr> <td class=\"indent1\">Clinical settings</td> <td>(0.4)</td> <td>&nbsp;</td> <td>0.7&#8226;</td> </tr> <tr> <td class=\"indent1\">Community surveys</td> <td>(0.1)</td> <td>&nbsp;</td> <td>0.1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These likelihood ratios represent the numerator of odds that have the number 1 as the denominator (eg, 0.25:1). For simplicity, we have omitted the 1 denominator from the table.<br />&para; Defined as: Prevalence of malignancy/(1-Prevalence of malignancy).</div><div class=\"graphic_reference\">Redrawn from Cummings, SR, Lillington, GA, Richard, RJ, Am Rev Respir Dis 1986; 134:449.</div><div id=\"graphicVersion\">Graphic 69674 Version 2.0</div></div></div>"},"69676":{"type":"graphic_diagnosticimage","displayName":"Coronary artery thickening OCT","title":"Coronary artery with mild, focal intimal thickening as visualized by intracoronary OCT","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Coronary artery with mild, focal intimal thickening as visualized by intracoronary OCT</div><div class=\"cntnt\"><img style=\"width:583px; height:352px;\" src=\"images/CARD/69676_Coronary_art_thickening_OCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cross sectional view of the coronary artery. The coronary lumen is signal-poor and black, whereas the vessel is visualized using sepia false color scale. The artery wall shows three-layer appearance. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.<br> (B) Magnification (2.8x) showing mild, focal thickening of the intima to 190 micron.<br> (C) Magnification (2.8x) showing three layer appearance; the intima (I) appears signal rich, bright yellow; the media (M) appears signal-poor, dark and the adventitia (A) appears signal-rich, bright yellow, peri-adventitial tissue is visible (PAT).</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 69676 Version 2.0</div></div></div>"},"69679":{"type":"graphic_table","displayName":"Diagnosis of X-linked SCID","title":"Diagnostic criteria for X-linked severe combined immunodeficiency (SCID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for X-linked severe combined immunodeficiency (SCID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with either (a) engraftment of transplacentally acquired maternal T cells or (b) less than 10% CD3+ T cells, less than 2% CD16/56+ NK cells, and more than 75% CD19+ B cells, and who has one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Mutation in the gene encoding the cytokine common gamma chain (gamma-c).</td> </tr> <tr> <td class=\"sublist1\">2. Absent gamma-c mRNA on Northern blot analysis of lymphocytes.</td> </tr> <tr> <td class=\"sublist1\">3. Absent gamma-c protein on the surface of lymphocytes or lymphocyte cell lines.</td> </tr> <tr> <td class=\"sublist1\">4. Maternal cousins, uncles, or nephews with SCID.</td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with less than 10% CD3+ T cells, less than 2% CD16/56+ NK cells, and more than 75% CD19+ B cells who has all of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Onset of failure to thrive before one year of age.</td> </tr> <tr> <td class=\"sublist1\">2. Serum IgG and IgA more than 2 SD below normal for age.</td> </tr> <tr> <td class=\"sublist1\">3. Persistent or recurrent diarrhea, URI, or thrush.</td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with greater than 40% CD19+ B cells in the peripheral circulation and one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Engraftment of transplacentally acquired maternal T cells.</td> </tr> <tr> <td class=\"sublist1\">2. Maternal cousins, uncles, or nephews with a history of SCID.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD: cluster of differentiation; NK: natural killer; mRNA: messenger ribonucleic acid;&nbsp;IgG: immunoglobulin G; IgA:&nbsp;immunoglobulin A; SD: standard deviation; URI: upper respiratory tract infection.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some, but not all, of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From: Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 69679 Version 6.0</div></div></div>"},"69680":{"type":"graphic_table","displayName":"GAA deficiency (Pompe disease) resources","title":"Internet resources for patients with acid alpha-glucosidase (GAA) deficiency and their families","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Internet resources for patients with acid&nbsp;alpha-glucosidase (GAA)&nbsp;deficiency and their families</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acid Maltase Deficiency Association (AMDA) </td> </tr> <tr> <td><a href=\"http://www.amda-pompe.org/\" spellcheck=\"true\">www.amda-pompe.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">Association for Glycogen Storage Disease </td> </tr> <tr> <td><a href=\"http://www.agsdus.org/\" spellcheck=\"true\">www.agsdus.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">Association for Glycogen Storage Disease, United Kingdom </td> </tr> <tr> <td><a href=\"http://www.agsd.org.uk/\" spellcheck=\"true\">www.agsd.org.uk</a></td> </tr> <tr> <td class=\"subtitle1_single\">United Pompe Foundation </td> </tr> <tr> <td><a href=\"http://www.unitedpompe.com/\" spellcheck=\"true\">www.unitedpompe.com</a></td> </tr> <tr> <td class=\"subtitle1_single\">International Pompe Association (IPA) </td> </tr> <tr> <td><a href=\"http://worldpompe.org/\" spellcheck=\"true\">worldpompe.org</a></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acid alpha-glucosidase deficiency is also known as acid maltase deficiency, Pompe disease, and glycogen storage disease type II (GSD II).</div><div class=\"graphic_reference\">Adapted from Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004; 144:S35.</div><div id=\"graphicVersion\">Graphic 69680 Version 3.0</div></div></div>"},"69681":{"type":"graphic_table","displayName":"Age-related chances of screening-related outcomes","title":"Chances of breast cancer-related outcomes among 1000 women screened annually or biennially, starting at age 40 or 50 and continuing through age 69 or 74","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chances of breast cancer-related outcomes among 1000 women screened annually or biennially, starting at age 40 or 50 and continuing through age 69 or 74</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Screening program</td> <td class=\"subtitle1\" colspan=\"4\">Cumulative consequences of screening program</td> </tr> <tr> <td class=\"subtitle2\">Mammogram frequency</td> <td class=\"subtitle2\">Starting age</td> <td class=\"subtitle2\">Ending age</td> <td class=\"subtitle2\">Lives saved (number)</td> <td class=\"subtitle2\">Life-years gained (number)</td> <td class=\"subtitle2\">False-positive mammograms (number)</td> <td class=\"subtitle2\">Unnecessary biopsies (number)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"7\">Annual</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td>40</td> <td>69</td> <td>8.3</td> <td>164</td> <td>2250</td> <td>158</td> </tr> <tr> <td>50</td> <td>69</td> <td>7.3</td> <td>132</td> <td>1350</td> <td>95</td> </tr> <tr> <td>40</td> <td>74</td> <td>10.5</td> <td>188</td> <td>2470</td> <td>173</td> </tr> <tr> <td>50</td> <td>74</td> <td>9.5</td> <td>156</td> <td>1570</td> <td>110</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"7\">Biennial</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td>40</td> <td>69</td> <td>6.1</td> <td>120</td> <td>1250</td> <td>88</td> </tr> <tr> <td>50</td> <td>69</td> <td>5.4</td> <td>99</td> <td>780</td> <td>55</td> </tr> <tr> <td>40</td> <td>74</td> <td>8.2</td> <td>142</td> <td>1410</td> <td>99</td> </tr> <tr> <td>50</td> <td>74</td> <td>7.5</td> <td>121</td> <td>940</td> <td>66</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted and calculated from: Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Ann Intern Med 2009; 151:738.</div><div id=\"graphicVersion\">Graphic 69681 Version 5.0</div></div></div>"},"69682":{"type":"graphic_algorithm","displayName":"Prevention falls algorithm","title":"Prevention falls algorithm","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Prevention falls algorithm</div><div class=\"cntnt\"><img style=\"width:564px; height:700px;\" src=\"images/PC/69682_Prevention_falls_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Prevention of Falls in Older Persons: Clinical Practice Guideline (http://www.medcats.com/FALLS/frameset.htm) from the American Geriatrics Society. For more information visit the AGS online at www.americangeriatrics.org.</div><div id=\"graphicVersion\">Graphic 69682 Version 5.0</div></div></div>"},"69683":{"type":"graphic_table","displayName":"Causes of elevated ICP","title":"Causes of intracranial hypertension*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of intracranial hypertension*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Traumatic brain injury/intracranial hemorrhage</td> </tr> <tr> <td class=\"sublist1\">Subdural, epidural, or intraparenchymal hemorrhage</td> </tr> <tr> <td class=\"sublist1\">Ruptured aneurysm</td> </tr> <tr> <td class=\"sublist1\">Diffuse axonal injury</td> </tr> <tr> <td class=\"sublist1\">Arteriovenous malformation or other vascular anomalies</td> </tr> <tr> <td>Central nervous system infections (eg, encephalitis, meningitis, abscess)</td> </tr> <tr> <td>Ischemic stroke </td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Hydrocephalus</td> </tr> <tr> <td>Hypertensive encephalopathy&nbsp;</td> </tr> <tr> <td>Idiopathic intracranial hypertension (pseudotumor cerebri)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For further information on clinical manifestations, diagnosis, or treatment of these conditions, refer to specific UpToDate topics. </div><div id=\"graphicVersion\">Graphic 69683 Version 9.0</div></div></div>"},"69684":{"type":"graphic_picture","displayName":"Cutaneous lightning injury","title":"Lightning injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lightning injury</div><div class=\"cntnt\"><img style=\"width:396px; height:236px;\" src=\"images/PULM/69684_Cutaneous_lightning_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Feathering skin injuries are pathognomonic for lightning strike, and are known as Lichtenberg figures (or flowers), filigree burns, keraunographic markings, or arborescent burns. While these have not been characterized histologically, they do not appear to be true burns, and usually fade within a few hours.</div><div class=\"graphic_reference\">Reproduced with permission from Elsevier Science (Vega, LA, Garcia, JA, Santamaria, CT, Porras, MC. Clinical picture: An unwanted tattoo. Lancet 2001; 358:1681).</div><div id=\"graphicVersion\">Graphic 69684 Version 2.0</div></div></div>"},"69685":{"type":"graphic_figure","displayName":"Central venous cath PI","title":"Diagram showing central venous catheter for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Diagram showing central venous catheter for hemodialysis</div><div class=\"cntnt\"><img style=\"width:505px; height:464px;\" src=\"images/PI/69685_Central_venous_cath_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a central venous catheter, which is a thin, flexible tube. One end is put into a large vein, usually in the neck. The other end stays outside the body. During hemodialysis, the end outside of the body is connected to tubes from the dialysis machine.</div><div id=\"graphicVersion\">Graphic 69685 Version 5.0</div></div></div>"},"69687":{"type":"graphic_picture","displayName":"HUS vascular II","title":"Light microscopy showing thrombotic microangiopathy with mucoid intimal thickening of a muscular renal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing thrombotic microangiopathy with mucoid intimal thickening of a muscular renal artery</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/69687_HUS_Vascular_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucoid intimal thickening of muscular renal arteries (arrows) as an early healing response to previous fibrinoid injury in any of the forms of the hemolytic uremic syndrome, including scleroderma and malignant hypertension.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69687 Version 5.0</div></div></div>"},"69691":{"type":"graphic_picture","displayName":"Liver in HELLP Light","title":"HELLP syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HELLP syndrome</div><div class=\"cntnt\"><img style=\"width:382px; height:270px;\" src=\"images/GAST/69691_Liver_in_HELLP_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy from a patient with HELLP syndrome. The zones immediately adjacent to the portal triads show collections of red blood cells, without inflammation or necrosis of hepatocytes.</div><div class=\"graphic_reference\">Courtesy of Caroline A Riely, MD.</div><div id=\"graphicVersion\">Graphic 69691 Version 1.0</div></div></div>"},"69692":{"type":"graphic_table","displayName":"Brain abscess neuro deficits","title":"Neurologic deficits in brain abscess by location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic deficits in brain abscess by location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Temporal lobe</td> </tr> <tr> <td>Werincke's aphasia</td> </tr> <tr> <td>Homonymous superior quadranopsia</td> </tr> <tr> <td>Mild contralateral facial muscle weakness</td> </tr> <tr> <td class=\"subtitle1_single\">Frontal lobe</td> </tr> <tr> <td>Drowsy</td> </tr> <tr> <td>Inattentive</td> </tr> <tr> <td>Disturbed judgment</td> </tr> <tr> <td>Mutism</td> </tr> <tr> <td>Seizures</td> </tr> <tr> <td>Presence of grasp, suck, and snout reflexes</td> </tr> <tr> <td>Contralateral hemiparesis (when the abscess is large)</td> </tr> <tr> <td class=\"subtitle1_single\">Parietal lobe</td> </tr> <tr> <td>Impaired position sense, two point discrimination, and stereognosis</td> </tr> <tr> <td>Focal sensory and motor seizures</td> </tr> <tr> <td>Homonymous hemianopsia</td> </tr> <tr> <td>Impaired opticokinetic nystagmus</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebellar</td> </tr> <tr> <td>Ataxia</td> </tr> <tr> <td>Nystagmus (coarser on gaze toward the lesion)</td> </tr> <tr> <td>Ipsilaterial incoordination of arm and leg movements with intention tremor</td> </tr> <tr> <td class=\"subtitle1_single\">Brainstem</td> </tr> <tr> <td>Facial weakness and dysphagia</td> </tr> <tr> <td>Multiple other cranial nerve palsies</td> </tr> <tr> <td>Contralateral hemiparesis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69692 Version 2.0</div></div></div>"},"69693":{"type":"graphic_figure","displayName":"Autonomic innervation","title":"Autonomic innervation of the heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autonomic innervation of the heart</div><div class=\"cntnt\"><img style=\"width:333px; height:461px;\" src=\"images/CARD/69693_Autonomic_innervation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart, especially the pacemaker tissue, is innervated by fibers from both the parasympathetic and sympathetic nervous systems.</div><div id=\"graphicVersion\">Graphic 69693 Version 1.0</div></div></div>"},"69697":{"type":"graphic_table","displayName":"AMDR","title":"Acceptable macronutrient distribution range","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acceptable macronutrient distribution range</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Carbohydrate</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Fat</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Children</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>45 to 65%</td> <td>5 to 20%</td> <td>30 to 40%</td> </tr> <tr> <td class=\"indent1\">4 to 18 years</td> <td>45 to 65%</td> <td>10 to 30%</td> <td>25 to 35%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Adults</td> </tr> <tr> <td class=\"indent1\">&#62;18 years</td> <td>45 to 65%</td> <td>10 to 35%</td> <td>20 to 35%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acceptable macronutrient distribution range (AMDR) is the range of intake for a particular energy source, expressed as a percentage of total caloric intakes that is associated with reduced risk of chronic disease while providing intakes of essential nutrients.</div><div class=\"graphic_reference\">Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2002/2005).</div><div id=\"graphicVersion\">Graphic 69697 Version 5.0</div></div></div>"},"69698":{"type":"graphic_table","displayName":"Available tests for the evaluation of anaphylaxis","title":"Available tests for the evaluation of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available tests for the evaluation of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Comment</td> <td class=\"subtitle1\">Availability</td> </tr> <tr class=\"divider_bottom\"> <td>Total tryptase (serum/plasma)</td> <td> <p>Mature + proforms of alpha/beta tryptases.</p> <p>Maximal elevation above baseline 15 to 60 minutes after onset of anaphylaxis. Declines to baseline with a half-life of approximately 2 hours.</p> Comparing acute and baseline levels improves sensitivity and specificity.</td> <td>Thermo Fisher Scientific Inc (many commercial laboratories)</td> </tr> <tr class=\"divider_bottom\"> <td>Mature tryptase (serum/plasma)</td> <td> <p>Mature tryptase.</p> Peaks<span style=\"color: black;\">&nbsp;30 to 90</span><span style=\"color: black;\"> minutes </span>after the onset of anaphylaxis and then declines with a half-life of approximately 2 hours.</td> <td>Virginia Commonwealth University*</td> </tr> <tr class=\"divider_bottom\"> <td>Histamine (plasma)</td> <td> <p>Peaks 5 to 10 minutes after symptom-onset and declines to baseline by 15 to 30 minutes.</p> Histamine may be released ex vivo by passing basophils in blood through a small-bore needle under vacuum or when blood clots.</td> <td>Most commercial laboratories</td> </tr> <tr class=\"divider_bottom\"> <td>Histamine (24-hour urine)</td> <td>May be elevated in urine collected up to 24 hours after symptom-onset, but <span style=\"color: black;\">histamine-containing foods and histamine-producing mucosal bacteria may be problematic sources.</span></td> <td>Most commercial laboratories</td> </tr> <tr class=\"divider_bottom\"> <td>N-methylhistamine (24-hour urine)</td> <td>&nbsp;</td> <td>Most commercial laboratories</td> </tr> <tr class=\"divider_bottom\"> <td>N-methylimidazole acetic acid (24-hour urine)</td> <td>&nbsp;</td> <td>Research laboratories</td> </tr> <tr class=\"divider_bottom\"> <td>11-beta-prostaglandin F<sub>2-alpha</sub> (24-hour urine)</td> <td>Prostaglandin D<sub>2</sub> metabolite; falsely low if cyclooxygenase inhibitor taken; produced by activated mast cells, antigen-presenting cells, megakaryocytes, and T helper type 2 lymphocytes but not by basophils.</td> <td>Some commercial laboratories (Mayo Clinic)</td> </tr> <tr class=\"divider_bottom\"> <td>Leukotriene E​​​<sub>4</sub> (24-hour urine)</td> <td>Leukotriene C<sub>4</sub> metabolite; produced by mast cells, basophils, eosinophils, certain phagocytic mononuclear cells, endothelial cells, vascular smooth muscle cells, and platelets.</td> <td>Some commercial laboratories (Mayo Clinic)</td> </tr> <tr> <td>Platelet-activating factor (plasma)</td> <td>May be useful for food-induced anaphylaxis; human cell source(s) uncertain.</td> <td>Research laboratories</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Available in the laboratory of Lawrence B Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 69698 Version 16.0</div></div></div>"},"69699":{"type":"graphic_figure","displayName":"Pathogenic indel","title":"Pathogenic indel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenic indel</div><div class=\"cntnt\"><img style=\"width:429px; height:242px;\" src=\"images/PC/69699_Pathogenic_indel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insertion of Cytosine at nucleotide position 3020 of the CARD15 gene results in frameshift mutation inducing a stop codon sequence in the following codon (denoted by *).</div><div id=\"graphicVersion\">Graphic 69699 Version 1.0</div></div></div>"},"69704":{"type":"graphic_table","displayName":"Parasomnias of childhood","title":"Overview of parasomnias and sleep-related movement disorders in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of parasomnias and sleep-related movement disorders in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorders of arousal from NREM sleep</td> <td class=\"subtitle1\">Parasomnias usually associated with REM sleep</td> <td class=\"subtitle1\">Other parasomnias</td> <td class=\"subtitle1\">Sleep-related movement disorders</td> <td class=\"subtitle1\">Isolated symptoms and normal variants</td> </tr> <tr> <td> <ul> <li>Confusional arousals </li> <li>Sleep walking </li> <li>Sleep&nbsp;terrors </li> </ul> </td> <td> <ul> <li>Nightmares </li> <li>Sleep paralysis </li> <li>REM sleep behavior disorder </li> <li>Parasomnia overlap disorder* </li> </ul> </td> <td> <ul> <li>Sleep enuresis (nocturnal enuresis)* </li> <li>Sleep-related groaning (catathrenia) </li> <li>Panic attacks </li> </ul> </td> <td> <ul> <li>Restless legs syndrome/periodic limb movement disorder </li> <li>Rhythmic movement disorder </li> <li>Bruxism </li> <li>Benign sleep myoclonus of infancy </li> <li>Sleep-related eating disorder</li> </ul> </td> <td> <ul> <li>Sleep&nbsp;starts (hypnic jerks) </li> <li>Hypnagogic foot tremor </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement; REM: rapid eye movement.<br />* May occur during both NREM and REM sleep.</div><div class=\"graphic_reference\">Courtesy of Suresh Kotagal.</div><div id=\"graphicVersion\">Graphic 69704 Version 6.0</div></div></div>"},"69706":{"type":"graphic_table","displayName":"Relaxation breathing PI","title":"Relaxation breathing exercises","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relaxation breathing exercises</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>This exercise can be used to help a child or adolescent who has chronic or recurrent pain. The exercise should be done for 10 minutes at least twice every day, and can be used at other times when pain is bothersome.</td> </tr> <tr> <td class=\"sublist1_start\">The parent can read the following instructions to their child, or an older child or adolescent may read the instructions on their own.</td> </tr> <tr> <td class=\"sublist1\">1. Lie down or sit in a comfortable chair. Remove any items that are uncomfortable, including tight clothing, glasses, or jewelry.</td> </tr> <tr> <td class=\"sublist1\">2. Close your eyes and try to relax every muscle in your body. Pay special attention to the muscles of the face, mouth, tongue, and jaw.</td> </tr> <tr> <td class=\"sublist1\">3. Place one hand on the belly; this hand should move when taking a deep breath.</td> </tr> <tr> <td class=\"sublist1\">4. Follow your breathing as you breathe in deeply and slowly through your nose into your belly. You should feel your belly rise and fall.</td> </tr> <tr> <td class=\"sublist1\">5. Breathe out through your mouth, keeping your mouth, tongue, and jaw relaxed.</td> </tr> <tr> <td class=\"sublist1\">6. Focus on the sound and feeling of long, slow, deep breaths.</td> </tr> <tr> <td class=\"sublist1\">7. Continue breathing in and out slowly for at least 10 minutes.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69706 Version 3.0</div></div></div>"},"69707":{"type":"graphic_figure","displayName":"Vagal nerve stimulator","title":"Vagal nerve stimulator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vagal nerve stimulator</div><div class=\"cntnt\"><img style=\"width:424px; height:420px;\" src=\"images/PEDS/69707_Vagal_nerve_stimulator.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Physician's Manual for the Model 100 NCP® Pulse Generator. Cyberonics. Copyright © Cyberonics.</div><div id=\"graphicVersion\">Graphic 69707 Version 2.0</div></div></div>"},"69708":{"type":"graphic_picture","displayName":"Herpes simplex keratitis - Dendritic corneal ulceration","title":"Herpes simplex (HSV) keratitis: Dendritic corneal ulceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex (HSV) keratitis: Dendritic corneal ulceration</div><div class=\"cntnt\"><img style=\"width:429px; height:292px;\" src=\"images/PC/69708_Dendritic_geographic_HSV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic dendritic geographic corneal ulceration of HSV keratitis. Stained with fluorescein and Rose Bengal.</div><div id=\"graphicVersion\">Graphic 69708 Version 2.0</div></div></div>"},"69711":{"type":"graphic_figure","displayName":"Cryos and LFTs after interferon","title":"Serologic response to interferon alfa in mixed cryoglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serologic response to interferon alfa in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:411px; height:271px;\" src=\"images/GAST/69711_Cryos_and_LFTs_after_interf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Efficacy of interferon alfa in 43 patients with hepatitis C virus-induced chronic liver disease and cryoglobulinemia as determined by the disappearance of circulating cryoglobulins and normalization (responders, n = 28) or lack of normalization (nonresponders, n = 15) of plasma aminotransferase levels. Cryoglobulins were more likely to disappear in aminotransferase responders - 57 versus 33 percent.</div><div class=\"graphic_reference\">Data from: Lunel F, Musset L, Cacoub P, et al. Gastroenterology 1994; 106:1291.</div><div id=\"graphicVersion\">Graphic 69711 Version 2.0</div></div></div>"},"69715":{"type":"graphic_picture","displayName":"Aryepiglottic fold cyst","title":"Cyst of aryepiglottic fold","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cyst of aryepiglottic fold</div><div class=\"cntnt\"><img style=\"width:371px; height:281px;\" src=\"images/PEDS/69715_Aryepiglottic_fold_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note obstruction of the glottic opening.</div><div class=\"graphic_footnotes\">c: cyst.</div><div class=\"graphic_reference\">Courtesy of Ellen S Deutsch, MD.</div><div id=\"graphicVersion\">Graphic 69715 Version 2.0</div></div></div>"},"69717":{"type":"graphic_figure","displayName":"Evaluation of obesity","title":"Clinical and laboratory data for the evaluation of overweight patients","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Clinical and laboratory data for the evaluation of overweight patients</div><div class=\"cntnt\"><img style=\"width:506px; height:468px;\" src=\"images/ENDO/69717_Evaluation_of_obesity.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein.</div><div id=\"graphicVersion\">Graphic 69717 Version 5.0</div></div></div>"},"69719":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 15b","title":"Selective right internal pudendal angiogram","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Selective right internal pudendal angiogram</div><div class=\"cntnt\"><img style=\"width:501px; height:606px;\" src=\"images/OBGYN/69719_Tumor_bleeding_15b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective right internal pudendal angiogram shows a prominent right cervicovaginal artery supplying a hypervascular metastatic renal cell carcinoma of the vagina (arrow).</div><div id=\"graphicVersion\">Graphic 69719 Version 2.0</div></div></div>"},"69723":{"type":"graphic_picture","displayName":"Rheumatoid leg ulcer","title":"Rheumatoid arthritis: skin ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis: skin ulcer</div><div class=\"cntnt\"><img style=\"width:304px; height:381px;\" src=\"images/RHEUM/69723_Rheumatoid_leg_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic ulcer with granulomatous base and undermined gunmetal-colored border in patient with rheumatoid arthritis.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 69723 Version 1.0</div></div></div>"},"69724":{"type":"graphic_figure","displayName":"Frequency of retained placenta by gestational age","title":"Rate of retained placenta by gestational age","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Rate of retained placenta by gestational age</div><div class=\"cntnt\"><img style=\"width:516px; height:354px;\" src=\"images/OBGYN/69724_Retained_placenta_gest_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retained placenta rate at different gestational ages.</div><div class=\"graphic_reference\">Data from: Dombrowski, MP, Bottoms, SF, Saleh, AA, et al. Third stage of labor: analysis of duration and clinical practice. Am J Obstet Gynecol 1995; 172:1279.</div><div id=\"graphicVersion\">Graphic 69724 Version 3.0</div></div></div>"},"69725":{"type":"graphic_picture","displayName":"Lupus erythematosus tumidus","title":"Lupus erythematosus tumidus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus erythematosus tumidus</div><div class=\"cntnt\"><img style=\"width:247px; height:237px;\" src=\"images/DERM/69725_Lupus_erythematosus_tumidus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-scaly inflammatory plaques are present on the chest.</div><div class=\"graphic_reference\">Reprinted with permission from: Cutis 2002; 69:227-230. Copyright © 2002 Quadrant HealthCom Inc.</div><div id=\"graphicVersion\">Graphic 69725 Version 5.0</div></div></div>"},"69726":{"type":"graphic_table","displayName":"CLIP score for HCC","title":"CLIP (Cancer of the Liver Italian Program) scoring system for hepatocellular cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CLIP (Cancer of the Liver Italian Program) scoring system for hepatocellular cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Child-Pugh stage</td> </tr> <tr> <td class=\"indent1\">A</td> <td>0</td> </tr> <tr> <td class=\"indent1\">B</td> <td>1</td> </tr> <tr> <td class=\"indent1\">C</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tumor morphology</td> </tr> <tr> <td class=\"indent1\">Uninodular and extension &#8804;50%</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Multinodular and extension &#8804;50%</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Massive or extension &#62;50%</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alpha-fetoprotein</td> </tr> <tr> <td class=\"indent1\">&#60;400</td> <td>0</td> </tr> <tr> <td class=\"indent1\">&#8805;400</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Portal vein thrombosis</td> </tr> <tr> <td class=\"indent1\">No</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Yes</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Cancer of the Liver Italian Program (CLIP) score has been used to predict survival in patients with hepatocellular carcinoma. The total score is derived by adding each of the subscores. In one study, median survival was 36, 22, 9, 7, and 3 months for patients in CLIP categories 0, 1, 2, 3, and 4 to 6, respectively.</div><div class=\"graphic_reference\">Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31:840. Copyright © 2000 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 69726 Version 5.0</div></div></div>"},"69728":{"type":"graphic_figure","displayName":"CTA false pos intracran aneurys","title":"False-positive intracranial aneurysms reported by CTA","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">False-positive intracranial aneurysms reported by CTA</div><div class=\"cntnt\"><img style=\"width:477px; height:293px;\" src=\"images/NEURO/69728_CTA_false_pos_intracran_ane.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bars represent the number of reported aneurysms of each size from 199 false-positive reports of aneurysms.</div><div class=\"graphic_reference\">Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.</div><div id=\"graphicVersion\">Graphic 69728 Version 1.0</div></div></div>"},"69729":{"type":"graphic_figure","displayName":"Stage 2 prolapse","title":"Stage II prolapse","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Stage II prolapse</div><div class=\"cntnt\"><img style=\"width:479px; height:305px;\" src=\"images/OBGYN/69729_Stage_2_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased distal abdominal pressure on a damaged perineal body may result in severe rectocele and perineal descent (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 69729 Version 2.0</div></div></div>"},"69730":{"type":"graphic_figure","displayName":"Vaginal anterior repair","title":"Transvaginal anterior repair","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Transvaginal anterior repair</div><div class=\"cntnt\"><img style=\"width:534px; height:614px;\" src=\"images/OBGYN/69730_Vaginal_anterior_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior colporraphy - With the patient in the dorsal lithotomy position, the anterior vaginal wall is clearly visualized. Using allis clamps to grasp the anterior vaginal wall, a transverse incision is made using a knife at the proximal aspect of the defect. Sharp dissection in a vertical manner is then performed as superficial as possible using Metzenbaum scissors along the midline of the anterior vaginal wall, staying at least 1 cm away from the external urethral orfice (Image A). Sharp dissection is performed bilaterally to clear the mucosa from the underlying muscularis and adventitia to the level of the pubic symphysis (Image B). Plication of the remaining muscularis and adventitia is then performed with a delayed absorbable suture, thereby repairing the anterior wall support defect (Image C). The vaginal muscosa is then trimmed and closed in a running manner.</div><div id=\"graphicVersion\">Graphic 69730 Version 2.0</div></div></div>"},"69731":{"type":"graphic_picture","displayName":"Apert syndrome syndactyly 2","title":"Apert syndrome: Syndactyly of the foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apert syndrome: Syndactyly of the foot</div><div class=\"cntnt\"><img style=\"width:399px; height:328px;\" src=\"images/PEDS/69731_Apert_syndrome_syndactyly_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apert syndrome: foot syndactyly.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169;2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69731 Version 1.0</div></div></div>"},"69732":{"type":"graphic_figure","displayName":"Flow-volume loop goiter","title":"Use of flow-volume loops to identify upper airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Use of flow-volume loops to identify upper airway obstruction</div><div class=\"cntnt\"><img style=\"width:548px; height:244px;\" src=\"images/ENDO/69732_Flow_volume_loop_goiter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume loops in three settings: normal, COPD, and fixed upper airway obstruction as might occur with a substernal goiter. In the last setting, flow is limited to a roughly equal degree during both inspiration and expiration, with flattening of both limbs of the flow-volume loop. In comparison, the decrease in flow is primarily limited to expiration in COPD.</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div class=\"graphic_reference\">Courtesy of Douglas S Ross, MD.</div><div id=\"graphicVersion\">Graphic 69732 Version 6.0</div></div></div>"},"69734":{"type":"graphic_table","displayName":"WHO Classification of anovulation","title":"World Health Organization classification of anovulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization classification of anovulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">WHO class 1: Hypogonadotropic hypogonadal anovulation (hypothalamic amenorrhea)</td> </tr> <tr> <td>These women have low or low-normal serum follicle-stimulating hormone (FSH) concentrations and low serum estradiol concentrations due to decreased hypothalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unresponsiveness to GnRH.</td> </tr> <tr> <td class=\"subtitle1_single\">WHO class 2: Normogonadotropic normoestrogenic anovulation</td> </tr> <tr> <td>These women may secrete normal amounts of gonadotropins and estrogens. However, FSH secretion during the follicular phase of the cycle is subnormal. This group includes women with polycystic ovary syndrome (PCOS). Some ovulate occasionally, especially those with oligomenorrhea.</td> </tr> <tr> <td class=\"subtitle1_single\">WHO class 3: Hypergonadotropic hypoestrogenic anovulation</td> </tr> <tr> <td>The primary causes are premature ovarian failure (absence of ovarian follicles due to early menopause) and ovarian resistance (follicular form).</td> </tr> <tr> <td class=\"subtitle1_single\">Hyperprolactinemic anovulation</td> </tr> <tr> <td>These women are anovulatory because hyperprolactinemia inhibits gonadotropin and therefore estrogen secretion; they may have regular anovulatory cycles, but most have oligomenorrhea or amenorrhea. Their serum gonadotropin concentrations are usually normal.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69734 Version 4.0</div></div></div>"},"69736":{"type":"graphic_figure","displayName":"Mesh nebulizers","title":"Mesh nebulizers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesh nebulizers</div><div class=\"cntnt\"><img style=\"width:432px; height:232px;\" src=\"images/PULM/69736_Nebulizers_vibrating_mesh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mesh nebulizers generate fine mists with more efficient drug delivery and minimal residual medication volume compared with conventional nebulizers.</div><div id=\"graphicVersion\">Graphic 69736 Version 3.0</div></div></div>"},"69737":{"type":"graphic_figure","displayName":"Vena cava filter models","title":"Inferior vena caval filter models","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Inferior vena caval filter models</div><div class=\"cntnt\"><img style=\"width:603px; height:717px;\" src=\"images/SURG/69737_Vena_cava_filter_models.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Outer diameter&nbsp;specified where the information is available.<br />¶&nbsp;Trademark names for the cobalt-chromium-nickel-molybdenum-iron alloy specified by ASTM F1058 and ISO 5832-7.<br />Δ Inner diameter.<br /></div><div id=\"graphicVersion\">Graphic 69737 Version 3.0</div></div></div>"},"69738":{"type":"graphic_table","displayName":"Consumer resources PI","title":"Consumer resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consumer resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Government websites with information about safety and quality of generic drugs:</p> <ul> <li>Generic Drugs: Same Medicine, Lower Cost: <a href=\"http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm\" spellcheck=\"true\" target=\"_blank\">www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm</a> </li> <li>Generic Drugs: Questions and Answers: <a href=\"http://www.fda.gov/drugs/resourcesforyou/consumers/questionsanswers/ucm100100.htm\" target=\"_blank\">www.fda.gov/drugs/resourcesforyou/consumers/questionsanswers/ucm100100.htm</a> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Websites with information about buying drugs online safely:</p> <ul> <li>Know Your Online Pharmacy: <a href=\"http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm\" target=\"_blank\">www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm</a> </li> <li>Buying Prescription Medicine Online: A Consumer Safety Guide:&nbsp;<span style=\"text-decoration: underline; color: #0066cc;\"><a href=\"http://www.fda.gov/downloads/drugs/resourcesforyou/ucm133237.pdf\">www.fda.gov/downloads/drugs/resourcesforyou/ucm133237.pdf</a></span> </li> <li>National Association of Boards of Pharmacy: <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><a href=\"https://nabp.pharmacy/programs/vipps/vipps-accredited-pharmacies-list/\" title=\"https://nabp.pharmacy/programs/vipps/vipps-accredited-pharmacies-list/\">https://nabp.pharmacy/programs/vipps/vipps-accredited-pharmacies-list/</a> (If you use an internet pharmacy, look for&nbsp;one&nbsp;certified by this group. They have a blue oval seal that reads \"VIPPS.\") </span></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Government websites with information about the risks of foreign and Internet pharmacies:</p> <ul> <li>The Possible Dangers of Buying Medicines Over the Internet: <a href=\"http://www.fda.gov/forconsumers/consumerupdates/ucm048396.htm\" target=\"_blank\">www.fda.gov/forconsumers/consumerupdates/ucm048396.htm</a> </li> <li>Buying Medicine from Outside the United States: <a href=\"http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/buyingmedicinefromoutsidetheunitedstates/default.htm\" target=\"_blank\">www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/buyingmedicinefromoutsidetheunitedstates/default.htm</a> </li> </ul> </td> </tr> <tr> <td> <p>Websites&nbsp;to help you find the lowest prescription prices in your area,&nbsp;and more&nbsp;information about reducing the costs of medicines:</p> <ul> <li>GoodRx: <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><a href=\"http://www.goodrx.com/\" title=\"http://www.goodrx.com/\">http://www.goodrx.com/</a>&nbsp;(This site is an easy way to compare prescription drugs at registered pharmacies in your area.) </span></li> <li>Consumer Reports Best Buy Drugs: <a href=\"http://www.consumerreports.org/health/best-buy-drugs/index.htm\" target=\"_blank\">www.consumerreports.org/health/best-buy-drugs/index.htm</a> </li> <li>Surprising Ways to Cut Your Drug Costs: <a href=\"http://www.consumerreports.org/cro/magazine/2013/09/how-to-cut-drug-costs-save-on-prescription-drugs-consumer-reports/index.htm\" target=\"_blank\">www.consumerreports.org/cro/magazine/2013/09/how-to-cut-drug-costs-save-on-prescription-drugs-consumer-reports/index.htm</a> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69738 Version 12.0</div></div></div>"},"69739":{"type":"graphic_figure","displayName":"Scalp pressure dressing","title":"Scalp pressure dressing","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Scalp pressure dressing</div><div class=\"cntnt\"><img style=\"width:506px; height:679px;\" src=\"images/EM/69739_Scalp-pressure-dressing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemostasis of deep scalp wounds may be provided by placement of a scalp pressure dressing. The wound is covered with topical antibiotic ointment and sterile gauze (figure A) and then the head is tightly wrapped circumferentially with a gauze roll and secured with tape (figure B).</div><div id=\"graphicVersion\">Graphic 69739 Version 2.0</div></div></div>"},"69742":{"type":"graphic_picture","displayName":"White centered RH","title":"White-centered retinal hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">White-centered retinal hemorrhages</div><div class=\"cntnt\"><img style=\"width:396px; height:310px;\" src=\"images/PEDS/69742_White_centered_RH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White-centered hemorrhages appear to be caused by fibrin plugs, ischemia, or central resolution.</div><div class=\"graphic_reference\">Courtesy of Brian Forbes, MD.</div><div id=\"graphicVersion\">Graphic 69742 Version 1.0</div></div></div>"},"69743":{"type":"graphic_figure","displayName":"Cosmetic units of the face","title":"Cosmetic units of the face","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Cosmetic units of the face</div><div class=\"cntnt\"><img style=\"width:477px; height:559px;\" src=\"images/DERM/69743_Cosmetic-units-of-the-face.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69743 Version 3.0</div></div></div>"},"69745":{"type":"graphic_figure","displayName":"Osmotic versus C. difficile diarrhea","title":"Antibiotic-associated osmotic versus <EM>Clostridium difficile</EM> diarrhea","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Antibiotic-associated osmotic versus <EM>Clostridium difficile</EM> diarrhea</div><div class=\"cntnt\"><img style=\"width:474px; height:254px;\" src=\"images/GAST/69745_OsmoticvCdifficilediarr.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69745 Version 4.0</div></div></div>"},"69746":{"type":"graphic_table","displayName":"Prev umbilical cath infection","title":"Prevention of infection with umbilical catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with umbilical catheters</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement and relocation of catheter</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Do not replace umbilical catheter if any sign of catheter-associated infection, vascular insufficiency, or thrombosis occurs.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td>Replace umbilical venous catheters only if mechanical malfunction of the catheter occurs.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of administration sets</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td>Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation*</strong> for replacement of tubing used for intermittent infusions.</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hang time for parenteral fluids</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Complete infusion of blood or blood products within four hours of hanging the blood.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td><strong>No recommendation*</strong> for the hang time of intravenous fluids, including nonlipid-containing parenteral nutrition fluids.</td>\n\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">*&#160;No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 69746 Version 1.0</div></div></div>"},"69747":{"type":"graphic_picture","displayName":"Fire ant mounds in field","title":"Fire ant mounds","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fire ant mounds</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/ALLRG/69747_Fire_ant_mounds_in_field.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows multiple fire ant mounds in a field.</div><div class=\"graphic_reference\">Courtesy of Richard D deShazo, MD.</div><div id=\"graphicVersion\">Graphic 69747 Version 2.0</div></div></div>"},"69748":{"type":"graphic_table","displayName":"Effects of physiologic maneuvers on heart murmurs","title":"Effects of physiologic maneuvers on heart murmurs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of physiologic maneuvers on heart murmurs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Respiration</td> </tr> <tr> <td class=\"indent1\">Right-sided murmurs (eg, tricuspid regurgitation) increase with inspiration due to increased venous return to the right heart.</td> </tr> <tr> <td class=\"subtitle1_single\">Abrupt standing</td> </tr> <tr> <td class=\"indent1\">Most murmurs diminish in intensity with standing due to reduced venous return to the heart and subsequently reduced right and left ventricular diastolic volumes. In contrast, the murmur of hypertrophic cardiomyopathy becomes louder, and the murmur of mitral valve prolapse lengthens and often is intensified.</td> </tr> <tr> <td class=\"subtitle1_single\">Squatting</td> </tr> <tr> <td class=\"indent1\">Most murmurs become louder with squatting (or passive leg raising). In contrast, the murmur of hypertrophic cardiomyopathy becomes softer. The murmur of mitral valve prolapse may shorten with squatting, although as mitral regurgitation becomes more severe, the murmur may increase in intensity with squatting due to increase in afterload.</td> </tr> <tr> <td class=\"subtitle1_single\">Valsalva maneuver</td> </tr> <tr> <td class=\"indent1\">Most murmurs decrease in intensity during the Valsalva maneuver. Two exceptions are the systolic murmur of hypertrophic cardiomyopathy, which becomes louder, and the systolic murmur of mitral valve prolapse, which becomes longer and often louder.</td> </tr> <tr> <td class=\"subtitle1_single\">Sustained hand grip</td> </tr> <tr> <td class=\"indent1\">Hand grip (sustained for 20 to 30 seconds) is most useful in differentiating the ejection systolic murmur of aortic stenosis from the murmur of mitral regurgitation: The intensity of the murmur of aortic stenosis tends to decrease, while the murmur of mitral regurgitation increases.</td> </tr> <tr> <td class=\"subtitle1_single\">Postextrasystolic potentiation</td> </tr> <tr> <td class=\"indent1\">During the cardiac cycle following a premature beat (or in the beat after a long cycle length in atrial fibrillation), the murmur of aortic stenosis increases in intensity, as does the ejection systolic murmur in hypertrophic cardiomyopathy. Carotid pulse volume increases in the former and decreases or remains unchanged in the latter. The murmur of mitral regurgitation does not usually change. However, the murmur of mitral regurgitation associated with mitral valve prolapse is prolonged since the click and onset of murmur occur earlier.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69748 Version 4.0</div></div></div>"},"69749":{"type":"graphic_picture","displayName":"Suction curettes","title":"Suction uterine curettes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suction uterine curettes</div><div class=\"cntnt\"><img style=\"width:435px; height:288px;\" src=\"images/OBGYN/69749_Suction_curettes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) No. 16. (B) No. 12. (C) No. 6.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69749 Version 3.0</div></div></div>"},"69751":{"type":"graphic_table","displayName":"Polyneuropathy associated with drugs and environmental toxins","title":"Polyneuropathy associated with drugs and environmental toxins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polyneuropathy associated with drugs and environmental toxins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drugs and toxins</td> <td class=\"subtitle1\">Level of evidence</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Drugs</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Aurothioglucose</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Bortezomib</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Colchicine</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Dideoxynucleosides (didanosine, stavudine)</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Disulfiram</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Ethambutol</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Leflunomide</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Nitrous oxide</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Platinum derivatives (cisplatin, oxaliplatin)</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Pyridoxine</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Statins</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Suramin</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Taxanes (docetaxel, paclitaxel)</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Thalidomide</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Tumour necrosis factor inhibitors (eg, infliximab)</td> <td>++</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vincristine</td> <td>+++</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Toxins</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Acrylamide</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Allyl chloride</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Arsenic</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Carbon disulfide</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ethylene oxide</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Karwinskia humboldtiana (buckthorn; tullidora) fruit</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Lead</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Metallic mercury</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Methyl bromide</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">n-hexane</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Organophosphates</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Polychlorinated biphenyls</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Styrene</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Thallium</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Trichloroethylene</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+++: strong; ++: moderate; +: weak.</div><div id=\"graphicVersion\">Graphic 69751 Version 3.0</div></div></div>"},"69752":{"type":"graphic_table","displayName":"Genetic syndromes CNS tumors","title":"Genetic syndromes associated with nervous system tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes associated with nervous system tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Syndrome</td>\n\n      <td class=\"subtitle1\">Chromosome</td>\n\n      <td class=\"subtitle1\">Inheritance</td>\n\n      <td class=\"subtitle1\">CNS tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>NF I</td>\n\n      <td>17q1</td>\n\n      <td>AD</td>\n\n      <td>Glioma, meningiomas</td>\n\n    </tr>\n\n    <tr>\n\n      <td>NF II</td>\n\n      <td>22q</td>\n\n      <td>AD</td>\n\n      <td>Acoustic neuroma, optic glioma, meningioma, ependymoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tuberous sclerosis</td>\n\n      <td>9q32-34</td>\n\n      <td>AD</td>\n\n      <td>Ependymoma, astrocytoma, ganglioneuroma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Von Hippel-Lindau</td>\n\n      <td>3p25-26 3p13, 14</td>\n\n      <td>AD</td>\n\n      <td>Hemangioblastoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sturge-Weber disease</td>\n\n      <td>&nbsp;</td>\n\n      <td>AD</td>\n\n      <td>Chorid plexus papilloma</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">NF: neurofibromatosis;&#160;AD: autosomal dominant.</div><div id=\"graphicVersion\">Graphic 69752 Version 1.0</div></div></div>"},"69754":{"type":"graphic_picture","displayName":"Hemorrhagic macular cyst","title":"Hemorrhagic macular cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic macular cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/PEDS/69754_Dome_shaped_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic cysts, such as this macular cyst, may break into the vitreous.</div><div class=\"graphic_reference\">Courtesy of Brian Forbes, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69754 Version 3.0</div></div></div>"},"69755":{"type":"graphic_table","displayName":"Juvenile fibromyalgia criteria","title":"Yunis and Masi criteria for juvenile primary fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Yunis and Masi criteria for juvenile primary fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The diagnosis for juvenile primary fibromyalgia is based upon all four major criteria plus 3 of the 10 minor criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\">1. Generalized musculoskeletal aching at &#8805;3 sites for at least three months</td> </tr> <tr> <td class=\"indent1\">2. Absence of an underlying condition or cause (eg, arthritis or trauma)</td> </tr> <tr> <td class=\"indent1\">3. Normal test results</td> </tr> <tr> <td class=\"indent1\">4. Five tender points</td> </tr> <tr> <td class=\"subtitle2_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">1. Chronic anxiety or tension</td> </tr> <tr> <td class=\"indent1\">2. Fatigue</td> </tr> <tr> <td class=\"indent1\">3. Poor sleep</td> </tr> <tr> <td class=\"indent1\">4. Chronic headaches</td> </tr> <tr> <td class=\"indent1\">5. Irritable bowel syndrome</td> </tr> <tr> <td class=\"indent1\">6. Subjective soft tissue swelling</td> </tr> <tr> <td class=\"indent1\">7. Numbness</td> </tr> <tr> <td class=\"indent1\">8. Pain modulation of physical activity</td> </tr> <tr> <td class=\"indent1\">9. Pain modulation by weather factors</td> </tr> <tr> <td class=\"indent1\">10. Pain modulation by anxiety and/or stress</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Yunis MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum 1985; 28:138.</div><div id=\"graphicVersion\">Graphic 69755 Version 3.0</div></div></div>"},"69756":{"type":"graphic_table","displayName":"Discharge summary contents","title":"Elements of discharge and summary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elements of discharge and summary</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Dates of admission and discharge</td>\n   </tr>\n   <tr>\n   <td>Reason for hospitalization</td>\n   </tr>\n   <tr>\n   <td>Significant findings from history and exam</td>\n   </tr>\n   <tr>\n   <td>Significant laboratory findings</td>\n   </tr>\n   <tr>\n   <td>Significant radiological findings</td>\n   </tr>\n   <tr>\n   <td>Significant findings from other tests</td>\n   </tr>\n   <tr>\n   <td>List of procedures performed</td>\n   </tr>\n   <tr>\n   <td>Procedure report findings</td>\n   </tr>\n   <tr>\n   <td>Stress test report findings</td>\n   </tr>\n   <tr>\n   <td>Pathology report findings</td>\n   </tr>\n   <tr>\n   <td>Discharge diagnosis</td>\n   </tr>\n   <tr>\n   <td>Condition at discharge</td>\n   </tr>\n   <tr>\n   <td>Discharge medications</td>\n   </tr>\n   <tr>\n   <td>Follow-up issues</td>\n   </tr>\n   <tr>\n   <td>Pending test results</td>\n   </tr>\n   <tr>\n   <td>Information provided to patient and/or family, as appropriate</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Source: O'Leary, KJ, Liebovitz, DM, Feinglass, J, et al. Creating A Better Discharge Summary: Improvement in Quality and Timeliness Using an Electronic Discharge Summary. J Hosp Med 2009; 4:219.</div><div id=\"graphicVersion\">Graphic 69756 Version 1.0</div></div></div>"},"69757":{"type":"graphic_picture","displayName":"Endosc RFA Barrx360","title":"Endoscopic images of a primary circumferential ablation of Barrett's esophagus using the Barrx360 system","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Endoscopic images of a primary circumferential ablation of Barrett's esophagus using the Barrx360 system</div><div class=\"cntnt\"><img style=\"width:510px; height:291px;\" src=\"images/GAST/69757_Endosc_RFA_HALO360.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(A)</STRONG> Long-segment Barrett's esophagus with high-grade dysplasia.<BR><STRONG>(B)</STRONG> The Barrx360 catheter is introduced and inflated at the upper end of the Barrett's segment.<BR><STRONG>(C)</STRONG> The whitish coagulum resulting from ablation.<BR><STRONG>(D)</STRONG> After ablation of the whole Barrett's segment and cleaning of the electrode and ablation zone, the catheter is reintroduced for a second ablation pass.<BR><STRONG>(E)</STRONG> The second ablation pass results in a tan-colored ablation zone.<BR><STRONG>(F)</STRONG> Treatment effect after two circumferential ablation passes.</div><div class=\"graphic_reference\">Reproduced with permission of www.endosurgery.eu. Copyright © 2010 Esophageal Research Foundation Amsterdam.</div><div id=\"graphicVersion\">Graphic 69757 Version 3.0</div></div></div>"},"69759":{"type":"graphic_picture","displayName":"Operative hysteroscope","title":"In-line operative hysteroscope with semirigid scissors","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">In-line operative hysteroscope with semirigid scissors</div><div class=\"cntnt\"><img style=\"width:504px; height:216px;\" src=\"images/OBGYN/69759_Operative_hysteroscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69759 Version 1.0</div></div></div>"},"69760":{"type":"graphic_table","displayName":"Ddx LPL path","title":"Histology, immunophenotype, and genetic features of differential diagnosis of lymphoplasmacytic lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histology, immunophenotype, and genetic features of differential diagnosis of lymphoplasmacytic lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Lymphoplasmacytic lymphoma</td> <td> <p>&#8805;10 percent infiltration by small lymphocytes, plasmacytoid lymphocytes, and plasma cells, with variable numbers of admixed immunoblasts.</p> <p>Characteristic (but not pathognomonic) hyperplasia of mast cells in marrow.</p> <p>Lymph nodes are usually diffusely effaced. Proliferation centers and marginal zone type differentiation are absent.</p> </td> <td> <p>Express pan B-cell antigens (CD19, CD20, CD22, CD79a). Most, but not all, cases fail to express CD5.</p> <p>Variable expression of CD11c, CD43, CD25. Most cases express IgM; fewer express IgG or IgA.</p> <p>CD10 and cyclin D1 are not expressed.</p> </td> <td> <p>Majority have a monoclonal IgM paraprotein.</p> <p>No specific chromosomal abnormalities.</p> </td> </tr> <tr> <td>Chronic lymphocytic leukemia/small lymphocytic lymphoma</td> <td>\"Typical\" CLL/SLL cells are small mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, no discernible nucleoli, and a narrow border of clear to slightly basophilic cytoplasm.</td> <td>Always express CD5, usually CD23 positive. Dim expression of CD20 and surface Ig.</td> <td>Del13q, del 11q, del17p, trisomy 12</td> </tr> <tr> <td>B-cell prolymphocytic leukemia</td> <td>Prolymphocytes &#62;55 percent of the neoplastic cells. Bone marrow has interstitial pattern of infiltration. Lymph nodes may show vague nodularity, but proliferation centers are absent.</td> <td>Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).</td> <td> <p>t(11;14) must be excluded.</p> <p>No associated paraproteinemia.</p> </td> </tr> <tr> <td>Follicular lymphoma</td> <td>Nodular growth pattern of follicle center cells (centrocytes and centroblasts).</td> <td>Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA.</td> <td>t(14;18)</td> </tr> <tr> <td>Multiple myeloma</td> <td>Infiltration of plasma cells in the bone marrow.</td> <td>Surface Ig is absent. Express CD138, CD38, CD79a, and VS38c. Infrequently express CD19. Approximately 70 percent of myeloma cells will express CD56.</td> <td>Cytogenetics usually abnormal, although there is no specific cytogenetic abnormality.</td> </tr> <tr> <td>Mantle cell lymphoma</td> <td>Monomorphous small to medium-sized B lymphocytes with irregular nuclei.</td> <td>CD5+ and CD23-; typically co-express surface IgM and IgD; the vast majority over-express cyclin D1.</td> <td>t(11;14)</td> </tr> <tr> <td>Marginal zone lymphoma</td> <td>Polymorphous infiltrate of small cells with paler-appearing marginal zone-type differentiation in lymph nodes.</td> <td>Expresses B cell markers CD19, CD20, and CD22, and not CD5, CD10, and CD23.</td> <td> <p>Chromosomal abnormalities, usually trisomy 3 or t(11;18), are found in most cases.</p> <p>May demonstrate mixed cryoglobulinemia +/- hepatitis C infection.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ig: immunoglobulin.</div><div id=\"graphicVersion\">Graphic 69760 Version 3.0</div></div></div>"},"69761":{"type":"graphic_algorithm","displayName":"Pelvic pain in the pregnant adolescent female with no bleed","title":"Pelvic pain in the pregnant adolescent female without vaginal bleeding","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Pelvic pain in the pregnant adolescent female without vaginal bleeding</div><div class=\"cntnt\"><img style=\"width:560px; height:327px;\" src=\"images/EM/69761_Pel_pain_preg_no_bleed_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">US: ultrasound; SI: sacroiliac.<br> * FABERE sign consists of pain when the ipsilateral hip is placed in flexion, abduction, and external rotation, and the contralateral hip is placed in extension.</div><div id=\"graphicVersion\">Graphic 69761 Version 5.0</div></div></div>"},"69763":{"type":"graphic_table","displayName":"Nonstandardized allergens - Effective doses","title":"United States nonstandardized extracts: Effective and ineffective doses and major allergen content","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States nonstandardized extracts: Effective and ineffective doses and major allergen content</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergen</td> <td class=\"subtitle1\">Effective doses*</td> <td class=\"subtitle1\">Ineffective doses*</td> <td class=\"subtitle1\">Labeling of United States nonstandardized extracts</td> <td class=\"subtitle1\">Average major allergen content<sup>&#182;</sup></td> </tr> <tr> <td>Dog (acetone precipitated)</td> <td>15 mcg Can f 1</td> <td>3 mcg Can f 1</td> <td>1:100 w/v</td> <td>140 mcg/mL Can f 1</td> </tr> <tr> <td>Dog (aqueous)</td> <td>15 mcg Can f 1</td> <td>3 mcg Can f 1</td> <td>1:10 w/v</td> <td>5 mcg/mL Can f 1</td> </tr> <tr> <td>Birch</td> <td>3.25 to 12 mcg Bet v 1</td> <td>Not determined</td> <td>1:10 w/v</td> <td>390 mcg/mL Bet v 1</td> </tr> <tr> <td>Olive</td> <td>Not determined</td> <td>Not determined</td> <td>1:10 w/v</td> <td>430 mcg/mL Ole e 1</td> </tr> <tr> <td>Sagebrush</td> <td>Not determined</td> <td>Not determined</td> <td>1:10 w/v</td> <td>1300 mcg/mL Art v 1</td> </tr> <tr> <td><em>Alternaria alternata</em></td> <td>1.6 <span style=\"color: black;\">and 8 </span>mcg Alt a 1</td> <td>Not determined</td> <td>1:20 w/v</td> <td>&#60;0.01 to 6.1 mcg/mL Alt a 1</td> </tr> <tr> <td><em>Aspergillus fumigatus</em></td> <td>Not determined</td> <td>Not determined</td> <td>1:20 w/v</td> <td>&#60;0.01 to 64 mcg/mL Asp f 1</td> </tr> <tr> <td>German cockroach</td> <td>Not determined</td> <td>Not determined</td> <td>1:20 w/v</td> <td>8 to 66 mcg/mL Bla g 2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">w/v: weight/volume.<br />* Effective and ineffective doses are based upon double-blind, placebo-controlled studies.<br />¶&nbsp;Mean values. Individual lots of extracts may vary considerably from these values.</div><div id=\"graphicVersion\">Graphic 69763 Version 8.0</div></div></div>"},"69764":{"type":"graphic_picture","displayName":"Hamstring strength testing with ER","title":"Hamstring strength testing with external rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hamstring strength testing with external rotation</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/EM/69764_Hamstring_strength_test_ER.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Performing strength testing of the hamstring with the leg externally rotated accentuates the stress placed upon the biceps femoris muscle.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 69764 Version 1.0</div></div></div>"},"69765":{"type":"graphic_diagnosticimage","displayName":"CT scan of internal hernia after gastric bypass","title":"Computed tomography (CT) scan of internal hernia after gastric bypass (mesenteric swirl sign)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) scan of internal hernia after gastric bypass (mesenteric swirl sign)</div><div class=\"cntnt\"><img style=\"width:403px; height:403px;\" src=\"images/SURG/69765_CT_scan_hernia_gast_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows an internal hernia through&nbsp;the mesenteric defect at the enteroenterostomy. Arrow points to a classic swirl sign of vessels with obstructed and collapsed bowel after gastric bypass.</div><div id=\"graphicVersion\">Graphic 69765 Version 5.0</div></div></div>"},"69766":{"type":"graphic_figure","displayName":"Oral cavity anatomy","title":"Oral cavity anatomy","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Oral cavity anatomy</div><div class=\"cntnt\"><img style=\"width:514px; height:486px;\" src=\"images/EM/69766_OP_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69766 Version 3.0</div></div></div>"},"69769":{"type":"graphic_table","displayName":"Cytochrome enzymes involved in metabolism of anticancer drugs","title":"Anticancer agents that are known substrates of cytochrome P450","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticancer agents that are known substrates of cytochrome P450</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cytochrome P450 isoenzymes involved in metabolism</td> </tr> <tr> <td>Busulfan</td> <td>3A4</td> </tr> <tr> <td>Cisplatin</td> <td>2E1, 3A4</td> </tr> <tr> <td>Cyclophosphamide </td> <td>2B6, 2C9, 3A4</td> </tr> <tr> <td>Cytarabine</td> <td>3A4</td> </tr> <tr> <td>Dacarbazine</td> <td>1A1, 1A2, 2E1</td> </tr> <tr> <td>Docetaxel</td> <td>1B1, 3A4, 3A5</td> </tr> <tr> <td>Doxorubicin</td> <td>2D6, 3A4</td> </tr> <tr> <td>Erlotinib</td> <td>1A1, 1A2, 3A4</td> </tr> <tr> <td>Etoposide</td> <td>1A2, 2E1, 3A4, 3A5</td> </tr> <tr> <td>Everolimus&nbsp;</td> <td>3A4</td> </tr> <tr> <td>Gefitinib</td> <td>3A4</td> </tr> <tr> <td>Hydroxyurea</td> <td>Specific isoenzyme not reported</td> </tr> <tr> <td>Idarubicin</td> <td>2D6, 2C9</td> </tr> <tr> <td>Ifosfamide</td> <td>2A6, 2B1, 2B6, 2C9, 2C18, 2C19, 3A4, 3A5</td> </tr> <tr> <td>Imatinib</td> <td>1A2, 2C9, 2C19, 2D6, 3A4</td> </tr> <tr> <td>Irinotecan</td> <td>3A4, 3A5</td> </tr> <tr> <td>Lapatinib&nbsp;</td> <td>2C8, 3A4</td> </tr> <tr> <td>Mitoxantrone</td> <td>Specific isoenzyme not reported</td> </tr> <tr> <td>Nilotinib&nbsp;</td> <td>3A4</td> </tr> <tr> <td>Paclitaxel </td> <td>2C8, 3A4, 3A5</td> </tr> <tr> <td>Procarbazine</td> <td>1A, 2B</td> </tr> <tr> <td>Sorafenib&nbsp;</td> <td>3A4</td> </tr> <tr> <td>Sunitinib&nbsp;</td> <td>3A4</td> </tr> <tr> <td>Tamoxifen</td> <td>1A1, 1A2, 1B1, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5</td> </tr> <tr> <td>Temsirolimus&nbsp;</td> <td>3A4</td> </tr> <tr> <td>Teniposide</td> <td>3A4, 3A5</td> </tr> <tr> <td>Topotecan</td> <td>3A4</td> </tr> <tr> <td>Toremifene</td> <td>1A2, 3A4</td> </tr> <tr> <td>Tretinoin</td> <td>2C8, 2C9, 2E, 3A4</td> </tr> <tr> <td>Vinblastine</td> <td>3A4</td> </tr> <tr> <td>Vincristine</td> <td>3A4</td> </tr> <tr> <td>Vinorelbine</td> <td>3A4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Scripture CD, Spareboome A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncology 2005; 6:780.</div><div id=\"graphicVersion\">Graphic 69769 Version 3.0</div></div></div>"},"69770":{"type":"graphic_table","displayName":"NCI CTCAE v5 hypotension","title":"NCI CTCAE v5.0 hypotension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hypotension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Hypotension</td> <td>Asymptomatic; intervention not indicated</td> <td>Non-urgent medical intervention indicated</td> <td>Medical intervention or hospitalization indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hypotension is characterized by a blood pressure that is below the normal expected for an individual in a given environment.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 69770 Version 8.0</div></div></div>"},"69771":{"type":"graphic_table","displayName":"DDx ADHD in children","title":"Differential diagnosis for attention-deficit hyperactivity disorder in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for attention-deficit hyperactivity disorder in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Methods to distinguish from ADHD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Developmental variations</td> </tr> <tr> <td class=\"indent1\">Intellectual disability</td> <td>Psychometric testing</td> </tr> <tr> <td class=\"indent1\">Giftedness</td> <td>Psychometric testing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normal variation</td> <td>History</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic or developmental disorders</td> </tr> <tr> <td class=\"indent1\">Learning disability</td> <td>Psychometric testing</td> </tr> <tr> <td class=\"indent1\">Language or communication disorder</td> <td>Psychometric testing</td> </tr> <tr> <td class=\"indent1\">Autism spectrum disorders</td> <td>History; structured observation&nbsp;</td> </tr> <tr> <td class=\"indent1\">Neurodevelopmental syndromes (eg, fetal alcohol syndrome, fragile X syndrome)</td> <td>History; examination; genetic testing</td> </tr> <tr> <td class=\"indent1\">Seizure disorder</td> <td>History; electroencephalography if clinically indicated</td> </tr> <tr> <td class=\"indent1\">Sequelae of central nervous system trauma or infection</td> <td>History</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Motor coordination disorder</td> <td>History; examination; occupational therapy evaluation </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Emotional/behavioral disorders</td> </tr> <tr> <td class=\"indent1\">Depression or mood disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"indent1\">Anxiety disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"indent1\">Oppositional defiant disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"indent1\">Conduct disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"indent1\">Obsessive compulsive disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"indent1\">Posttraumatic stress disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adjustment disorder</td> <td>Broadband behavior scale; mental health evaluation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychosocial or environmental problems</td> </tr> <tr> <td class=\"indent1\">Child abuse or neglect</td> <td>Medical history; psychosocial history; examination</td> </tr> <tr> <td class=\"indent1\">Stressful home environment</td> <td>Psychosocial history</td> </tr> <tr> <td class=\"indent1\">Inadequate or punitive parenting</td> <td>Psychosocial history</td> </tr> <tr> <td class=\"indent1\">Parental psychopathology or substance abuse</td> <td>Psychosocial history</td> </tr> <tr> <td class=\"indent1\">Inappropriate educational setting</td> <td>Symptoms occur at school but not at home</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Frequent school absence</td> <td>Psychosocial history</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Selected medical conditions</td> </tr> <tr> <td class=\"indent1\">Hearing or vision impairment</td> <td>Hearing and vision screen</td> </tr> <tr> <td class=\"indent1\">Sleep disorder</td> <td>History; sleep study as indicated by clinical findings</td> </tr> <tr> <td class=\"indent1\">Iron deficiency anemia</td> <td>Complete blood count and other hematologic studies as indicated</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> <td>Measurement of blood lead level</td> </tr> <tr> <td class=\"indent1\">Endocrine disorders (eg, thyroid disease, diabetes mellitus)</td> <td>Laboratory studies as indicated by clinical findings</td> </tr> <tr> <td class=\"indent1\">Cardiac disorders (eg, heart failure)</td> <td>Medical history; echocardiograph/pediatric cardiology consultation as indicated</td> </tr> <tr> <td class=\"indent1\">Substance abuse</td> <td>History; toxicology screening</td> </tr> <tr> <td class=\"indent1\">Food allergy</td> <td>History; allergy testing as indicated</td> </tr> <tr> <td class=\"indent1\">Undernutrition</td> <td>Assessment of growth parameters</td> </tr> <tr> <td class=\"indent1\">Medication side effects</td> <td>History</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: Attention deficit hyperactivity disorder.<br />* These conditions may mimic or co-occur with ADHD.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.85. </LI>&#xD;&#xA;<LI>Leslie LK, Guevara JP. Attention-deficit/hyperactivity disorder. In: American Academy of Pediatrics Textbook of Pediatric Care, McInerny TK (Ed), American Academy of Pediatrics, Elk Grove Village, IL, 2009. p.1201. </LI>&#xD;&#xA;<LI>Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2011: 128:1007. </LI></OL></div><div id=\"graphicVersion\">Graphic 69771 Version 3.0</div></div></div>"},"69772":{"type":"graphic_table","displayName":"Drug and toxin related hypoxia","title":"Drugs and toxins that cause hypoxia/hypoxemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and toxins that cause hypoxia/hypoxemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">By CNS depression</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Ethanol, ethylene glycol, methanol, isopropyl alcohol</td> </tr> <tr> <td>Sedative-hypnotics (usually if co-ingested with another CNS depressant)</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Clonidine</td> </tr> <tr> <td class=\"subtitle1_single\">By impairing oxygen diffusion</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Hydrocarbons (aspiration pneumonitis)</td> </tr> <tr> <td>Paraquat</td> </tr> <tr> <td>Smoke inhalation</td> </tr> <tr> <td>Phosgene and chlorine</td> </tr> <tr> <td class=\"subtitle1_single\">By complications</td> </tr> <tr> <td>Any CNS depressant can result in aspiration.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">By paralysis of the ventilatory muscles</td> </tr> <tr> <td>Neuromuscular blockers (pancuronium, vecuronium, succinylcholine, etc.)</td> </tr> <tr> <td>Organophosphates and carbamates</td> </tr> <tr> <td>Snakebites</td> </tr> <tr> <td>Tetanus toxin</td> </tr> <tr> <td>Strychnine</td> </tr> <tr> <td>Botulinum toxin</td> </tr> <tr> <td class=\"subtitle1_single\">Simple asphyxiants (Displace oxygen in the lungs)</td> </tr> <tr> <td>Methane</td> </tr> <tr> <td>Propane</td> </tr> <tr> <td>Nitrogen</td> </tr> <tr> <td>Carbon dioxide</td> </tr> <tr> <td class=\"subtitle1_single\">Cellular asphyxiants (Inability to deliver or utilize oxygen by the cell)</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Cyanide</td> </tr> <tr> <td>&nbsp;Hydrogen sulfide</td> </tr> <tr> <td>Methemoglobinemia</td> </tr> <tr> <td>Sulfhemoglobinemia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69772 Version 5.0</div></div></div>"},"69773":{"type":"graphic_picture","displayName":"Structureless areas","title":"Dermoscopic images of structureless/featureless lesions or lesions with nonspecific/nondiagnostic dermoscopic features","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic images&nbsp;of structureless/featureless lesions or lesions with nonspecific/nondiagnostic dermoscopic features</div><div class=\"cntnt\"><img style=\"width:338px; height:550px;\" src=\"images/DERM/69773_Structureless_areas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hypopigmented lesion with structureless areas.<br />(B) Heavily pigmented with structureless areas.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 69773 Version 4.0</div></div></div>"},"69774":{"type":"graphic_algorithm","displayName":"Syncope ED algorithm","title":"Algorithm representing the emergency department approach to an adult patient with syncope","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Algorithm representing the emergency department approach to an adult patient with syncope</div><div class=\"cntnt\"><img style=\"width:550px; height:677px;\" src=\"images/EM/69774_Syncope_ED_algorithm.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69774 Version 1.0</div></div></div>"},"69778":{"type":"graphic_table","displayName":"Pulm drug complication II","title":"Pulmonary complications of cardiovascular drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary complications of cardiovascular drugs</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Agent</td>\n\n      <td class=\"subtitle1\">Syndrome</td>\n\n      <td class=\"subtitle1\">Frequency</td>\n\n      <td class=\"subtitle1\">Potential mechanism</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Beta blockers</td>\n\n      <td>Cough or bronchospasm</td>\n\n      <td>Common; usually occurs in patients with asthma or COPD;&nbsp;&#946;1-selective agents, labetalol, esmolol, and pindolol are\nbetter tolerated than nonselective agents</td>\n\n      <td>Direct antagonism of &#946;2 receptor-mediated\nbronchodilation</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td>Pulmonary fibrosis</td>\n\n      <td>Rare&nbsp;</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n      <td>Lupus-like syndrome</td>\n      <td>Rare</td>\n      <td> Unknown</td>\n    </tr>\n    <tr>\n\n      <td>Hydralazine</td>\n\n      <td>Lupus-like syndrome</td>\n\n      <td>Renal disease more common than in other drug-induced\nlupus-like syndromes</td>\n\n      <td>Unknown; slow acetylation may be a risk factor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dipyridamole (IV form only)</td>\n\n      <td>Bronchospasm</td>\n\n      <td>Occurs in about 0.15 percent of patients during\ninfusion for stress testing</td>\n\n      <td>Induction of mast cell mediator release</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Protamine</td>\n\n      <td>Anaphylaxis, uritcaria, angioedema, bronchospasm</td>\n\n      <td>Occurs in 0.2 percent of patients</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Pulmonary hypertension</td>\n\n      <td>Mild pulmonary hypertension and systemic hypotension in\nup to 5 percent of patients; severe reaction rare</td>\n\n      <td>Antiprotamine antibodies; activated neutrophils;\nthromboxane A2 generation</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Zitnik, RJ, J Respir Dis 1996; 17:254; and Zitnik, RJ, J Respir Dis 1996; 17:293.</div><div id=\"graphicVersion\">Graphic 69778 Version 1.0</div></div></div>"},"69781":{"type":"graphic_picture","displayName":"Facial stigmata of congenital syphilis","title":"Congenital syphilis: Facial stigmata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Facial stigmata</div><div class=\"cntnt\"><img style=\"width:344px; height:432px;\" src=\"images/PEDS/69781_Facial_stig_cong_syph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial stigmata of congenital syphilis depicted above include bulging of the frontal bones and depression of the nasal bridge (&quot;saddle nose&quot;), both due to periostitis; rhinitis from weeping nasal mucosal lesions (&quot;snuffles&quot;); and a circumoral rash.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69781 Version 2.0</div></div></div>"},"69782":{"type":"graphic_figure","displayName":"Structures of the axilla","title":"Structures of the axilla","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Structures of the axilla</div><div class=\"cntnt\"><img style=\"width:552px; height:471px;\" src=\"images/SURG/69782_Structures_of_the_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structures of the axilla. Most of the anterior wall of the axilla and the axillary fat pad have been removed, revealing the axilla's medial and posterior walls and neurovascular contents. Of the structures forming the anterior wall, only portions of the pectoralis major (attaching ends, a central part overlying the pectoralis minor, and a cube of muscle reflected superior to the clavicle) and the pectoralis minor remain. All the clavipectoral fascia has been removed, as has the axillary sheath surrounding the neurovascular bundle. Observe the axillary artery emerging from the cervicoaxillary canal inferior to the clavicle and subclavius muscle and then passing a finger's breadth inferior to the coracoid process of the scapula. As the axillary artery passes through the axilla, it is surrounded by the brachial plexus of nerves. The major nerves arising from the lateral and medial cords (anterior divisions) of the plexus have been elevated by an applicator stick.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, Fourth Ed. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69782 Version 2.0</div></div></div>"},"69784":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound unilateral kidney adrenal","title":"Prenatal ultrasound longitudinal view, normal kidney with adrenal gland","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound longitudinal view, normal kidney with adrenal gland</div><div class=\"cntnt\"><img style=\"width:425px; height:293px;\" src=\"images/OBGYN/69784_Unilateral_kidney_adrenal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal view of a normal kidney and adrenal gland in the third trimester.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 69784 Version 4.0</div></div></div>"},"69785":{"type":"graphic_picture","displayName":"Infiltrating UC IHC","title":"Infiltrating urothelial carcinoma: immunohistochemical features","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma: immunohistochemical features</div><div class=\"cntnt\"><img style=\"width:515px; height:201px;\" src=\"images/ONC/69785_Infiltrating_UC_IHC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cords and individual urothelial carcinoma cells infiltrating muscularis propria showing diffuse, strong cytoplasmic reactivity for CK7 (A, 20x), and CK20 (B, 20x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69785 Version 1.0</div></div></div>"},"69787":{"type":"graphic_table","displayName":"Clues RD early childhood","title":"Clues to dyslexia in early childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to dyslexia in early childhood</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   The preschool years\n   </td>\n   </tr>\n   <tr>\n   <td>Trouble learning common nursery rhymes, such as \"Jack and Jill\" and \"Humpty Dumpty\"</td>\n   </tr>\n   <tr>\n   <td>A lack of appreciation of rhymes</td>\n   </tr>\n   <tr>\n   <td>Mispronounced words; persistent baby talk</td>\n   </tr>\n   <tr>\n   <td>Difficulty in learning (and remembering) names of letters</td>\n   </tr>\n   <tr>\n   <td>Failure to know the letters in his own name</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Kindergarten and first grade\n   </td>\n   </tr>\n   <tr>\n   <td>Failure to understand that words come apart; for example, that <em>batboy</em> can be pulled apart into <em>bat</em> and <em>boy</em>, and, later on, that the word <em>bat</em> can be broken down still further and sounded out as: \"<em>b</em>\" \"<em>aaa</em>\" \"<em>t</em>\"</td>\n   </tr>\n   <tr>\n   <td>Inability to learn to associate letters with sounds, such as being unable to connect the letter <em>b</em> with the \"<em>b</em>\" sound</td>\n   </tr>\n   <tr>\n   <td>Reading errors that show no connection to the sounds of the letters; for example, the word <em>big</em> is read as <em>goat</em></td>\n   </tr>\n   <tr>\n   <td>The inability to read common one-syllable words or to sound out even the simplest of words such as <em>mat</em>, <em>cat</em>, <em>hop</em>, <em>nap</em></td>\n   </tr>\n   <tr>\n   <td>Complaints about how hard reading is, or running and hiding when it is time to read</td>\n   </tr>\n   <tr>\n   <td>A history of reading problems in parents or siblings</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">2/26/2008 - Fax permission request\r\n10/10/2008--Permission granted for a 5-year period; figures to Terrence, invoices to Susan (JD).\r\n\r\n The total fee of $&amp;quot;110.00&amp;quot;was originally charged to\r\nClues_RD_early_childhood\r\nClues_RD_2nd_grade_and_up\r\nClues_RD_young_adult</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51022&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Clues_RD_early_childhood.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright © 2003 by Sally Shaywitz, M.D. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For online information about other Random House, Inc. books and authors, see the internet website at www.randomhouse.com.</div><div id=\"graphicVersion\">Graphic 69787 Version 4.0</div></div></div>"},"69788":{"type":"graphic_figure","displayName":"Hypospadias TIP repair","title":"Hypospadias TIP repair (tubularized urethroplasty with or without incision of the urethra plate)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Hypospadias TIP repair (tubularized urethroplasty with or without incision of the urethra plate)</div><div class=\"cntnt\"><img style=\"width:537px; height:705px;\" src=\"images/PEDS/69788_HypospadiasTIPrepair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Proximal hypospadias with a stent in the abnormal urethral meatus. Note the location of the abnormal urethral meatus at the penoscrotal junction. In the initial dissection, a ventral strip of skin (the urethral plate) has been preserved on the penile shaft.<br />(B) In this case, the urethral plate is adequate in width and, therefore, is reconstructed into a tube over the stent, bringing the new urethral meatus to a normal position at the tip of the glans penis.<br />(C) If the urethral plate is not wide enough to be reconstructed into an adequate tube, then the plate can be incised with a relaxing incision, and then sewn into an adequate tube. The raw area that is incised will undergo epithelization during the healing process.<br />(D) The glans penis is reconstructed, and subcutaneous tissue is used to cover the urethra with extra layers to prevent fistula formation.<br />(E) The extra dorsal skin is trimmed and sewn together to complete the hypospadias repair by primary tubularization with or without incision of the urethral plate.</div><div class=\"graphic_footnotes\">TIP: tubularized incised plate.</div><div class=\"graphic_reference\">Reproduced from: Transverse Preputial Onlay Island Flap. In: Hinman's Atlas of Pediatric Urologic Surgery, 2nd ed, Hinman F, Baskin LS (Eds), Elsevier, Oxford 2008. Copyright © 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69788 Version 6.0</div></div></div>"},"69790":{"type":"graphic_figure","displayName":"Cervico-uterine hypoplasia","title":"Uterine/cervical hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine/cervical hypoplasia</div><div class=\"cntnt\"><img style=\"width:406px; height:325px;\" src=\"images/OBGYN/69790_Cervicouterinehypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69790 Version 12.0</div></div></div>"},"69791":{"type":"graphic_diagnosticimage","displayName":"Pseudosac","title":"Endometrial pseudosac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrial pseudosac</div><div class=\"cntnt\"><img style=\"width:354px; height:269px;\" src=\"images/OBGYN/69791_Pseudosac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of the uterus demonstrates a centrally located fluid collection without echogenic ring (arrow), representing a pseudosac. The patient had surgically proven ectopic pregnancy.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 69791 Version 2.0</div></div></div>"},"69792":{"type":"graphic_figure","displayName":"Anatomic criteria for endovascular AAA repair","title":"Anatomic criteria for endovascular abdominal aortic aneurysm repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic criteria for endovascular abdominal aortic aneurysm repair</div><div class=\"cntnt\"><img style=\"width:327px; height:586px;\" src=\"images/SURG/69792_Anatomic_boundary_consid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortic and iliac arterial anatomy boundary conditions defined by the instructions for use that are packaged with each Food and Drug Administration-approved commercial endovascular aortic device.</div><div class=\"graphic_footnotes\">CIA: common iliac artery; EIA: external iliac artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Schanzer A, Greenberg RK, Hevelone N, et al. Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. Circulation 2011; 123:2848. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69792 Version 4.0</div></div></div>"},"69793":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step one","title":"Standard cricothyrotomy step one","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step one</div><div class=\"cntnt\"><img style=\"width:372px; height:320px;\" src=\"images/EM/69793_Cric_standard_step_one.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red color=black><FONT color=black>Immobilize the larynx and palpate the cricothyroid membrane with the index finger of the non-dominant hand.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 69793 Version 3.0</div></div></div>"},"69794":{"type":"graphic_figure","displayName":"The string wrap technique","title":"String wrap method of ring removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">String wrap method of ring removal</div><div class=\"cntnt\"><img style=\"width:307px; height:263px;\" src=\"images/EM/69794_Stringwraptechnique2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The success of this technique depends upon tight, close wrapping of the digit or penis. Do not attempt this technique if the patient has ischemia of the digit or penis or an open wound, fracture, or dislocation distal to the ring. After appropriate analgesia, place one end of a 2.0 or 3.0 suture, Penrose drain, or umbilical tape 20 to 25 inches (0.5 to 0.6 m) in length under the ring from the proximal to the distal side with 5 inches (12.5 cm) of material remaining proximally. Wrap the suture material, drain, or tape tightly around the digit or penis beginning at the distal aspect of the ring. Overlap the wrappings so that no tissue is visible. Continue wrapping beyond the proximal interphalangeal joint of the digit or beyond the coronal sulcus of the penis. Once the wrapping is complete, pull on the proximal end of the wrapping material so that the ring is removed from the finger or penis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69794 Version 11.0</div></div></div>"},"69796":{"type":"graphic_table","displayName":"Sx of hyperparathyroidism","title":"Symptoms and signs of excess parathyroid hormone secretion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of excess parathyroid hormone secretion</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Symptoms and signs of hypercalcemia</td>\n</tr>\n<tr>\n<td>Bone disease</td>\n</tr>\n<tr>\n<td>Nephrolithiasis</td>\n</tr>\n<tr>\n<td>Hypophosphatemia</td>\n</tr>\n<tr>\n<td>Increased production of calcitriol</td>\n</tr>\n<tr>\n<td>Proximal renal tubular acidosis</td>\n</tr>\n<tr>\n<td>Hypomagnesemia</td>\n</tr>\n<tr>\n<td>Hyperuricemia and gout</td>\n</tr>\n<tr>\n<td>Anemia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69796 Version 1.0</div></div></div>"},"69797":{"type":"graphic_picture","displayName":"Diverticulosis fecolith","title":"Fecolith in diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fecolith in diverticulum</div><div class=\"cntnt\"><img style=\"width:287px; height:392px;\" src=\"images/GAST/69797_Diverticulosis_fecolith.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view shows a fecolith within a colonic diverticulum.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 69797 Version 1.0</div></div></div>"},"69798":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of inconclusive mammographic findings - case 1","title":"Breast MRI of inconclusive mammographic findings - case 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast MRI of inconclusive mammographic findings - case 1</div><div class=\"cntnt\"><img style=\"width:384px; height:442px;\" src=\"images/SURG/69798_Br_MRI_incon_mamm_find_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be useful for problem solving in cases with inconclusive clinical or imaging findings.<br />(A) The mammogram shows distortion in the medial right breast, visible only on the CC projection.<br />(B) Breast MRI revealed a suspicious irregular enhancing mass in the medial superior breast. Biopsy confirmed invasive lobular carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CC: craniocaudal.<br /></div><div id=\"graphicVersion\">Graphic 69798 Version 6.0</div></div></div>"},"69799":{"type":"graphic_picture","displayName":"Acrodermatitis continua of Hallopeau","title":"Acrodermatitis continua of Hallopeau","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrodermatitis continua of Hallopeau</div><div class=\"cntnt\"><img style=\"width:356px; height:237px;\" src=\"images/DERM/69799_Acroderm_con_Hallopeau.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, pustules, and nail dystrophy are present on the distal finger.</div><div id=\"graphicVersion\">Graphic 69799 Version 1.0</div></div></div>"},"69800":{"type":"graphic_table","displayName":"Stem cells in medicine","title":"Stem cells in medicine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stem cells in medicine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cell therapy</td> </tr> <tr> <td>Drugs targeting stem cells to induce tissue regeneration</td> </tr> <tr> <td>Models of disease to drive drug therapy development</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69800 Version 1.0</div></div></div>"},"69801":{"type":"graphic_picture","displayName":"Fusarium hyphae","title":"<EM>Fusarium</EM> hyphae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> hyphae</div><div class=\"cntnt\"><img style=\"width:445px; height:337px;\" src=\"images/ID/69801_Fusarium_hyphae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The septate hyaline hyphae of <EM>Fusarium</EM> spp are 3 to 8 microns in diameter and typically branch at acute angles.</div><div id=\"graphicVersion\">Graphic 69801 Version 3.0</div></div></div>"},"69802":{"type":"graphic_picture","displayName":"Nipple inversion associated with malignancy","title":"Nipple inversion associated with malignancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nipple inversion associated with malignancy</div><div class=\"cntnt\"><img style=\"width:397px; height:442px;\" src=\"images/SURG/69802_Nipple_inver_assoc_malig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nipple inversion associated with a malignancy tends to be asymmetric and distorts the areola.</div><div id=\"graphicVersion\">Graphic 69802 Version 1.0</div></div></div>"},"69803":{"type":"graphic_diagnosticimage","displayName":"Lateral view of the lumbar spine showing syndesmophytes","title":"Lateral view of the lumbar spine showing syndesmophytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral view of the lumbar spine showing syndesmophytes</div><div class=\"cntnt\"><img style=\"width:251px; height:584px;\" src=\"images/RHEUM/69803_Lat_view_lumbar_spine_synde.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syndesmophytes are shown in white arrows.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, PLA Hospital, China.</div><div id=\"graphicVersion\">Graphic 69803 Version 2.0</div></div></div>"},"69804":{"type":"graphic_picture","displayName":"Pectus excavat photo","title":"Pectus excavatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pectus excavatum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/69804_Pectus_excavat_photo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pectus excavtum in an adolescent patient demonstrating severe invagination of the lower sternum. The patient had significant exercise intolerance.</div><div class=\"graphic_reference\">Reproduced with permission from: Chung EK. Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69804 Version 3.0</div></div></div>"},"69805":{"type":"graphic_table","displayName":"Histologic features LIP","title":"Histologic features of lymphoid interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of lymphoid interstitial pneumonia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Key histologic features\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diffuse interstitial infiltration of involved areas.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Predominantly alveolar septal distribution.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Infiltrates compromised mostly of T and/or B lymphocytes, plasma cells, and macrophages.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphoid hyperplasia (mucosa-associated lymphoid tissue (MALT) hyperplasia) - frequent.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Pertinent negative findings\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lack of tracking along lymphatic routes (bronchovascular bundles, pleura, and interlobular septa), characteristic of lymphomas.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Organizing pneumonia, inconspicuous or absent.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lack of Dutcher bodies (ie, intranuclear vacuoles containing IgM monoclonal protein seen in Waldenstrom's macroglobulinemia).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lack of monoclonal light chain staining pattern of plasma cells (polyclonal pattern present).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lack of extensive pleural involvement or lymph node involvement.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lack of necrotizing granulomas.</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 69805 Version 1.0</div></div></div>"},"69806":{"type":"graphic_table","displayName":"Radiographic patterns in ILD I","title":"Helpful radiographic patterns in the differential diagnosis of interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful radiographic patterns in the differential diagnosis of interstitial lung disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">End-stage or honeycomb lung</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Upper zone predominance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Pulmonary Langerhans cell histiocytosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Chronic hypersensitivity pneumonitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Lower zone predominance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Idiopathic pulmonary fibrosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Rheumatoid arthritis (associated with usual interstitial pneumonia)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Asbestosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Increased lung volumes</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberous sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis (stage 3)</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary Langerhans cell histiocytosis&nbsp;(chronic, with cyst formation)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Neurofibromatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic hypersensitivity pneumonitis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Reticular or nodular infiltration, increased lung volumes and bullous changes</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberous sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td>Neurofibromatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary Langerhans cell histiocytosis</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic hypersensitivity pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Endstage pulmonary involvement in microscopic polyangiitis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Intravenous drug abuse (Ritalin)</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Associated with pneumothorax</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary Langerhans cell histiocytosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberous sclerosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Pleural involvement</td></tr>\n\t\t\t\t\t\t<tr><td>Asbestosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Connective tissue disorders</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1 sublist1\">Systemic lupus erythematosus</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1 sublist1\">Rheumatoid arthritis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1 sublist1\">Scleroderma</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1 sublist1\">Mixed connective tissue disease</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangitic carcinomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis (chylous effusion)</td></tr>\n\t\t\t\t\t\t<tr><td>Drug-induced (nitrofurantoin)</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis (lymphocytic effusion)</td></tr>\n\t\t\t\t\t\t<tr><td>Radiation pneumonitis (chronic with mediastinal lymphatic obstruction)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Hilar or mediastinal lymphadenopathy</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphoma</td></tr>\n\t\t\t\t\t\t<tr><td>Kaposi's sarcoma</td></tr>\n\t\t\t\t\t\t<tr><td>Methotrexate-induced lung disease</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangitic carcinomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Berylliosis</td></tr>\n\t\t\t\t\t\t<tr><td>Amyloidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Gaucher's disease</td></tr>\n\t\t\t\t\t\t<tr><td>Acute disseminated histoplasmosis</td></tr>\n\t\t\t\t\t\t<tr><td>Acute disseminated coccidioidomycosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Eggshell calcification of lymph nodes</td></tr>\n\t\t\t\t\t\t<tr><td>Silicosis</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Radiation</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69806 Version 1.0</div></div></div>"},"69809":{"type":"graphic_table","displayName":"Immunomodulatory agents pulmonary diseases","title":"Pulmonary diseases associated with immunomodulatory agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary diseases associated with immunomodulatory agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup width=\"76%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Drug class</td> <td class=\"subtitle1_left\">Drug</td> <td class=\"subtitle1_left\">Complications</td> </tr> <tr class=\"divider_top\"> <td class=\"divider_bottom\" rowspan=\"34\"><strong>TNF-alpha inhibitors</strong></td> <td class=\"divider_bottom\" rowspan=\"10\"><strong>Etanercept</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus pleural disease</td> </tr> <tr> <td class=\"indent1\">Pulmonary fibrosis</td> </tr> <tr> <td class=\"indent1\">Granulomatous inflammation</td> </tr> <tr> <td class=\"indent1\">Pneumonitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Exacerbation of interstitial disease</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"19\"><strong>Infliximab</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Bovine tuberculosis</td> </tr> <tr> <td class=\"indent1\">Cryptococcosis</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\">Legionellosis</td> </tr> <tr> <td class=\"indent1\">Invasive and allergic aspergillosis</td> </tr> <tr> <td class=\"indent1\"><em>Scedosporium</em> infection</td> </tr> <tr> <td class=\"indent1\">Actinomycosis</td> </tr> <tr> <td class=\"indent1\"><em>Pneumocystis jirovecii</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Coccidioidomycosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Drug-induced alveolitis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus pleural or parenchymal disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Interstitial pneumonitis</td> </tr> <tr> <td class=\"indent1\">Diffuse alveolar hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fibrosing alveolitis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Adalimumab</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aspergillosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pulmonary fibrosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>IL-1 inhibitor</strong></td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Anakinra</strong></td> <td><strong>Infectious</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Costimulation blockade</strong></td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Abatacept</strong></td> <td><strong>Infectious</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bacterial pneumonia</td> </tr> <tr> <td rowspan=\"3\"><strong>B-cell depletion</strong></td> <td rowspan=\"3\"><strong>Rituximab</strong></td> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class=\"indent1\">Interstitial pneumonitis</td> </tr> <tr> <td class=\"indent1\">Pulmonary fibrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNF-alpha: tumor necrosis factor-alpha; IL-1: interleukin-1.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor alpha therapy. Am J Respir Crit Care Med 2003; 167:1279. </li>&#xD;&#xA;    <li>Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosis presenting as a unilateral pleural effusion. Chest 2008; 134:850. </li>&#xD;&#xA;    <li>Judson MA. Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cell cytokine balance. Chest 2009; 135:1358. </li>&#xD;&#xA;    <li>Larsen MV, Sorensen IJ, Thomsen VO, Ravn P. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J 2008; 32:229. </li>&#xD;&#xA;    <li>Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South Med J 2007; 100:517. </li>&#xD;&#xA;    <li>O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006; 55:978. </li>&#xD;&#xA;    <li>Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006; 33:1189. </li>&#xD;&#xA;    <li>Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395. </li>&#xD;&#xA;    <li>De Rosa FG, Shaz D, Campagna AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24:477. </li>&#xD;&#xA;    <li>Allanore Y, Devos Francosis G, Caramella C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65:834. </li>&#xD;&#xA;    <li>Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated with lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonal 2009; 44:922. </li>&#xD;&#xA;    <li>Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916. </li>&#xD;&#xA;    <li>Biehn SE, Kirk D, Rivera MP, et al. Bronchioltis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkins lymphoma. Hematol Oncol 2006; 24:234. </li>&#xD;&#xA;    <li>Kuru T, Lynch LP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20:623. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69809 Version 6.0</div></div></div>"},"69810":{"type":"graphic_table","displayName":"Treatment goals Steno type 2 study","title":"Treatment goals in the Steno type 2 diabetes study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment goals in the Steno type 2 diabetes study</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Standard</td> <td class=\"subtitle1\">Intensive</td> </tr> <tr> <td>Systolic blood pressure (mmHg)</td> <td class=\"centered\">&#60;160</td> <td class=\"centered\">&#60;140</td> </tr> <tr> <td>Diastolic blood pressure (mmHg)</td> <td class=\"centered\">&#60;95</td> <td class=\"centered\">&#60;85</td> </tr> <tr> <td>HbA1c (percent)</td> <td class=\"centered\">&#60;7.5</td> <td class=\"centered\">&#60;6.5</td> </tr> <tr> <td>Serum triglycerides (mg/dL)</td> <td class=\"centered\">&#60;194</td> <td class=\"centered\">&#60;150</td> </tr> <tr> <td>Serum total cholesterol (mg/dL)</td> <td class=\"centered\">&#60;250</td> <td class=\"centered\">&#60;193</td> </tr> <tr> <td>Serum HDL cholesterol (mg/dL)</td> <td class=\"centered\">&#62;35</td> <td class=\"centered\">&#62;42</td> </tr> <tr> <td>ACE inhibitor therapy independent of blood pressure</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Aspirin therapy in patients with known ischemia</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Aspirin therapy in patients with peripheral vascular disease</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">To convert serum triglyceride values to mmol/L multiply by 0.011, and to convert serum cholesterol values to mmol/L multiply by 0.026.</div><div class=\"graphic_reference\">Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617.</div><div id=\"graphicVersion\">Graphic 69810 Version 5.0</div></div></div>"},"69811":{"type":"graphic_diagnosticimage","displayName":"MRI ganglion cyst","title":"MRI ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI ganglion cyst</div><div class=\"cntnt\"><img style=\"width:429px; height:439px;\" src=\"images/NEURO/69811_MRI_ganglion_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of intraneural ganglion cyst involving the posterior tibial nerve. The cyst is both supra- and infrapatellar.<br />(A) Sagittal T1 image of the knee showing an extensive intraneural ganglion cyst (bracket) of the posterior tibial nerve (arrows). The signal is higher than expected for simple fluid, likely from elevated protein content.<br />(B) With gadolinium administration, there is extensive enhancement of the tumor (bracket) suprapatellar and less extensive below the knee.<br />(C) Axial image showing gadolinium enhancement of the ganglion cyst with neural elements surrounding it.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of James M Gilchrist, MD.</div><div id=\"graphicVersion\">Graphic 69811 Version 3.0</div></div></div>"},"69813":{"type":"graphic_table","displayName":"FDA advisory on vacuum extraction","title":"Food and Drug Administration advisory for caution when using vacuum-assisted delivery devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food and Drug Administration advisory for caution when using vacuum-assisted delivery devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Be sure that persons who use vacuum devices for assisted delivery are versed in their use and that they are aware of the indications, contraindications, and precautions as supported in the accepted literature and current device labeling. </td> </tr> <tr> <td>2. Before using a vacuum-assisted delivery device, read and understand the device's instructions. Pay particular attention to the manufacturer's instructions regarding cup placement, vacuum strength to be used, cumulative duration of applications, and number of recommended extraction attempts. The recommended use for all these products is to apply steady traction in the line of the birth canal. Rocking movements or applying torque to the device may be dangerous. Since the instructions may be different for each device type or style, it is important to use the instructions provided by the manufacturer of the particular product being used.</td> </tr> <tr> <td>3. Alert those who will be responsible for the infant's care that a vacuum-assisted delivery device has been used so that they can monitor the infant for signs of complications.</td> </tr> <tr> <td>4. Educate the neonatal care staff about the complications of vacuum-assisted delivery devices that have been reported to the FDA and in the literature. They should watch for the signs of these complications in any infant in whom a vacuum-assisted delivery device was used.</td> </tr> <tr> <td>5. Report reactions associated with the use of vacuum-assisted delivery devices to the FDA.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">United States Food and Drug Adminsitration, May 21, 1998. http://www.fda.gov/cdrh/fetal598.html.</div><div id=\"graphicVersion\">Graphic 69813 Version 3.0</div></div></div>"},"69814":{"type":"graphic_picture","displayName":"Invasive UC squamous diff","title":"Invasive urothelial carcinoma with squamous differentiation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Invasive urothelial carcinoma with squamous differentiation</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/69814_Invasive_UC_squamous_diff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of intercellular bridges and focal keratinization can be easily appreciated (20x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69814 Version 1.0</div></div></div>"},"69815":{"type":"graphic_figure","displayName":"SEER survival gast CA","title":"Observed survival rates for 10,601 surgically resected gastric adenocarcinomas","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Observed survival rates for 10,601 surgically resected gastric adenocarcinomas</div><div class=\"cntnt\"><img style=\"width:510px; height:552px;\" src=\"images/ONC/69815_SEERsurvivalgastCA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the SEER 1973-2005 Public Use File diagnosed in years 1991 to 2000. Stage IA includes 1194; Stage IB, 655; Stage IIA, 1161; Stage IIB, 1195; Stage IIIA; 1031; Stage IIIB, 1660; Stage IIIC, 1053; and stage IV, 6148.</div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology, and End Results.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 69815 Version 12.0</div></div></div>"},"69816":{"type":"graphic_table","displayName":"Positive vs neg likelihood","title":"Samples of positive and negative likelihood ratios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Samples of positive and negative likelihood ratios</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Poor-fair</td>\n<td class=\"subtitle1\">Good</td>\n<td class=\"subtitle1\">Excellent</td>\n</tr>\n<tr>\n<td>Positive likelihood ratio</td>\n<td>2.1 - 5.0</td>\n<td>5.1 - 10.0</td>\n<td>&#62;10</td>\n</tr>\n<tr>\n<td>Negative likelihood ratio</td>\n<td>0.5 - 0.2</td>\n<td>0.19 - 0.1</td>\n<td>&#60;0.1</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69816 Version 1.0</div></div></div>"},"69817":{"type":"graphic_table","displayName":"Coombs test in AIHA","title":"Significance of the pattern of positive direct antiglobulin (Coombs) test in the diagnosis of autoimmune hemolytic anemia (AIHA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Significance of the pattern of positive direct antiglobulin (Coombs) test in the diagnosis of autoimmune hemolytic anemia (AIHA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anti-IgG</td> <td class=\"subtitle1\">Anti-C3</td> <td class=\"subtitle1\">Occurrence</td> <td class=\"subtitle1\">Antibody</td> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>+</td> <td>-</td> <td>AIHA</td> <td>IgG</td> <td>Rh protein complex</td> <td>Not seen in SLE; aldomet-induced</td> </tr> <tr> <td>+</td> <td>-</td> <td>Drug-induced</td> <td>IgG</td> <td>Drug attached to Rh complex</td> <td>Penicillin and aldomet</td> </tr> <tr> <td>+</td> <td>+</td> <td>Drug-induced</td> <td>IgG</td> <td>?</td> <td>Fludarabine and cogeners</td> </tr> <tr> <td>+</td> <td>+</td> <td>AIHA</td> <td>IgG</td> <td>Glycoprotein</td> <td>Antibody fixes complement</td> </tr> <tr> <td>+</td> <td>+</td> <td>Drug-induced</td> <td>IgG</td> <td>Drug + protein</td> <td>Drug affixed to protein; needed to detect in serum</td> </tr> <tr> <td>-</td> <td>+</td> <td>Drug-induced</td> <td>IgM or IgG</td> <td>Drug + protein</td> <td>Drug not firmly affixed to protein; drug needed to detect serum antibody</td> </tr> <tr> <td>-</td> <td>+</td> <td>AIHA</td> <td>IgG</td> <td>?</td> <td>Antibody of low affinity (may be detected with enzyme treated red cells)</td> </tr> <tr> <td>+</td> <td>+</td> <td>AIHA</td> <td>IgM or IgA</td> <td>?</td> <td>Warm-reacting antibody detected with specific anti-isotype antisera</td> </tr> <tr> <td>-</td> <td>+</td> <td>Cold agglutinin disease</td> <td>IgM</td> <td>Polysaccharide</td> <td>Cold agglutinins in high titer in serum</td> </tr> <tr> <td>-</td> <td>+</td> <td>Paroxysmal cold hemoglobinuria</td> <td>IgG</td> <td>P antigen (polysaccharide)</td> <td>Antibody fixes complement in the cold; hemolysis occurs when sample/patient is warmed; Donath-Landsteiner test may be positive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">C3: complement component 3;&nbsp;IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Courtesy of Wendell F Rosse, MD.</div><div id=\"graphicVersion\">Graphic 69817 Version 6.0</div></div></div>"},"69818":{"type":"graphic_figure","displayName":"Ottawa ankle rules","title":"Ottawa ankle rules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ottawa ankle rules</div><div class=\"cntnt\"><img style=\"width:371px; height:578px;\" src=\"images/EM/69818_Ottawa_ankle_rules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankle films: A series of ankle radiograph films is required only if there is any pain in malleolar zone and any of these findings: bone tenderness at A; bone tenderness at B; inability to bear weight both immediately and in the emergency department.<br />Foot films: A series of foot radiograph films is required only if there is any pain in midfoot zone and any of these findings: bone tenderness at C; bone tenderness at D; inability to bear weight both immediately and in the emergency department.</div><div class=\"graphic_reference\">Modified from Stiell, IG, McKnight, RD, Greenberg, GH, et al, JAMA 1994; 271:827.</div><div id=\"graphicVersion\">Graphic 69818 Version 3.0</div></div></div>"},"69819":{"type":"graphic_figure","displayName":"MHT invasive breast cancer WHI","title":"MHT increases invasive breast cancer","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">MHT increases invasive breast cancer</div><div class=\"cntnt\"><img style=\"width:538px; height:566px;\" src=\"images/ENDO/69819_HRTinvasivebreastCAWHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Women's Health Initiative (WHI), combined estrogen-progestin replacement therapy was associated with a significant increase in invasive breast cancer (unadjusted HR 1.24, 95% CI 1.01-1.54) when compared with placebo.</div><div class=\"graphic_footnotes\">MHT: menopausal hormone therapy; HR: hazard ratio.</div><div class=\"graphic_reference\">Data from: Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003; 289:3243.</div><div id=\"graphicVersion\">Graphic 69819 Version 4.0</div></div></div>"},"69820":{"type":"graphic_figure","displayName":"TSH receptor antibody function","title":"TSH receptor antibodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TSH receptor antibodies</div><div class=\"cntnt\"><img style=\"width:416px; height:280px;\" src=\"images/ENDO/69820_TSH_receptor_antibody_funct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antibodies to the TSH receptor may be stimulatory (eg, in patients with Graves' disease) and cause hyperthyroidism, or inhibitory (eg, in chronic autoimmune thyroiditis) and cause hypothyroidism.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 69820 Version 2.0</div></div></div>"},"69821":{"type":"graphic_diagnosticimage","displayName":"Diffuse esophageal spasm barium swallow","title":"Diffuse esophageal spasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse esophageal spasm</div><div class=\"cntnt\"><img style=\"width:206px; height:358px;\" src=\"images/GAST/69821_Diffuse_esoph_spasm_Ba_swal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This barium swallow in an older man with noncardiogenic chest pain shows multiple areas of spasm (arrows) throughout the length of the esophagus. This spasm was accentuated by stasis within the esophageal lumen and esophagitis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69821 Version 6.0</div></div></div>"},"69824":{"type":"graphic_table","displayName":"Carboplatin plus docetaxel for adv non-small cell lung cancer","title":"Carboplatin plus docetaxel for advanced non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carboplatin plus docetaxel for advanced non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days, for a maximum of six cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Carboplatin</td> <td>AUC* = 6 mg/mL &times; min IV</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#182;</sup> and administer over 30 minutes. Carboplatin should be administered after the completion of docetaxel infusion.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS<sup>&#182;</sup> to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes. Docetaxel should be infused prior to carboplatin.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin and docetaxel are irritants, but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia approximately 4%<sup>[1]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &#62;1.5 &times; ULN in conjunction with alkaline phosphatase &#62;2.5 &times; ULN.</li> <li>Refer to UpToDate topics on \"Dosing of anticancer agents in adults\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each cycle of treatment.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes and liver and renal function prior to each cycle of treatment.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The United States Prescribing Information recommends reducing the dose of carboplatin by 25% if platelets are &#60;50,000/microL and/or ANC is &#60;500 cells/microL.<sup>[3]</sup> Docetaxel should only be administered if the ANC is &#62;1500 cells/microL. A 25% dose reduction of docetaxel is recommended for subsequent cycles in patients who develop severe prolonged neutropenia (&#60;500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences).<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nonhematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>No formal dosing recommendations were reported in the final publication.<sup>[1]</sup> However, dose reductions for each agent may be needed for serious nonhematologic toxicity.</li> <li>Refer to UpToDate topics on \"Carboplatin: Drug information\" and \"Docetaxel: Drug information\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, the dose of docetaxel should be reduced from 75 to 60 mg/m<sup>2</sup>.<sup>[2]</sup> If toxicity persists, treatment should be discontinued.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ULN: upper limit of normal; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.<br />* AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fossella F, et al. J Clin Oncol 2003; 21:3016.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 15, 2011).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 15, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 69824 Version 23.0</div></div></div>"},"69825":{"type":"graphic_figure","displayName":"Reconstruction with an implant PI","title":"Reconstruction with an implant","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Reconstruction with an implant</div><div class=\"cntnt\"><img style=\"width:544px; height:331px;\" src=\"images/PI/69825_Reconstr_implant_ed2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have reconstruction using an implant usually have a device that is similar to a balloon&nbsp;– called an expander&nbsp;– inserted under a layer of muscle. At the same time, they have a piece of mesh called a graft sewn into the muscle. The graft keeps the muscle from being stretched too tightly. Over time, doctors add more and more fluid to the expander. That helps the muscle and skin on the chest stretch, so that it can hold an implant the same size as the other breast. The graft gets absorbed with time.</div><div id=\"graphicVersion\">Graphic 69825 Version 4.0</div></div></div>"},"69827":{"type":"graphic_picture","displayName":"Actinic damage renal transplant","title":"Actinic damage in a renal transplant patient","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Actinic damage in a renal transplant patient</div><div class=\"cntnt\"><img style=\"width:497px; height:264px;\" src=\"images/DERM/69827_Actinic_damage_renal_trans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal transplant patient with actinically damaged skin studded with verruca, actinic keratoses, and early squamous cell carcinoma.</div><div id=\"graphicVersion\">Graphic 69827 Version 2.0</div></div></div>"},"69828":{"type":"graphic_picture","displayName":"Bullous pemphigoid 2","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:396px; height:335px;\" src=\"images/DERM/69828_Bullous_pemphigoid_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 82-year-old female with bullous pemphigoid exhibited pruritic, tense bullae with underlying erythema on the arms, trunk, and legs.</div><div class=\"graphic_reference\">Copyright © Katsuya Hisamichi, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 69828 Version 5.0</div></div></div>"},"69829":{"type":"graphic_figure","displayName":"Detailed anatomy fifth metatarsal","title":"Detailed anatomy fifth metatarsal","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Detailed anatomy fifth metatarsal</div><div class=\"cntnt\"><img style=\"width:508px; height:249px;\" src=\"images/EM/69829_Detailed_anatomy_fifth_meta.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69829 Version 3.0</div></div></div>"},"69831":{"type":"graphic_diagnosticimage","displayName":"Parotid enlarge SS","title":"Parotid gland enlargement in Sjögren's syndrome on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parotid gland enlargement in Sj&#246;gren's syndrome on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:244px; height:356px;\" src=\"images/RHEUM/69831_Parotid_enlarge_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sj&#246;gren's syndrome can lead to massive salivary gland enlargement,&nbsp;which is shown here&nbsp;on magnetic resonance imaging (MRI). MRI studies should be performed with gadolinium and with \"fat subtraction\" to permit evaluation of the ductal system.</div><div class=\"graphic_reference\">Courtesy of Robert Fox, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69831 Version 2.0</div></div></div>"},"69832":{"type":"graphic_figure","displayName":"Sacroiliac tenderness I","title":"Testing for sacroiliac tenderness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing for sacroiliac tenderness</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/RHEUM/69832_Sacroiliac_tenderness_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient can be examined for sacroiliac joint tenderness due to active sacroiliitis by applying direct pressure over each sacroiliac joint.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 69832 Version 2.0</div></div></div>"},"69833":{"type":"graphic_figure","displayName":"Causes of maternal death in the UK","title":"Causes of maternal death in the UK","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Causes of maternal death in the UK</div><div class=\"cntnt\"><img style=\"width:603px; height:671px;\" src=\"images/CARD/69833_Cause_mat_death_UK_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Causes of maternal death in the United Kingdom (2003-2005). Direct maternal deaths are those resulting from conditions or complications or their management which are unique to pregnancy, occurring during the antenatal, intrapartum or postpartum period. Indirect maternal deaths are those resulting from previously existing disease or disease that develops during pregnancy, not due to direct obstetric causes, but which were aggravated by physiologic effects of pregnancy.</div><div class=\"graphic_reference\">Created with data from: Lewis G (Ed). The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer - 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, London 2007.</div><div id=\"graphicVersion\">Graphic 69833 Version 3.0</div></div></div>"},"69834":{"type":"graphic_picture","displayName":"AC Paxinos shear test","title":"Acromioclavicular Paxinos shear test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular Paxinos shear test</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/EM/69834_AC_Paxinos_shear_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A one-handed technique can also be used to exert a shear force across the acromioclavicular joint.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 69834 Version 1.0</div></div></div>"},"69836":{"type":"graphic_table","displayName":"Tamoxifen toxicities NSABP P1","title":"Toxicities of tamoxifen for patients at high risk of breast cancer in NSABP P-01","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicities of tamoxifen for patients at high risk of breast cancer in NSABP P-01</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Adverse event</td>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle1\">Annual\nrate per 1000 women</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">RR (95% CI)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2\" colspan=\"2\">Placebo </td>\n\n      <td class=\"subtitle2\" colspan=\"2\">Tamoxifen</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3\">&#8804;49 years</td>\n\n      <td class=\"subtitle3\">&#8805;50 years</td>\n\n      <td class=\"subtitle3\">&#8804;49 years</td>\n\n      <td class=\"subtitle3\">&#8805;50 years</td>\n\n      <td class=\"subtitle3\">&#8804;49 years</td>\n\n      <td class=\"subtitle3\">&#8805;50 years</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrovascular accident</td>\n\n      <td>0.5</td>\n\n      <td>1.7</td>\n\n\t  <td>0.57</td>\n\t\n\t  <td>2.5</td>\n\t\n\t  <td>1.13 (0.39-3.36)</td>\n\n      <td>1.47 (0.97-2.22)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transient ischemic attack</td>\n\n      <td>0.44</td>\n\n\t  <td>1.10</td>\n\n      <td>0.25</td>\n\n\t  <td>1.09</td>\n\n      <td>0.57 (0.12-2.25)</td>\n\n\t  <td>0.99 (0.56-1.76)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary embolism</td>\n\n      <td>0.13</td>\n\n\t  <td>0.44</td>\n\n      <td>0.25</td>\n\n\t  <td>0.96</td>\n\n      <td>2.01 (0.29-22.19)</td>\n\n \t  <td>2.16 (1.02-4.89)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Deep vein thrombosis</td>\n\n      <td>0.76</td>\n\n\t  <td>0.89</td>\n\t\n\t  <td>1.01</td>\n\n      <td>1.33</td>\n\n      <td>1.34 (0.59-3.10)</td>\n\n\t  <td>1.49 (0.84-2.68)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Invasive endometrial cancer</td>\n\n      <td>0.82</td>\n\n\t  <td>0.58</td>\n\t\n\t  <td>1.16</td>\n\n      <td>3.08</td>\n\n      <td>1.42 (0.55-3.81)</td>\n\n\t  <td>5.33 (2.47-13.17)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">RR: risk ratio for women in the tamoxifen group relative to women in the placebo group; CI: confidence interval.</div><div class=\"graphic_reference\">Data from: Fisher B, et al. J Natl Cancer Inst 2005; 97:1658.</div><div id=\"graphicVersion\">Graphic 69836 Version 2.0</div></div></div>"},"69840":{"type":"graphic_diagnosticimage","displayName":"Solitary pulmonary nodule CT I","title":"Malignant pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:269px; height:261px;\" src=\"images/PULM/69840_Solitary_pulmonary_nodule1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung window setting (from the same patient as radiograph 10) shows scattered spiculations as well as Rigler's notch in this malignant solitary pulmonary nodule. Pleural plaques are again visible (arrows).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69840 Version 2.0</div></div></div>"},"69841":{"type":"graphic_table","displayName":"Causes elevated muscle enzymes","title":"Neuromuscular causes of elevated muscle enzymes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuromuscular causes of elevated muscle enzymes</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inflammatory myopathy</td> </tr> <tr> <td>Dermatomyositis and polymyositis</td> </tr> <tr> <td>Juvenile dermatomyositis and polymyositis</td> </tr> <tr> <td>Myositis with associated connective tissue disease: Sj&#246;gren's syndrome, scleroderma, lupus, rheumatoid arthritis</td> </tr> <tr> <td>Localized myositis</td> </tr> <tr> <td>Inclusion body myositis</td> </tr> <tr> <td>Systemic necrotizing vasculitis</td> </tr> <tr> <td>Polymyositis associated with graft-versus-host disease</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious myopathy</td> </tr> <tr> <td>Bacterial pyomyositis</td> </tr> <tr> <td>Viral myositis</td> </tr> <tr> <td>Mycobacterial myositis</td> </tr> <tr> <td>Fungal myositis</td> </tr> <tr> <td>Parasitic myositis</td> </tr> <tr> <td>Spirochetal myositis</td> </tr> <tr> <td class=\"subtitle1_single\">Dystrophinopathies</td> </tr> <tr> <td>Duchenne</td> </tr> <tr> <td>Becker</td> </tr> <tr> <td>Fascio-scapulo-humeral</td> </tr> <tr> <td>Limb-girdle</td> </tr> <tr> <td>Myotonic dystrophy</td> </tr> <tr> <td>Duchenne and Becker carriers</td> </tr> <tr> <td class=\"subtitle1_single\">Rhabdomyolysis</td> </tr> <tr> <td>Trauma, crush injuries, coma</td> </tr> <tr> <td>Extreme exertion</td> </tr> <tr> <td>Environmental heat illness</td> </tr> <tr> <td>Seizures, delerium tremens</td> </tr> <tr> <td>Electrolyte disturbances: hypokalemia, hypophosphatemia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Colchicine</td> </tr> <tr> <td>Antimalarials</td> </tr> <tr> <td>Penicillamine</td> </tr> <tr> <td>Zidovudine</td> </tr> <tr> <td>Lipid-lowering agents: statins, fibrates, niacin</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Nondepolarizing muscle relaxants with high-dose corticosteroids</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic myopathies</td> </tr> <tr> <td>Carbohydrate metabolism enzyme deficiencies</td> </tr> <tr> <td>Lipid metabolism enzyme deficiencies</td> </tr> <tr> <td>Purine metabolism enzyme deficiencies</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant hyperthermia</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine myopathies</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Acromegaly</td> </tr> <tr> <td class=\"subtitle1_single\">Periodic paralyses</td> </tr> <tr> <td>Familial periodic paralysis</td> </tr> <tr> <td>Thyrotoxic periodic paralysis</td> </tr> <tr> <td class=\"subtitle1_single\">Post-exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td>Intra-muscular injection</td> </tr> <tr> <td>Electromyography</td> </tr> <tr> <td>Intraoperative muscle injury</td> </tr> <tr> <td class=\"subtitle1_single\">Motor neuron disease</td> </tr> <tr> <td>Amyotrophic lateral sclerosis</td> </tr> <tr> <td>Spinal muscular atrophies</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69841 Version 2.0</div></div></div>"},"69842":{"type":"graphic_picture","displayName":"Campylobacter jejuni colonies on CAMPY agar","title":"<EM>Campylobacter jejuni </EM>colonies on CAMPY-agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Campylobacter jejuni </EM>colonies on CAMPY-agar</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/69842_CampylobacteronCAMPYagar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolation of <EM>Campylobacter jejuni </EM>from stool is best accomplished by use of CAMPY-agar, which contains several antibiotics to inhibit normal stool flora. Cultures are incubated at 42ºC in a microaerophilic environment for 48 to 72 hours.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 69842 Version 3.0</div></div></div>"},"69843":{"type":"graphic_table","displayName":"Differential dx CNS TB","title":"Differential diagnosis of central nervous system tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of central nervous system tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Fungal meningitis (cryptococcosis, histoplasmosis, blastomycosis, coccidioidomycosis)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Viral meningoencephalitis (herpes simplex, mumps)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Parameningeal infection (sphenoid sinusitis, brain abscess, spinal epidural abscess)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Partially treated bacterial meningitis</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Neurosyphilis</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Neoplastic meningitis (lymphoma, carcinoma)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Neurosarcoidosis</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Neurobrucellosis</td>\r\n\t\t\t\t</tr>\r\n</tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 69843 Version 2.0</div></div></div>"},"69845":{"type":"graphic_table","displayName":"Fetal mean corpuscular vol by GA","title":"Fetal mean corpuscular volume by gestational age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal mean corpuscular volume by gestational age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">GA</td> <td class=\"subtitle1\">5th percentile</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">95th percentile</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">119</td> <td class=\"centered\">129</td> <td class=\"centered\">140</td> </tr> <tr> <td class=\"centered\">22</td> <td class=\"centered\">114</td> <td class=\"centered\">124</td> <td class=\"centered\">134</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">110</td> <td class=\"centered\">119</td> <td class=\"centered\">130</td> </tr> <tr> <td class=\"centered\">26</td> <td class=\"centered\">107</td> <td class=\"centered\">116</td> <td class=\"centered\">126</td> </tr> <tr> <td class=\"centered\">28</td> <td class=\"centered\">104</td> <td class=\"centered\">113</td> <td class=\"centered\">123</td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">103</td> <td class=\"centered\">112</td> <td class=\"centered\">122</td> </tr> <tr> <td class=\"centered\">32</td> <td class=\"centered\">102</td> <td class=\"centered\">111</td> <td class=\"centered\">121</td> </tr> <tr> <td class=\"centered\">34</td> <td class=\"centered\">102</td> <td class=\"centered\">110</td> <td class=\"centered\">120</td> </tr> <tr> <td class=\"centered\">36</td> <td class=\"centered\">102</td> <td class=\"centered\">110</td> <td class=\"centered\">120</td> </tr> <tr> <td class=\"centered\">38</td> <td class=\"centered\">102</td> <td class=\"centered\">110</td> <td class=\"centered\">120</td> </tr> <tr> <td class=\"centered\">40</td> <td class=\"centered\">102</td> <td class=\"centered\">110</td> <td class=\"centered\">120</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">MCV is measured in femtoliters.</div><div class=\"graphic_footnotes\">GA: gestational age.</div><div id=\"graphicVersion\">Graphic 69845 Version 4.0</div></div></div>"},"69846":{"type":"graphic_table","displayName":"FTT pathophysiologic causes","title":"Causes of failure to thrive, according to pathophysiologic mechanism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of failure to thrive, according to pathophysiologic mechanism</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inadequate nutrient intake</td> </tr> <tr> <td class=\"indent1\">Inappropriate feeding technique</td> </tr> <tr> <td class=\"indent1\">Disturbed caregiver/child relationship</td> </tr> <tr> <td class=\"indent1\">Economic deprivation</td> </tr> <tr> <td class=\"indent1\">Inappropriate nutrient intake (eg, excess fruit juice consumption, factitious food allergy, inappropriate preparation of formula, inadequate quantity of food, inappropriate food for age, neglect, food fads)</td> </tr> <tr> <td class=\"indent1\">Inappropriate parental knowledge of appropriate diet for infants and toddlers</td> </tr> <tr> <td class=\"indent1\">Insufficient lactation in mother</td> </tr> <tr> <td class=\"indent1\">Picky eater</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> </tr> <tr> <td class=\"indent1\">Psychosocial problems</td> </tr> <tr> <td class=\"indent1\">Maternal/infant dysfunction</td> </tr> <tr> <td class=\"indent1\">Mechanical problems (cleft palate, nasal obstruction, adenoidal hypertrophy, dental lesions)</td> </tr> <tr> <td class=\"indent1\">Sucking&nbsp;or swallowing dysfunction (CNS, neuromuscular, esophageal motility problems) or chewing difficulty</td> </tr> <tr> <td class=\"subtitle1_single\">Inadequate appetite or inability to eat large amounts</td> </tr> <tr> <td class=\"indent1\">Oral aversion/problem with certain textures</td> </tr> <tr> <td class=\"indent1\">Psychosocial problems&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">&ndash;</span> apathy or rumination</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary disease</td> </tr> <tr> <td class=\"indent1\">Hypotonia, muscle weakness, or hypertonia</td> </tr> <tr> <td class=\"indent1\">Anorexia of chronic infection or immune deficiency</td> </tr> <tr> <td class=\"indent1\">Cerebral palsy</td> </tr> <tr> <td class=\"indent1\">CNS pathology (eg, tumor, hydrocephalus)</td> </tr> <tr> <td class=\"indent1\">Genetic syndromes</td> </tr> <tr> <td class=\"indent1\">Anemia (eg, iron deficiency)</td> </tr> <tr> <td class=\"indent1\">Chronic constipation</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal disorder (eg, pain from gastroesophageal reflux, intestinal tract obstruction)</td> </tr> <tr> <td class=\"indent1\">Craniofacial anomalies (eg, cleft lip and palate, micrognathia)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inadequate nutrient absorption or increased losses</td> </tr> <tr> <td class=\"indent1\">Malabsorption (lactose intolerance, cystic fibrosis, cardiac disease, malrotation, IBD, milk allergy, parasites, celiac disease)</td> </tr> <tr> <td class=\"indent1\">Biliary atresia, cirrhosis</td> </tr> <tr> <td class=\"indent1\">Vomiting or \"spitting up\" (related to infectious gastroenteritis, increased intracranial pressure, adrenal insufficiency, or drugs [eg, purposeful administration of syrup of ipecac])</td> </tr> <tr> <td class=\"indent1\">Intestinal tract obstruction (pyloric stenosis, hernia, malrotation, intussusception)</td> </tr> <tr> <td class=\"indent1\">Infectious diarrhea</td> </tr> <tr> <td class=\"indent1\">Necrotizing enterocolitis or short bowel syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Increased nutrient requirements or ineffective metabolic utilization</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Malignancy (including brain tumors such as diencephalic syndrome)</td> </tr> <tr> <td class=\"indent1\">Chronic IBD</td> </tr> <tr> <td class=\"indent1\">Chronic systemic disease (juvenile idiopathic arthritis)</td> </tr> <tr> <td class=\"indent1\">Chronic or recurrent systemic infection (urinary tract infection, tuberculosis, toxoplasmosis)</td> </tr> <tr> <td class=\"indent1\">Chronic metabolic problems (hypercalcemia, storage diseases, and inborn errors of metabolism, such as galactosemia, methylmalonic acidemia, diabetes mellitus, adrenal insufficiency)</td> </tr> <tr> <td class=\"indent1\">Chronic respiratory insufficiency (bronchopulmonary dysplasia, cystic fibrosis)</td> </tr> <tr> <td class=\"indent1\">Congenital or acquired heart disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CNS: central nervous system; IBD: inflammatory bowel disease.</div><div id=\"graphicVersion\">Graphic 69846 Version 8.0</div></div></div>"},"69847":{"type":"graphic_picture","displayName":"Occipital encephalocele","title":"Occipital encephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occipital encephalocele</div><div class=\"cntnt\"><img style=\"width:353px; height:282px;\" src=\"images/PEDS/69847_Occipital_encephalocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small skin-covered encephalocele is visible in the occipital region.</div><div class=\"graphic_reference\">Courtesy of Marvin A Fishman, MD.</div><div id=\"graphicVersion\">Graphic 69847 Version 1.0</div></div></div>"},"69848":{"type":"graphic_figure","displayName":"Technique vertical mattress","title":"Technique for placing a vertical mattress suture","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Technique for placing a vertical mattress suture</div><div class=\"cntnt\"><img style=\"width:509px; height:256px;\" src=\"images/EM/69848_Techniqueverticalmattress.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To place a vertical mattress suture, the needle is initially inserted at a distance from the wound edge, exiting through the skin on the opposite side, at an equal distance from the wound edge (far-far). The needle is then rotated 180 degrees in the needle holder and the direction of the suture loop is reversed. On the return, small bites are taken at the epidermal/dermal edges (near-near).</div><div class=\"graphic_reference\">Modified from: McNamara R, DeAngelis M. Laceration repair with sutures, staples, and wound closure tapes. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008.</div><div id=\"graphicVersion\">Graphic 69848 Version 3.0</div></div></div>"},"69849":{"type":"graphic_picture","displayName":"Bone marrow biopsy from a patient with systemic mastocytosis","title":"Bone marrow biopsy from a patient with systemic mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow biopsy from a patient with systemic mastocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/ALLRG/69849_Sys_masto_BM_ckit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mast cells in this bone marrow specimen stain brown for the presence of KIT, the receptor for stem cell factor.</div><div class=\"graphic_reference\">Courtesy of Mariana C Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69849 Version 4.0</div></div></div>"},"69850":{"type":"graphic_picture","displayName":"Plasma cell infiltrate AASLD","title":"Plasma cell infiltrate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma cell infiltrate</div><div class=\"cntnt\"><img style=\"width:384px; height:267px;\" src=\"images/GAST/69850_Plasma_cell_infiltrate_AASL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plasma cells are identified by their eccentric, clock-face nucleus and pale perinuclear cytoplasmic crescent. They are characteristic of autoimmune hepatitis, but neither pathognomonic of the disease or required for its diagnosis. Staining by hematoxylin-eosin; original magnification x 400.</div><div class=\"graphic_reference\">Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2002; 36:479.</div><div id=\"graphicVersion\">Graphic 69850 Version 1.0</div></div></div>"},"69851":{"type":"graphic_diagnosticimage","displayName":"Benign granuloma PA","title":"Benign granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign granuloma</div><div class=\"cntnt\"><img style=\"width:363px; height:302px;\" src=\"images/PULM/69851_Benign_granuloma_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with solitary pulmonary nodule in the right lung, suspicious for lung cancer but proven to represent a coccidioidal granuloma. Chest radiograph shows a subpleural nodule in the lateral segment of the right middle lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69851 Version 2.0</div></div></div>"},"69852":{"type":"graphic_table","displayName":"Poor prognostic features after cardiac arrest","title":"Clinical parameters associated with an unfavorable prognosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical parameters associated with an unfavorable prognosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Clinical parameters</td>\n<td class=\"subtitle1\">Unfavorable prognosis</td>\n</tr>\n<tr>\n<td>Duration of anoxia</td>\n<td>&#62;8-10 minutes</td>\n</tr>\n<tr>\n<td>Duration of CPR</td>\n<td>&#62;30 minutes</td>\n</tr>\n<tr>\n<td>Pupillary light reaction</td>\n<td>Absent on day 3</td>\n</tr>\n<tr>\n<td>Motor response to pain</td>\n<td>Absent on day 3</td>\n</tr>\n<tr>\n<td>Brainstem reflexes</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td>Blood glucose on admission</td>\n<td>&#62;300 mg/dL</td>\n</tr>\n<tr>\n<td>Glascow coma score on day 3</td>\n<td>&#60;5</td>\n</tr>\n<tr>\n<td>GPCS on day 3</td>\n<td>&#60;22</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69852 Version 2.0</div></div></div>"},"69853":{"type":"graphic_picture","displayName":"Toxoplasma chorioretinitis","title":"Toxoplasma chorioretinitis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Toxoplasma chorioretinitis</div><div class=\"cntnt\"><img style=\"width:515px; height:385px;\" src=\"images/RHEUM/69853_Toxoplasma_chorioretinitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chorioretinitis characteristic of toxoplasmosis. A pigmented scar is seen with an adjacent area of active chorioretinitis. The diagnosis of toxoplasmosis is based primarily on the appearance of the chorioretinal lesion rather than serologic studies.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 69853 Version 3.0</div></div></div>"},"69854":{"type":"graphic_figure","displayName":"Endoscopic component separation technique incision placement","title":"Endoscopic component separation technique incision placement","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Endoscopic component separation technique incision placement</div><div class=\"cntnt\"><img style=\"width:485px; height:431px;\" src=\"images/SURG/69854_ECST-incision-placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the placement sites for the two short incisions medial to the anterior iliac spine. This figure also includes the locations of the incisions for insertion of the trochars for the endoscopic approach to the component separation technique.</div><div class=\"graphic_reference\">Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted &quot;components separation&quot; for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.</div><div id=\"graphicVersion\">Graphic 69854 Version 5.0</div></div></div>"},"69856":{"type":"graphic_diagnosticimage","displayName":"Periosteal thickening of tibial stress fracture","title":"Periosteal thickening of tibial stress fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periosteal thickening of tibial stress fracture</div><div class=\"cntnt\"><img style=\"width:256px; height:360px;\" src=\"images/EM/69856_Periosteal_thickening.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cortical thickening and sclerosis are evident at the site of this stress fracture. However, it is important to remember that most plain films taken during the first few weeks following injury will be negative.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 69856 Version 4.0</div></div></div>"},"69857":{"type":"graphic_diagnosticimage","displayName":"Eumycetoma with cavities","title":"Mycetoma with many cavities","html":"<div class=\"graphic\"><div style=\"width: 677px\" class=\"figure\"><div class=\"ttl\">Mycetoma with many cavities</div><div class=\"cntnt\"><img style=\"width:657px; height:368px;\" src=\"images/ID/69857_Eumycetoma_with_cavities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of pedal eumycetoma demonstrating an unusually large number of cavities on the tarsal and metatarsal bones.</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 69857 Version 3.0</div></div></div>"},"69859":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound ARKPD","title":"Prenatal ultrasound ARKPD coronal section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound ARKPD coronal section</div><div class=\"cntnt\"><img style=\"width:396px; height:306px;\" src=\"images/OBGYN/69859_ARKPD1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autosomal recessive polycystic kidney disease (ARPKD)-Bilateral massively enlarged kidneys with no corticomedullary differentiation. Note associated oligohydramnios.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 69859 Version 4.0</div></div></div>"},"69860":{"type":"graphic_picture","displayName":"Urothelial CIS D","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/ONC/69860_Urothelial_CIS_D.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69860 Version 1.0</div></div></div>"},"69861":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma MRI II","title":"Cystic hygroma in infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in infant</div><div class=\"cntnt\"><img style=\"width:396px; height:270px;\" src=\"images/PULM/69861_Cystic_hygroma_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An MR scan, T2-weighted spin echo sequence shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69861 Version 2.0</div></div></div>"},"69862":{"type":"graphic_figure","displayName":"Rest and exercise flow volume loop","title":"Example of rest and peak exercise flow-volume responses in a healthy, average fit adult plotted within the maximal flow-volume loop","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of rest and peak exercise&nbsp;flow-volume responses in a healthy, average fit adult plotted within the maximal flow-volume loop</div><div class=\"cntnt\"><img style=\"width:328px; height:456px;\" src=\"images/PULM/69862_Rest_and_exercise_flow_vol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of rest and peak exercise FV responses in a healthy, average fit adult plotted within the MFVL. Key features of the minute ventilation response in the healthy adult include the following: (1) a drop in the EELV due to the recruitment of expiratory muscles; (2) an increase in Vt through equal encroachment on inspiratory and expiratory reserve volumes (IRV and ERV, respectively); (3) expiratory flow rates generally well within the maximum available flow rates (especially at the higher lung volumes); (4) avoidance of high EILVs (a high elastic load) or extremely low EELVs (reduced compliance and airway closure); and (5) inspiratory flow rates that are well within the maximal available flows.</div><div class=\"graphic_footnotes\">FV: flow volume; MFVL: maximal flow-volume loop; Exp: expiration; ex FVL: tidal flow-volume loop measurement during exercise; FVL: flow-volume loop; EILV: end-inspiratory lung volume; Insp: inspiration; EELV: end-expiratory lung volume; IRV: inspiratory reserve volume; ERV: expiratory reserve volume; rest FVL: flow-volume loop at rest;&nbsp;TLC: total lung capacity.</div><div class=\"graphic_reference\">Reproduced with permission from: Johnson BD, Beck KC, Zeballos J, Weisman IM. Advances in pulmonary laboratory testing. Chest 1999; 116:1377-1387. Copyright &copy; 1999 American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 69862 Version 3.0</div></div></div>"},"69864":{"type":"graphic_picture","displayName":"Myofibroblast on electron microscopy","title":"Myofibroblast on electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Myofibroblast on electron microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:394px;\" src=\"images/SURG/69864_Myofibroblast_elect_micr_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myofibroblast viewed by electron microscopy. Myofibroblasts have an important role in the repair reaction. These cells, with features intermediate between those of smooth muscle cells and fibroblasts, are characterized by the presence of discrete bundles of myofilaments in the cytoplasm (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69864 Version 1.0</div></div></div>"},"69865":{"type":"graphic_table","displayName":"Some genes of interest in schizophrenia","title":"Some genes of interest in schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some genes of interest in schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\" span=\"3\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene name or product</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Hypothesized function</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Catechol-O-methyl transferase</td> <td>COMT</td> <td>Catecholamine (including dopamine) metabolism</td> <td> <p>At position 158 in the resulting protein: a VAL/VAL allele is more active than a VAL/MET or MET/MET allele.</p> The VAL/VAL allele is associated with greater risk of psychosis in cannabis users<sup>[1]</sup>. Position 22q11.</td> </tr> <tr class=\"divider_bottom\"> <td>D-amino acid oxidase activator/D-amino acid oxidase</td> <td>DAOA/G30 and DAO</td> <td>DAO breaks down D-serine, which is an NMDA receptor cofactor</td> <td>DAOA/G30 and DAO are an interacting pair of genes<sup>[2]</sup>​.</td> </tr> <tr class=\"divider_bottom\"> <td>Disrupted in schizophrenia 1</td> <td>DISC1</td> <td>Wide array of hypothesized functions from cell migration during development to dendritic outgrowths and cell adhesion</td> <td>Discovered from studying a Scottish family with many members having a severe mental disorder and also a translocation disrupting the expression of the gene. Position 1q42.</td> </tr> <tr class=\"divider_bottom\"> <td>Dystrobrevin binding protein 1 (dysbindin)</td> <td>DTNBP1</td> <td>Axon stability</td> <td>Also associated with skeletal muscle. Position 6p22.</td> </tr> <tr class=\"divider_bottom\"> <td>Gamma-aminobutyric acid (GABA) A receptor subunit beta 2</td> <td>GABRB2</td> <td>Inhibitory neurotransmission</td> <td>There is evidence of GABA signaling system abnormalities in schizophrenia. Position 5q34.</td> </tr> <tr class=\"divider_bottom\"> <td>Neuregulin 1</td> <td>NRG1</td> <td>Signal transduction related to cell growth and differentiation</td> <td>NRG1 undergoes alternative splicing into several proteins. Position 8p12-21.</td> </tr> <tr> <td>Zinc finger protein 804A</td> <td>ZNF804A</td> <td>Unknown (may be transcription factor)</td> <td> <p>Identified in GWAS study<sup>[3]</sup>.</p> <p>Also associated with bipolar disorders.</p> Examination of rare alleles of the gene found no difference in rates in schizophrenia compared to controls<sup>[4]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-O-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31:2748.</LI>&#xD;&#xA;<LI>Corvin A, McGhee KA, Murphy K, et al. Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:949.</LI>&#xD;&#xA;<LI>O'Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 4:1053.</LI>&#xD;&#xA;<LI>Dwyer S, Williams H, Holmans P, et al. No evidence that rare coding variants in ZNF804A confer risk of schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2010; 153B:1411.</LI></OL></div><div id=\"graphicVersion\">Graphic 69865 Version 3.0</div></div></div>"},"69866":{"type":"graphic_diagnosticimage","displayName":"Greenstick fracture","title":"Greenstick fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Greenstick fracture</div><div class=\"cntnt\"><img style=\"width:317px; height:371px;\" src=\"images/EM/69866_Greenstick_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greenstick fractures of radius and ulna in a 6-year-old boy.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 69866 Version 4.0</div></div></div>"},"69867":{"type":"graphic_table","displayName":"US patterns infectious diarrhea","title":"Sonographic pattern of infectious diarrhea (and important differential diagnosis) with respect to bowel wall thickening in the right and left colon, terminal ileum, mesenteric lymphadenopathy, and fluid filled small bowel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sonographic pattern of infectious diarrhea (and important differential diagnosis) with respect to bowel wall thickening in the right and left colon, terminal ileum, mesenteric lymphadenopathy, and fluid filled small bowel</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Terminal ileum</td>\n\n      <td class=\"subtitle1\">Right colon</td>\n\n      <td class=\"subtitle1\">Left colon</td>\n\n      <td class=\"subtitle1\">Mesenteric lymphadenopathy</td>\n\n      <td class=\"subtitle1\">Fluid filled small bowel</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Salmonella sp</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>+</td>\n\n      <td>(+)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Campylobacter sp</td>\n\n      <td>+(+)</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Yersinia sp</td>\n\n      <td>++</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enterohemorrhagic ecoli</td>\n\n      <td>(+)</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>+</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tuberculosis</td>\n\n      <td>++</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>(+)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pseudomembranous colitis</td>\n\n      <td>-</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Segmental hemorrhagic colitis</td>\n\n      <td>-</td>\n\n      <td>++</td>\n\n      <td>(+)</td>\n\n      <td>(+)</td>\n\n      <td>-</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Antibiotic related diarrhea without colitis</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Whipple's disease</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neutropenic colitis</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>(-)</td>\n\n      <td>-</td>\n\n      <td>(+)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Virus related enteritis*</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cytomegalovirus </td>\n\n      <td>(+)</td>\n\n      <td>++</td>\n\n      <td>+</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Herpes simplex virus </td>\n\n      <td>-</td>\n\n      <td>(+)</td>\n\n      <td>+</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Giardia lamblia infection</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n      <td>(+)</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Amebiasis</td>\n\n      <td>-</td>\n\n      <td>++</td>\n\n      <td>++</td>\n\n      <td>(+)</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ischemic colitis</td>\n\n      <td>-</td>\n\n      <td>+</td>\n\n      <td>++</td>\n\n      <td>-</td>\n\n      <td>-</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Except CMV and Herpes simplex colitis.</div><div id=\"graphicVersion\">Graphic 69867 Version 1.0</div></div></div>"},"69868":{"type":"graphic_table","displayName":"Major causes of TTP, HUS, and related syndromes","title":"Thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and related syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and related syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Childhood syndromes</td> </tr> <tr> <td>Typical HUS: Caused by Shiga toxin-producing <em>Escherichia coli</em>, typically <em>E. coli</em> O157:H7, or <em>Shigella</em> species. Children present with abdominal pain and diarrhea, typically bloody, and acute kidney injury.&nbsp;Ninety percent of childhood HUS.</td> </tr> <tr> <td>Atypical HUS: Acute kidney injury without preceding diarrhea. Some cases may be familial, caused by mutation of genes involved in complement regulation.&nbsp;Ten percent of childhood HUS.</td> </tr> <tr> <td>Hereditary&nbsp;TTP (Upshaw-Schulman syndrome). Caused by mutation(s) in the <em>ADAMTS13</em> gene.</td> </tr> <tr> <td>Acquired autoimmune TTP: Caused by autoantibody inhibition of ADAMTS 13 activity; rare in children.</td> </tr> <tr> <td class=\"subtitle1_single\">Adult syndromes</td> </tr> <tr> <td>Acquired autoimmune TTP:&nbsp;Caused by&nbsp;autoantibody inhibition of ADAMTS 13 activity.</td> </tr> <tr> <td class=\"sublist1_start\">Drug-induced thrombotic microangiopathy (DITMA)</td> </tr> <tr> <td class=\"sublist1\">Immune mediated </td> </tr> <tr> <td class=\"sublist2\">Quinine is the most common cause. </td> </tr> <tr> <td class=\"sublist1\">Dose-dependent toxicity</td> </tr> <tr> <td class=\"sublist2\">Cancer chemotherapy (mitomycin C, gemcitabine, possibly others)</td> </tr> <tr> <td class=\"sublist2\">Immunosuppressive agents (cyclosporine, tacrolimus, sirolimus)</td> </tr> <tr> <td>Following bloody diarrhea caused by Shiga toxin-producing <em>E. coli </em>or <em>Shigella </em>species</td> </tr> <tr> <td>Pregnancy or postpartum: May be indistinguishable from severe preeclampsia, eclampsia, and the HELLP syndromes.</td> </tr> <tr> <td>Hereditary&nbsp;TTP (Upshaw-Schulman syndrome) may present during adulthood, sometimes triggered by another condition (eg, infection, pregnancy).</td> </tr> <tr> <td class=\"sublist1_start\">Autoimmune disorders</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus (SLE) can mimic all features of a thrombotic microangiopathy.&nbsp;Patients may have both TTP caused by severe ADAMTS13 deficiency and SLE.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on the approach to the patient with suspected&nbsp;TTP or HUS and on&nbsp;specific syndromes for further details. </div><div class=\"graphic_footnotes\">TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome.</div><div id=\"graphicVersion\">Graphic 69868 Version 10.0</div></div></div>"},"69869":{"type":"graphic_table","displayName":"Acute stroke differential diagnosis","title":"Acute stroke differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute stroke differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Migraine aura</td> </tr> <tr> <td>Seizure with postictal paresis (Todd paralysis), aphasia, or neglect</td> </tr> <tr> <td>Central nervous system tumor or abscess</td> </tr> <tr> <td>Cerebral venous thrombosis</td> </tr> <tr> <td>Functional deficit (conversion reaction)</td> </tr> <tr> <td>Hypertensive encephalopathy</td> </tr> <tr> <td>Head trauma</td> </tr> <tr> <td>Mitochondrial disorder (eg, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes or MELAS)</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Posterior reversible encephalopathy syndrome (PRES)</td> </tr> <tr> <td>Reversible cerebral vasoconstriction syndromes (RCVS)</td> </tr> <tr> <td>Spinal cord disorder (eg, compressive myelopathy, spinal dural arteriovenous fistula)</td> </tr> <tr> <td>Subdural hematoma</td> </tr> <tr> <td>Syncope</td> </tr> <tr> <td>Systemic infection</td> </tr> <tr> <td>Toxic-metabolic disturbance (eg, hypoglycemia, exogenous drug intoxication)</td> </tr> <tr> <td>Transient global amnesia</td> </tr> <tr> <td>Viral encephalitis (eg, herpes simplex encephalitis)</td> </tr> <tr> <td>Wernicke encephalopathy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69869 Version 7.0</div></div></div>"},"69870":{"type":"graphic_figure","displayName":"Flexion point fetal skull","title":"Flexion point in relation to fetal skull landmarks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexion point in relation to fetal skull landmarks</div><div class=\"cntnt\"><img style=\"width:364px; height:418px;\" src=\"images/OBGYN/69870_Flexion_point_fetal_skull.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flexion point is the location on the fetal head where outward traction pulls the head so as to allow flexion at the neck while keeping the mentovertical diameter in the direction of the birth canal. In the normally molded fetal head, the flexion point is in the midline, over the sagittal suture, approximately 6 cm from the anterior fontanelle and 3 cm from the posterior fontanelle. Since most of the commonly used vacuum cups have a diameter between 50 and 70 mm, when the center of the cup is placed over the flexion point, the edges of the cup should be approximately 3 cm from the anterior fontanelle and just at the edge of the posterior fontanelle. The anterior fontanelle is the reference point for checking the application because access to the posterior fontanelle is partially blocked once the extractor cup is in place.</div><div class=\"graphic_reference\">Modified from: O'Grady PJ, Gimovsky ML, McIIhargie CJ. Vacuum Extraction. Modern Obstetric Practice 1995; 63.</div><div id=\"graphicVersion\">Graphic 69870 Version 4.0</div></div></div>"},"69872":{"type":"graphic_waveform","displayName":"Sinus rhythm tutorial","title":"Sinus rhythm","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"69873":{"type":"graphic_picture","displayName":"Barretts esophagus Endosc","title":"Barrett's esophagus: endoscopic appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus: endoscopic appearance</div><div class=\"cntnt\"><img style=\"width:216px; height:238px;\" src=\"images/GAST/69873_Barretts_esophagus_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows long segments of columnar epithelium extending well above the esophagogastric junction. This is the characteristic endoscopic appearance of Barrett's esophagus.</div><div class=\"graphic_reference\">Courtesy of Stuart J Spechler, MD.</div><div id=\"graphicVersion\">Graphic 69873 Version 2.0</div></div></div>"},"69874":{"type":"graphic_table","displayName":"Bacterial skin infections OLT","title":"Bacterial skin infections after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacterial skin infections after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Bacteria</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Atypical mycobacteria (M. kansasii, M. chelonae, M. fortuitum, M. marinum)</td> <td>Cutaneous lesions most commonly on the extremities. Isolated nodules that have a violet color, are necrotic, or are ulcerative. These lesions can appear months to years after transplantation. The possibility of environmental contamination of the cultures, causing false positive results, should be taken into account. Sequencing the hsp65 gene from the skin biopsy may accelerate the diagnosis and improve its accuracy<sup>[1]</sup>.</td> </tr> <tr> <td>Nocardia</td> <td>Usually appear as subcutaneous abscesses or nodules in association with other manifestations of disseminated nocardiosis.</td> </tr> <tr> <td>Staphylococcus aureus</td> <td>Responsible for pyoderma, wound infections, and toxic shock syndrome.</td> </tr> <tr> <td>Treponema pallidum</td> <td>Skin lesions of secondary syphilis accompanying hepatitis with prolonged fever has been reported following liver transplantation.</td> </tr> <tr> <td>Bartonella henselae</td> <td>Localized bacillary angiomatosis. Skin lesions occur in only 24 percent of cases<sup>[2]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Lau SK, Curreem SO, Ngan AH, et al. First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing. J Clin Microbiol 2011; 49:3733.</li>&#xD;&#xA;    <li>Psarros G, Riddell J 4th, Gandhi T, et al. Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. Medicine (Baltimore) 2012; 91:111.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 69874 Version 4.0</div></div></div>"},"69875":{"type":"graphic_picture","displayName":"Oral paracocci","title":"Oral lesions in chronic paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lesions in chronic paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:251px; height:432px;\" src=\"images/ID/69875_Oral_paracocci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral lesions in a patient with chronic paracoccidioidomycosis. A. Gingivostomatitis. B. Stomatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Shikanai-Yasuda MA, Queiroz Telles Filho F, Mendes RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright ©2006 Sociedade Brasileira de Medicina Tropical.</div><div id=\"graphicVersion\">Graphic 69875 Version 2.0</div></div></div>"},"69879":{"type":"graphic_table","displayName":"Major causes of hypernatremia","title":"Major causes of hypernatremia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypernatremia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Unreplaced water loss (which requires an impairment in either thirst or access to water)</td> </tr> <tr> <td>Insensible and sweat losses</td> </tr> <tr> <td>Gastrointestinal losses</td> </tr> <tr> <td>Central or nephrogenic diabetes insipidus</td> </tr> <tr> <td class=\"sublist1_start\">Osmotic diuresis</td> </tr> <tr> <td class=\"sublist1\">Glucose in uncontrolled diabetes mellitus</td> </tr> <tr> <td class=\"sublist1\">Urea in high-protein tube feedings</td> </tr> <tr> <td class=\"sublist1\">Mannitol</td> </tr> <tr> <td class=\"sublist1_start\">Hypothalamic lesions impairing thirst or osmoreceptor function</td> </tr> <tr> <td class=\"sublist1\">Primary hypodipsia</td> </tr> <tr> <td class=\"sublist1\">Reset osmostat in mineralocorticoid excess</td> </tr> <tr> <td class=\"subtitle1_single\">Water loss into cells</td> </tr> <tr> <td>Severe exercise or seizures</td> </tr> <tr> <td class=\"subtitle1_single\">Sodium overload</td> </tr> <tr> <td>Intake or administration of hypertonic sodium solutions</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69879 Version 3.0</div></div></div>"},"69880":{"type":"graphic_figure","displayName":"Technique for Z-track injection","title":"Technique for Z-track injection","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Technique for Z-track injection</div><div class=\"cntnt\"><img style=\"width:584px; height:420px;\" src=\"images/PSYCH/69880_Technique_Z_track_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Step 1: By blocking the needle pathway after an injection, the Z-track technique allows I.M. injection while minimizing the risk of subcutaneous irritation. The illustrations here show how to perform a Z-track injection. Before the procedure begins, the skin, subcutaneous fat, and muscle lie in their normal positions.<BR>(B) Step 2: To begin, place your finger on the skin surface, and pull the skin and subcutaneous layers out of alignment with the underlying muscle. You should move the skin about 1 cm.<BR>(C) Step 3: Insert the needle at a 90-degree angle approximately 1.5 inches at the site where you initially placed your finger. Inject the drug and withdraw the needle.<BR>(D) Step 4: Finally, remove your finger from the skin surface, allowing the layers to return to their normal positions. The needle track (shown by the dotted line) is now broken at the junction of each tissue layer, trapping the drug in the muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: Nursing Procedures, 4th Edition. Ambler: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69880 Version 3.0</div></div></div>"},"69881":{"type":"graphic_picture","displayName":"Herald patch dark skin 2","title":"Herald patch of pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herald patch of pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:308px; height:396px;\" src=\"images/DERM/69881_Herald_patch_dark_skin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has a herald patch on her chest. Other, smaller lesions can be seen.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69881 Version 2.0</div></div></div>"},"69882":{"type":"graphic_picture","displayName":"Apprehension relocation tests","title":"Anterior shoulder instability tests","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Anterior shoulder instability tests</div><div class=\"cntnt\"><img style=\"width:515px; height:647px;\" src=\"images/EM/69882_Apprehension_relocation_tes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These tests work in combination and are most easily performed with the patient supine. Further details are found in the text.</div><div id=\"graphicVersion\">Graphic 69882 Version 2.0</div></div></div>"},"69885":{"type":"graphic_picture","displayName":"Reactive node vs FL","title":"Reactive lymph node versus follicular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reactive lymph node versus follicular lymphoma</div><div class=\"cntnt\"><img style=\"width:404px; height:288px;\" src=\"images/HEME/69885_Reactive_node_vs_FL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: lymph node with reactive follicular hyperplasia. Discrete follicles, well separated by interfollicular tissue, are disposed predominantly in the cortex. Right panel: lymph node from a patient with follicular lymphoma, showing uniform nodularity throughout the node and little variation in size and shape of the follicles, which show a back-to-back arrangement.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 69885 Version 1.0</div></div></div>"},"69886":{"type":"graphic_waveform","displayName":"ECG Bifascicular block RBBB LAFB","title":"12-lead electrocardiogram (ECG) showing bifascicular block with right bundle branch block and left anterior fascicular block","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing bifascicular&nbsp;block with right bundle branch block and left anterior fascicular block</div><div class=\"cntnt\"><img style=\"width:492px; height:509px;\" src=\"images/CARD/69886_ECG_RBBB_LAFB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG from a patient with a history of an anteroseptal myocardial infarction (Q waves seen in lead V1-V3) shows bifascicular block with RBBB and LAFB.&nbsp;A typical&nbsp;RBBB is seen&nbsp;with a QRS duration of 0.16 seconds and an rSR' configuration in lead V1 and a deep S wave in V6. The QRS complexes in leads II, III, and avF are negative, with a rS morphology, diagnostic of a pathologic left axis deviation, known as LAFB.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; RBBB: right bundle branch block; LAFB: left anterior fascicular block.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 69886 Version 4.0</div></div></div>"},"69887":{"type":"graphic_picture","displayName":"Partial penile glans injury","title":"Partial penile glans injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partial penile glans injury</div><div class=\"cntnt\"><img style=\"width:316px; height:360px;\" src=\"images/PEDS/69887_Partial_penile_glans_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partial glans injury without surgical repair.</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 69887 Version 3.0</div></div></div>"},"69888":{"type":"graphic_table","displayName":"Reasons for adolescent suicide","title":"Percentage of persons aged ≤17 years who reported reasons for attempting suicide*, by age and sex - Oregon, 1990-1993","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of persons aged &le;17 years who reported reasons for attempting suicide*, by age and sex - Oregon, 1990-1993</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Reason</td> <td class=\"subtitle1\" colspan=\"2\">Sex</td> <td class=\"subtitle1\" colspan=\"3\">Age group, years</td> <td class=\"subtitle1\" rowspan=\"2\">Total<sup>&#182;</sup>, n=2231</td> </tr> <tr> <td class=\"subtitle2\">Male n=436</td> <td class=\"subtitle2\">Female, n=1749</td> <td class=\"subtitle2\">&#60;12, n=1001</td> <td class=\"subtitle2\">13-14, n=640</td> <td class=\"subtitle2\">15-17, n=1490</td> </tr> <tr> <td>Family discord</td> <td>53.9</td> <td>60.8</td> <td>73</td> <td>65</td> <td>56.1</td> <td>59.4</td> </tr> <tr> <td>Argument with boyfriend/girlfriend</td> <td>31</td> <td>33</td> <td>8</td> <td>23.1</td> <td>38.3</td> <td>32.6</td> </tr> <tr> <td>School-related problems</td> <td>27.5</td> <td>21.9</td> <td>32</td> <td>26.9</td> <td>20.7</td> <td>23</td> </tr> <tr> <td>Rape/sexual abuse</td> <td>4.1</td> <td>11.2</td> <td>7</td> <td>13</td> <td>8.7</td> <td>9.8</td> </tr> <tr> <td>Peer pressure/conflict</td> <td>7.3</td> <td>8.2</td> <td>10</td> <td>10</td> <td>7</td> <td>8</td> </tr> <tr> <td>Substance abuse</td> <td>15.1</td> <td>6</td> <td>3</td> <td>5.9</td> <td>8.9</td> <td>7.8</td> </tr> <tr> <td>Move or new school</td> <td>5.7</td> <td>6</td> <td>7</td> <td>8.6</td> <td>4.8</td> <td>6</td> </tr> <tr> <td>Legal system encounters</td> <td>14</td> <td>2.6</td> <td>4</td> <td>4.7</td> <td>5</td> <td>4.8</td> </tr> <tr> <td>Death of family member/friend</td> <td>4.8</td> <td>4.5</td> <td>6</td> <td>4.2</td> <td>4.6</td> <td>4.5</td> </tr> <tr> <td>Physical abuse</td> <td>3.7</td> <td>3.3</td> <td>5</td> <td>2.7</td> <td>3.6</td> <td>3.4</td> </tr> <tr> <td>Suicide of friend/relative<sup>&#916;</sup></td> <td>4.4</td> <td>3.1</td> <td>2</td> <td>4.8</td> <td>2.8</td> <td>3.4</td> </tr> <tr> <td>Pregnancy</td> <td>0.9</td> <td>2.7</td> <td>-</td> <td>1.6</td> <td>2.9</td> <td>2.4</td> </tr> <tr> <td>Other reasons</td> <td>15.8</td> <td>14.1</td> <td>9</td> <td>13.9</td> <td>15</td> <td>14.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Categories are not mutually exclusive because more than one reason may have been reported.<br />¶ Includes one person for whom sex and age data were missing.<br />Δ Includes suicide attempts.</div><div class=\"graphic_reference\">Source: Oregon Adolescent Suicide Attempt Data System. 1990 was the first full year the reason for the attempt was collected. Only attempts for which reasons were given are included.<br />Adapted from MMWR Morb Mortal Wkly Rep 1995; 44:312.</div><div id=\"graphicVersion\">Graphic 69888 Version 2.0</div></div></div>"},"69889":{"type":"graphic_picture","displayName":"Pellagra dermatitis","title":"Pellagra dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pellagra dermatitis</div><div class=\"cntnt\"><img style=\"width:369px; height:557px;\" src=\"images/PC/69889_Pellagra_dermatitis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermatitis due to niacin deficiency (pellagra). The term &quot;pellagra&quot; derives from the Italian words for &quot;rough skin&quot;. The condition is characterized by an erythematous, blistering rash that may be pruritic or painful. The rash occurs in areas of sun exposure, and is therefore often seen around the neck (&quot;Casal's necklace&quot;), arms, hands, or malar area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 69889 Version 6.0</div></div></div>"},"69891":{"type":"graphic_diagnosticimage","displayName":"Langerhans histiocytosis CT II","title":"Cystic changes in Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic changes in Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:364px; height:225px;\" src=\"images/PULM/69891_Langerhans_histiocytosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Langerhans cell pulmonary histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasal patchy lower lobe opacities are also part of the disease process.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69891 Version 3.0</div></div></div>"},"69894":{"type":"graphic_table","displayName":"Rx recs pulm histo","title":"Treatment recommendations for pulmonary manifestations of histoplasmosis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment recommendations for pulmonary manifestations of histoplasmosis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Recommendation</td> </tr> <tr> <td rowspan=\"2\">Acute pulmonary: moderately severe to severe</td> <td>Liposomal AmB 3 mg/kg/day IV or AmB lipid complex 5 mg/kg/day IV or AmB deoxycholate* 0.7 to 1 mg/kg/day IV for one to two weeks followed by itraconazole load<sup>&#182;</sup> then 200 mg PO twice daily for a total of 12 weeks</td> </tr> <tr> <td>Methylprednisolone, 0.5 to 1 mg/kg/day IV for one to two weeks for respiratory complications (eg, hypoxemia or respiratory distress)</td> </tr> <tr> <td rowspan=\"2\">Acute pulmonary: mild to moderate</td> <td>Symptoms &#60;4 weeks: none</td> </tr> <tr> <td>Symptoms &#62;4 weeks: itraconazole load<sup>&#182;</sup> then 200 mg once or twice daily for 6 to 12 weeks</td> </tr> <tr> <td>Chronic cavitary pulmonary</td> <td>Itraconazole load<sup>&#182;</sup> then 200 mg once or twice daily for at least 12 months<sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"2\">Mediastinal granuloma</td> <td>Asymptomatic: none</td> </tr> <tr> <td>Symptomatic: itraconazole load<sup>&#182;</sup> then 200 mg once or twice daily for 6 to 12 weeks</td> </tr> <tr> <td rowspan=\"2\">Mediastinal fibrosis</td> <td>Antifungal treatment not recommended<sup>&#916;</sup></td> </tr> <tr> <td>Stenting of obstructed vessels can be useful</td> </tr> <tr> <td rowspan=\"2\">Broncholithiasis</td> <td>None</td> </tr> <tr> <td>Bronchoscopic or surgical removal of the broncholith is recommended</td> </tr> <tr> <td>Pulmonary nodule</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AmB: amphotericin B; IV: intravenously; PO: orally.<br />* The deoxycholate formulation of amphotericin B 0.7 to 1 mg/kg/day is an alternative to a lipid formulation in patients who are at low risk for nephrotoxicity.<br />&para; Itraconazole should be given as a loading dose of 200 mg every eight hours for the first three days.<br />&Delta; If unable to differentiate mediastinal fibrosis from mediastinal granuloma: Itra 200 mg once or twice daily for 6 to 12 weeks.<br /><span class=\"lozenge\">&loz;</span> Concentrations of itraconazole in serum should be monitored in patients being treated for chronic pulmonary histoplasmosis; a random serum concentration &gt;1 mcg/mL should be sought. Drug monitoring is infrequently needed for patients receiving shorter courses of therapy for acute pulmonary histoplasmosis and its complications.</div><div class=\"graphic_reference\">Reproduced with permission from: Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807. Copyright &copy; 2007 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 69894 Version 5.0</div></div></div>"},"69895":{"type":"graphic_picture","displayName":"IgA nephropathy IF","title":"Immunofluorescence microscopy showing mesangial immunoglobulin A (IgA) deposits","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing mesangial immunoglobulin A (IgA) deposits</div><div class=\"cntnt\"><img style=\"width:394px; height:253px;\" src=\"images/NEPH/69895_IgA_nephropathy_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy demonstrating large, globular mesangial IgA deposits that are diagnostic of IgA nephropathy or Henoch-Schönlein purpura (IgA vasculitis). Note that the capillary walls are not outlined since the deposits are primarily limited to the mesangium.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 69895 Version 5.0</div></div></div>"},"69898":{"type":"graphic_picture","displayName":"White piedra","title":"White piedra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">White piedra</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/DERM/69898_White_piedra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple white nodules completely encircling the hair shafts. Groin, axillary, and, less commonly, scalp hair can be involved.</div><div class=\"graphic_reference\">Copyright © Samuel Freire da Silva, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 69898 Version 9.0</div></div></div>"},"69902":{"type":"graphic_figure","displayName":"Dialysis patients with ICDs","title":"Cumulative number and percent of dialysis patients receiving ICDs/CRT-Ds","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Cumulative number and percent of dialysis patients receiving ICDs/CRT-Ds</div><div class=\"cntnt\"><img style=\"width:528px; height:300px;\" src=\"images/NEPH/69902_DialysisptsICDs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Period prevalent dialysis patients.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator; CRT-D: cardiac resynchronization therapy with defibrillator.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Full report available at: <a href=\"http://www.usrds.org/adr.htm\" target=\"_blank\">http://www.usrds.org/adr.htm</a>.</div><div id=\"graphicVersion\">Graphic 69902 Version 4.0</div></div></div>"},"69903":{"type":"graphic_diagnosticimage","displayName":"TEE right atrial appendage","title":"Right atrium and appendage on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Right atrium and appendage on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:478px; height:341px;\" src=\"images/CARD/69903_TEE_right_atrial_appendage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal (0º) imaging plane with advancement of the probe towards the gastroesophageal junction with slight anterior rotation demonstrates the right atrium (RA) and right atrial appendage (RAA, panel A). In panel B, the probe is rotated posteriorly and the RA and coronary sinus (CS) are seen. With further advancement of the probe (panel C), the right ventricle (RV) and tricuspid valve (TV) are seen.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 69903 Version 2.0</div></div></div>"},"69904":{"type":"graphic_figure","displayName":"Dirofilaria repens life cycle","title":"<em>Dirofilaria repens</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\"><em>Dirofilaria repens</em> life cycle</div><div class=\"cntnt\"><img style=\"width:564px; height:477px;\" src=\"images/ID/69904_Dirofilaria_repens_life_cyc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal, an infected mosquito (<em>Aedes</em>, <em>Anopheles</em>, <em>Culex</em>, <em>Mansonia</em>) introduces third-stage filarial larvae of <em>Dirofilaria repens</em> onto the skin of the canine definitive host (but also occasionally humans, especially in Europe), where they penetrate into the bite wound <strong>(1)</strong>. In the definitive host, the L3 larvae undergo two more molts into L4 and adults, the latter of which resides in subcutaneous tissues <strong>(2)</strong>. Adult females are usually 100 to 170 mm long by 460 to 650 micrometers wide; males are usually 50 to 70 mm long by 370 to 450 micrometers wide. Adults can live for 5 to 10 years. In subcutaneous tissue, the female worms are capable of producing microfilariae over their lifespan. The microfilariae are found in peripheral blood <strong>(3)</strong>. A mosquito ingests the microfilariae during a blood meal <strong>(4)</strong>. After ingestion, the microfilariae migrate from the mosquito's midgut through the hemocoel to the Malpighian tubules in the abdomen <strong>(5)</strong>. There the microfilariae develop into first-stage larvae <strong>(6)</strong> and subsequently into third-stage infective larvae <strong>(7)</strong>. The third-stage infective larvae migrate to the mosquito's proboscis <strong>(8)</strong> and can infect another definitive host when it takes a blood meal <strong>(1)</strong>. In humans <strong>(9)</strong>, <em>D. repens</em> usually manifests as either a wandering worm in the subcutaneous tissue or a granulomatous nodule, although there are reports of pulmonary dirofilariasis with this species.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dirofilariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/dirofilariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/dirofilariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 69904 Version 4.0</div></div></div>"},"69905":{"type":"graphic_figure","displayName":"Left right face positions","title":"Left and right positions in face presentations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left and right positions in face presentations</div><div class=\"cntnt\"><img style=\"width:442px; height:310px;\" src=\"images/OBGYN/69905_Left_right_face_positions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left mentum anterior, right mentum anterior, and right mentum posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Dystocia Caused by abnormalities in Presentation, Position, or Development of the Fetus. In: Williams Obstetrics, 16th Edition, Pritchard, JA, MacDonald, PC (Eds), Appleton-Century-Crofts, New York 1980. p.808. Copyright © 1980 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 69905 Version 3.0</div></div></div>"},"69907":{"type":"graphic_table","displayName":"Characteristics of stroke subtypes","title":"Characteristics of stroke subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of stroke subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Stroke type</td>\r\n            <td class=\"subtitle1\">Clinical course</td>\r\n            <td class=\"subtitle1\">Risk factors</td>\r\n            <td class=\"subtitle1\">Other clues</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Intracerebral hemorrhage</td>\r\n            <td>Gradual progression during minutes or hours</td>\r\n            <td>Hypertension, trauma, bleeding diatheses, illicit drugs (eg, amphetamines, cocaine), vascular malformations. More common in blacks and Asians than in whites.</td>\r\n            <td>May be precipitated by sex or other physical activity. Patient may have reduced alertness.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Subarachnoid hemorrhage</td>\r\n            <td>Abrupt onset of sudden, severe headache. Focal brain dysfunction less common than with other types.</td>\r\n            <td>Smoking, hypertension,&nbsp;moderate to heavy alcohol use, genetic susceptibility (eg, polycystic kidney disease,&nbsp;family history of subarachnoid hemorrhage) and sympathomimetic drugs (eg, cocaine)</td>\r\n            <td>May be precipitated by sex or other physical activity. Patient may have reduced alertness.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ischemic (thrombotic)</td>\r\n            <td>Stuttering progression with periods of improvement. Lacunes develop over hours or at most a few days; large artery ischemia may evolve over longer periods.</td>\r\n            <td>Atherosclerotic risk factors (age, smoking, diabetes mellitus, etc.). Men affected more commonly than women. May have history of TIA.</td>\r\n            <td>May have neck bruit.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ischemic (embolic)</td>\r\n            <td>Sudden onset with deficit maximal at onset. Clinical findings may improve quickly.</td>\r\n            <td>Atherosclerotic risk factors as listed above. Men affected more commonly than women. History of heart disease (valvular, atrial fibrillation, endocarditis).</td>\r\n            <td>Can be precipitated by getting up at night to urinate, or sudden coughing or sneezing.</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 69907 Version 3.0</div></div></div>"},"69908":{"type":"graphic_table","displayName":"ILD with BAL lymphocytosis","title":"Interstitial lung disease associated with BAL lymphocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interstitial lung disease associated with BAL lymphocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hypersensitivity pneumonitis (60 to 80 percent)</td> </tr> <tr> <td>Sarcoidosis (Acute - 40 to 60 percent)</td> </tr> <tr> <td>Idiopathic pulmonary fibrosis (15 to 30 percent)</td> </tr> <tr> <td>Berylliosis</td> </tr> <tr> <td>Granite workers</td> </tr> <tr> <td>Amiodarone pneumonitis</td> </tr> <tr> <td>Lymphoma/Pseudolymphoma</td> </tr> <tr> <td>Pulmonary Langerhans cell histiocytosis (Early)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div id=\"graphicVersion\">Graphic 69908 Version 2.0</div></div></div>"},"69909":{"type":"graphic_diagnosticimage","displayName":"NSCLC liver met PET","title":"Liver metastasis-PET","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver metastasis-PET</div><div class=\"cntnt\"><img style=\"width:396px; height:326px;\" src=\"images/PULM/69909_NSCLC_liver_met_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 76-year-old woman with a right upper lobe mass and this PET-CT of the liver showing multiple areas of hypermetabolic activity. Ultrasound guided needle aspirate of the liver revealed metastatic adenocarcinoma.</div><div class=\"graphic_footnotes\">PET-CT: positron emission tomography-computed tomography.</div><div id=\"graphicVersion\">Graphic 69909 Version 3.0</div></div></div>"},"69910":{"type":"graphic_table","displayName":"Immune functions of cytokines","title":"Contributions of important cytokines to immunologic responses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contributions of important cytokines to immunologic responses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Critical functions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cytokine</td> </tr> <tr> <td class=\"indent1\">IL-1</td> <td>Macrophage<br /> Many cells</td> <td>Fever, induces other cytokines, T cell stimulation<br /> Induces metalloproteinases and prostglandins<br /> Increases adhesion molecule expression</td> </tr> <tr> <td class=\"indent1\">IL-2</td> <td>T cells</td> <td>Increase T cell proliferation, activates B cells</td> </tr> <tr> <td class=\"indent1\">IL-4</td> <td>T cells</td> <td>Signal for immunoglobulin switch, increases IgE<br /> Decreases production of proinflammatory cytokines<br /> Suppresses delayed type hypersensitivity (Th1 cells)</td> </tr> <tr> <td class=\"indent1\">IL-6</td> <td>Many cells</td> <td>B and T cell proliferation, acute phase reactants<br /> Induces natural protease inhibitor (TIMP)</td> </tr> <tr> <td class=\"indent1\">IL-12</td> <td>Macrophages</td> <td>Increase IFN-gamma production and Th1 cell differentiation</td> </tr> <tr> <td class=\"indent1\">IL-13</td> <td>T cells</td> <td>Similar to IL-4</td> </tr> <tr> <td class=\"indent1\">IL-15</td> <td>T cells<br /> Macrophages</td> <td>Induces TNF-alpha release from synovial macrophages, induces mitogenesis, and inhibits apoptosis</td> </tr> <tr> <td class=\"indent1\">IL-17</td> <td>T cells<br /> Innate lymphoid cells&nbsp;</td> <td>Activates neutrophils and a variety of stromal cells to regulate host defense and also matrix disruption</td> </tr> <tr> <td class=\"indent1\">IL-23</td> <td>Dendritic cells<br /> Macrophages</td> <td>Promotes T cell differentiation, particularly of the Th17 type</td> </tr> <tr> <td class=\"indent1\">TNF-alpha</td> <td>T cells<br /> Macrophages</td> <td>Cachexia, induces other cytokines, T cell stimulation<br /> Induces metalloproteinases and prostaglandins<br /> Increases adhesion molecule expression</td> </tr> <tr> <td class=\"indent1\">IFN-gamma</td> <td>T cells</td> <td>Adhesion molecules, HLA-DR expression, activation of T cells, NK cells, macrophages</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Colony-stimulating factors</td> </tr> <tr> <td class=\"indent1\">GM-CSF</td> <td>Macrophages<br /> Fibroblasts<br /> T cells</td> <td>Myeloid differentiation, macrophage activation</td> </tr> <tr> <td class=\"indent1\">G-CSF</td> <td>Macrophages</td> <td>Granulocyte differentiation and activation</td> </tr> <tr> <td class=\"indent1\">M-CSF</td> <td>Macrophages</td> <td>Myeloid differentiation, macrophage activation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chemokines</td> </tr> <tr> <td class=\"indent1\">C-X-C family</td> <td>Many cells</td> <td>Activate neutrophils, chemotactic to neutrophil (IL-8, ENA-78, etc) and T cells</td> </tr> <tr> <td class=\"indent1\">C-C family</td> <td>Many cells</td> <td>Chemotactic for monocytes and T cells (MCP-1, MIP-1, etc)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Growth factors</td> </tr> <tr> <td class=\"indent1\">TGF-beta</td> <td>Many cells</td> <td>Fibroblast proliferation, collagen and TIMP synthesis<br /> Decrease metalloproteinases, decreases T cell proliferation<br /> Angiogenesis, decreased proinflammatory cytokines</td> </tr> <tr> <td class=\"indent1\">FGF, VEGF</td> <td>Many cells</td> <td>Fibroblast proliferation, angiogenesis</td> </tr> <tr> <td class=\"indent1\">PDGF</td> <td>Many cells</td> <td>Fibroblast proliferation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IL: interleukin; IgE: immunoglobulin E; Th1: T helper type 1; TIMP: tissue inhibitor of metalloproteinase; IFN-gamma: interferon gamma; TFN-alpha: tumor necrosis factor alpha; Th17: T helper type 17; HLA: human leukocyte antigen; NK: natural killer; GM-CSF: granulocyte-macrophage colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; M-CSF: macrophage colony-stimulating factor. C-X-C family: chemokines with two N-terminal cysteines (C)&nbsp;separated by one amino acid (X); ENA-78: epithelial cell-derived neutrophil-activating peptide; C-C family: chemokines with two N-terminal cysteines (C); MCP-1: monocyte chemotactic protein-1; MIP-1: macrophage inflammatory protein 1; TGF-beta:&nbsp;transforming growth factor beta; FGF: fibroblast growth factor; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor.</div><div id=\"graphicVersion\">Graphic 69910 Version 3.0</div></div></div>"},"69912":{"type":"graphic_figure","displayName":"Thiazide side effects and dose","title":"Dose dependence of thiazide-induced side effects","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Dose dependence of thiazide-induced side effects</div><div class=\"cntnt\"><img style=\"width:488px; height:220px;\" src=\"images/NEPH/69912_Thiazide_side_effects_and_d.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metabolic complications induced by bendrofluazide in relation to daily dose (multiply by 10 to get equivalent doses of hydrochlorothiazide). Increasing the dose led to progressive hypokalemia and hyperuricemia and a greater likelihood of a mild elevation in the FBG, all without a further reduction in the systemic blood pressure. Each treatment group contained approximately 52 patients.</div><div class=\"graphic_footnotes\">FBG: fasting blood glucose.</div><div class=\"graphic_reference\">Data from: Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.</div><div id=\"graphicVersion\">Graphic 69912 Version 5.0</div></div></div>"},"69915":{"type":"graphic_diagnosticimage","displayName":"Intracranial epidural abscess by CT","title":"Intracranial epidural abscess by CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracranial epidural abscess by CT</div><div class=\"cntnt\"><img style=\"width:288px; height:270px;\" src=\"images/ID/69915_Intracranial_epidural_absce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial contrast-enhanced CT scan in a 36-year-old woman with frontal sinusitis who has developed headache and fever. There is a large peripherally enhancing extraaxial fluid collection in the anterior cranial fossa. The biconvex shape is a classic finding with an epidural empyema.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Andrew L Wagner, MD.</div><div id=\"graphicVersion\">Graphic 69915 Version 4.0</div></div></div>"},"69916":{"type":"graphic_table","displayName":"Strategies to prevent VAP","title":"Summary of recommendations for preventing ventilator-associated pneumonia (VAP) in adult patients — Society for Healthcare Epidemiology of America/Infectious Diseases Society of America (SHEA/IDSA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for preventing ventilator-associated pneumonia (VAP) in adult patients &mdash; Society for Healthcare Epidemiology of America/Infectious Diseases Society of America (SHEA/IDSA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendation</td> <td class=\"subtitle1\">Rationale</td> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Quality of evidence</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Basic practices</td> <td class=\"divider_bottom\" rowspan=\"9\">Good evidence that the intervention decreases the average duration of mechanical ventilation, length of stay, mortality, and/or costs; benefits likely outweigh risks</td> <td>Use noninvasive positive pressure ventilation in selected populations</td> <td class=\"centered\">High</td> </tr> <tr> <td>Manage patients without sedation whenever possible</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Interrupt sedation daily</td> <td class=\"centered\">High</td> </tr> <tr> <td>Assess readiness to extubate daily</td> <td class=\"centered\">High</td> </tr> <tr> <td>Perform spontaneous breathing trials with sedatives turned off</td> <td class=\"centered\">High</td> </tr> <tr> <td>Facilitate early mobility</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Utilize endotracheal tubes with subglottic secretion drainage ports for patients expected to require greater than 48 or 72 hours of mechanical ventilation</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Change the ventilator circuit only if visibly soiled or malfunctioning</td> <td class=\"centered\">High</td> </tr> <tr class=\"divider_bottom\"> <td>Elevate the head of the bed to 30 to 45&#176;</td> <td class=\"centered\">Low*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Special approaches</td> <td>Good evidence that the intervention improves outcomes but insufficient data available on possible risks</td> <td>Selective oral or digestive decontamination</td> <td class=\"centered\">High<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">May lower VAP rates but insufficient data to determine impact on duration of mechanical ventilation, length of stay, or mortality</td> <td>Regular oral care with chlorhexidine</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Prophylactic probiotics</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Ultrathin polyurethane endotracheal tube cuffs</td> <td class=\"centered\">Low</td> </tr> <tr> <td>Automated control of endotracheal tube cuff pressure</td> <td class=\"centered\">Low</td> </tr> <tr> <td>Saline instillation before tracheal suctioning</td> <td class=\"centered\">Low</td> </tr> <tr class=\"divider_bottom\"> <td>Mechanical tooth brushing</td> <td class=\"centered\">Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Generally not recommended</td> <td rowspan=\"3\">Lowers VAP rates but ample data suggest no impact on duration of mechanical ventilation, length of stay, or mortality</td> <td>Silver-coated endotracheal tubes</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Kinetic beds</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Prone positioning</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">No impact on VAP rates, average duration of mechanical ventilation, length of stay, or mortality<sup>&#916;</sup></td> <td>Stress ulcer prophylaxis</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>Early tracheotomy</td> <td class=\"centered\">High</td> </tr> <tr> <td>Monitoring residual gastric volumes</td> <td class=\"centered\">Moderate</td> </tr> <tr class=\"divider_bottom\"> <td>Early parenteral nutrition</td> <td class=\"centered\">Moderate</td> </tr> <tr> <td>No recommendation</td> <td>No impact on VAP rates or other patient outcomes, unclear impact on costs</td> <td>Closed/in-line endotracheal suctioning</td> <td class=\"centered\">Moderate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There are very little data on head-of-bed elevation, but it is classified as a basic practice because of its simplicity, ubiquity, low cost, and potential benefit.<br />&para; There are abundant data on the benefits of digestive decontamination but insufficient data on the long-term impact of this strategy on antimicrobial resistance rates.<br />&Delta; May be indicated for reasons other than VAP prevention.</div><div class=\"graphic_reference\">Adapted with permission: Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35:915. Copyright © 2014 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 69916 Version 9.0</div></div></div>"},"69917":{"type":"graphic_picture","displayName":"Intentional human bite","title":"Intentional human bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intentional human bite</div><div class=\"cntnt\"><img style=\"width:440px; height:260px;\" src=\"images/EM/69917_Intentionalhumanbite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B) A 3-year-old boy with human bites on his back.</div><div class=\"graphic_reference\">Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 69917 Version 12.0</div></div></div>"},"69920":{"type":"graphic_figure","displayName":"Coagulation cascade detailed/traditional view","title":"Coagulation cascade detailed/traditional view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coagulation cascade detailed/traditional view</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/HEME/69920_Coagulationcascade.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the coagulation cascade including our improved understanding of the role of the tissue factor (TF) pathway in initiating clotting; interactions between pathways; and the role of thrombin in sustaining the cascade by feedback activation of coagulation factors.</div><div class=\"graphic_footnotes\">HK: high-molecular-weight kininogen; PK: prekallikrein; PL: phospholipid.</div><div class=\"graphic_reference\">Adapted from: Ferguson et al. Eur Heart J 1998; Suppl 19:8.</div><div id=\"graphicVersion\">Graphic 69920 Version 8.0</div></div></div>"},"69924":{"type":"graphic_figure","displayName":"Collagen synthesis and tensile strength","title":"Collagen synthesis and tensile strength","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Collagen synthesis and tensile strength</div><div class=\"cntnt\"><img style=\"width:608px; height:405px;\" src=\"images/SURG/69924_Collagen_synthesis_tenisle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation of the rate of collagen synthesis to the gain of tensile strength of rat skin wounds.</div><div class=\"graphic_reference\">Reproduced from: Madden JW, Peacock EE Jr. Studies on the biology of collagen during wound healing. 1. Rate of collagen synthesis and deposition in cutaneous wounds of the rat. Surgery 1968; 64:288. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 69924 Version 2.0</div></div></div>"},"69925":{"type":"graphic_figure","displayName":"Water manometer for pleural pressure measurement","title":"Water manometer for pleural pressure measurement","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Water manometer for pleural pressure measurement</div><div class=\"cntnt\"><img style=\"width:563px; height:412px;\" src=\"images/PULM/69925_Water_manometer_pl_press_mm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A schematic diagram illustrating the complete pleural manometer setup.</div><div class=\"graphic_footnotes\">PC: personal computer.</div><div class=\"graphic_reference\">Reproduced with permission from the American College of Chest Physicians. Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764. Copyright © 2004.</div><div id=\"graphicVersion\">Graphic 69925 Version 3.0</div></div></div>"},"69926":{"type":"graphic_figure","displayName":"Flow cytometric analysis for MSMD","title":"Flow cytometric analysis for mendelian susceptibility to mycobacterial disease","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Flow cytometric analysis for mendelian susceptibility to mycobacterial disease</div><div class=\"cntnt\"><img style=\"width:662px; height:432px;\" src=\"images/ALLRG/69926_Flow_cyto_analysis_MSMD_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whole blood peripheral blood mononuclear cells (PBMCs) were stained with antibodies to IFN-gamma-R1 or IL-12-R-beta-1, respectively (top panels). Loss of these proteins is seen in mendelian susceptibility to mycobacterial diseases.<br />Bottom panels represent defective phosphorylation of STAT1 in response to IFN-gamma (left) or STAT4 in response to IL-12 (right).</div><div class=\"graphic_footnotes\">IFN-gamma-R1: interferon-gamma-receptor 1; IL-12-R-beta-1: interleukin-12-receptor-beta-1; STAT: signal transducer and activator of transcription.</div><div id=\"graphicVersion\">Graphic 69926 Version 3.0</div></div></div>"},"69928":{"type":"graphic_waveform","displayName":"12-lead ECG left anterior lateral WPW","title":"12-lead electrocardiogram (ECG) of a left anterior lateral accessory pathway","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a left anterior lateral accessory pathway</div><div class=\"cntnt\"><img style=\"width:502px; height:280px;\" src=\"images/CARD/69928_Left_anterior_lateral_WPW.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram during atrial pacing in a patient with the Wolff-Parkinson-White syndrome shows QRS complexes that are maximally preexcited. The PR interval is short, there is a right bundle branch morphology, and the axis is rightward. The delta wave is positive in the lateral leads I, avL, and V6, localizing the pathway to the left anterior lateral region.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 69928 Version 3.0</div></div></div>"},"69929":{"type":"graphic_table","displayName":"Four habits model","title":"Approach to effective clinical communication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to effective clinical communication</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Habit</td>\n\t\t\t\t\t<td class=\"subtitle1\">Skills</td>\n\t\t\t\t\t<td class=\"subtitle1\">Techniques and examples</td>\n\t\t\t\t\t<td class=\"subtitle1\">Payoff</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"3\">Invest in the beginning</td>\n\t\t\t\t\t<td>Create rapport quickly</td>\n\t\t\t\t\t<td><p>&#8226; Introduce self to everyone in the room</p>\n\t\t\t\t\t\t<p>&#8226; Acknowledge patient wait time, if appropriate</p>\n\t\t\t\t\t\t<p>&#8226; Convey knowledge of patient's history by commenting on prior visit or problem</p>\n\t\t\t\t\t\t<p>&#8226; Attend to patient's comfort</p>\n\t\t\t\t\t\t<p>&#8226; Make a social comment or ask a nonmedical question to put patient at ease</p>\n\t\t\t\t\t\t<p>&#8226; Adapt own language, pace, and posture in response to patient</p></td>\n\t\t\t\t\t<td rowspan=\"3\"><p>&#8226; Establishes a welcoming atmosphere</p>\n\t\t\t\t\t\t<p>&#8226; Allows faster access to real reason for visit</p>\n\t\t\t\t\t\t<p>&#8226; Increases diagnostic accuracy</p>\n\t\t\t\t\t\t<p>&#8226; Requires less work</p>\n\t\t\t\t\t\t<p>&#8226; Minimizes \"Oh, by the way...\" at the end of visit</p>\n\t\t\t\t\t\t<p>&#8226; Facilitates negotiating an agenda</p>\n\t\t\t\t\t\t<p>&#8226; Decreases potential for conflict</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Elicit patient's concerns</td>\n\t\t\t\t\t<td><p>&#8226; Start with open-ended questions:</p>\n\t\t\t\t\t\t<p>&nbsp;&nbsp;- \"What would you like help with today?\" OR,</p>\n\t\t\t\t\t\t<p>&nbsp;&nbsp;- \"I understand that you're here for... Could you tell me more about that?\"</p>\n\t\t\t\t\t\t<p>&nbsp;&nbsp;- \"What else?\"</p>\n\t\t\t\t\t\t<p>&#8226; Speak directly with patient when using an interpreter</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plan the visit with the patient</td>\n\t\t\t\t\t<td><p>&#8226; Repeat concerns back to check understanding</p>\n\t\t\t\t\t\t<p>&#8226; Let patient know what to expect: \"How about if we start with talking more about..., then I'll do an exam, and then we'll go over possible tests/ways to treat this? Sound OK?\"</p>\n\t\t\t\t\t\t<p>&#8226; Prioritize when necessary: \"Let's make sure we talk about X and Y.  It sounds like you also want to make sure we cover Z.  If we can't get to the other concerns, let's...\"</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"3\">Elicit the patient's perspective</td>\n\t\t\t\t\t<td>Ask for patient's ideas</td>\n\t\t\t\t\t<td><p>&#8226; Assess patient's point of view:</p>\n\t\t\t\t\t\t<p>&nbsp;&nbsp;- \"What do you think is causing your symptoms?</p>\n\t\t\t\t\t\t<p>&nbsp;&nbsp;- \"What worries you most about this problem?\"</p>\n\t\t\t\t\t\t<p>&#8226; Ask about ideas from significant others</p></td>\n\t\t\t\t\t<td rowspan=\"3\"><p>&#8226; Respects diversity</p>\n\t\t\t\t\t\t<p>&#8226; Allows patient to provide important diagnostic clues</p>\n\t\t\t\t\t\t<p>&#8226; Uncovers hidden concerns</p>\n\t\t\t\t\t\t<p>&#8226; Reveals use of alternative treatments or requests for tests</p>\n\t\t\t\t\t\t<p>&#8226; Improves diagnosis of depression and anxiety</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Elicit specific requests</td>\n\t\t\t\t\t<td>&#8226; Determine patient's goal in seeking care: \"When you've been thinking about this visit, how were you hoping I could help?\"</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Explore the impact on the patient's life</td>\n\t\t\t\t\t<td>&#8226; Check context: \"How has the illness affected your daily activities/work/family?\"</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">Demonstrate empathy</td>\n\t\t\t\t\t<td>Be open to patient's emotions</td>\n\t\t\t\t\t<td><p>&#8226; Assess changes in body language and voice tone</p>\n\t\t\t\t\t\t<p>&#8226; Look for opportunities to use brief empathetic comments or gestures</p></td>\n\t\t\t\t\t<td rowspan=\"4\"><p>&#8226; Adds depth and meaning to the visit</p>\n\t\t\t\t\t\t<p>&#8226; Builds trust, leading to better diagnostic information, adherence, and outcomes</p>\n\t\t\t\t\t\t<p>&#8226; Makes limit-setting or saying \"no\" easier</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Make at least one empathetic statement</td>\n\t\t\t\t\t<td><p>&#8226; Name a likely emotion: \"That sounds really upsetting.\"</p>\n\t\t\t\t\t\t<p>&#8226; Compliment patient on efforts to address problem</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Convey empathy nonverbally</td>\n\t\t\t\t\t<td>&#8226; Use a pause, touch, or facial expression</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Be aware of your own reactions</td>\n\t\t\t\t\t<td><p>&#8226; Use own emotional response as a clue to what patient might be feeling</p>\n\t\t\t\t\t\t<p>&#8226; Take a brief break if necessary</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">Invest in the end</td>\n\t\t\t\t\t<td>Deliver diagnostic information</td>\n\t\t\t\t\t<td><p>&#8226; Frame diagnosis in terms of patient's original concerns</p>\n\t\t\t\t\t\t<p>&#8226; Test patient's comprehension</p></td>\n\t\t\t\t\t<td rowspan=\"4\"><p>&#8226; Increases potential for collaboration</p>\n\t\t\t\t\t\t<p>&#8226; Influences health outcomes</p>\n\t\t\t\t\t\t<p>&#8226; Improves adherence</p>\n\t\t\t\t\t\t<p>&#8226; Reduces return calls and visits</p>\n\t\t\t\t\t\t<p>&#8226; Encourages self care</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Provide education</td>\n\t\t\t\t\t<td><p>&#8226; Explain rationale for tests and treatments</p>\n\t\t\t\t\t\t<p>&#8226; Review possible side effects and expected course of recovery</p>\n\t\t\t\t\t\t<p>&#8226; Recommend lifestyle changes</p>\n\t\t\t\t\t\t<p>&#8226; Provide written materials and refer to other sources</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Involve patient in making decisions</td>\n\t\t\t\t\t<td><p>&#8226; Discuss treatment goals</p>\n\t\t\t\t\t\t<p>&#8226; Explore options, listening for the patient's preferences</p>\n\t\t\t\t\t\t<p>&#8226; Set limits respectfully: \"I can understand how getting that test makes sense to you. From my point of view, since the results won't help us diagnose or treat your symptoms, I suggest we consider this instead.\"</p>\n\t\t\t\t\t\t<p>&#8226; Assess patient's ability and motivation to carry out plan</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Complete the visit</td>\n\t\t\t\t\t<td><p>&#8226; Ask for additional questions: \"What questions do you have?\"</p>\n\t\t\t\t\t\t<p>&#8226; Assess satisfaction: \"Did you get what you needed?\"</p>\n\t\t\t\t\t\t<p>&#8226; Reassure patient of ongoing care</p></td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Frankel RM, Stein T. Getting the most out of the clinical encounter: The Four Habits Model. J Med Pract Manage 2001; 16:184. Copyright ©2001 Greenbranch Publishing.</div><div class=\"contractual\"><br/><a href=\"http://www.mpmnetwork.com/\">http://www.mpmnetwork.com</a></div><div id=\"graphicVersion\">Graphic 69929 Version 2.0</div></div></div>"},"69932":{"type":"graphic_figure","displayName":"Age pulmonary histiocytosis X","title":"Age at onset of pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age at onset of pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:374px; height:245px;\" src=\"images/PULM/69932_Age_pulmonary_histiocytosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The data shown were obtained from published papers in which the age at onset of symptoms or diagnosis could be determined (total number of subjects = 168). The peak age at onset is between 20 and 40.</div><div id=\"graphicVersion\">Graphic 69932 Version 1.0</div></div></div>"},"69933":{"type":"graphic_figure","displayName":"Early development edema","title":"Early development of interstitial pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early development of interstitial pulmonary edema</div><div class=\"cntnt\"><img style=\"width:314px; height:479px;\" src=\"images/PULM/69933_Early_development_edema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breakdown of the capillary endothelial barrier allows leakage of serum proteins into the interstitial space, undoing the osmotic gradient which normally promotes fluid reabsorption. Arrows represent lymphatic movement; small circles represent protein.</div><div id=\"graphicVersion\">Graphic 69933 Version 2.0</div></div></div>"},"69935":{"type":"graphic_picture","displayName":"Frozen fingers in NSF","title":"Picture showing thickened skin in hands of patient with nephrogenic system fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Picture showing thickened skin in hands of patient with nephrogenic system fibrosis</div><div class=\"cntnt\"><img style=\"width:401px; height:364px;\" src=\"images/NEPH/69935_Frozen_fingers_in_NSF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin of the hands of this patient with nephrogenic systemic fibrosis are so thickened that flexibility is lost. The fingers are \"frozen\" in place by excess collagen in the skin.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 69935 Version 3.0</div></div></div>"},"69936":{"type":"graphic_figure","displayName":"Cradle position PI","title":"Cradle position for breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Cradle position for breastfeeding</div><div class=\"cntnt\"><img style=\"width:475px; height:331px;\" src=\"images/PI/69936_CradlepositionPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cradle hold can be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's left forearm. The mother's left hand usually supports the baby's buttocks or upper thighs. Some women use a pillow to support this arm. The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.</div><div id=\"graphicVersion\">Graphic 69936 Version 5.0</div></div></div>"},"69937":{"type":"graphic_table","displayName":"Mitochondrial disorders","title":"Selected mitochondrial disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected mitochondrial disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Pyruvate carboxylase deficiency</td> </tr> <tr> <td>Phosphoenopyruvate carboxylase deficiency</td> </tr> <tr> <td>Pyruvate dehydrogenase complex deficiency</td> </tr> <tr> <td>Kearns-Sayre syndrome</td> </tr> <tr> <td>Mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS)</td> </tr> <tr> <td>Myoclonic epilepsy, ragged red fiber disease (MERRF)</td> </tr> <tr> <td>Freidrich ataxia</td> </tr> <tr> <td>Pearson syndrome</td> </tr> <tr> <td>Succinate dehydrogenase deficiency</td> </tr> <tr> <td>Cytochrome C oxidase (COX) deficiency</td> </tr> <tr> <td>Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE)</td> </tr> <tr> <td>Mitochondrial DNA depletion syndromes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69937 Version 4.0</div></div></div>"},"69939":{"type":"graphic_diagnosticimage","displayName":"Upper GI pyloric stenosis","title":"Pyloric stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyloric stenosis</div><div class=\"cntnt\"><img style=\"width:334px; height:306px;\" src=\"images/PEDS/69939_Upper_GI_pyloric_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI of pyloric stenosis. Note the characteristic \"apple core\" or \"string\" sign caused by the narrowed lumen of the pylorus (arrow).</div><div class=\"graphic_reference\">Courtesy of Mary L Brandt, MD.</div><div id=\"graphicVersion\">Graphic 69939 Version 3.0</div></div></div>"},"69940":{"type":"graphic_algorithm","displayName":"Screen Wilson sibling child","title":"Screening for Wilson disease (WD) in sibling or child of a patient with secure diagnosis of WD","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Screening for Wilson disease (WD) in sibling or child of a patient with secure diagnosis of WD</div><div class=\"cntnt\"><img style=\"width:517px; height:540px;\" src=\"images/GAST/69940_Screen_Wilson_sibling_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If molecular testing is available in the index patient, then this is the most efficient screening strategy. If initial screening by blood and urine testing is normal, then consider repeat screening in 2 to 5 years.<BR>Conversion to SI units: CPN &lt;20 mg/dL or 0.2 g/L; 24-hour urinary Cu &gt;40 micrograms/day or 0.6 micromol/day.<BR>Baseline testing = complete blood count including platelet count (CBC), liver biochemistries, international normalized ratio (INR), serum ceruloplasmin, 24-hour urine copper excretion; liver biopsy when appropriate.</div><div class=\"graphic_footnotes\">KF: Kayser-Fleischer.</div><div class=\"graphic_reference\">Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.</div><div id=\"graphicVersion\">Graphic 69940 Version 3.0</div></div></div>"},"69941":{"type":"graphic_diagnosticimage","displayName":"Clostridial myonecrosis computed tomography","title":"Clostridial myonecrosis computed tomography","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Clostridial myonecrosis computed tomography</div><div class=\"cntnt\"><img style=\"width:592px; height:245px;\" src=\"images/ID/69941_Clostridial_myonecrosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotizing fasciitis due to <EM>Clostridium septicum</EM>. Air is demonstrated in the external iliac vein, with air fluid level (Arrow A). Gas in the soft tissue of the buttock is also seen (Arrow B).</div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 69941 Version 4.0</div></div></div>"},"69942":{"type":"graphic_table","displayName":"HCW infections after stick","title":"Documented occupational infections following exposure to blood or body fluids in healthcare workers or laboratory personnel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Documented occupational infections following exposure to blood or body fluids in healthcare workers or laboratory personnel</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"container\">\n\t\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Viral infections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bolivian viral hemorrhagic fever (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Crimean Congo viral hemorrhagic fever (nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dengue (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ebola viral hemorrhagic fever (nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hepatitis B virus (needlestick, nonintact skin, mucous membranes)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hepatitis C virus (needlestick, nonintact skin, mucous membranes)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hepatitis D virus (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hepatitis G virus (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Herpes simplex 1 (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Human immunodeficiency virus 1 (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lassa viral hemorrhagic fever (nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Marburg viral hemorrhagic fever (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Varicella zoster virus (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Yellow fever virus (nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t\n\t\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Bacterial and rickettsial infections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Corynebacterium diphtheriae (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Corynebacterium striatum (scalpel cut)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Mycobacterium leprae (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Mycobacterium marinum (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Mycobacterium tuberculosis (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rickettsia rickettsii (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Staphylococcus aureus (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Streptococcus pyogenes (scapel cut)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Streptococcus pyogenes {necrotizing fasciitis}(nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t\n\t\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Fungal and parasitic infections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blastomyces dermatitidis (scalpel cut)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cryptococcus neoformans (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Leishmania sp. (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plasmodium falciparum (nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plasmodium malariae (needlestick, nonintact skin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plasmodium vivax (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Trypanosoma brucei (needlestick)</td>\n\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Tarantola, A, Abiteboul, D, Rachline, A. Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases. Am J Infect Control 2006; 34:367.</div><div id=\"graphicVersion\">Graphic 69942 Version 1.0</div></div></div>"},"69943":{"type":"graphic_picture","displayName":"Peritonsillar abscess","title":"Peritonsillar abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peritonsillar abscess</div><div class=\"cntnt\"><img style=\"width:397px; height:259px;\" src=\"images/ID/69943_Peritonsillarabscessed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large unilateral abscess is visible in the pharynx of a patient examined in the emergency department. Prominent swelling of the anterior pillar and soft palate is present.</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 69943 Version 3.0</div></div></div>"},"69944":{"type":"graphic_figure","displayName":"Cardiac remodeling after anterior MI","title":"Cardiac remodeling after anterior myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cardiac remodeling after anterior myocardial infarction</div><div class=\"cntnt\"><img style=\"width:468px; height:429px;\" src=\"images/CARD/69944_Cardiac_remodeling_post_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Late ventricular enlargement, or remodeling, resulting from increased circumference and sphericity, produces a marked increase in volume. The late change in circumference is due to lengthening of contractile tissue rather than further expansion of the infarcted, noncontractile segment. The increased sphericity results from a rounding out of the sharp abnormalities in contour at the margins of the infarct.</div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology, J Am Coll Cardiol 1992; 19:1136.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 69944 Version 2.0</div></div></div>"},"69946":{"type":"graphic_waveform","displayName":"EP study tracings RF ablation atrial flutter","title":"Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of typical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of typical atrial flutter</div><div class=\"cntnt\"><img style=\"width:559px; height:392px;\" src=\"images/CARD/69946_RFablationatrialflutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), a mapping catheter in the isthmus between the tricuspid valve and inferior vena cava (TV-IVC) (HBE1-2), eight recordings from a catheter extending from the lateral right atrial wall through the TV-IVC isthmus and into the ostium of the coronary sinus (CS15-1 to CS1-2), and right ventricular apex (RVA3-4) in a patient with typical atrial flutter. The tip of the mapping catheter was initially positioned on the tricuspid annulus, and then dragged through the TV-IVC isthmus to the ostium of the IVC during RF application; atrial flutter terminated. Note that the atrial activation (A) blocks between CS7-8 and CS5-6, which on fluoroscopy corresponded to the position of the mapping catheter.</div><div class=\"graphic_footnotes\">Fl: flutter waves; V: ventricular electrogram.</div><div id=\"graphicVersion\">Graphic 69946 Version 4.0</div></div></div>"},"69947":{"type":"graphic_figure","displayName":"Boutonniere finger PI","title":"Boutonniere deformity","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Boutonniere deformity</div><div class=\"cntnt\"><img style=\"width:489px; height:341px;\" src=\"images/PI/69947_Boutonniere-finger-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A “boutonniere deformity” is a finger injury that makes the finger joint nearest the finger tip stay straight, and the finger joint in the middle of the finger stay bent.</div><div id=\"graphicVersion\">Graphic 69947 Version 2.0</div></div></div>"},"69949":{"type":"graphic_figure","displayName":"Macula densa","title":"Anatomy of the juxtaglomerular apparatus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the juxtaglomerular apparatus</div><div class=\"cntnt\"><img style=\"width:437px; height:249px;\" src=\"images/NEPH/69949_Macula_densa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The juxtaglomerular cells in the wall of the afferent arteriole secrete renin into the lumen of the afferent arteriole and the renal lymph. Stretch receptors in the afferent arteriole, the sympathetic nerves ending in the juxtaglomerular cells, and the composition of the tubular fluid reaching the macula densa all contribute to the regulation of renin secretion.</div><div class=\"graphic_reference\">Adapted from Davis JO, Am J Med 1973; 55:333.</div><div id=\"graphicVersion\">Graphic 69949 Version 1.0</div></div></div>"},"69951":{"type":"graphic_figure","displayName":"Structure romiplostim","title":"Structure of romiplostim (Nplate, AMG 531)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of romiplostim (Nplate, AMG 531)</div><div class=\"cntnt\"><img style=\"width:445px; height:133px;\" src=\"images/HEME/69951_Structure_AMG_531.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Romiplostim is a \"peptibody\" composed of two disulphide-bonded human IgG1 kappa&nbsp;heavy chain&nbsp;constant regions (Fc fragment), each of which is covalently linked at residue 228 via polyglycine with two identical TPO agonist peptide sequences.</div><div class=\"graphic_reference\">Courtesy of Janet Nichol, Amgen, Inc, Thousand Oaks, CA.</div><div id=\"graphicVersion\">Graphic 69951 Version 3.0</div></div></div>"},"69952":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaque CT","title":"Calcified pleural plaque","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified pleural plaque</div><div class=\"cntnt\"><img style=\"width:349px; height:320px;\" src=\"images/PULM/69952_Calcified_pleural_plaque_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right-sided calcified pleural plaque with adjacent calcification in the lung parenchyma, likely representing a granuloma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69952 Version 3.0</div></div></div>"},"69954":{"type":"graphic_diagnosticimage","displayName":"Lymphangioleiomyomatosis CT I","title":"Lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:249px;\" src=\"images/PULM/69954_Lymphangioleiomyomatosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphangioleiomyomatosis in a 42-year-old woman. Multiple small cysts permeate the entire lung parenchyma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69954 Version 2.0</div></div></div>"},"69955":{"type":"graphic_figure","displayName":"Piggyback method","title":"Techniques for transbronchial penetration: piggyback method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Techniques for transbronchial penetration: piggyback method</div><div class=\"cntnt\"><img style=\"width:286px; height:223px;\" src=\"images/PULM/69955_Piggyback_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram shows the piggyback method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope and needle assembly are moved forward as a unit.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 69955 Version 1.0</div></div></div>"},"69958":{"type":"graphic_figure","displayName":"Tessier classification of facial clefts","title":"Tessier classification of facial clefts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tessier classification of facial clefts</div><div class=\"cntnt\"><img style=\"width:382px; height:541px;\" src=\"images/PEDS/69958_Tessier_class_fac_cleft_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kawamoto HK Jr, Cranofacial anomalies. In: Grab &amp; Smith's Plastic Surgery, 4th ed, Smith J, Aston S (Eds), Little, Brown, New York 1991. Copyright © 1991 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 69958 Version 8.0</div></div></div>"},"69959":{"type":"graphic_table","displayName":"Causes of postoperative fever","title":"Causes of postoperative fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of postoperative fever</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Infectious</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Surgical site infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pneumonia (ventilator-associated and aspiration)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary tract infection (usually with an indwelling bladder catheter)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intravascular catheter-associated infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antibiotic-associated diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sinusitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Otitis media</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Parotitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intraabdominal abscess</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Meningitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acalculous cholecystitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transfusion-associated viral infections</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Foreign body infection (orthopedic hardware, endovascular devices eg, prosthetic heart valves, grafts, and stents)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Osteomyelitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Endocarditis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Noninfectious</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Surgical site inflammation without infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hematoma/seroma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Suture reaction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Thrombosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Deep vein thrombosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pulmonary embolism (thrombotic or fat embolism)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Inflammatory</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Gout/pseudogout</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pancreatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Vascular</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cerebral infarction/hemorrhage</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Subarachnoid hemorrhage</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Myocardial infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bowel ischemia/infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Other</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Medications</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Drug/alcohol withdrawal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Transfusion reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Transplant rejection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hyperthyroidism (including thyroid storm)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hypoadrenalism</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cancer/neoplastic fever</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 69959 Version 2.0</div></div></div>"},"69960":{"type":"graphic_table","displayName":"Hip examination","title":"Detailed examination of the hip","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Detailed examination of the hip</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr><td class=\"subtitle1\">Examination\nsigns</td> <td class=\"subtitle1\">Diagnosis</td>\n<td class=\"subtitle1\">Confirmation</td> \n</tr><tr><td>Tenderness mid or superior trochanter**</td><td colspan=\"1\" rowspan=\"3\">#1\nTrochanteric bursitis</td><td colspan=\"1\" rowspan=\"3\">Local\nanesthetic block</td></tr><tr><td>Associations:\nstiff back, short\nleg, ankle or knee pathology, stroke</td></tr><tr><td>Normal\nrange of motion of the hip\nwith minimal end point stiffness</td></tr><tr><td>Stiffness\nand mild pain with internal\nor external rotation or both**</td><td colspan=\"1\" rowspan=\"3\">Osteoarthritis of\nthe hip</td><td colspan=\"1\" rowspan=\"3\">Standing AP pelvis x-ray</td></tr><tr><td>Tenderness\nover the anterior hip</td></tr><tr><td>Abnormal\nPatrick's maneuver</td></tr><tr><td>Hypesthesia\nor paresthesias over the\nanterolateral thigh**</td><td colspan=\"1\" rowspan=\"3\">Meralgia paresthetica</td><td colspan=\"1\" rowspan=\"3\">&nbsp;</td></tr><tr><td>No\nevidence of lumbar radiculopathy</td></tr><tr><td>No\nevidence\nof hip disease</td></tr><tr><td>Acute\nloss and severe pain with internal or external\nrotation or both**</td><td colspan=\"1\" rowspan=\"4\">Avascular necrosis of the hip;\nacute arthritis;\nseptic arthritis</td><td colspan=\"1\" rowspan=\"4\">MRI; AP pelvis x-ray; or\naspiration of the hip by fluoroscopy</td></tr><tr><td>Limping\nwith an antalgic gait</td></tr><tr><td>Tenderness\nover the\nanterior hip</td></tr><tr><td>Abnormal\nPatrick's maneuver</td></tr><tr><td>Acute\nloss and severe pain\nwith internal or external rotation or both following an injury**</td><td colspan=\"1\" rowspan=\"4\">Occult\nhip fracture </td><td colspan=\"1\" rowspan=\"4\">MRI; AP pelvis x-ray</td></tr><tr><td>Severe\nantalgic gait or refusal to bear weight</td></tr><tr><td>Tenderness\nover the anterior\nhip</td></tr><tr><td>Abnormal\nPatrick's maneuver</td></tr><tr><td>Diminished\ndorsalis pedis and posterior\ntibial pulses**</td><td colspan=\"1\" rowspan=\"2\">Vascular insufficiency</td><td colspan=\"1\" rowspan=\"2\">Doppler\nstudy</td></tr><tr><td>Delayed\ncapillary fill times</td></tr><tr><td>Straight\nleg maneuver\nreproduces radicular pain**</td><td colspan=\"1\" rowspan=\"3\">Lumbar\nradiculopathy </td><td colspan=\"1\" rowspan=\"3\">CT or MRI demonstrating nerve\ncompression</td></tr><tr><td>Painful\nand limited flexion and lateral\nbending</td></tr><tr><td>Abnormal\nlower extremity neurologic examination</td></tr><tr><td>Pain\naggravated\nby torque applied to the femur**</td><td colspan=\"1\" rowspan=\"3\">Primary or\nsecondary involvement of the femur</td><td colspan=\"1\" rowspan=\"3\">Full x-ray of\nthe femur; bone\nscan</td></tr><tr><td>Localized\nbony tenderness</td></tr><tr><td>Positive\nAnvil sign</td></tr>\n</tbody></table></div><div class=\"graphic_footnotes\">** is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.<br> #1 refers to the most common condition affecting the hip.</div><div id=\"graphicVersion\">Graphic 69960 Version 1.0</div></div></div>"},"69962":{"type":"graphic_figure","displayName":"Maze vs radial surgery for AF","title":"Schema of the maze procedure and the radial approach for atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Schema of the maze procedure and the radial approach for atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:480px; height:217px;\" src=\"images/CARD/69962_Maze_vs_radial_surgery_for.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The large outer circle denotes the atria and its outer limit is bounded by the atrioventricular annular margins. The small circle indicates the sinoatrial node (SAN), the shaded area indicates the isolated portion of the atrium, and the atrial coronary arteries, arising at the atrioventricular groove, are also schematically drawn. Arrows indicate the activation wavefront from the sinoatrial node, radiating toward the annular margins. The radial approach (right panel) preserves a more physiologic activation sequence and the blood supply to most atrial segments, whereas the atrial incisions of the maze procedure (left panel) desynchronize the activation sequence, and some of the incisions cross the atrial coronary arteries.</div><div class=\"graphic_reference\">Reprinted with permission from the Society of Thoracic Surgeons. Netta T, Cox R, Schuessler RB, et al. Ann Thorac Surg 1999; 67:27.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 69962 Version 2.0</div></div></div>"},"69963":{"type":"graphic_table","displayName":"Water sol vit DRI","title":"Dietary Reference Index (DRIs) of water soluble vitamins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary Reference Index (DRIs) of water soluble vitamins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"14\" width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Life stage group</td> <td class=\"subtitle1\" colspan=\"2\">Thiamine<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Riboflavin<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Niacin<br /> (mg/d)*</td> <td class=\"subtitle1\" colspan=\"2\">Pantothenic acid<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Vitamin B<sub>6</sub><br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Biotin<br /> (mcg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Vitamin C<br /> (mg/d)</td> </tr> <tr> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI</strong></td> <td class=\"subtitle2\">UL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Infants</td> </tr> <tr> <td class=\"indent1\">0 to 6 mo</td> <td><strong>0.2<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.3<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.7<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.1<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>40<sup>&#182;</sup></strong></td> <td>ND</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">7 to 12 mo</td> <td><strong>0.3<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.4<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.8<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.3<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>6<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>50<sup>&#182;</sup></strong></td> <td>ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Children</td> </tr> <tr> <td class=\"indent1\">1 to 3 y</td> <td><strong>0.5</strong></td> <td>ND</td> <td><strong>0.5</strong></td> <td>ND</td> <td><strong>6</strong></td> <td>10</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.5</strong></td> <td>30</td> <td><strong>8<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>15</strong></td> <td>400</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">4 to 8 y</td> <td><strong>0.6</strong></td> <td>ND</td> <td><strong>0.6</strong></td> <td>ND</td> <td><strong>8</strong></td> <td>15</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.6</strong></td> <td>40</td> <td><strong>12<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>25</strong></td> <td>650</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Males</td> </tr> <tr> <td class=\"indent1\">9 to 13 y</td> <td><strong>0.9</strong></td> <td>ND</td> <td><strong>0.9</strong></td> <td>ND</td> <td><strong>12</strong></td> <td>20</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1</strong></td> <td>60</td> <td><strong>20<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>45</strong></td> <td>1200</td> </tr> <tr> <td class=\"indent1\">14 to 18 y</td> <td><strong>1.2</strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>ND</td> <td><strong>16</strong></td> <td>30</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>80</td> <td><strong>25<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>75</strong></td> <td>1800</td> </tr> <tr> <td class=\"indent1\">19 to 30 y</td> <td><strong>1.2</strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>ND</td> <td><strong>16</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>90</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31 to 50 y</td> <td><strong>1.2</strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>ND</td> <td><strong>16</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>90</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">51 to 70 y</td> <td><strong>1.2</strong></td> <td>ND</td> <td><strong>RDA</strong></td> <td>ND</td> <td><strong>16</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.7</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>90</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;70 y</td> <td><strong>1.2</strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>ND</td> <td><strong>16</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.7</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>90</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Females</td> </tr> <tr> <td class=\"indent1\">9 to 13 y</td> <td><strong>0.9</strong></td> <td>ND</td> <td><strong>0.9</strong></td> <td>ND</td> <td><strong>12</strong></td> <td>20</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1</strong></td> <td>60</td> <td><strong>20<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>45</strong></td> <td>1200</td> </tr> <tr> <td class=\"indent1\">14 to 18 y</td> <td><strong>1</strong></td> <td>ND</td> <td><strong>1</strong></td> <td>ND</td> <td><strong>14</strong></td> <td>30</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.2</strong></td> <td>80</td> <td><strong>25<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>65</strong></td> <td>1800</td> </tr> <tr> <td class=\"indent1\">19 to 30 y</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>14</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>75</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31 to 50 y</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>14</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.3</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>75</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">51 to 70 y</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>14</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.5</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>75</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;70 y</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>1.1</strong></td> <td>ND</td> <td><strong>14</strong></td> <td>35</td> <td><strong>5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.5</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>75</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">14 to 18 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>18</strong></td> <td>30</td> <td><strong>6<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.9</strong></td> <td>80</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>80</strong></td> <td>1800</td> </tr> <tr> <td class=\"indent1\">19 to 30 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>18</strong></td> <td>35</td> <td><strong>6<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.9</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>85</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">31 to 50 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>18</strong></td> <td>35</td> <td><strong>6<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.9</strong></td> <td>100</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>85</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">Lactation</td> </tr> <tr> <td class=\"indent1\">14 to 18 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.6</strong></td> <td>ND</td> <td><strong>17</strong></td> <td>30</td> <td><strong>7<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2</strong></td> <td>80</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>115</strong></td> <td>1800</td> </tr> <tr> <td class=\"indent1\">19 to 30 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.6</strong></td> <td>ND</td> <td><strong>17</strong></td> <td>35</td> <td><strong>7<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2</strong></td> <td>100</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>120</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31 to 50 y</td> <td><strong>1.4</strong></td> <td>ND</td> <td><strong>1.6</strong></td> <td>ND</td> <td><strong>17</strong></td> <td>35</td> <td><strong>7<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2</strong></td> <td>100</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>120</strong></td> <td>2000</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dietary reference intakes (DRIs) include the following measures describing optimal nutrient intake:<br /><ul>&#xD;&#xA;    <li>Recommended Dietary Allowance (RDA) - The level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group. </li>&#xD;&#xA;    <li>Adequate Intake (AI) - An approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.</li>&#xD;&#xA;    <li>Upper Tolerable Level (UL) - The maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.</li>&#xD;&#xA;</ul>&#xD;&#xA;RDAs and AIs may both be used as goals for individual intake. The AI is used when there is insufficient data to determine the RDA for a given nutrient.</div><div class=\"graphic_footnotes\">d: day; mo: months; y: years.<br />* Niacin is dosed as niacin equivalents (NE), where 1 mg niacin = 60&nbsp;mg of tryptophan. Infants 0 to 6 months: only preformed niacin (not NE).&nbsp;<br />¶ As adequate intake (AI). </div><div class=\"graphic_reference\">Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Reprinted with permission from the National Academies Press, Copyright © 2006, National Academy of Sciences.<br />Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B<SUB>6</SUB>, Folate, Vitamin B<SUB>12</SUB>, Panthothenic acid, Biotin, and Choline (1998); Dietary reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000). These reports may be accessed via <A href=\"http://www.nap.edu/\" target=_blank>www.nap.edu</A>.</div><div id=\"graphicVersion\">Graphic 69963 Version 18.0</div></div></div>"},"69968":{"type":"graphic_figure","displayName":"Comparison of dapsone (a sulfone) and sulfonamide structures","title":"Comparison of dapsone (a sulfone) and sulfonamide structures","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Comparison of dapsone (a sulfone) and sulfonamide structures</div><div class=\"cntnt\"><img style=\"width:460px; height:363px;\" src=\"images/ALLRG/69968_Dapsone_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dapsone is a sulfone medication, rather than a sulfonamide. Dapsone can cause hypersensitivity reactions that are clinically similar to those caused by sulfonamides, however.<br> </div><div class=\"graphic_footnotes\">* R: substituted aromatic ring.</div><div id=\"graphicVersion\">Graphic 69968 Version 3.0</div></div></div>"},"69969":{"type":"graphic_table","displayName":"ESC prevention SCD LQTS","title":"European Society of Cardiology recommendations for prevention of sudden cardiac death: Long QT syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology recommendations for prevention of sudden cardiac death: Long QT syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Primary prevention</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Avoidance of QT prolonging agents/potassium lowering agents</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Silent gene carriers</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Asymptomatic</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Avoidance of competitive sport/strenuous activity</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic</td>\n\n  <td>Class I</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Silent gene carriers</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Asymptomatic</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Beta blockers</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic</td>\n\n  <td>Class I</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Asymptomatic</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Left cardiac sympathetic denervation + beta-blockers</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic with recurrences on beta-blockers</td>\n\n  <td>Class IIb</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Pacemaker (plus beta-blockers)\n\n  </td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic with pause- or bradycardia-dependent arrhythmias</td>\n\n  <td>Class IIb</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Implantable cardioverter defibrillator (ICD) + beta-blockers</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"indent1\">Symptomatic with recurrences on beta blockers</td>\n\n  <td>Class IIa</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Secondary prevention</td>\n\n  </tr>\n\n  <tr>\n\n  <td>ICD + beta blockers</td>\n\n  <td>Class I</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Avoidance of competitive sport/strenuous activity*</td>\n\n  <td>Class I</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Avoidance of QT prolonging agents*</td>\n\n  <td>Class I</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">Classification</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\"><strong>Class I:</strong> Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\"><strong> Class II:</strong> Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\"><strong> Class IIa:</strong> Weight of evidence/opinion is in favor of usefulness/efficacy.</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\"><strong>Class IIb:</strong> Usefulness/efficacy less well established by evidence/opinion.</td>\n\n  </tr>\n\n  <tr>\n\n  <td colspan=\"2\" rowspan=\"1\"><strong> Class III:</strong> Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.</td>\n\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Life-style measures to be adopted in conjunction with ICD implant in CA survivors.</div><div class=\"graphic_reference\">Priori, SG, Aliot, E, Blomstrom-Lundqvist, C, et al, Eur Heart J 2001; 22:1374.</div><div id=\"graphicVersion\">Graphic 69969 Version 1.0</div></div></div>"},"69972":{"type":"graphic_diagnosticimage","displayName":"MRI MTS FLAIR","title":"MRI MTS FLAIR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI MTS FLAIR</div><div class=\"cntnt\"><img style=\"width:360px; height:377px;\" src=\"images/NEURO/69972_MRI_MTS_FLAIR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FLAIR sequence of the same patient; because FLAIR nulls CSF signal, abnormal signal intensity in the hippocampus (arrow) is relatively more apparent.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; MTS: mesial temporal sclerosis; CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 69972 Version 3.0</div></div></div>"},"69974":{"type":"graphic_picture","displayName":"Typ carcinoid bronchoscopy","title":"Typical carcinoid at bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid at bronchoscopy</div><div class=\"cntnt\"><img style=\"width:300px; height:306px;\" src=\"images/ONC/69974_Typ_carcinoid_bronchoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles F Thomas, Jr, MD.</div><div id=\"graphicVersion\">Graphic 69974 Version 1.0</div></div></div>"},"69976":{"type":"graphic_waveform","displayName":"Advanced case 1 with answer","title":"Electrocardiogram in hypothermia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in hypothermia</div><div class=\"cntnt\"><img style=\"width:540px; height:285px;\" src=\"images/CARD/69976_Advancedcase1withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ECG reveals marked sinus bradycardia (about 40 beats/min) with a prolonged PR interval (0.23 sec). The slow heart rate in this patient is due to hypothermia (90°F, 32.2°C), which also produces prominent convex deflections at the J point (junction of QRS and ST segments),&nbsp;which are best seen in the precordial leads. The J waves or Osborn waves (arrows) are characteristic of severe hypothermia and resolve with rewarming; how they occur is not fully understood (Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Europace 2017; 19:665). </div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 69976 Version 6.0</div></div></div>"},"69977":{"type":"graphic_figure","displayName":"Amebiasis life cycle","title":"Amebiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Amebiasis life cycle</div><div class=\"cntnt\"><img style=\"width:546px; height:610px;\" src=\"images/ID/69977_Amebiasis_life_cycle_sharpened.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cysts and trophozoites are passed in feces <strong>(1)</strong>. Cysts are typically found in formed stool, whereas trophozoites are typically found in diarrheal stool. Infection by <em>Entamoeba histolytica</em> occurs by ingestion of mature cysts <strong>(2)</strong> in fecally contaminated food, water, or hands. Excystation <strong>(3)</strong> occurs in the small intestine and trophozoites <strong>(4)</strong> are released, which migrate to the large intestine. The trophozoites multiply by binary fission and produce cysts <strong>(5)</strong>, and both stages are passed in the feces <strong>(1)</strong>. Because of the protection conferred by their walls, the cysts can survive days to weeks in the external environment and are responsible for transmission. Trophozoites passed in the stool are rapidly destroyed once outside the body, and if ingested would not survive exposure to the gastric environment. In many cases, the trophozoites remain confined to the intestinal lumen (<strong>A:</strong> noninvasive infection) of individuals who are asymptomatic carriers, passing cysts in their stool. In some patients the trophozoites invade the intestinal mucosa (<strong>B:</strong> intestinal disease), or, through the bloodstream, extraintestinal sites such as the liver, brain, and lungs (<strong>C:</strong> extraintestinal disease), with resultant pathologic manifestations. It has been established that the invasive and noninvasive forms represent two separate species, respectively <em>E. histolytica</em> and <em>E. dispar</em>. These two species are morphologically indistinguishable unless <em>E. histolytica</em> is observed with ingested red blood cells (erythrophagocystosis). Transmission can also occur through exposure to fecal matter during sexual contact (in which case not only cysts, but also trophozoites could prove infective).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Amebiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/amebiasis/\" target=\"_blank\">http://www.cdc.gov/dpdx/amebiasis/</a>.</div><div id=\"graphicVersion\">Graphic 69977 Version 6.0</div></div></div>"},"69978":{"type":"graphic_picture","displayName":"Disseminated gonorrhea","title":"Skin lesions in disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin lesions in disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:504px; height:367px;\" src=\"images/DERM/69978_Disseminated_gonorrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hemorrhagic vesicopustule is present in the web space of this adolescent patient's hand. There is also a pustule on the sole of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 69978 Version 2.0</div></div></div>"},"69979":{"type":"graphic_figure","displayName":"Skin stapling","title":"Placement of skin staples","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Placement of skin staples</div><div class=\"cntnt\"><img style=\"width:508px; height:596px;\" src=\"images/EM/69979_Skin_stapling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place the stapler perpendicular to and centered over the wound while everting the wound edges (figure A above) with forceps (preferable)&nbsp;or thumb and forefinger. While pinching the edges of the wound together, gently squeeze the stapler handle to eject the staple into the skin. If the stapler does not automatically release, then release the staple from the stapler by pulling the stapler back. When properly placed, the crossbar of the staple is elevated a few millimeters above the skin surface (figure B above).</div><div id=\"graphicVersion\">Graphic 69979 Version 3.0</div></div></div>"},"69980":{"type":"graphic_figure","displayName":"Radial bone density IHH","title":"Reduced bone density in men with idiopathic hypogonadotropic hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reduced bone density in men with idiopathic hypogonadotropic hypogonadism</div><div class=\"cntnt\"><img style=\"width:311px; height:414px;\" src=\"images/ENDO/69980_Radial_bone_density_IHH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Radial (cortical) bone density as function of age in 16 men with idiopathic hypogonadotropic hypogonadism who had fused epiphyses. The lines indicate the mean (±SD) radial bone density in normal men. Panel B: Radial bone density as function of age in seven men with idiopathic hypogonadotropic hypogonadism who had open epiphyses. Radial bone density was at least 2 SD below normal in 16 of the 23 men; in addition, eight had spinal bone densities below the fracture threshold (not shown).</div><div class=\"graphic_reference\">Modified and reproduced with permission from: Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.&nbsp;Ann Intern Med 1987; 106:354.</div><div id=\"graphicVersion\">Graphic 69980 Version 2.0</div></div></div>"},"69981":{"type":"graphic_diagnosticimage","displayName":"Esophageal adenocarcinoma EUS CPC","title":"Esophageal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:286px; height:265px;\" src=\"images/GAST/69981_Esoph_adenoca_EUS_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound view of the distal esophageal mass revealed extension of the lesion beyond the muscularis propia layer (arrow).</div><div class=\"graphic_reference\">Courtesy of Douglas Pleskow, MD.</div><div id=\"graphicVersion\">Graphic 69981 Version 4.0</div></div></div>"},"69982":{"type":"graphic_figure","displayName":"Placement of meshed skin graft","title":"Skinning vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skinning vulvectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:334px;\" src=\"images/OBGYN/69982_Placement_of_meshed_skin_gr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The meshed skin graft is being secured. Long sutures are used to tie down a bolster dressing, thus avoiding&nbsp;graft shear.</div><div id=\"graphicVersion\">Graphic 69982 Version 3.0</div></div></div>"},"69983":{"type":"graphic_table","displayName":"Complications IV opioid use","title":"Complications of intravenous opioid use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of intravenous opioid use</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Infectious</td></tr>\n\t\t\t\t\t\t<tr><td>Bacterial endocarditis</td></tr>\n\t\t\t\t\t\t<tr><td>Tetanus</td></tr>\n\t\t\t\t\t\t<tr><td>Hepatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberculosis</td></tr>\n\t\t\t\t\t\t<tr><td>HIV infection</td></tr>\n\t\t\t\t\t\t<tr><td>Mycotic aneurysms</td></tr>\n\t\t\t\t\t\t<tr><td>Skin abscesses</td></tr>\n\t\t\t\t\t\t<tr><td>Wound botulism</td></tr>\n\t\t\t\t\t\t<tr><td>Cellulitis</td></tr>\n\t\t\t\t\t\t<tr><td>Septic arthritis</td></tr>\n\t\t\t\t\t\t<tr><td>Osteomyelitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Renal</td></tr>\n\t\t\t\t\t\t<tr><td>Nephropathy (heroin, morphine, pentazocine)</td></tr>\n\t\t\t\t\t\t<tr><td>Myoglobinuric renal failure</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Gastrointestinal</td></tr>\n\t\t\t\t\t\t<tr><td>Intestinal pseudo-obstruction (due to fecal impaction)</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cardiovascular</td></tr>\n\t\t\t\t\t\t<tr><td>Bacterial endocarditis</td></tr>\n\t\t\t\t\t\t<tr><td>Venous thrombosis</td></tr>\n\t\t\t\t\t\t<tr><td>Talc and cornstarch emboli (lungs, liver, kidney, retina)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Respiratory</td></tr>\n\t\t\t\t\t\t<tr><td>Septic pulmonary emboli</td></tr>\n\t\t\t\t\t\t<tr><td>Aspiration pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberculosis</td></tr>\n\t\t\t\t\t\t<tr><td>Pneumothorax</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Neurologic</td></tr>\n\t\t\t\t\t\t<tr><td>Pseudoaneurysm</td></tr>\n\t\t\t\t\t\t<tr><td>Parkinsonian effects (MPTP)</td></tr>\n\t\t\t\t\t\t<tr><td>Transverse myelitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Musculoskeletal</td></tr>\n\t\t\t\t\t\t<tr><td>Septic arthritis</td></tr>\n\t\t\t\t\t\t<tr><td>Polymyositis</td></tr>\n\t\t\t\t\t\t<tr><td>Fibrous myopathy</td></tr>\n\t\t\t\t\t\t<tr><td>Osteomyelitis</td></tr>\n\t\t\t\t\t\t<tr><td>Compartment syndrome</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Glick, CA, Evan, OB, Parks, BR. South Med J 1996; 889:1119.</div><div id=\"graphicVersion\">Graphic 69983 Version 1.0</div></div></div>"},"69984":{"type":"graphic_diagnosticimage","displayName":"Lateral neck radiograph of a child with pneumomediastinum","title":"Lateral neck radiograph of a child with pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral neck radiograph of a child with pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:331px; height:424px;\" src=\"images/PEDS/69984_SPM_lat_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this lateral neck radiograph of a young child with pneumomediastinum, characteristic findings include retropharyngeal lucency (arrowheads), and subcutaneous emphysema of the anterior and posterior neck and anterior chest wall (arrows).</div><div class=\"graphic_reference\">Courtesy of Ibrahim Janahi and Ammar Saadoon.</div><div id=\"graphicVersion\">Graphic 69984 Version 4.0</div></div></div>"},"69985":{"type":"graphic_table","displayName":"Ear canal normal flora","title":"Ear canal normal flora","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ear canal normal flora</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Percent*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aerobic bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus epidermis</em></td> <td>78</td> </tr> <tr> <td class=\"indent1\">Diptheroid species</td> <td>29</td> </tr> <tr> <td class=\"indent1\">Alpha hemolytic streptococcus</td> <td>18</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>11</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anaerobic bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em></td> <td>18</td> </tr> <tr> <td class=\"indent1\"><em>Peptococcus</em></td> <td>3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percent of total patients with growth of this organism (n = 72).</div><div class=\"graphic_reference\">Data from Brook, I, Acta Otolaryngol 1980; 91:285.</div><div id=\"graphicVersion\">Graphic 69985 Version 2.0</div></div></div>"},"69986":{"type":"graphic_picture","displayName":"Skin appearance post injection","title":"Central blanching and peau d'orange appearance of skin after intralesional injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central blanching and peau d'orange appearance of skin after intralesional injection</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/PC/69986_Skin_appearance_post_inject.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 69986 Version 2.0</div></div></div>"},"69987":{"type":"graphic_diagnosticimage","displayName":"Severe bronchiectasis CT","title":"Severe bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe bronchiectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:332px;\" src=\"images/PULM/69987_Severe_bronchiectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe bronchiectasis in a destroyed right lung as a sequela of necrotizing pneumonia. Complete cicatrization atelectasis of the right lung with a cardiomediastinal shift to the right. The right lung is permeated by small cystic structures consistent with cystic bronchiectasis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 69987 Version 3.0</div></div></div>"},"69988":{"type":"graphic_waveform","displayName":"12-lead ECG right posteroseptal WPW I","title":"12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:516px; height:289px;\" src=\"images/CARD/69988_Right_posteroseptal_WPW_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in sinus rhythm from a patient with Wolff-Parkinson-White syndrome shows a maximally preexcited QRS complex. There is early transition across the precordial leads, with R/S ratio of 1 occurring in lead V2. The delta waves are positive in the lateral leads I, aVL, and V6, and negative in leads III and aVF, localizing the pathway to the posteroseptal area. The positive delta wave in lead II and in the lateral leads localize the pathway to the right side.</div><div id=\"graphicVersion\">Graphic 69988 Version 3.0</div></div></div>"},"69989":{"type":"graphic_table","displayName":"Arthropod bite and infestations","title":"Arthropod bites and infestations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Arthropod bites and infestations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Arthropod </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Bedbug</td> <td>Usual reaction is limited to a punctum at the site of the bite. Pruritic red papules, often clustered, are the common allergic response. Reactions may also be maculopapular, petechial, or hemorrhagic. Anaphylaxis has been reported in sensitized persons.</td> </tr> <tr> <td>Black fly (<em>Simulium</em>)</td> <td>Itchy or painful; may vesiculate</td> </tr> <tr> <td>Chigger (<em>Trombicula irritans</em>, others)</td> <td>Itchy maculopapular lesion</td> </tr> <tr> <td>Deer fly (<em>Chrysops</em>)</td> <td>Painful papule with central punctum</td> </tr> <tr> <td>Flea</td> <td>Early urticaria and erythema; itchy papules, often clustered</td> </tr> <tr> <td>Mosquito</td> <td>Itchy papule, wheal</td> </tr> <tr> <td>Myiasis</td> <td>Infestation of human tissue by fly larvae. Manifestations vary with fly species.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Pediculosis due to </td> </tr> <tr> <td class=\"sublist1\"><em>Pediculus humanus </em>(body lice) </td> <td class=\"sublist_other\">Itchy wheals; maculopapular rash, may be hemorrhagic </td> </tr> <tr> <td class=\"sublist1\"><em>Pediculus humanus </em>(head lice) </td> <td class=\"sublist_other\">Itching; red papules, white nits </td> </tr> <tr> <td>Phthiriasis due to <em>Phirus pubis </em>(pubic lice)</td> <td>Itching; lice attach to pubic hair, eyelids</td> </tr> <tr> <td>Midge (<em>Culicoides</em>)</td> <td>Itchy wheal and papule</td> </tr> <tr> <td>Sand fly (<em>Phlebotomus</em>)</td> <td>Itchy or painful wheal, papule</td> </tr> <tr> <td>Scabies (<em>Scarcoptes scabiei</em>)</td> <td>Itchy papules, vesicles; linear burrows; occasional urticaria, nodules</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Tick </td> </tr> <tr> <td class=\"sublist1\">Hard ticks </td> <td class=\"sublist_other\">Regional edema; chronic nodule (tick granuloma) </td> </tr> <tr> <td class=\"sublist1\">Soft ticks </td> <td class=\"sublist_other\">Macules, papules, central necrosis </td> </tr> <tr> <td>Triatomine bugs (<em>Reduviidae</em>)</td> <td>Transient urticaria; vesicles or pruritic papules</td> </tr> <tr> <td>Tsetse fly (<em>Glossina</em>)</td> <td>Painful, red indurated lesion</td> </tr> <tr> <td>Tungiasis (Chigoe fleas, <em>Tunga penetrans</em>)</td> <td>Burrow into host tissue, often feet; itchy white papules or vesicles with central black depression; may ulcerate</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 69989 Version 3.0</div></div></div>"},"69990":{"type":"graphic_table","displayName":"Therapy for agents that cause encephalitis","title":"Suggested initial therapy for agents that cause encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested initial therapy for agents that cause encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Specific therapy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>ADEM</strong></td> <td>Corticosteroids</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Bacteria</strong></td> </tr> <tr> <td class=\"indent1\"><em>Mycoplasma pneumonia</em></td> <td>Macrolide (eg, azithromycin, clarithromycin, erythromycin), doxycycline, or fluoroquinolone<sup>*</sup> (eg, levofloxacin, ciprofloxacin, moxifloxacin)</td> </tr> <tr> <td class=\"indent1\"><em>Listeria monocytogenes</em></td> <td>Ampicillin plus gentamicin; trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"indent1\"><em>Tropheryma whipplei</em></td> <td>Ceftiaxone, followed by either trimethoprim-sulfamethoxazole or cefixime</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Fungi</strong></td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides</em></td> <td>Fluconazole, itraconazole, voriconazole, amphotericin B</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus neoformans</em></td> <td>Amphotericin B plus flucytosine</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum</em></td> <td>Liposomal amphotericin B</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Helminths</strong></td> </tr> <tr> <td class=\"indent1\"><em>Baylisascaris procyonis</em></td> <td>Albendazole plus diethylcarbamazine</td> </tr> <tr> <td class=\"indent1\"><em>Gnathostoma</em></td> <td>Albendazole or ivermectin</td> </tr> <tr> <td class=\"indent1\"><em>Taenia solium</em> (cycticercosis)</td> <td>Albendazole and corticosteroids</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Mycobacteria</strong></td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em></td> <td>4-drug regimen; consider addition of corticosteroid</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Protozoa</strong></td> </tr> <tr> <td class=\"indent1\"><em>Acanthamoeba</em></td> <td>Trimethoprim-sulfamethoxazole plus rifampin plus ketoconazole</td> </tr> <tr> <td class=\"indent1\"><em>Balamuthia mandrillaris</em></td> <td>Pentamidine plus macrolide and fluconazole and sulfadiazine and flucytosine and phenothiazine</td> </tr> <tr> <td class=\"indent1\"><em>Naegleria fowleri</em></td> <td>Amphotericin B and rifampin</td> </tr> <tr> <td class=\"indent1\"><em>Plasmodium falciparum</em></td> <td>Quinine, quinidine or artemether</td> </tr> <tr> <td class=\"indent1\"><em>Toxoplasma gondii</em></td> <td>Pyrimethamine plus sulfadiazine or clindamycin</td> </tr> <tr> <td class=\"indent1\"><em>Trypanosoma brucei gambiense</em></td> <td>Eflornithine</td> </tr> <tr> <td class=\"indent1\"><em>Trypanosoma brucei rhodesiense</em></td> <td>Melarsoprol</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Rickettsioses and ehrlichioses</strong></td> </tr> <tr> <td class=\"indent1\"><em>Anaplasma phagocytophilum</em></td> <td>Doxycycline</td> </tr> <tr> <td class=\"indent1\"><em>Ehrlichia chafeensis</em></td> <td>Doxycycline</td> </tr> <tr> <td class=\"indent1\"><em>Rickettsia rickettsii</em></td> <td>Doxycycline</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Spirochetes</strong></td> </tr> <tr> <td class=\"indent1\"><em>Borrelia burgdorferi</em></td> <td>Ceftriaxone, cefotaxime</td> </tr> <tr> <td class=\"indent1\"><em>Treponema pallidum</em></td> <td>Penicillin G</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Viruses</strong></td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> <td>Ganciclovir plus foscarnet</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr</td> <td>No specific treatment</td> </tr> <tr> <td class=\"indent1\">Herpes B virus</td> <td>Valgancyclovir</td> </tr> <tr> <td class=\"indent1\">Herpes simplex</td> <td>Acyclovir</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6</td> <td>Gancyclovir or foscarnet</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> <td>Antiretroviral therapy</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>Oseltamivir</td> </tr> <tr> <td class=\"indent1\">JC virus</td> <td>Reversal of immunosuppression if possible</td> </tr> <tr> <td class=\"indent1\">Measles</td> <td>Ribavirin</td> </tr> <tr> <td class=\"indent1\">Nipah</td> <td>Ribavirin</td> </tr> <tr> <td class=\"indent1\">St. Louis encephalitis</td> <td>Interferon-2 alpha</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster</td> <td>Acyclovir</td> </tr> <tr> <td class=\"indent1\">West Nile</td> <td>No specific treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>ADEM: acute disseminated encephalomyelitis.<br /><br />* In pediatric patients, fluoroquinolones are not routinely used as&nbsp;first-line therapy, but may be a reasonable alternative for situations where no safe and effective substitute is available.</FONT></div><div class=\"graphic_reference\">Adapted from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303-27.</div><div id=\"graphicVersion\">Graphic 69990 Version 8.0</div></div></div>"},"69993":{"type":"graphic_picture","displayName":"Urothelial dysplasia B","title":"Urothelial dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial dysplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/69993_Urothelial_dysplasia_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 69993 Version 1.0</div></div></div>"},"69995":{"type":"graphic_figure","displayName":"Basic shoulder anatomy posterior view","title":"Posterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Posterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:546px; height:504px;\" src=\"images/EM/69995_Shoulder_anatomy_posterior.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 69995 Version 7.0</div></div></div>"},"69996":{"type":"graphic_table","displayName":"Potassium iodide after radiation exposure","title":"Recommended doses of potassium iodide after radiation exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses of potassium iodide after radiation exposure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td colspan=\"1\" class=\"subtitle1\">Age of\npatient</td>\n\n      <td class=\"subtitle1\">Predicted thyroid dose (cGy)</td>\n\n      <td class=\"subtitle1\">Daily dose of KI (mg)*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;40 years</td>\n\n      <td>&#8805;\n500</td>\n\n      <td>130</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;18 through 40</td>\n\n      <td>&#8805; 10</td>\n\n      <td>130</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnant or\nlactating</td>\n\n      <td> &#8805; 5</td>\n\n      <td>130 </td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;12 though 18 years</td>\n\n      <td> &#8805; 5</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;3 through 12 years</td>\n\n      <td> &#8805; 5</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;1 month through 3 years</td>\n\n      <td> &#8805; 5</td>\n\n      <td>32</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Birth through 1 month</td>\n\n      <td> &#8805; 5</td>\n\n      <td>16</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26322&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Potass_iodide_radiation_exp.htm</title></head></div><div class=\"graphic_footnotes\">KI: potassium iodide.<br />* Potassium iodide is available as 130 or 65 mg tablets, or as Lugol's solution. KI must be used within&nbsp;four to&nbsp;six hours of exposure to block uptake of radioactive iodine by the thyroid. If radioactive iodines are not part of the radiation exposure, KI is not needed. Refer to UpToDate topics for details.</div><div class=\"graphic_reference\">Based on FDA Guidance, 2001. Available at <A spellcheck=true href=\"http://www.fda.gov/Guidances/ucm070107.pdf\">http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070107.pdf</A>.</div><div id=\"graphicVersion\">Graphic 69996 Version 3.0</div></div></div>"},"69997":{"type":"graphic_figure","displayName":"ARF fistulotomy","title":"Schematic depiction of a fistulotomy and marsupialization","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Schematic depiction of a fistulotomy and marsupialization</div><div class=\"cntnt\"><img style=\"width:542px; height:269px;\" src=\"images/SURG/69997_ARFfistulotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows the probe extending through the primary opening of the anal fistula and the insertion of the probe. The internal opening is excised and the fistulous tract is marsupialized.</div><div id=\"graphicVersion\">Graphic 69997 Version 7.0</div></div></div>"},"69998":{"type":"graphic_table","displayName":"Adult abdominal and pelvic effective doses","title":"Adult abdominal and pelvic effective doses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult abdominal and pelvic effective doses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Average effective dose (mSv)</td> <td class=\"subtitle1\">Number of chest x-rays (PA/lateral) with equivalent radiation dose*</td> </tr> <tr> <td>Pelvic radiograph</td> <td>Conventional radiography</td> <td>0.6</td> <td>6</td> </tr> <tr> <td>Abdominal radiograph</td> <td>Conventional radiography</td> <td>0.7</td> <td>7</td> </tr> <tr> <td>Intravenous pyelogram</td> <td>Conventional radiography</td> <td>2.5</td> <td>25</td> </tr> <tr> <td>Renogram</td> <td>Nuclear medicine</td> <td>2.6</td> <td>26</td> </tr> <tr> <td>HIDA scan</td> <td>Nuclear medicine</td> <td>3.1</td> <td>31</td> </tr> <tr> <td>ERCP</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>4</td> <td>40</td> </tr> <tr> <td>Small bowel follow through</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>5</td> <td>50</td> </tr> <tr> <td>Upper gastrointestinal series</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>6</td> <td>60</td> </tr> <tr> <td>CT pelvis</td> <td>Computed tomography</td> <td>6</td> <td>60</td> </tr> <tr> <td>GI bleeding study</td> <td>Nuclear medicine</td> <td>7.8</td> <td>78</td> </tr> <tr> <td>Barium enema</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>8</td> <td>80</td> </tr> <tr> <td>CT abdomen</td> <td>Computed tomography</td> <td>8</td> <td>80</td> </tr> <tr> <td>Abdominal angiogram</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>12</td> <td>120</td> </tr> <tr> <td>Whole body PET</td> <td>Nuclear medicine</td> <td>14.1</td> <td>141</td> </tr> <tr> <td>CT triphasic liver</td> <td>Computed tomography</td> <td>15</td> <td>150</td> </tr> <tr> <td>CT angiogram aorta</td> <td>Computed tomography</td> <td>24</td> <td>240</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography; HIDA: hepatobiliary aminodiacetic acid; PET: positron-emission tomography.<br> * PA and lateral chest radiograph = .1 mSv.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254. </li> <li>Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078. </li> <li>Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968. </li> </ol></div><div id=\"graphicVersion\">Graphic 69998 Version 3.0</div></div></div>"}};